Sponsored Project Activity

July 2011 – June 2012
### Annual Research Report

**Federal**

<table>
<thead>
<tr>
<th>Source</th>
<th>Code</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Direct Federal</td>
<td>421</td>
<td>125,123,318</td>
</tr>
<tr>
<td>NIH</td>
<td>305</td>
<td>94,623,368</td>
</tr>
<tr>
<td>Other</td>
<td>116</td>
<td>30,499,950</td>
</tr>
<tr>
<td>Federal Flow-through</td>
<td>271</td>
<td>29,352,633</td>
</tr>
</tbody>
</table>

**Corporate**

<table>
<thead>
<tr>
<th>Source</th>
<th>Code</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>363</td>
<td>48,051,019</td>
</tr>
</tbody>
</table>

**State of South Carolina**

<table>
<thead>
<tr>
<th>Source</th>
<th>Code</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>30</td>
<td>14,931,408</td>
</tr>
</tbody>
</table>

**Foundation**

<table>
<thead>
<tr>
<th>Source</th>
<th>Code</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>145</td>
<td>14,161,427</td>
</tr>
</tbody>
</table>

**Other Support**

<table>
<thead>
<tr>
<th>Source</th>
<th>Code</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>12</td>
<td>490,093</td>
</tr>
</tbody>
</table>

**Total**

<table>
<thead>
<tr>
<th>Source</th>
<th>Code</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>1,242</td>
<td>$232,109,898</td>
</tr>
</tbody>
</table>
Executive Summary

In Fiscal Year 2012, MUSC’s Office of Research and Sponsored Programs (ORSP) recorded 1,242 awards for an overall extramural funding total of $232,109,898. During FY 2012, MUSC Investigators submitted 1,729 proposals for nearly 400 million dollars in proposed funding.

Table 1 shows overall proposals in FY 2012 increased by 3.9% when compared with the FY 2011 data. Nearly all units experienced increases in the number of proposals submitted during FY 2012.

The total number of overall awards accepted in FY 2012 decreased by 3.1%, down 40 awards from the prior year. Correspondingly total awarded dollars also decreased by 4.5% from the FY 2011 total, though still resulted in more than $232M in overall funding during FY 2012. A review of MUSC’s total funding by source reveals where increases and decreases were experienced when compared with data from the prior fiscal year.
Impact of ARRA (American Recovery and Reinvestment Act)

MUSC received just 16 ARRA funded awards in FY 2012 accounting for $3.36M, which was $16.3M less than the ARRA funding received in FY 2011. In contrast with the past two years, most of the ARRA awards in FY 2012 were in the federal flow-down funding category (12 awards), with the other 4 ARRA awards received in the direct federal funding category. In FY 2012 the National Institutes of Health (NIH) did not provide any ARRA funded awards to MUSC in the direct federal funding category; there were 2 awards from the Agency for Healthcare Research and Quality (AHRQ), 1 from the Department of Energy (DOE) and 1 from the Health Resources and Services Administration (HRSA).

Table 2: ARRA Funding Comparison

| ARRA Awards | # of Awards | $ Amount | | | | |
|-------------|-------------|----------|---|---|---|
|             | FY11 | FY12 | +/- | FY11 | FY12 | +/- |
| AHRQ        | 1    | 2    | 1   | 473,277 | 1,428,185 | 954,908 |
| DOE         | 1    | 1    | 0   | 808,391 | 752,407   | (55,984) |
| HRSA        | 4    | 1    | -3  | 1,053,919 | 299,685   | (754,234) |
| NIH         | 30   | 0    | -30 | 13,096,315 | -         | (13,096,315) |
| Federal     | 36   | 4    | -32 | 15,431,902 | 2,480,277 | (12,951,625) |
| Totals      | 63   | 16   | -47 | 19,696,040 | 3,363,537 | (16,332,503) |

Funding Sources and Agency Summary

Figure 2: 2012 Funding by Source

FY 2012 Funding

Figure 3: 2011 Funding by Source

FY 2011 Funding
The total number of awards received in the direct federal funding category decreased by 8.48% (460 awards in FY 2011 down to 421 in FY 2012). Similarly, MUSC’s overall direct federal funding level decreased from $146.8M in FY 2011 to $125.1M in FY 2012. Most of this 14.78% decline in the direct federal funding category reflects the substantial reduction in the number of ARRA funded awards made to MUSC during FY 2012 (63 in FY 2011 down to 16 in FY 2012). Excluding all ARRA funding from the totals, MUSC’s direct federal funding category decreased by 6.65% from the prior fiscal year ($131.3M in FY 2011 down to $122.6M in FY 2012).

Federal Funding by Agency

![Diagram showing Federal Funding by Agency]

Figure 4: Federal Funding Breakdown

<table>
<thead>
<tr>
<th>Agency</th>
<th># Awards</th>
<th>$ Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>NIH</td>
<td>46</td>
<td>13,476,127</td>
</tr>
<tr>
<td>NIH/NCATS</td>
<td>4</td>
<td>3,948,265</td>
</tr>
<tr>
<td>NIH/NCCAM</td>
<td>1</td>
<td>271,935</td>
</tr>
<tr>
<td>NIH/NCI</td>
<td>28</td>
<td>2,719,354</td>
</tr>
<tr>
<td>NIH/NIA</td>
<td>10</td>
<td>1,720,338</td>
</tr>
<tr>
<td>NIH/NIAAA</td>
<td>14</td>
<td>1,342,433</td>
</tr>
<tr>
<td>NIH/NICHD</td>
<td>7</td>
<td>2,612,595</td>
</tr>
<tr>
<td>NIH/NIDA</td>
<td>46</td>
<td>15,265,850</td>
</tr>
<tr>
<td>NIH/NIDCD</td>
<td>8</td>
<td>3,324,256</td>
</tr>
<tr>
<td>NIH/NIDCR</td>
<td>16</td>
<td>2,997,044</td>
</tr>
<tr>
<td>NIH/NIDDK</td>
<td>27</td>
<td>6,512,335</td>
</tr>
<tr>
<td>NIH/NIEHS</td>
<td>7</td>
<td>838,965</td>
</tr>
<tr>
<td>NIH/NIGMS</td>
<td>24</td>
<td>3,621,160</td>
</tr>
<tr>
<td>NIH/NIMH</td>
<td>17</td>
<td>6,333,649</td>
</tr>
<tr>
<td>NIH/NINDS</td>
<td>19</td>
<td>6,298,607</td>
</tr>
<tr>
<td>NIH/NINR</td>
<td>2</td>
<td>939,057</td>
</tr>
<tr>
<td>NIH/NLM</td>
<td>2</td>
<td>135,000</td>
</tr>
<tr>
<td>NOAA</td>
<td>1</td>
<td>75,000</td>
</tr>
<tr>
<td>NSF</td>
<td>5</td>
<td>620,254</td>
</tr>
<tr>
<td>SAMHSA</td>
<td>1</td>
<td>335,333</td>
</tr>
<tr>
<td>US Army</td>
<td>5</td>
<td>5,018,453</td>
</tr>
<tr>
<td>US Dept. of State</td>
<td>1</td>
<td>46,000</td>
</tr>
<tr>
<td>VA Boston</td>
<td>4</td>
<td>104,750</td>
</tr>
<tr>
<td>VAMC Charleston</td>
<td>44</td>
<td>8,059,130</td>
</tr>
<tr>
<td>WJB Dorn VAMC</td>
<td>6</td>
<td>91,336</td>
</tr>
<tr>
<td>Total for Federal (41 Agencies)</td>
<td>42</td>
<td>$125,123,318</td>
</tr>
</tbody>
</table>

The pie chart and bar graph above illustrate the distribution of federal funding by agency. NIH accounts for the largest share at 75.62%, followed by DOD at 7.00%, and HRSA at 2.17%. The smallest share is represented by NOAA, which accounts for only 0.06% of federal funding.
In FY 2012 the NIH accounted for 40.77% of all funding garnered by MUSC and 75.62% of the direct federal funding category. MUSC tallied 305 NIH awards (down 41 from FY 2011), which accounted for $94.6M (down from 118.5M in FY 2011) in funding. The 305 NIH awards MUSC received consisted of the following: 59 new, 10 competing continuations, 194 non-competing continuations, 29 supplements and 13 transfers. When compared with the data from a year ago, the number of new NIH awards increased, while competing continuations, non-competing continuations, supplements and transfers decreased.

Figure 4 shows the percentage breakdown by agency funding source of all direct federal funding awarded to MUSC during FY 2012. A comparison of these data with the FY 2011 data shows the NIH percentage of all direct federal funding decreased by 5.1% from the prior year. Increases in the percentage of all direct federal funding by source were recognized from the Department of Defense (up 2.79%) and the Agency for Healthcare Research and Quality (up 1.62%). Most of the other agencies listed in Figure 4 showed very little deviation (less than 1%) from the previous year.

NIH

Table 3 provides a comparison of the NIH award types and the resultant funding compared with the prior fiscal year. The investigator initiated Research Projects (R-awards) were down 47 awards, resulting in a $15.69M decrease in this funding mechanism from a year ago. Though the number of awards remained mostly unchanged, the Career Development (K-awards), the Program Projects/Centers (P awards), the Cooperative Agreements (U-awards) and the Contract awards all experienced decreases in funding levels from the previous year. Modest increases, either the number of awards obtained or amount of funding received, occurred in the following funding mechanisms: Research Related (S-awards), Training (T and D awards) and Fellowships (F-awards). The lack of any NIH ARRA funding in FY 2012 compared with the $13.1M of NIH ARRA funding obtained in FY 2011 explained most of the declines in the NIH funding sector, however it does not account for the entire decrease. In FY 2012, the NIH non-ARRA funding level experienced a decrease of 10.24% when compared with the same data from a year ago. This non-ARRA NIH funding decline can be mainly attributed to MUSC’s loss of a few large grant awards (U and P type awards) funded in prior fiscal years. In addition, for several competing renewals in FY11, the timing of the award notice created an anomaly where the renewal and non-competing cycle were awarded and reported in a single year.

Table 3: NIH Funding by Activity Type

<table>
<thead>
<tr>
<th>NIH Award Types</th>
<th>Number FY11</th>
<th>Number FY12</th>
<th>+/-</th>
<th>Amount FY11</th>
<th>Amount FY12</th>
<th>Net Change</th>
</tr>
</thead>
<tbody>
<tr>
<td>Research Projects (R)</td>
<td>233</td>
<td>186</td>
<td>-47</td>
<td>$69,447,131</td>
<td>$53,756,979</td>
<td>$(15,690,152)</td>
</tr>
<tr>
<td>Research Related (S)</td>
<td>1</td>
<td>2</td>
<td>1</td>
<td>205,168</td>
<td>724,876</td>
<td>519,708</td>
</tr>
<tr>
<td>Career Development (K)</td>
<td>29</td>
<td>31</td>
<td>2</td>
<td>5,095,494</td>
<td>5,088,725</td>
<td>(6,769)</td>
</tr>
<tr>
<td>Program Projects/Centers (P)</td>
<td>16</td>
<td>15</td>
<td>-1</td>
<td>16,883,190</td>
<td>15,704,821</td>
<td>(1,178,369)</td>
</tr>
<tr>
<td>Training (T,D)</td>
<td>15</td>
<td>15</td>
<td>0</td>
<td>4,285,576</td>
<td>4,448,335</td>
<td>162,759</td>
</tr>
<tr>
<td>Fellowships (F)</td>
<td>25</td>
<td>30</td>
<td>5</td>
<td>1,025,589</td>
<td>1,292,105</td>
<td>266,516</td>
</tr>
<tr>
<td>Cooperative Agreements (U)</td>
<td>20</td>
<td>20</td>
<td>0</td>
<td>17,873,904</td>
<td>12,780,738</td>
<td>(5,093,166)</td>
</tr>
<tr>
<td>Construction/Instrumentation (C,G)</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Contracts</td>
<td>7</td>
<td>6</td>
<td>-1</td>
<td>3,704,855</td>
<td>826,789</td>
<td>(2,878,066)</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>346</strong></td>
<td><strong>305</strong></td>
<td><strong>-41</strong></td>
<td><strong>$118,520,907</strong></td>
<td><strong>$94,623,368</strong></td>
<td><strong>$(23,897,539)</strong></td>
</tr>
</tbody>
</table>

*Note This difference includes 26 ARRA awards in FY11; NIH did not fund any ARRA projects in FY12.
## Federal Flow-Down Funding

<table>
<thead>
<tr>
<th>Federal Flow-Down</th>
<th># Awards</th>
<th>$ Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Academic Pediatric Assoc.</td>
<td>1</td>
<td>4,400</td>
</tr>
<tr>
<td>Actuated Medical, Inc.</td>
<td>1</td>
<td>52,584</td>
</tr>
<tr>
<td>Adv. Technology Inst.</td>
<td>1</td>
<td>80,639</td>
</tr>
<tr>
<td>Allegheny-Singer Inst.</td>
<td>2</td>
<td>81,787</td>
</tr>
<tr>
<td>Amer. Coll. of Radiology</td>
<td>1</td>
<td>9,000</td>
</tr>
<tr>
<td>Apogee</td>
<td>1</td>
<td>470,505</td>
</tr>
<tr>
<td>Aretech, LLC</td>
<td>2</td>
<td>58,315</td>
</tr>
<tr>
<td>Arizona State University</td>
<td>1</td>
<td>97,177</td>
</tr>
<tr>
<td>Assoc. of University Centers on Disabilities</td>
<td>1</td>
<td>4,000</td>
</tr>
<tr>
<td>Audiology, Inc.</td>
<td>1</td>
<td>121,135</td>
</tr>
<tr>
<td>Baylor Univ.</td>
<td>4</td>
<td>608,479</td>
</tr>
<tr>
<td>Brigham &amp; Womens Hosp.</td>
<td>2</td>
<td>139,000</td>
</tr>
<tr>
<td>Case Western Reserve.</td>
<td>2</td>
<td>179,532</td>
</tr>
<tr>
<td>Cell &amp; Tissue Systems, Inc.</td>
<td>2</td>
<td>76,902</td>
</tr>
<tr>
<td>Ctr. for Public Service Communications</td>
<td>2</td>
<td>66,945</td>
</tr>
<tr>
<td>Chas. Cty. School Dist.</td>
<td>1</td>
<td>11,678</td>
</tr>
<tr>
<td>Charleston Research Inst.</td>
<td>1</td>
<td>6,598</td>
</tr>
<tr>
<td>Childrens Hosp. Research</td>
<td>1</td>
<td>60,000</td>
</tr>
<tr>
<td>Childrens Trust of SC</td>
<td>1</td>
<td>207,316</td>
</tr>
<tr>
<td>City College of New York</td>
<td>1</td>
<td>42,974</td>
</tr>
<tr>
<td>Clemson Univ.</td>
<td>6</td>
<td>296,008</td>
</tr>
<tr>
<td>Coll. of Charleston</td>
<td>7</td>
<td>121,532</td>
</tr>
<tr>
<td>Dartmouth Coll.</td>
<td>1</td>
<td>14,025</td>
</tr>
<tr>
<td>Duke Univ.</td>
<td>11</td>
<td>735,596</td>
</tr>
<tr>
<td>Emory Univ.</td>
<td>6</td>
<td>388,924</td>
</tr>
<tr>
<td>GOG</td>
<td>1</td>
<td>86,110</td>
</tr>
<tr>
<td>GA Health Sciences Univ.</td>
<td>1</td>
<td>20,532</td>
</tr>
<tr>
<td>Harvard University</td>
<td>1</td>
<td>36,875</td>
</tr>
<tr>
<td>Henry M. Jackson Fdn.</td>
<td>1</td>
<td>102,986</td>
</tr>
<tr>
<td>Hermes, LLC</td>
<td>1</td>
<td>48,500</td>
</tr>
<tr>
<td>Johns Hopkins Univ.</td>
<td>7</td>
<td>626,100</td>
</tr>
<tr>
<td>LAM Foundation</td>
<td>1</td>
<td>45,005</td>
</tr>
<tr>
<td>Loyola University Chicago</td>
<td>2</td>
<td>1,022,537</td>
</tr>
<tr>
<td>Mass. General Hosp.</td>
<td>2</td>
<td>130,127</td>
</tr>
<tr>
<td>Medical Coll. of Wisconsin</td>
<td>2</td>
<td>102,995</td>
</tr>
<tr>
<td>Miriam Hospital</td>
<td>1</td>
<td>7,807</td>
</tr>
<tr>
<td>Moffitt Cancer Center</td>
<td>1</td>
<td>30,246</td>
</tr>
<tr>
<td>Morehouse School of Medicine</td>
<td>1</td>
<td>70,000</td>
</tr>
<tr>
<td>NASA Research Fdn.</td>
<td>1</td>
<td>5,260</td>
</tr>
<tr>
<td>NSABP</td>
<td>1</td>
<td>101,513</td>
</tr>
<tr>
<td>Natl. Childhood Cancer Fdn.</td>
<td>3</td>
<td>122,784</td>
</tr>
<tr>
<td>Natl. Environmental Educ. Fdn.</td>
<td>2</td>
<td>9,000</td>
</tr>
<tr>
<td>National Reach Coalition</td>
<td>1</td>
<td>112,500</td>
</tr>
<tr>
<td>New England Research Inst.</td>
<td>4</td>
<td>118,695</td>
</tr>
<tr>
<td>New York University</td>
<td>1</td>
<td>13,500</td>
</tr>
<tr>
<td>Northwestern Univ.</td>
<td>1</td>
<td>22,954</td>
</tr>
<tr>
<td>Oklahoma Univ. HSC</td>
<td>2</td>
<td>111,077</td>
</tr>
<tr>
<td>Optima Neuroscience, Inc.</td>
<td>2</td>
<td>119,053</td>
</tr>
<tr>
<td>Oregon Health Sciences Univ.</td>
<td>2</td>
<td>59,952</td>
</tr>
<tr>
<td>Q. R. Pharma</td>
<td>1</td>
<td>10,000</td>
</tr>
<tr>
<td>Radiation Therapy Oncology Group</td>
<td>1</td>
<td>109,250</td>
</tr>
<tr>
<td>Rady Childrens Hospital San Diego</td>
<td>1</td>
<td>42,087</td>
</tr>
<tr>
<td>SAIC-Frederick, Inc.</td>
<td>1</td>
<td>82,124</td>
</tr>
<tr>
<td>SC Cancer Alliance</td>
<td>1</td>
<td>8,550</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Federal Flow-Down</th>
<th># Awards</th>
<th>$ Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>SC DHEC</td>
<td>7</td>
<td>3,039,120</td>
</tr>
<tr>
<td>SC DHHS</td>
<td>2</td>
<td>36,000</td>
</tr>
<tr>
<td>SC Dept. of Public Safety</td>
<td>7</td>
<td>283,674</td>
</tr>
<tr>
<td>SC Developmental Disabilities Council</td>
<td>1</td>
<td>1,500</td>
</tr>
<tr>
<td>SC Emergency Preparedness Div.</td>
<td>2</td>
<td>4,561,953</td>
</tr>
<tr>
<td>SC Primary Health Care Assoc.</td>
<td>1</td>
<td>42,000</td>
</tr>
<tr>
<td>SC Research Authority</td>
<td>14</td>
<td>1,973,722</td>
</tr>
<tr>
<td>SC Tobacco Collaborative</td>
<td>2</td>
<td>50,000</td>
</tr>
<tr>
<td>SCUREF</td>
<td>20</td>
<td>4,023,929</td>
</tr>
<tr>
<td>Shepherd Center</td>
<td>1</td>
<td>37,347</td>
</tr>
<tr>
<td>Southwest Oncology Group</td>
<td>1</td>
<td>107,643</td>
</tr>
<tr>
<td>The Jackson Laboratory</td>
<td>1</td>
<td>31,860</td>
</tr>
<tr>
<td>Tulane Univ.</td>
<td>1</td>
<td>61,384</td>
</tr>
<tr>
<td>UT Southwestern</td>
<td>3</td>
<td>568,385</td>
</tr>
<tr>
<td>Univ. of Alabama, Birmingham</td>
<td>7</td>
<td>652,373</td>
</tr>
<tr>
<td>Univ. of California, Los Angeles</td>
<td>3</td>
<td>151,801</td>
</tr>
<tr>
<td>Univ. of California, San Diego</td>
<td>4</td>
<td>824,374</td>
</tr>
<tr>
<td>Univ. of California, San Francisco</td>
<td>5</td>
<td>97,249</td>
</tr>
<tr>
<td>Univ. of Central Florida</td>
<td>2</td>
<td>178,959</td>
</tr>
<tr>
<td>Univ. of Cincinnati</td>
<td>5</td>
<td>331,928</td>
</tr>
<tr>
<td>Univ. of Colorado</td>
<td>1</td>
<td>258,852</td>
</tr>
<tr>
<td>Univ. of Illinois, Chicago</td>
<td>3</td>
<td>164,404</td>
</tr>
<tr>
<td>Univ. of Iowa</td>
<td>2</td>
<td>33,219</td>
</tr>
<tr>
<td>Univ. of Maryland</td>
<td>11</td>
<td>158,780</td>
</tr>
<tr>
<td>Univ. of Massachusetts</td>
<td>1</td>
<td>16,846</td>
</tr>
<tr>
<td>Univ. of Massachusetts, Lowell</td>
<td>1</td>
<td>65,850</td>
</tr>
<tr>
<td>Univ. of Miami</td>
<td>1</td>
<td>1,475</td>
</tr>
<tr>
<td>Univ. of Michigan</td>
<td>4</td>
<td>142,741</td>
</tr>
<tr>
<td>Univ. of New Mexico HSC</td>
<td>1</td>
<td>110,455</td>
</tr>
<tr>
<td>Univ. of North Carolina</td>
<td>5</td>
<td>162,802</td>
</tr>
<tr>
<td>Univ. of Oklahoma</td>
<td>1</td>
<td>100,765</td>
</tr>
<tr>
<td>Univ. of Pennsylvania</td>
<td>3</td>
<td>214,992</td>
</tr>
<tr>
<td>Univ. of Pittsburgh</td>
<td>2</td>
<td>42,582</td>
</tr>
<tr>
<td>Univ. of Rochester</td>
<td>2</td>
<td>32,955</td>
</tr>
<tr>
<td>Univ. of South Carolina</td>
<td>18</td>
<td>1,424,889</td>
</tr>
<tr>
<td>Univ. of Texas</td>
<td>1</td>
<td>80,300</td>
</tr>
<tr>
<td>Univ. of Texas HSC</td>
<td>1</td>
<td>200,836</td>
</tr>
<tr>
<td>Univ. of Toledo</td>
<td>2</td>
<td>60,000</td>
</tr>
<tr>
<td>Univ. of Vermont</td>
<td>1</td>
<td>216,246</td>
</tr>
<tr>
<td>Univ. of Virginia</td>
<td>4</td>
<td>661,484</td>
</tr>
<tr>
<td>Univ. of the Virgin Islands</td>
<td>1</td>
<td>149,792</td>
</tr>
<tr>
<td>University of Waterloo</td>
<td>2</td>
<td>42,251</td>
</tr>
<tr>
<td>Veterans Education &amp; Research</td>
<td>1</td>
<td>482,489</td>
</tr>
<tr>
<td>Association of Michi</td>
<td>1</td>
<td>65,850</td>
</tr>
<tr>
<td>Washington Univ.</td>
<td>1</td>
<td>54,073</td>
</tr>
<tr>
<td>Wayne State Univ.</td>
<td>3</td>
<td>60,959</td>
</tr>
<tr>
<td>Westat</td>
<td>1</td>
<td>37,620</td>
</tr>
<tr>
<td>Yale Univ.</td>
<td>1</td>
<td>6,605</td>
</tr>
</tbody>
</table>

**Total for Federal Flow-Down (101 Agencies)** | 271     | $29,352,633 |
MUSC recognized a 13.21% increase in the federal flow-down funding category from $25.9M to $29.3 in FY 2012. Though ARRA funding for federal flow-down decreased nearly 80% ($4.2M in FY 2011 down to $883,260 in FY 2012), non ARRA funding in the federal flow-down category was up 31.42% from a year ago. Overall, MUSC secured 271 (no change from the FY 2011 total) federal flow-down awards from 101 different sponsoring organizations.

### Foundation and Other Not for Profit Funding

<table>
<thead>
<tr>
<th>Foundation/Other Non-Profit</th>
<th># Awards</th>
<th>$ Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACR Research &amp; Educ. Fdn.</td>
<td>1</td>
<td>500</td>
</tr>
<tr>
<td>AMA Foundation</td>
<td>1</td>
<td>2,500</td>
</tr>
<tr>
<td>Advocates for Youth</td>
<td>1</td>
<td>2,000</td>
</tr>
<tr>
<td>Alpha-1 Assoc.</td>
<td>1</td>
<td>65,912</td>
</tr>
<tr>
<td>Alpha-1 Fdn.</td>
<td>3</td>
<td>305,431</td>
</tr>
<tr>
<td>Alzheimers Assoc.</td>
<td>1</td>
<td>66,666</td>
</tr>
<tr>
<td>Amer. Acad. of Otolaryngology</td>
<td>1</td>
<td>8,000</td>
</tr>
<tr>
<td>Amer. Acad. of Pediatrics</td>
<td>1</td>
<td>10,460</td>
</tr>
<tr>
<td>Amer. Cancer Soc.</td>
<td>1</td>
<td>150,000</td>
</tr>
<tr>
<td>Amer. College of Gastroenterology</td>
<td>1</td>
<td>75,000</td>
</tr>
<tr>
<td>Amer. College of Rheumatology</td>
<td>2</td>
<td>1,500</td>
</tr>
<tr>
<td>Amer. Federation for Aging</td>
<td>1</td>
<td>98,500</td>
</tr>
<tr>
<td>Amer. Health Assistance Fdn.</td>
<td>1</td>
<td>133,433</td>
</tr>
<tr>
<td>Amer. Heart Assoc.</td>
<td>10</td>
<td>577,938</td>
</tr>
<tr>
<td>Amer. Heart/Mid-Atlantic</td>
<td>5</td>
<td>169,000</td>
</tr>
<tr>
<td>Amer. Soc. of Hematology</td>
<td>1</td>
<td>5,000</td>
</tr>
<tr>
<td>American Academy of Otolaryngic Allergy</td>
<td>1</td>
<td>7,500</td>
</tr>
<tr>
<td>Annie E. Casey Fdn.</td>
<td>2</td>
<td>347,527</td>
</tr>
<tr>
<td>Arthritis Fdn.</td>
<td>1</td>
<td>50,000</td>
</tr>
<tr>
<td>Autism Speaks</td>
<td>1</td>
<td>275,000</td>
</tr>
<tr>
<td>Avon Fdn.</td>
<td>1</td>
<td>110,000</td>
</tr>
<tr>
<td>Bill and Melinda Gates Fdn.</td>
<td>1</td>
<td>100,000</td>
</tr>
<tr>
<td>Blue Cross Blue Shield of SC Fdn.</td>
<td>1</td>
<td>250,000</td>
</tr>
<tr>
<td>Boston Scientific Fdn.</td>
<td>1</td>
<td>40,000</td>
</tr>
<tr>
<td>Chas. Research Inst.</td>
<td>3</td>
<td>145,068</td>
</tr>
<tr>
<td>Cicatricial Alopecia Research Fdn.</td>
<td>1</td>
<td>20,000</td>
</tr>
<tr>
<td>Coastal Community Fdn. of SC</td>
<td>1</td>
<td>2,500</td>
</tr>
<tr>
<td>Conquer Cancer Fdn.</td>
<td>1</td>
<td>66,666</td>
</tr>
<tr>
<td>Copper Development Assoc.</td>
<td>1</td>
<td>28,000</td>
</tr>
<tr>
<td>Cystic Fibrosis Fdn.</td>
<td>4</td>
<td>213,127</td>
</tr>
<tr>
<td>Dana Foundation</td>
<td>1</td>
<td>67,967</td>
</tr>
<tr>
<td>Dee Norton Lowcountry</td>
<td>1</td>
<td>448,041</td>
</tr>
<tr>
<td>Childrens Center</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diabetes Action Research and Educ. Fdn.</td>
<td>1</td>
<td>5,000</td>
</tr>
<tr>
<td>Donald W. Reynolds Fdn.</td>
<td>1</td>
<td>500,000</td>
</tr>
<tr>
<td>Duke Endowment</td>
<td>3</td>
<td>890,304</td>
</tr>
<tr>
<td>Fdn. Fighting Blindness</td>
<td>3</td>
<td>369,440</td>
</tr>
<tr>
<td>FAMRI</td>
<td>2</td>
<td>340,109</td>
</tr>
<tr>
<td>Foundation for Anesthesia</td>
<td>1</td>
<td>50,000</td>
</tr>
<tr>
<td>Friends of CARRA</td>
<td>1</td>
<td>2,000</td>
</tr>
<tr>
<td>Health Sciences SC</td>
<td>3</td>
<td>1,423,806</td>
</tr>
<tr>
<td>Helene Fuld Health Trust</td>
<td>1</td>
<td>200,000</td>
</tr>
<tr>
<td>Hispanic Association of</td>
<td>1</td>
<td>45,000</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Foundation/Other Non-Profit</th>
<th># Awards</th>
<th>$ Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Colleges &amp; Universities</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hyundai Hope on Wheels</td>
<td>1</td>
<td>50,000</td>
</tr>
<tr>
<td>Juvenile Diabetes Fdn.</td>
<td>1</td>
<td>110,000</td>
</tr>
<tr>
<td>Keep America Beautiful</td>
<td>1</td>
<td>300</td>
</tr>
<tr>
<td>Klarman Family Fdn.</td>
<td>1</td>
<td>150,000</td>
</tr>
<tr>
<td>Komen for the Cure</td>
<td>1</td>
<td>81,120</td>
</tr>
<tr>
<td>Leducq Foundation</td>
<td>3</td>
<td>311,040</td>
</tr>
<tr>
<td>Lupus Fdn. of America</td>
<td>1</td>
<td>100,000</td>
</tr>
<tr>
<td>Lupus Research Institute</td>
<td>1</td>
<td>77,071</td>
</tr>
<tr>
<td>MIND Institute</td>
<td>1</td>
<td>46,000</td>
</tr>
<tr>
<td>MUSC Fdn.</td>
<td>29</td>
<td>3,392,520</td>
</tr>
<tr>
<td>Moffitt Cancer Center</td>
<td>1</td>
<td>11,613</td>
</tr>
<tr>
<td>Natl. Film Preservation Fdn.</td>
<td>1</td>
<td>1,540</td>
</tr>
<tr>
<td>Natl. League for Nursing</td>
<td>1</td>
<td>3,150</td>
</tr>
<tr>
<td>New Morning Fdn.</td>
<td>1</td>
<td>200,000</td>
</tr>
<tr>
<td>New York Foundling</td>
<td>1</td>
<td>16,532</td>
</tr>
<tr>
<td>NA Spine Society</td>
<td>1</td>
<td>35,075</td>
</tr>
<tr>
<td>Orthopaedic Res. and Educ. Fdn.</td>
<td>1</td>
<td>7,223</td>
</tr>
<tr>
<td>Parkinsons Disease Fdn.</td>
<td>1</td>
<td>47,500</td>
</tr>
<tr>
<td>Rally Fdn.</td>
<td>1</td>
<td>20,000</td>
</tr>
<tr>
<td>Research to Prevent Blindness</td>
<td>1</td>
<td>100,000</td>
</tr>
<tr>
<td>RW Johnson Fdn.</td>
<td>2</td>
<td>199,995</td>
</tr>
<tr>
<td>Scleroderma Fdn.</td>
<td>3</td>
<td>225,000</td>
</tr>
<tr>
<td>Scoliosis Research Society</td>
<td>1</td>
<td>25,000</td>
</tr>
<tr>
<td>Seattle Childrens Hospital</td>
<td>1</td>
<td>17,646</td>
</tr>
<tr>
<td>Sigma Theta Tau</td>
<td>1</td>
<td>2,000</td>
</tr>
<tr>
<td>Soc. of Hospital Medicine</td>
<td>1</td>
<td>9,600</td>
</tr>
<tr>
<td>St. Baldricks Fdn.</td>
<td>1</td>
<td>5,000</td>
</tr>
<tr>
<td>Susan Thompson Buffet Fdn.</td>
<td>1</td>
<td>138,834</td>
</tr>
<tr>
<td>Systemic Lupus Intl</td>
<td>1</td>
<td>5,000</td>
</tr>
<tr>
<td>The Mastocytosis Society</td>
<td>1</td>
<td>52,516</td>
</tr>
<tr>
<td>Thoracic Surgery Fdn.</td>
<td>1</td>
<td>23,500</td>
</tr>
<tr>
<td>Thrasher Research Fund</td>
<td>1</td>
<td>146,099</td>
</tr>
<tr>
<td>Trident United Way</td>
<td>1</td>
<td>55,680</td>
</tr>
<tr>
<td>USC Research Foundation</td>
<td>4</td>
<td>727,878</td>
</tr>
<tr>
<td>Whitehall Foundation</td>
<td>1</td>
<td>75,000</td>
</tr>
<tr>
<td>Wound, Ostomy &amp; Continence Nurses Society</td>
<td>1</td>
<td>10,000</td>
</tr>
<tr>
<td>InTIME</td>
<td>2</td>
<td>13,100</td>
</tr>
<tr>
<td>Total for Foundation</td>
<td>145</td>
<td>$14,161,427</td>
</tr>
<tr>
<td>(79 Agencies)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Another area where MUSC experienced a significant increase was in the foundation sector. Funding derived from foundations increased from $10.6M in FY 2011 to $14.1M in FY 2012, which represented a 32.8% increase. The number of foundation awards also increased from 132 in FY 2011 to 145 in FY 2012.

**State Funding**

<table>
<thead>
<tr>
<th>State of South Carolina</th>
<th># Awards</th>
<th>$ Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clemson Univ.</td>
<td>2</td>
<td>50,620</td>
</tr>
<tr>
<td>SC DHEC</td>
<td>3</td>
<td>206,376</td>
</tr>
<tr>
<td>SC EPSCOR</td>
<td>1</td>
<td>46,152</td>
</tr>
<tr>
<td>SC Smart State COEE</td>
<td>7</td>
<td>8,940,247</td>
</tr>
<tr>
<td>SC Sea Grant Consortium</td>
<td>1</td>
<td>2,600</td>
</tr>
<tr>
<td>SC Spinal Cord Injury Fund</td>
<td>8</td>
<td>617,839</td>
</tr>
<tr>
<td>State of SC</td>
<td>4</td>
<td>5,000,000</td>
</tr>
<tr>
<td>Univ. of South Carolina</td>
<td>4</td>
<td>67,574</td>
</tr>
<tr>
<td><strong>Total for State (8 Agencies)</strong></td>
<td><strong>30</strong></td>
<td><strong>$14,931,408</strong></td>
</tr>
</tbody>
</table>

In FY 2012, state funding dropped by 37.67% to $14.9M. The total number of awards in this sector also decreased from 35 in FY 2011 to 30 in FY 2012. The majority of MUSC’s funding in this area emanates from the SmartState SC Centers of Economic Excellence program. During FY 2012, 6 MUSC researchers garnered 7 awards accounting for nearly $9M in funding to MUSC. These strategic investments by the State in these important research and development areas are working to invigorate South Carolina’s economic future.

**Corporate and Corporate Flow-Down Funding**

<table>
<thead>
<tr>
<th>Corporate</th>
<th># Awards</th>
<th>$ Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abbott Labs</td>
<td>7</td>
<td>728,712</td>
</tr>
<tr>
<td>Acclarent, Inc.</td>
<td>1</td>
<td>20,250</td>
</tr>
<tr>
<td>Actelion Pharmaceuticals</td>
<td>2</td>
<td>317,097</td>
</tr>
<tr>
<td>Adv. Cardio Systems</td>
<td>2</td>
<td>36,725</td>
</tr>
<tr>
<td>Aga Medical Corp.</td>
<td>1</td>
<td>317,822</td>
</tr>
<tr>
<td>Alcon, Inc.</td>
<td>1</td>
<td>44,631</td>
</tr>
<tr>
<td>Alexion Pharmaceuticals</td>
<td>1</td>
<td>110,977</td>
</tr>
<tr>
<td>Alimera Sciences</td>
<td>1</td>
<td>47,200</td>
</tr>
<tr>
<td>Allegro Diagnostics, Inc.</td>
<td>1</td>
<td>120,000</td>
</tr>
<tr>
<td>Allergan, Inc.</td>
<td>3</td>
<td>330,959</td>
</tr>
<tr>
<td>Amgen</td>
<td>1</td>
<td>2,500</td>
</tr>
<tr>
<td>Aptiv Solutions</td>
<td>1</td>
<td>11,800</td>
</tr>
<tr>
<td>Astellas Pharma US, Inc.</td>
<td>2</td>
<td>1,036,456</td>
</tr>
<tr>
<td>BG Medicine, Inc.</td>
<td>1</td>
<td>29,158</td>
</tr>
<tr>
<td>Bausch and Lomb</td>
<td>1</td>
<td>52,255</td>
</tr>
<tr>
<td>Baxter Health Care</td>
<td>1</td>
<td>13,150</td>
</tr>
<tr>
<td>Becton Dickinson</td>
<td>2</td>
<td>8,719</td>
</tr>
<tr>
<td>Behavioral Health Systems</td>
<td>1</td>
<td>11,625</td>
</tr>
<tr>
<td>Biosite, Inc.</td>
<td>2</td>
<td>96,556</td>
</tr>
<tr>
<td>Biosphere/Merit Medical</td>
<td>2</td>
<td>159,795</td>
</tr>
<tr>
<td>Boehringer Ingelheim</td>
<td>4</td>
<td>789,767</td>
</tr>
<tr>
<td>Boston Scientific Corp.</td>
<td>1</td>
<td>208,594</td>
</tr>
<tr>
<td>Brainway</td>
<td>3</td>
<td>99,770</td>
</tr>
<tr>
<td>Brigham &amp; Womens Hosp.</td>
<td>1</td>
<td>20,190</td>
</tr>
<tr>
<td>Bristol Myers Squibb</td>
<td>2</td>
<td>95,619</td>
</tr>
<tr>
<td>CROfessionals, LLC</td>
<td>1</td>
<td>88,645</td>
</tr>
<tr>
<td>Celgene Corp.</td>
<td>1</td>
<td>92,464</td>
</tr>
<tr>
<td>Cell and Tissue Systems</td>
<td>1</td>
<td>15,026</td>
</tr>
<tr>
<td>Cervel Neuro Tech Inc.</td>
<td>3</td>
<td>535,840</td>
</tr>
<tr>
<td>Chiltemn International, Inc.</td>
<td>1</td>
<td>203,139</td>
</tr>
<tr>
<td>Cincinnati Childrens Hosp.</td>
<td>1</td>
<td>94,342</td>
</tr>
<tr>
<td>Clemson Univ.</td>
<td>1</td>
<td>72,611</td>
</tr>
<tr>
<td>Clinical Financial Services</td>
<td>3</td>
<td>220,532</td>
</tr>
<tr>
<td>Clinpace, Inc.</td>
<td>2</td>
<td>93,723</td>
</tr>
<tr>
<td>Codman and Shurtleff, Inc.</td>
<td>2</td>
<td>39,503</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Corporate</th>
<th># Awards</th>
<th>$ Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Colorado Prevention Ctr.</td>
<td>1</td>
<td>36,914</td>
</tr>
<tr>
<td>Cook, Inc.</td>
<td>3</td>
<td>17,923</td>
</tr>
<tr>
<td>Core Sciences Solutions</td>
<td>1</td>
<td>96,090</td>
</tr>
<tr>
<td>Covance, Inc.</td>
<td>4</td>
<td>573,269</td>
</tr>
<tr>
<td>Cubist Pharmaceuticals</td>
<td>1</td>
<td>45,575</td>
</tr>
<tr>
<td>CytoPherx, Inc.</td>
<td>1</td>
<td>267,000</td>
</tr>
<tr>
<td>Diagnostica Stago, Inc.</td>
<td>1</td>
<td>175,938</td>
</tr>
<tr>
<td>Dialysis Clinics, Inc.</td>
<td>4</td>
<td>566,756</td>
</tr>
<tr>
<td>Duke Clinical Research Inst.</td>
<td>1</td>
<td>186,500</td>
</tr>
<tr>
<td>Duke Univ.</td>
<td>3</td>
<td>156,250</td>
</tr>
<tr>
<td>Dyax Corp.</td>
<td>1</td>
<td>179,950</td>
</tr>
<tr>
<td>Dynavax Technologies</td>
<td>2</td>
<td>105,507</td>
</tr>
<tr>
<td>Edge Therapeutics, Inc.</td>
<td>1</td>
<td>34,000</td>
</tr>
<tr>
<td>Edison Pharmaceuticals</td>
<td>1</td>
<td>307,219</td>
</tr>
<tr>
<td>Edwards Lifesciences</td>
<td>1</td>
<td>186,500</td>
</tr>
<tr>
<td>Eisai, Inc.</td>
<td>3</td>
<td>239,769</td>
</tr>
<tr>
<td>Eli Lilly</td>
<td>6</td>
<td>504,605</td>
</tr>
<tr>
<td>Endo Pharmaceuticals Inc</td>
<td>1</td>
<td>276,887</td>
</tr>
<tr>
<td>Endocyte, Inc.</td>
<td>1</td>
<td>1,800</td>
</tr>
<tr>
<td>Endosense, Inc.</td>
<td>1</td>
<td>59,325</td>
</tr>
<tr>
<td>Epigenomics, Inc.</td>
<td>1</td>
<td>3,000</td>
</tr>
<tr>
<td>Exalenz Bioscience Ltd.</td>
<td>1</td>
<td>33,750</td>
</tr>
<tr>
<td>Fibro Therapeutics, Inc.</td>
<td>1</td>
<td>30,000</td>
</tr>
<tr>
<td>Fox Chase Cancer Center</td>
<td>1</td>
<td>26,009</td>
</tr>
<tr>
<td>GE Healthcare, Inc.</td>
<td>1</td>
<td>152,256</td>
</tr>
<tr>
<td>GTX, Inc.</td>
<td>1</td>
<td>60,540</td>
</tr>
<tr>
<td>Galil Medical Inc.</td>
<td>1</td>
<td>30,235</td>
</tr>
<tr>
<td>Gen-Probe Inc.</td>
<td>1</td>
<td>6,000</td>
</tr>
<tr>
<td>Genentech, Inc.</td>
<td>4</td>
<td>3,244,002</td>
</tr>
<tr>
<td>Georgetown University</td>
<td>1</td>
<td>15,000</td>
</tr>
<tr>
<td>Gilead Sciences, Inc.</td>
<td>4</td>
<td>446,012</td>
</tr>
<tr>
<td>GlaxoSmithKline</td>
<td>6</td>
<td>2,358,263</td>
</tr>
<tr>
<td>Global Life Technologies</td>
<td>1</td>
<td>33,125</td>
</tr>
<tr>
<td>Globus Medical, Inc.</td>
<td>2</td>
<td>1,179,450</td>
</tr>
<tr>
<td>Halimed Pharmaceuticals</td>
<td>1</td>
<td>6,000</td>
</tr>
</tbody>
</table>
For the second straight fiscal year MUSC’s corporate funding sector recognized a significant increase (up 36.2%). This increase includes both direct and flow-through funding from corporate entities. Though the total number of awards decreased slightly from 374 in FY 2011 to 363 in FY 2012, the funding level grew from $35.2M in FY 2011 to just over $48M in FY 2012. Some of MUSC’s largest direct corporate projects in FY 2012 were funded by Penumbra, Inc., Weight Watchers International, Inc., GlaxoSmithKline, Genentech, Inc., and Siemens Medical Solutions USA.
## Other Support

<table>
<thead>
<tr>
<th>Other Support</th>
<th># Awards</th>
<th>$ Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Atomic Energy of Canada</td>
<td>1</td>
<td>15,000</td>
</tr>
<tr>
<td>District of Columbia</td>
<td>2</td>
<td>134,583</td>
</tr>
<tr>
<td>Indiana University</td>
<td>1</td>
<td>20,000</td>
</tr>
<tr>
<td>Johns Hopkins Univ.</td>
<td>2</td>
<td>59,604</td>
</tr>
<tr>
<td>Margaret B. Plowden</td>
<td>1</td>
<td>100,000</td>
</tr>
<tr>
<td>New York University</td>
<td>1</td>
<td>7,262</td>
</tr>
<tr>
<td>Purdue University</td>
<td>1</td>
<td>50,000</td>
</tr>
</tbody>
</table>

Total for Other Support (10 Agencies) | 12 | $490,093

<table>
<thead>
<tr>
<th>Other Support</th>
<th># Awards</th>
<th>$ Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>UT Southwestern</td>
<td>1</td>
<td>45,219</td>
</tr>
<tr>
<td>Univ. of Vermont</td>
<td>1</td>
<td>17,600</td>
</tr>
<tr>
<td>Univ. of Waterloo</td>
<td>1</td>
<td>40,825</td>
</tr>
</tbody>
</table>

Total for Other Support (10 Agencies) | 12 | $490,093
College and Department Summary

Administration

University Administration received 56 awards in FY 2012, an increase of 15 from the previous year. Similarly overall funding increased by $5.46M, or 61.7%, due to the increases achieved in nearly every sector of funding (corporate, federal, federal flow-down and foundation). State funding was the only area wherein Administration experienced a slight decline, down just $13,351 from a year ago.

Nursing

The College of Nursing obtained 28 awards in FY 2012, down 6 from the FY 2011 total. Overall funding in the College was $4.35M, a $1.97M decline. Decreases were experienced in all funding sectors. Most of these declines from the prior year can be explained by the extraordinary funding levels experienced by the College in the previous year.

College of Medicine

The College of Medicine had a decrease of 52 awards for a total of 1,095 in FY 2012. This decrease in awards resulted in a 4.7% reduction in overall funding, still accounting for over $204.9M in overall funding for the College. Corporate (up $12.6M, or 36.45%), federal flow-down (up $556,565, or 2.44%) foundation (up $2.6M, or 30.91%) and other (up $106,699, or 27.83%) sectors all increased in funding from the previous year. These gains did not offset the decreases experienced in the federal (down $17.8M, or 14.14%) and state (down $8.3M, or 36.52%) sectors of funding. Most of the decrease in the direct federal funding category can be explained by the reduction of ARRA funding. The College received just 3 (down 27 from FY 2011) ARRA funded awards in the direct federal funding category representing $2.18M, down $11.3M from the ARRA funding levels of the prior year.
Dental Medicine

The College of Dental Medicine received 13 awards in FY 2012, 1 more than the previous year. Total funding for the College decreased by 48.61% to $2.14M for the year. The majority of this decrease occurred in the direct federal funding sector which was down $2.23M (53.9%) from a year ago. This decline can be attributed to the fact that a large NIH P-20 grant, previously awarded to the College, was under competitive-renewal review during FY 2012 and resulted in a renewal award (a P-30 award) in early FY 2013. The College experienced some gains in the corporate and federal flow-down areas, while the other sectors either slightly decreased or remained unchanged from a year ago.

Pharmacy

The College of Pharmacy received 21 awards in FY 2012, up 1 award from last year. Overall funding in the College was down 35.10% to $2.79M. This decline in funding from a year ago occurred in nearly all funding sectors, with the exception of the federal flow-down category which was up significantly over last year’s level in the College.

College of Health Related Professions

The College of Health Related Professions obtained 28 awards in FY 2012, up 2 from the previous year. Overall funding in the College was down by 14.9% to a $3.49M funding level for the year. While the College experienced significant increases in corporate, foundation and federal flow-down areas, these gains did not offset decreases recognized in the direct federal and state funding sectors. Most of the overall funding decline in the College can be attributed to reductions in ARRA funded awards. ARRA funding awarded the College dropped by nearly $775K in FY 2012.
# Proposal and Award Summary by College and Department

<table>
<thead>
<tr>
<th>Colleges Departments</th>
<th>Proposals</th>
<th>Awards</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td># Submitted</td>
<td>$ Submitted</td>
</tr>
<tr>
<td><strong>Administration</strong></td>
<td>40</td>
<td>8,656,068</td>
</tr>
<tr>
<td>Academic Affairs/Provost</td>
<td>5</td>
<td>306,658</td>
</tr>
<tr>
<td>Assoc. Provost for Research</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Chief Operations Officer</td>
<td>2</td>
<td>1,300</td>
</tr>
<tr>
<td>Library Science &amp; Informatics</td>
<td>23</td>
<td>692,663</td>
</tr>
<tr>
<td>Physical Plant</td>
<td>1</td>
<td>500</td>
</tr>
<tr>
<td>President's Office</td>
<td>2</td>
<td>1,919,328</td>
</tr>
<tr>
<td>Risk Management</td>
<td>2</td>
<td>4,561,953</td>
</tr>
<tr>
<td>SC AHEC</td>
<td>5</td>
<td>1,173,666</td>
</tr>
<tr>
<td><strong>Dental Medicine</strong></td>
<td>27</td>
<td>7,655,556</td>
</tr>
<tr>
<td>Craniofacial Biology</td>
<td>20</td>
<td>6,923,856</td>
</tr>
<tr>
<td>Dental Medicine</td>
<td>3</td>
<td>91,528</td>
</tr>
<tr>
<td>Pediatric Dentistry &amp; Orthodontics</td>
<td>2</td>
<td>60,208</td>
</tr>
<tr>
<td>Restorative Dentistry</td>
<td>1</td>
<td>395,589</td>
</tr>
<tr>
<td>Stomatology</td>
<td>1</td>
<td>184,375</td>
</tr>
<tr>
<td><strong>Graduate Studies</strong></td>
<td>2</td>
<td>96,819</td>
</tr>
<tr>
<td><strong>Health Professions</strong></td>
<td>36</td>
<td>7,707,410</td>
</tr>
<tr>
<td>Health Administration &amp; Policy</td>
<td>1</td>
<td>126,969</td>
</tr>
<tr>
<td>Health Professions</td>
<td>8</td>
<td>1,758,210</td>
</tr>
<tr>
<td>Health Sciences &amp; Research</td>
<td>27</td>
<td>5,822,231</td>
</tr>
<tr>
<td><strong>Medicine</strong></td>
<td>1,533</td>
<td>353,634,897</td>
</tr>
<tr>
<td>Anesthesia &amp; Perioperative Med.</td>
<td>9</td>
<td>1,909,595</td>
</tr>
<tr>
<td>Biochemistry &amp; Molecular Biology</td>
<td>63</td>
<td>16,796,434</td>
</tr>
<tr>
<td>Cell &amp; Molecular Pharmacology</td>
<td>43</td>
<td>10,310,654</td>
</tr>
<tr>
<td>Comparative Medicine</td>
<td>6</td>
<td>251,409</td>
</tr>
<tr>
<td>Dean's Office</td>
<td>4</td>
<td>967,883</td>
</tr>
<tr>
<td>Dermatology</td>
<td>1</td>
<td>125,000</td>
</tr>
<tr>
<td>Family Medicine</td>
<td>21</td>
<td>3,384,545</td>
</tr>
<tr>
<td>Medicine</td>
<td>409</td>
<td>97,875,666</td>
</tr>
<tr>
<td>Microbiology &amp; Immunology</td>
<td>74</td>
<td>17,696,433</td>
</tr>
<tr>
<td>Neurosciences</td>
<td>187</td>
<td>39,748,324</td>
</tr>
<tr>
<td>Obstetrics &amp; Gynecology</td>
<td>26</td>
<td>9,352,293</td>
</tr>
<tr>
<td>Ophthalmology</td>
<td>27</td>
<td>4,830,540</td>
</tr>
<tr>
<td>Orthopaedic Surgery</td>
<td>6</td>
<td>1,306,061</td>
</tr>
<tr>
<td>Otolaryngology</td>
<td>39</td>
<td>7,249,656</td>
</tr>
<tr>
<td>Pathology &amp; Laboratory Med.</td>
<td>52</td>
<td>10,528,667</td>
</tr>
<tr>
<td>Pediatrics</td>
<td>109</td>
<td>16,060,914</td>
</tr>
<tr>
<td>Psychiatry &amp; Behavioral Sc.</td>
<td>244</td>
<td>70,485,642</td>
</tr>
<tr>
<td>Radiation Oncology</td>
<td>4</td>
<td>544,823</td>
</tr>
<tr>
<td>Radiology</td>
<td>45</td>
<td>8,855,221</td>
</tr>
<tr>
<td>Regenerative Med. &amp; Cell Biology</td>
<td>94</td>
<td>23,850,784</td>
</tr>
<tr>
<td>Surgery</td>
<td>58</td>
<td>9,544,410</td>
</tr>
<tr>
<td>Urology</td>
<td>12</td>
<td>1,959,943</td>
</tr>
<tr>
<td><strong>Nursing</strong></td>
<td>52</td>
<td>12,674,028</td>
</tr>
<tr>
<td><strong>Pharmacy</strong></td>
<td>39</td>
<td>8,992,813</td>
</tr>
<tr>
<td>Drug Discovery &amp; Biomedical Sc.</td>
<td>36</td>
<td>8,933,656</td>
</tr>
<tr>
<td>Pharmacy &amp; Clinical Sciences</td>
<td>3</td>
<td>59,157</td>
</tr>
<tr>
<td><strong>Grand Totals</strong></td>
<td>1,729</td>
<td>$399,417,591</td>
</tr>
</tbody>
</table>
RESEARCH FACULTY ACTIVITY FY 2012

Administration

Academic Affairs/Provost

Lanier, Stephen
Principal Investigator
SmartState Endowed Chair in Health Informatics Quality and Safety Evaluation at USC
MUSC Fdn.
Budget Dates: 07/01/11 - 06/30/13
Project Dates: 07/01/10 - 06/30/13
Direct F & A Total
39,072 0 39,072

SmartState Endowed Chair in Translational Cancer Therapeutics
MUSC Fdn.
Budget Dates: 07/01/11 - 06/30/13
Project Dates: 07/01/10 - 06/30/13
Direct F & A Total
77,642 0 77,642

SmartState Endowed Chair in Stroke USC
MUSC Fdn.
Budget Dates: 07/01/11 - 06/30/13
Project Dates: 07/01/10 - 06/30/13
Direct F & A Total
78,889 0 78,889

SmartState Center for Vision Science Research at USC
MUSC Fdn.
Budget Dates: 07/01/11 - 06/30/12
Project Dates: 07/01/11 - 06/30/12
Direct F & A Total
57,346 0 57,346

Assoc. Provost for Research

Sullivan, Joann
Principal Investigator
South Carolina NASA Space Grant
Coll. of Charleston
Budget Dates: 06/25/12 - 06/24/13
Project Dates: 06/25/10 - 06/24/15
Direct F & A Total
3,000 0 3,000

Chief Operations Officer

Malmrose, John
Principal Investigator
FY2012 Collegiate Recycling Grant
SC DHEC
Budget Dates: 08/26/11 - 06/30/12
Project Dates: 08/26/11 - 06/30/12
Direct F & A Total
1,000 0 1,000

Recyclemania Grant 2012
Keep America Beautiful
Budget Dates: 02/01/12 - 03/31/12
Project Dates: 02/01/12 - 03/31/12
Direct F & A Total
300 0 300

Library Science and Informatics

Buff, Scotty
Co-PI/Project Director
SE VIEW Phase II (JDOH)
Pl: Sabra Slaughter Sponsor: DOD Total: $ 257,967
Dept: Presidents Office Award: W81XWH-11-2-0164 (12030345-3)

Fox, Elizabeth
Principal Investigator
Research on Film: The Experiment of Robert Petrie Walton, M.D., Ph.D.
National Film Preservation Foundation
Budget Dates: 10/01/11 - 12/03/12
Project Dates: 10/01/11 - 12/03/12
Direct F & A Total
1,540 0 1,540

Hazard, E.
Co-Investigator
NSF EPSCoR RII Track 2: Cyberinfrastructure
Pl: Stephen Lanier Sponsor: SC Research Authority Total: $ 192,801
Dept: Cell and Molecular Pharmacology Award: EPS-0919440 (08121730-3)

Hill, Monique
Principal Investigator
Express Exhibit Award
Univ. of Maryland
Budget Dates: 09/14/11 - 02/10/12
Project Dates: 09/14/11 - 02/10/12
Direct F & A Total
1,987 0 1,987

Express Exhibit Award 46 (12010126)
### Hill, Monique

**Principal Investigator**

<table>
<thead>
<tr>
<th>Exhibit Award: Diabetes Fall Symposium, SC Library Assn, Greenville County Health Fair</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Univ. of Maryland</strong> Budget Dates: 09/14/11 - 04/28/12</td>
</tr>
<tr>
<td>Direct F &amp; A Total</td>
</tr>
<tr>
<td>EEA-45 (12020189) Project Dates: 09/14/11 - 04/28/12</td>
</tr>
<tr>
<td>2,000 0 2,000</td>
</tr>
</tbody>
</table>

**Exhibit: SC HIV/STD Conference, School Nurse Conference Yr3**

| **Univ. of Maryland** Budget Dates: 05/01/12 - 04/30/13 |
| Direct F & A Total |
| EEA 189 (12091204) Project Dates: 05/01/12 - 04/30/13 |
| 2,000 0 2,000 |

**Exhibit: SC's Family Connection Conf, School Non-Profit Assoc Conf**

| **Univ. of Maryland** Budget Dates: 05/01/12 - 04/30/13 |
| Direct F & A Total |
| EEA 210 (12091205) Project Dates: 05/01/12 - 04/30/13 |
| 2,000 0 2,000 |

**Exhibit: SC Public Health Assoc Conference, SC Campaign to Prevent Teen Pregnancy**

| **Univ. of Maryland** Budget Dates: 05/01/12 - 04/30/13 |
| Direct F & A Total |
| EEA 211 (12091206) Project Dates: 05/01/12 - 04/30/13 |
| 2,000 0 2,000 |

### Mauldin, Mary

**Principal Investigator**

**Information Technology and Policy Awareness - Tech Fair**

| **Univ. of Maryland** Budget Dates: 09/14/11 - 04/30/12 |
| Direct F & A Total |
| Award 78 (12030416) Project Dates: 09/14/11 - 04/30/12 |
| 4,800 0 4,800 |

**Co-Investigator**

**TF-CBT for Adjudicated Youth in Residential Treatment**

| PI: Benjamin Saunders Sponsor: Allegheny-Singer Research In Total: $ 46,322 |
| Dept: Psychiatry and Behavioral Sciences Award: R01 MH095208-01 (10111770-1) |

**Development and Evaluation of an Online Dental Student Alcohol Curriculum**

| PI: Peter Miller Sponsor: NIH/NIAAA Total: $ 148,926 |
| Dept: Psychiatry and Behavioral Sciences Award: 5R25AA019647-02 (12070956-1) |

**TF-CBT for Adjudicated Youth in Residential Treatment**

| PI: Benjamin Saunders Sponsor: Allegheny-Singer Research In Total: $ 35,465 |
| Dept: Psychiatry and Behavioral Sciences Award: R01MH096206-02 (12091189-1) |

### Moorer, Candace

**Principal Investigator**

**Mobile Health Information Initiatives: Reaching Rural and Underserved Communities Project**

| **Univ. of Maryland** Budget Dates: 09/14/11 - 04/30/12 |
| Direct F & A Total |
| EMTA-48 (12030400) Project Dates: 09/14/11 - 04/30/12 |
| 5,000 0 5,000 |

**Express Outreach: Improving Health Literacy Project**

| **Univ. of Maryland** Budget Dates: 05/01/12 - 04/30/13 |
| Direct F & A Total |
| EOPA 193 (12091220) Project Dates: 05/01/12 - 04/30/13 |
| 6,000 0 6,000 |

### Rivers, David

**Principal Investigator**

**Corp. Support - National Conference on Health Disparities**

| Multiple Sponsors Budget Dates: 02/01/07 - 12/31/11 |
| Direct F & A Total |
| Conference (07012513) Project Dates: 02/01/07 - 12/31/11 |
| 219,750 0 219,750 |

**Corp. Support - Nuclear Energy Conference**

| Multiple Sponsors Budget Dates: 03/01/08 - 12/31/16 |
| Direct F & A Total |
| Conference (09022189) Project Dates: 03/01/08 - 12/31/16 |
| 66,615 0 66,615 |

**Community Leaders Institute, Mod. #4**

| DOE Budget Dates: 10/01/11 - 09/30/12 |
| Direct F & A Total |
| DE-LM0000122 (11032167) Project Dates: 10/01/11 - 09/30/12 |
| 171,919 44,699 216,618 |

**A Collaborative Response to Public Health Challenges Linked to Climate Change Impacts in the Virgin Islands and the Caribbean**

| Univ. of the Virgin Islands Budget Dates: 09/21/11 - 06/30/12 |
| Direct F & A Total |
| CERC-MUSC-2011 (11041377) Project Dates: 09/21/11 - 06/30/12 |
| 118,882 30,910 149,792 |

**Community Leaders Institute**

| DOE Budget Dates: 10/01/09 - 09/30/12 |
| Direct F & A Total |
| DE-LM0000122 (11120257) Project Dates: 10/01/09 - 09/30/12 |
| 21,683 5,638 27,321 |
### Presidents Office

#### Greenberg, Raymond

**Principal Investigator**
Charleston Area eHealth Alliance
MUSC Fdn.
6146-C (09010879)  
**Budget Dates:** 11/24/08 - 12/30/12  
**Project Dates:** 11/24/08 - 12/30/12  
**Direct F & A** 200,000  
**Total** 200,000

**Expansion of the Regionalized Health Information Network (CeHA)**
MUSC Fdn.
6335-C (13030317)  
**Budget Dates:** 01/01/12 - 12/31/13  
**Project Dates:** 01/01/12 - 12/31/13  
**Direct F & A** 600,000  
**Total** 600,000

#### Higerd, Thomas

**Principal Investigator**
Program Administration Core
SC Spinal Cord Injury Fund
(02090301)  
**Budget Dates:** 07/01/11 - 06/30/12  
**Project Dates:** 07/01/02 - 06/30/12  
**Direct F & A** 51,625  
**Total** 51,625

#### Slaughter, Sabra

**Principal Investigator**
Southeastern Virtual Institute for Health Equity and Wellness (SE VIEW)- Project
US Army/USAMRAA
W81XWH-10-2-0057 (10071968)  
**Budget Dates:** 07/01/10 - 07/01/13  
**Project Dates:** 07/01/10 - 07/01/13  
**Direct F & A** 2,900,949  
**Total** 1,344,718  
**Total** 4,245,667

**SE VIEW Phase II**
DOD
W81XWH-11-2-0164 (12030345)  
**Budget Dates:** 09/01/11 - 09/30/14  
**Project Dates:** 09/01/11 - 09/30/14  
**Direct F & A** 1,300,529  
**Total** 614,664  
**Total** 1,915,193

**Co-PI/Project Director**
A Collaborative Response to Public Health Challenges Linked to Climate Change Impacts in the Virgin Islands and the Caribbean
**Pl:** David Rivers  
**Sponsor:** Univ. of the Virgin Islands  
**Total:** $ 149,792

**Dept:** Library Science and Informatics  
**Award:** CERC-MUSC-2011 (11041377-1)

### Risk Management

#### Brannan, Wayne

**Principal Investigator**
Pre-Disaster Mitigation Grant for MUHA
SC Emergency Preparedness Div.
(12040538)  
**Budget Dates:** 09/27/11 - 10/30/14  
**Project Dates:** 10/27/10 - 09/30/14  
**Direct F & A** 3,000,000  
**Total** 3,000,000

**Pre-Disaster Mitigation Grant for University**
SC Emergency Preparedness Div.
(12040539)  
**Budget Dates:** 09/21/11 - 09/30/14  
**Project Dates:** 09/21/11 - 09/30/14  
**Direct F & A** 1,561,953  
**Total** 1,561,953
SC AHEC

Carson, Deborah

**Principal Investigator**

SC Search Program

SC Primary Health Care Assoc.

Budget Dates: 09/30/11 - 09/29/12

Direct F & A Total

HHSH250200900037C (10012243)

Project Dates: 10/01/09 - 09/29/12

38,889 3,111 42,000

Co-PI/Project Director

Palmetto State Geriatric Education Centers

PI: David Garr

Sponsor: Univ. of South Carolina

Total: $59,000

Dept: SC AHEC

Award: 12-2014/UB4HP19212 (12020179-1)

Garr, David

**Principal Investigator**

SC Office Healthcare Workforce Analysis and Planning

Duke Endowment

Budget Dates: 12/01/11 - 11/30/12

Direct F & A Total

6155-SPC (08061639)

Project Dates: 11/04/08 - 11/30/12

511,804 0 511,804

Palmetto State Geriatric Education Centers

Univ. of South Carolina

Budget Dates: 07/01/11 - 07/31/12

Direct F & A Total

12-2014/UB4HP19212 (12020179)

Project Dates: 07/01/10 - 06/30/15

54,630 4,370 59,000

Model State Supported AHEC Program

HRSA

Budget Dates: 09/01/11 - 08/31/12

Direct F & A Total

6 U77HP03019-18-01 (12040478)

Project Dates: 09/30/09 - 08/31/12

395,546 4,970 400,516

Recruitment and Retention of Future Health Professionals: Bridging the Gap in the Education Pipeline

Duke Endowment

Budget Dates: 11/08/11 - 11/07/12

Direct F & A Total

6340-SP (12050648)

Project Dates: 11/08/11 - 11/08/14

250,000 0 250,000
## RESEARCH FACULTY ACTIVITY FY 2012

### Craniofacial Biology

#### Buff, Amanda
- **Principal Investigator**
- **pGlcNAc Stimulates Wound Healing and Defensin Expression via AKT1**
- **NIH/NIDCR**
- **Budget Dates:** 07/01/11 - 06/30/12
- **Project Dates:** 07/01/11 - 06/30/14
- **Direct F & A:** 42,045
- **Total:** 42,045

#### DeFee, Michael
- **Principal Investigator**
- **The Role of Cell Surface Heat Shock Protein 90 in KSHV Pathogenesis**
- **NIH/NIDCR**
- **Budget Dates:** 12/01/11 - 11/30/12
- **Project Dates:** 12/01/09 - 11/30/13
- **Direct F & A:** 48,032
- **Total:** 48,032

#### Jakymiw, Andrew
- **Principal Investigator**
- **RNA Silencing in the Oral Cavity**
- **NIH/NIDCR**
- **Budget Dates:** 09/01/11 - 06/30/12
- **Project Dates:** 09/15/10 - 08/31/13
- **Direct F & A:** 162,259
- **Total:** 239,332

#### Kirkwood, Keith
- **Principal Investigator**
- **Training in Craniofacial and Oral Health Research**
- **NIH/NIDCR**
- **Budget Dates:** 07/01/11 - 06/30/12
- **Project Dates:** 07/01/06 - 06/30/16
- **Direct F & A:** 501,446
- **Total:** 530,113

- **Post-Transcriptional Regulation of Periodontal Disease**
- **NIH/NIDCR**
- **Budget Dates:** 07/01/11 - 06/30/12
- **Project Dates:** 07/01/11 - 06/30/16
- **Direct F & A:** 250,000
- **Total:** 368,750

- **T-COHR: Summer Undergraduate Research Program**
- **NIH/NIDCR**
- **Budget Dates:** 05/15/12 - 05/31/13
- **Project Dates:** 05/15/12 - 05/31/17
- **Direct F & A:** 48,781
- **Total:** 52,683

- **Multi-Center, Phase 3, Trial of Minocycline HCl 1mg Microsphere for Use in Subjects with Peri-Implantitis: Clinical and Microbiological Evaluations**
- **OraPharma, Inc.**
- **Budget Dates:** 01/30/12 - 02/14/13
- **Project Dates:** 01/30/12 - 09/14/13
- **Direct F & A:** 49,730
- **Total:** 61,412

- **Integrating Biomechanics and Cell Biology to Understand TMJ Pathology**
- **Clemson Univ.**
- **Budget Dates:** 03/06/12 - 02/28/13
- **Project Dates:** 03/06/12 - 02/28/17
- **Direct F & A:** 99,159
- **Total:** 146,260

#### Pilcher, Elizabeth
- **Principal Investigator**
- **Postdoctoral Training in General, Pediatric and Public Health Dentistry and Dental Hygiene**
- **HRSA**
- **Budget Dates:** 07/01/11 - 06/30/12
- **Project Dates:** 09/01/10 - 06/30/15
- **Direct F & A:** 331,740
- **Total:** 358,279

#### Ravenel, Michele
- **Co-Investigator**
- **Development and Evaluation of an Online Dental Student Alcohol Curriculum**
- **NIH/NIAAA**
- **Budget Dates:** 06/29/12 - 06/28/14
- **Project Dates:** 06/29/12 - 06/28/14
- **Direct F & A:** 148,926
- **Total:** 148,926

#### Sentelle, Richard
- **Principal Investigator**
- **Role of Ceramide in Inducing Lethal Autophagy in Head and Neck Cancer**
- **NIH/NIDCR**
- **Budget Dates:** 09/01/11 - 08/31/12
- **Project Dates:** 09/01/10 - 08/31/13
- **Direct F & A:** 47,600
- **Total:** 47,600
Westwater, Caroline  
**Co-Investigator**  
**Post-Transcriptional Regulation of Periodontal Disease**  
*PI: Keith Kirkwood  Sponsor: NIH/NIDCR  Total: $368,750  Dept: Craniofacial Biology  Award: 1R01DE021423-01A1 (10110528-1)*

---

**Dental Medicine**

Zhang, Xiaoyi  
**Principal Investigator**  
**The Role of Mitogen-Activated Protein Kinase Phosphatase-1 in Tumor Progression**  
*AMA Foundation  Budget Dates: 03/01/12 - 02/28/13  Direct F & A Total  (12121666)  Project Dates: 03/01/12 - 02/28/13  2,500 0 2,500*

---

**Pediatric Dentistry and Orthodontics**

Salinas, Carlos  
**Principal Investigator**  
**Craniofacial Anomalies and Cleft Lip and Palate Tea**  
*SC DHEC  Budget Dates: 07/01/11 - 06/30/12  Direct F & A Total  (12010118)  Project Dates: 04/15/00 - 06/30/12  28,015 2,193 30,208*

---

**Stomatology**

Leite, Renata  
**Principal Investigator**  
**Hollywood Smiles**  
*NIDCR  Budget Dates: 08/01/11 - 07/31/12  Direct F & A Total  (11051106)  Project Dates: 08/01/11 - 07/31/13  150,000 71,250 221,250*

---

**Co-PI/Project Director**  
**SE VIEW Phase II (CBPR)**  
*PI: Sabra Slaughter  Sponsor: DOD  Total: $239,938  Dept: Presidents Office  Award: W81XWH-11-2-0164 (12030345-9)*

---

**Co-Investigator**  
**Post-Transcriptional Regulation of Periodontal Disease**  
*PI: Keith Kirkwood  Sponsor: NIH/NIDCR  Total: $368,750  Dept: Craniofacial Biology  Award: 1R01DE021423-01A1 (10110528-1)*

---

**Robust Nonparametric Methods with Variable Selection for Clustered Dental Data**  
*PI: Dipankar Bandyopadhyay  Sponsor: NIH/NIDCR  Total: $142,239  Dept: Medicine  Award: 5R03DE020114-02 (11051212-1)*

---

**Robust Nonparametric Methods with Variable Selection for Clustered Dental Data**  
*PI: Dipankar Bandyopadhyay  Sponsor: NIH/NIDCR  Total: $1,436  Dept: Medicine  Award: 5R03DE020114-02 (11051212-2)*

---

**Multi-Center, Phase 3, Trial of Minocycline HCl 1mg Microsphere for Use in Subjects with Peri-Implantitis: Clinical and Microbiological Evaluations**  
*PI: Keith Kirkwood  Sponsor: OraPharma, Inc.  Total: $61,412  Dept: Craniofacial Biology  Award: OP-P-5266-M (12081057-1)*

---

**The Effect of Statin on Diabetes-Associated Perodontal Disease**  
*PI: Yan Huang  Sponsor: NIH/NIDCD  Total: $365,063  Dept: Medicine  Award: 5R01DE016353-08 (12091250-1)*
# RESEARCH FACULTY ACTIVITY FY 2012

## College of Graduate Studies

### Graduate Studies

Parker, Anthony  
**Principal Investigator**  

<table>
<thead>
<tr>
<th>Estimation of Periodontal Disease Progression in the Presence of Diagnostic Error</th>
</tr>
</thead>
<tbody>
<tr>
<td>NIH/NIDCR</td>
</tr>
<tr>
<td>1F31DE022246-01 (10121362)</td>
</tr>
</tbody>
</table>

**Budget Dates:** 08/01/11 - 07/31/12  
**Project Dates:** 08/01/11 - 07/31/12  
**Direct:** 42,600  
**F & A:** 0  
**Total:** 42,600
RESEARCH FACULTY ACTIVITY FY 2012

College of Health Professions

Health Administration and Policy

Kazley, Abby  
Co-Investigator  
A Program to Increase Living Donation in African Americans  
PI: Prabhakar Baliga  
Sponsor: NIH/NIDDK  
Total: $ 199,832  
Dept: Surgery  
Award: 1R01DK062596-10 (11120270-1)

Prevention of Stroke after STOP, A Retrospective Chart Review
PI: Robert Adams  
Sponsor: NIH/NHLBI  
Total: $ 675,579  
Dept: Neurosciences  
Award: 5R01HL096789-03 (12020214-1)

Health Professions

Bailey, Jennifer  
Co-Investigator  
Transferring and Integrating Graduate Education in Rural Education  
PI: Paul Jacques  
Sponsor: HRSA  
Total: $ 299,685  
Dept: Health Professions  
Award: 6 D5BHP20435-01-01 (10051959-2)

Brotherton, Sandra  
Co-Investigator  
Ambulation and Secondary Complications: Participants with Chronic Spinal Cord Injury  
PI: James Krause  
Sponsor: Dept. of Education  
Total: $ 199,972  
Dept: Health Sciences and Research  
Award: H133G090059-11 (12020146-1)

Chipas, Anthony  
Principal Investigator  
Nurse Anesthetist Traineeships  
HRSA  
Budget Dates: 07/01/11 - 06/30/12  
Project Dates: 07/01/00 - 06/30/12  
Direct F & A Total  
2 A22HP00023-12-00 (10121357)  
5,385 0 5,385

Co-PI/Project Director  
Advanced Education Nursing Traineeship Program  
PI: Robin Bissinger  
Sponsor: HRSA  
Total: $ 8,083  
Dept: Nursing  
Award: 2 A10HP08284-05-00 (10120946-3)

Coker, Patricia  
Principal Investigator  
2011 Camp Hand to Hands  
Coastal Community Fdn. of SC (11050989)  
Budget Dates: 07/01/11 - 06/30/12  
Project Dates: 07/01/11 - 06/30/12  
Direct F & A Total  
2,500 0 2,500

Dean, Jesse  
Principal Investigator  
Development of a Passive Elastic Exoskeleton for Gait Rehabilitation  
NIH/NICHD  
Budget Dates: 04/01/12 - 03/31/13  
Project Dates: 04/15/11 - 03/31/13  
Direct F & A Total  
5R21HD064964-02 (12081049)  
125,000 48,363 173,363

Ellis, Jr., Charles  
Principal Investigator  
Racial/Ethnic Differences in Post-Stroke Outcomes  
VAMC  
Budget Dates: 08/01/11 - 07/31/12  
Project Dates: 08/01/09 - 07/31/12  
Direct F & A Total  
CD107012 (09102973)  
60,000 0 60,000

Jacques, Paul  
Principal Investigator  
Transferring and Integrating Graduate Education in Rural Education  
HRSA  
Budget Dates: 09/01/11 - 08/31/12  
Project Dates: 09/01/10 - 08/31/15  
Direct F & A Total  
6 D5BHP20435-01-01 (10051959)  
277,486 22,199 299,685

Mitcham, Maralynne  
Co-Investigator  
Transferring and Integrating Graduate Education in Rural Education  
PI: Paul Jacques  
Sponsor: HRSA  
Total: $ 299,685  
Dept: Health Professions  
Award: 6 D5BHP20435-01-01 (10051959-2)
Moreau, Noelle  
**Co-Investigator**

**Lower Extremity Power and Locomotor Function after Stroke**  
*PI:* Christopher Gregory  
*Sponsor:* Amer. Heart Assoc.  
*Total:* $76,975  
*Dept:* Health Sciences and Research  
*Award:* 11BG1A7450016 (11012407-1)

Simpson, Kit  
**Principal Investigator**

**A Study of Antiretroviral Drugs in Pregnant Women in the U.S.**  
*Abbott Labs*  
*Budget Dates:* 10/15/11 - 06/30/12  
*Project Dates:* 10/15/11 - 06/30/12  
*Direct F & A Total* 40,000 10,000 50,000

**Co-Investigator**

**Collaborative Applied Research Supplement NIDCD**  
*PI:* Judy Dubno  
*Sponsor:* NIH/NIDCD  
*Total:* $40,000  
*Dept:* Otolaryngology  
*Award:* 3P50DC000422-24S1 (12091272-1)

Virella, Sara  
**Co-Investigator**

**Ambulation and Secondary Complications: Participants with Chronic Spinal Cord Injury**  
*PI:* James Krause  
*Sponsor:* Dept. of Education  
*Total:* $199,972  
*Dept:* Health Sciences and Research  
*Award:* H133G090055-11 (12020146-1)

Wise, Holly  
**Co-Investigator**

**Rehabilitation and Research Training Center on Secondary Conditions in Individuals with SCI**  
*PI:* James Krause  
*Sponsor:* Dept. of Education  
*Total:* $791,037  
*Dept:* Health Sciences and Research  
*Award:* H133B090005-11 (12020145-1)

Woody, Jaime  
**Co-Investigator**

**Transitioning and Integrating Graduate Education in Rural Education**  
*PI:* Paul Jacques  
*Sponsor:* HRSA  
*Total:* $299,685  
*Dept:* Health Professions  
*Award:* 6 D5BHP20435-01-01 (10051959-2)

Health Sciences and Research

Bowden, Mark  
**Principal Investigator**

**Propulsive Training in Incomplete Spinal Cord Injury**  
*SC Spinal Cord Injury Fund*  
*Budget Dates:* 12/01/11 - 11/30/12  
*Project Dates:* 12/01/10 - 11/30/13  
*Direct F & A Total* 28,417 0 28,417

**Co-Investigator**

**Do Spinal and Cortical tDCS Suggest Distinct and Synergistic Neuromechanical Mechanisms for Post-Stroke Walking Recovery?**  
*PI:* Steven Kautz  
*Sponsor:* Amer. Heart Assoc.  
*Total:* $75,000  
*Dept:* Health Sciences and Research  
*Award:* 12IRG9430057 (12010018-1)

**ZeroG: Dynamic Over-Ground Body Weight Support System**  
*PI:* Steven Kautz  
*Sponsor:* Aretech, LLC  
*Total:* $28,727  
*Dept:* Health Sciences and Research  
*Award:* 2 R44 HD061131-02A1 (12020171-1)

**Randomized Trial of the Innovative Neurotronics WalkAide Compared to Conventional Ankle-Foot Orthosis in Stroke Patients**  
*PI:* Steven Kautz  
*Sponsor:* Innovative Neurotronics, Inc.  
*Total:* $148,320  
*Dept:* Health Sciences and Research  
*Award:* INSTRIDE (12030312-1)

**Development of a Passive Elastic Exoskeleton for Gait Rehabilitation**  
*PI:* Jesse Dean  
*Sponsor:* NIH/NICHD  
*Total:* $173,363  
*Dept:* Health Professions  
*Award:* 5R21HD064964-02 (12081049-1)

**ZeroG: Dynamic Over-Ground Body Weight Support System**  
*PI:* Steven Kautz  
*Sponsor:* Aretech, LLC  
*Total:* $29,588  
*Dept:* Health Sciences and Research  
*Award:* 5 R44 HD061131-03 (12101414-1)

Cao, Yue  
**Principal Investigator**

**The Application of Medical Sociology to the Study of Health and Mortality after Spinal Cord Injury**  
*SC Spinal Cord Injury Fund*  
*Budget Dates:* 11/01/11 - 10/31/12  
*Project Dates:* 11/01/11 - 10/31/14  
*Direct F & A Total* 41,625 0 41,625
Cao, Yue

**Co-Investigator**

Center on Health Outcomes Research and Capacity Building for Underserved Populations with Spinal Cord Injury and Traumatic Brain Injury (SUPPLEMENT)

**PI:** James Krause  
**Sponsor:** Dept. of Education  
**Total:** $31,530

**Dept:** Health Sciences and Research  
**Award:** H133A080064-11E (12020161-1)

Embry, Aaron

**Co-Investigator**

Development of a Rehabilitation Research Program to Study the Biomechanics of Walking Following Incomplete Spinal Cord Injury

**PI:** Chris Gregory  
**Sponsor:** SC Spinal Cord Injury Fund  
**Total:** $32,269

**Dept:** Health Sciences and Research  
**Award:** SCIRF 10-004 (10120222-2)

**Propulsive Training in Incomplete Spinal Cord Injury**

**PI:** Mark Bowden  
**Sponsor:** SC Spinal Cord Injury Fund  
**Total:** $28,417

**Dept:** Health Sciences and Research  
**Award:** SCIRF 10-003 (10120223-2)

Gregory, Christopher

**Principal Investigator**

Development of a Rehabilitation Research Program to Study the Biomechanics of Walking Following Incomplete Spinal Cord Injury

**SC Spinal Cord Injury Fund**  
**Budget Dates:** 12/01/11 - 11/30/12  
**Direct F & A**  
**Total**

**SCIRF 10-004 (10120222)**  
**Project Dates:** 12/01/10 - 11/30/13  
$32,269  
0  
$32,269

**Lower Extremity Power and Locomotor Function after Stroke**

**Amer. Heart Assoc.**  
**Budget Dates:** 07/01/11 - 06/30/13  
**Direct F & A**  
**Total**

**11BG1A7450016 (11012407)**  
**Project Dates:** 07/01/11 - 06/30/13  
$69,978  
6,997  
$76,975

**Skeletal Muscle Properties and the Metabolic Cost of Walking Post-Stroke**

**VAMC**  
**Budget Dates:** 08/01/11 - 07/31/12  
**Direct F & A**  
**Total**

**B6341W (12020259)**  
**Project Dates:** 08/01/08 - 07/31/12  
$122,004  
0  
$122,004

**Co-Investigator**

Randomized Trial of the Innovative Neurotronics WalkAide Compared to Conventional Ankle-Foot Orthosis in Stroke Patients

**PI:** Steven Kautz  
**Sponsor:** Innovative Neurotronics, Inc.  
**Total:** $148,320

**Dept:** Health Sciences and Research  
**Award:** INSTRIDE (12030312-1)

Kautz, Steven

**Principal Investigator**

Do Spinal and Cortical tDCS Suggest Distinct and Synergistic Neuromechanical Mechanisms for Post-Stroke Walking Recovery?

**Amer. Heart Assoc.**  
**Budget Dates:** 01/01/12 - 12/31/12  
**Direct F & A**  
**Total**

**12IRG9430057 (12010018)**  
**Project Dates:** 01/01/12 - 12/31/13  
$68,182  
6,818  
$75,000

**ZeroG: Dynamic Over-Ground Body Weight Support System**

**Aretech, LLC**  
**Budget Dates:** 07/01/11 - 03/31/12  
**Direct F & A**  
**Total**

**2 R44 HD061131-02A1 (12020171)**  
**Project Dates:** 07/01/11 - 03/31/12  
$19,476  
9,251  
$28,727

**Randomized Trial of the Innovative Neurotronics WalkAide Compared to Conventional Ankle-Foot Orthosis in Stroke Patients**

**Innovative Neurotronics, Inc.**  
**Budget Dates:** 08/17/11 - 04/30/13  
**Direct F & A**  
**Total**

**INSTRIDE (12030312)**  
**Project Dates:** 08/17/11 - 04/30/13  
$119,256  
29,064  
$148,320

**ZeroG: Dynamic Over-Ground Body Weight Support System**

**Aretech, LLC**  
**Budget Dates:** 04/01/12 - 02/28/13  
**Direct F & A**  
**Total**

**5 R44 HD061131-03 (12101414)**  
**Project Dates:** 07/01/11 - 02/28/13  
$20,060  
9,528  
$29,588

**Co-Investigator**

South Carolina Clinical and Translational Research Institute (UL1)

**PI:** Kathleen Brady  
**Sponsor:** NIH/NCRR  
**Total:** $301,173

**Dept:** Psychiatry and Behavioral Sciences  
**Award:** 5UL1RR029882-03 (11012750-2)

South Carolina Clinical and Translational Research Institute (SCTR): UL1

**PI:** Kathleen Brady  
**Sponsor:** NIH/NCATS  
**Total:** $2,537,859

**Dept:** Psychiatry and Behavioral Sciences  
**Award:** 8UL1TR000062-04 (12070938-1)

South Carolina Clinical and Translational Research Institute (SCTR): UL1

**PI:** Kathleen Brady  
**Sponsor:** NIH/NCATS  
**Total:** $798,196

**Dept:** Psychiatry and Behavioral Sciences  
**Award:** 8UL1TR000062-04 (12070938-2)
Krause, James

**Principal Investigator**

**Research Development Core (FY2011 - 2012)**

Research Faculty Activity Health Sciences and Research

Krause, James

Principal Investigator

Research Development Core (FY2011 - 2012)

SC Spinal Cord Injury Fund  
(02100202)

Budget Dates: 07/01/11 - 06/30/12  
Project Dates: 07/01/02 - 06/30/12  
Direct F & A Total

68,903 0 68,903


Dept. of Education  
H133G110157 (11013173)

Budget Dates: 10/01/11 - 09/30/12  
Project Dates: 10/01/11 - 09/30/14  
Direct F & A Total

135,592 64,406 199,998

**Center on Health Outcomes Research and Capacity Building for Underserved Populations with SCI and TBI**

Dept. of Education  
H133A080064-11 (12010120)

Budget Dates: 10/01/11 - 09/30/12  
Project Dates: 10/01/08 - 09/30/13  
Direct F & A Total

264,202 88,931 353,133

---

**Nott, Cameron**

**Co-Investigator**

Development of a Rehabilitation Research Program to Study the Biomechanics of Walking Following Incomplete Spinal Cord Injury

Dept: Health Sciences and Research  
Award: SCIRF 10-004 (10120222-2)

**Saladin, Michael**

**Co-Investigator**

ORWH: SCOR on Sex and Gender Factors Affecting Women’s Health (Project 4)

Dept: Psychiatry and Behavioral Sciences  
Award: 5R33DA026085-04 (11051208-1)

---

**Saunders, Lee**

**Principal Investigator**

Measuring Outcomes after Spinal Cord Injury Throughout South Carolina: A System of Tracking, Research, and Referral

Dept: Health Sciences and Research  
Award: SCIRF09-001 (09120850-3)

---

Medical University of South Carolina
### Saunders, Lee

**Co-Investigator**
**PI:** James Krause  
**Sponsor:** Dept. of Education  
**Dept:** Health Sciences and Research  
**Total:** $199,998  
**Award:** H133G110157 (11013173-1)

**Center on Health Outcomes Research and Capacity Building for Underserved Populations with SCI and TBI**  
**PI:** James Krause  
**Sponsor:** Dept. of Education  
**Dept:** Health Sciences and Research  
**Total:** $353,133  
**Award:** H133A080064-11 (12010120-1)

**Rehabilitation and Research Training Center on Secondary Conditions in Individuals with SCI**  
**PI:** James Krause  
**Sponsor:** Dept. of Education  
**Dept:** Health Sciences and Research  
**Total:** $791,037  
**Award:** H133B090005-11 (12020145-1)

**Center on Health Outcomes Research and Capacity Building for Underserved Populations with Spinal Cord Injury and Traumatic Brain Injury (SUPPLEMENT)**  
**PI:** James Krause  
**Sponsor:** Dept. of Education  
**Dept:** Health Sciences and Research  
**Total:** $31,530  
**Award:** H133A080064-11E (12020161-1)

### Simpson, Kit

**Principal Investigator**
**Economic Models of Kaletra for Europe**  
**Abbott Labs**  
**Budget Dates:** 03/18/09 - 12/31/11  
**Direct F & A Total**  
FJ08002-005 (09022474)  
Project Dates: 03/18/09 - 12/31/11  
145,600 36,400 182,000

**JIA Economic Model**  
**Abbott Labs**  
**Budget Dates:** 05/26/10 - 06/30/12  
**Direct F & A Total**  
FJ08002-09 H10.HUMIRAJA01 (10061427)  
Project Dates: 05/26/10 - 06/30/12  
129,600 32,400 162,000

**Co-Investigator**
**Interventional Management of Stroke Phase III Trial - SDCC**  
**PI:** Yuko Palesch  
**Sponsor:** NIH/NINDS  
**Dept:** Medicine  
**Total:** $487,035  
**Award:** 1U01NS077304-01 (11012863-1)

**A Program to Increase Living Donation in African Americans**  
**PI:** Prabhakar Baliga  
**Sponsor:** NIH/NIDDK  
**Dept:** Surgery  
**Total:** $199,832  
**Award:** 1R01DK062596-10 (11120270-1)

### Woodbury, Michelle

**Principal Investigator**
**A Toolbox for Measuring Post-Stroke Upper Extremity Motor Ability**  
**VAMC**  
**Budget Dates:** 09/01/11 - 08/31/12  
**Direct F & A Total**  
B6332W (12020266)  
Project Dates: 09/01/08 - 08/31/12  
99,540 0 99,540
RESEARCH FACULTY ACTIVITY FY 2012

College of Medicine

Anesthesia and Perioperative Medicine

Abernathy, Ill, James

Principal Investigator

Translating CER Results from ICU Study to Improve Outcomes in Cardiac Surgery

Johns Hopkins Univ.  
R18 HS019934-02 (12060730)  
Budget Dates: 08/01/11 - 07/31/12  
Project Dates: 09/30/10 - 07/31/13  
Direct F & A Total  
26,657 12,662 39,319

Lidocaine for Neuroprotection During Cardiac Surgery

Duke Univ.  
203-1119/R01 HL096978-03 (12070814)  
Budget Dates: 11/01/11 - 05/31/12  
Project Dates: 11/01/11 - 05/31/12  
Direct F & A Total  
32,542 15,458 48,000

Craig, Jean

Principal Investigator

Mass Casualty Triage Validation Study

Univ. of South Carolina  
1101885/R21 LM010833 (12020220)  
Budget Dates: 08/01/11 - 07/31/12  
Project Dates: 10/04/10 - 07/31/12  
Direct F & A Total  
8,358 3,970 12,328

McEvoy, Matthew

Principal Investigator

Cognitive Aid for Perioperative Emergencies

Foundation for Anesthesia  
(11120367)  
Budget Dates: 07/01/11 - 06/30/13  
Project Dates: 07/01/11 - 06/30/13  
Direct F & A Total  
50,000 0 50,000

Sanderson, lain

Principal Investigator

Go Grant: An Open Source Research Permissions Management System for South Carolina

Univ. of South Carolina  
11-1875/RC2 LM010796-02 (10120738)  
Budget Dates: 09/30/10 - 09/29/12  
Project Dates: 09/30/09 - 09/29/12  
Direct F & A Total  
214,513 101,893 316,406

MUSC CHQ IT Infrastructure Grant

Health Sciences SC  
HSSC2012-002-02 (12070923)  
Budget Dates: 07/01/11 - 06/30/12  
Project Dates: 07/01/11 - 06/30/12  
Direct F & A Total  
1,176,790 0 1,176,790

SmartState Funding Dr. Sanderson

USC Research Foundation  
(12081025)  
Budget Dates: 07/01/08 - 06/30/12  
Project Dates: 07/01/08 - 06/30/12  
Direct F & A Total  
177,691 0 177,691

Co-Investigator

South Carolina Clinical and Translational Research Institute (UL1)  
PI: Kathleen Brady  
Dept: Psychiatry and Behavioral Sciences  
Sponsor: NIH/NCRR  
Award: 5UL1RR029882-03 (11012750-2)  
Total: $ 301,173

South Carolina Clinical and Translational Research Institute (SCTR): UL1  
PI: Kathleen Brady  
Dept: Psychiatry and Behavioral Sciences  
Sponsor: NIH/NCATS  
Award: 8UL1TR000062-04 (12070938-1)  
Total: $ 798,196

Biochemistry and Molecular Biology

Bastia, Deepak

Principal Investigator

Control of Programmed Replication Fork Arrest by Chromosome Kissing

NIH/NIGMS  
1R01GM098013-01A1 (10121573)  
Budget Dates: 07/01/11 - 03/31/12  
Project Dates: 07/01/11 - 03/31/15  
Direct F & A Total  
289,000 127,972 416,972

Control of Programmed Replication Fork Arrest by Chromosome Kissing

NIH/NIGMS  
5R01GM098013-02 (12081141)  
Budget Dates: 04/01/12 - 03/31/13  
Project Dates: 07/01/11 - 03/31/15  
Direct F & A Total  
273,836 128,011 401,947

Bielsawska, Alicja

Co-PI/Project Director

COBRE in Lipidomics and Pathobiology (Core B)  
PI: Craig Crosson  
Dept: Ophthalmology  
Sponsor: NIH/NCRR  
Award: 5P20RR017677-10 (12040490-3)  
Total: $ 292,001

Medical University of South Carolina
Bielawska, Alicja  
**Co-PI/Project Director**

- **Spingolipids in Cancer Biology and Therapy (Core B)**
  - PI: Yusuf Hannun  
  - Sponsor: NIH/NCI  
  - Total: $192,206
  - Dept: Biochemistry and Molecular Biology  
  - Award: 5P01CA097132-09 (12040548-3)

  **MUSC CCSG: Lipidomics Shared Resource**
  - PI: Andrew Kraft  
  - Sponsor: NIH/NCI  
  - Total: $91,684
  - Dept: Medicine  
  - Award: 5P30CA138313-04 (12070914-8)

Bielawska, Jacek  
**Co-Investigator**

- **COBRE in Lipidomics and Pathobiology (Core B)**
  - PI: Craig Crosson  
  - Sponsor: NIH/NCRR  
  - Total: $292,001
  - Dept: Ophthalmology  
  - Award: 5P20RR017677-10 (12040490-5)

Brice, Sarah  
**Principal Investigator**

- **Metabolic Determinants of Cardiac Bioactive Sphingolipids in Lipid Overload**
  - NIH/NIDDK  
  - Budget Dates: 09/01/11 - 08/31/12
  - Direct F & A  
  - Total
  - Project Dates: 09/01/11 - 08/31/14
  - 36,703 0 36,703

Bullesbach, Erika  
**Co-Investigator**

- **COBRE in Lipidomics and Pathobiology (Core D)**
  - PI: Craig Crosson  
  - Sponsor: NIH/NCRR  
  - Total: $146,000
  - Dept: Ophthalmology  
  - Award: 5P20RR017677-10 (12040490-5)

Chao, Julie  
**Principal Investigator**

- **Recombinant Human Kallistatin**
  - Baxter Health Care  
  - Budget Dates: 02/24/12 - 02/20/13
  - Direct F & A  
  - Total
  - Project Dates: 02/24/12 - 02/20/13
  - 10,000 3,150 13,150

- **Regulation and Function of Tissue Kallikrein**
  - NIH/NHLBI  
  - Budget Dates: 06/01/12 - 05/31/13
  - Direct F & A  
  - Total
  - Project Dates: 07/01/86 - 05/31/13
  - 247,500 117,563 365,063

Cowart, Lauren  
**Co-PI/Project Director**

- **COBRE in Lipidomics and Pathobiology (Project 1)**
  - PI: Craig Crosson  
  - Sponsor: NIH/NCRR  
  - Total: $73,000
  - Dept: Ophthalmology  
  - Award: 5P20RR017677-10 (12040490-6)

Davies, Christopher  
**Principal Investigator**

- **Crystallization Robotics to Support X-Ray Crystallography at MUSC**
  - NIH/NCRR  
  - Budget Dates: 07/01/11 - 06/30/12
  - Direct F & A  
  - Total
  - Project Dates: 07/01/11 - 06/30/12
  - 124,876 0 124,876

- **Molecular Targets in Peptidoglycan Synthesis**
  - NIH/NIGMS  
  - Budget Dates: 03/01/12 - 12/31/12
  - Direct F & A  
  - Total
  - Project Dates: 02/01/03 - 12/31/15
  - 257,679 90,180 347,859

- **GAANN in Lipidomics and Systems Biology**
  - Dept. of Education  
  - Budget Dates: 08/16/11 - 08/15/12
  - Direct F & A  
  - Total
  - Project Dates: 08/16/10 - 08/16/13
  - 131,925 0 131,925

Del Poeta, Maurizio  
**Principal Investigator**

- **Host Sphingolipids and Fungal Infection**
  - NIH/NIAID  
  - Budget Dates: 08/01/11 - 07/31/13
  - Direct F & A  
  - Total
  - Project Dates: 08/01/11 - 07/31/13
  - 266,500 116,375 382,875

- **Sphingolipid-Mediated Fungal Pathogenesis**
  - NIH/NIAID  
  - Budget Dates: 09/01/11 - 08/31/12
  - Direct F & A  
  - Total
  - Project Dates: 07/01/03 - 08/31/14
  - 196,020 93,110 289,130

- **Role of Phagocytosis in Pathogenesis of Cryptococcus Neoforans**
  - NIH/NIAID  
  - Budget Dates: 12/01/11 - 11/30/12
  - Direct F & A  
  - Total
  - Project Dates: 12/15/07 - 11/30/12
  - 233,604 107,985 341,589
### Fernandes, Daniel
**Hematological Malignancies Symposium**
- **Principal Investigator**
- **Multiple Sponsors**
- **Budget Dates**: 12/06/05 - 06/30/12
- **Project Dates**: 12/06/05 - 06/30/12

<table>
<thead>
<tr>
<th>Source</th>
<th>Direct</th>
<th>F &amp; A</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>(05101038)</strong></td>
<td></td>
<td>5,500</td>
<td>5,500</td>
</tr>
</tbody>
</table>

### Gruber, Jordan
**The Role of DHQ in Quorum-Sending Regulation and Pathogenesis of Pseudomonas Aeruginosa**
- **Principal Investigator**
- **Cystic Fibrosis Fdn.**
- **Budget Dates**: 09/01/11 - 12/31/11
- **Project Dates**: 09/01/11 - 12/31/11

<table>
<thead>
<tr>
<th>Source</th>
<th>Direct</th>
<th>F &amp; A</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>GRUBER11H0 (11120262)</strong></td>
<td></td>
<td>1,500</td>
<td>1,500</td>
</tr>
</tbody>
</table>

### Hama, Hiroko
**Utilizing Skin Lipid Profiles to Identify Dermatological Diseases**
- **Principal Investigator**
- **Cicatricial Alopecia Research Fdn.**
- **Budget Dates**: 07/01/11 - 06/30/12
- **Project Dates**: 07/01/11 - 06/30/12

<table>
<thead>
<tr>
<th>Source</th>
<th>Direct</th>
<th>F &amp; A</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>11051318</strong></td>
<td></td>
<td>192,938</td>
<td>281,689</td>
</tr>
</tbody>
</table>

### Hannun, Yusuf
**SmartState Center for Lipidomics, Pathobiology, and Therapy**
- **Principal Investigator**
- **SC Research Centers of Economic Excellence**
- **Budget Dates**: 07/01/11 - 06/30/12
- **Project Dates**: 07/01/11 - 06/30/12

<table>
<thead>
<tr>
<th>Source</th>
<th>Direct</th>
<th>F &amp; A</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>12040452</strong></td>
<td>2,200,766</td>
<td>0</td>
<td>2,200,766</td>
</tr>
</tbody>
</table>

### Hennig, Mirko
**Structure and Dynamics of the Spider Dragline Silk Assembly Process**
- **Principal Investigator**
- **NSF**
- **Budget Dates**: 09/01/11 - 08/31/12
- **Project Dates**: 09/01/11 - 08/31/12

<table>
<thead>
<tr>
<th>Source</th>
<th>Direct</th>
<th>F &amp; A</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>DMR-1105307 (10102669)</strong></td>
<td>130,341</td>
<td>27,992</td>
<td>158,333</td>
</tr>
</tbody>
</table>

### Howe, Philip
**Transforming Growth Factor Beta Signaling Pathways**
- **Principal Investigator**
- **NIH/NCI**
- **Budget Dates**: 09/12/11 - 01/31/13
- **Project Dates**: 09/12/11 - 01/31/13

<table>
<thead>
<tr>
<th>Source</th>
<th>Direct</th>
<th>F &amp; A</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>7R01CA055536-21 (12010128)</strong></td>
<td>70,000</td>
<td>33,250</td>
<td>103,250</td>
</tr>
</tbody>
</table>

### Additional Projects
- **Co-Investigator**
- **COBRE in Lipidomics and Pathobiology (Core A)**
- **PI**: Craig Crosson
- **Sponsor**: NIH/NCRR
- **Dept**: Ophthalmology
- **Award**: 5P20RR017677-10 (12040490-2)
- **Total**: $1,139,238

- **Co-Investigator**
- **COBRE in Lipidomics and Pathobiology (Core A)**
- **PI**: Craig Crosson
- **Sponsor**: NIH/NCRR
- **Dept**: Cell and Molecular Pharmacology
- **Award**: 1P20RR024485-01A2 (09062764-5)
- **Total**: $347,859

- **Co-Investigator**
- **South Carolina COBRE in Oxidants, Redox Balance and Stress Signaling (Core C)**
- **PI**: Christopher Davies
- **Sponsor**: NIH/NIGMS
- **Dept**: Biochemistry and Molecular Biology
- **Award**: 2R01GM066861-09A1 (10071661-1)
- **Total**: $347,859

---

Medical University of South Carolina
<table>
<thead>
<tr>
<th>Principal Investigator</th>
<th>Project Title</th>
<th>Sponsor</th>
<th>Budget Dates</th>
<th>Direct F &amp; A</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Howe, Philip</td>
<td>TGF-Regulated EMT</td>
<td>NIH/NCI</td>
<td>09/08/11 - 12/31/11</td>
<td>158,445</td>
<td>233,706</td>
</tr>
<tr>
<td></td>
<td>TGF Beta-Induced Apoptosis in B-Lymphocytes</td>
<td>NIH/NCI</td>
<td>12/01/11 - 11/30/12</td>
<td>183,130</td>
<td>270,115</td>
</tr>
<tr>
<td></td>
<td>TGF-Regulated EMT</td>
<td>NIH/NCI</td>
<td>01/01/12 - 12/31/12</td>
<td>207,500</td>
<td>306,062</td>
</tr>
<tr>
<td>Hsu, Yi-Te</td>
<td></td>
<td>NIH/NCI</td>
<td>01/01/11 - 12/31/15</td>
<td>207,500</td>
<td>306,062</td>
</tr>
<tr>
<td>Joseph, Kusumam</td>
<td></td>
<td>NIH/NCI</td>
<td>07/01/11 - 06/30/12</td>
<td>23,000</td>
<td>23,000</td>
</tr>
<tr>
<td>Krupenko, Sergey</td>
<td></td>
<td>NIH/NIDDK</td>
<td>07/01/11 - 06/30/12</td>
<td>196,902</td>
<td>287,477</td>
</tr>
<tr>
<td>Luberto, Chiara</td>
<td></td>
<td>NIH/NIAID</td>
<td>07/01/11 - 06/30/12</td>
<td>168,387</td>
<td>248,371</td>
</tr>
<tr>
<td>Mozes, Christina</td>
<td></td>
<td>NIH/NIGMS</td>
<td>04/01/11 - 03/31/13</td>
<td>52,190</td>
<td>52,190</td>
</tr>
<tr>
<td>Ogretmen, Besim</td>
<td></td>
<td>NIH/NIDCR</td>
<td>08/01/11 - 07/31/13</td>
<td>137,682</td>
<td>201,015</td>
</tr>
</tbody>
</table>

Hussey, George

Principal Investigator

Mechanism of Transforming Growth Factor-Beta-Mediated Translational Regulation of EMT-Inducer mRNAs Award Number: 10PRE3870024

Pl: Craig Crosson
Dept: Ophthalmology
Total: $ 146,000
Award: 5P20RR017677-10 (12040490-5)

Joseph, Kusumam

Principal Investigator

Development of a Functional Assay for C1 Inhibitor

Dyax Corp.
Total: $ 179,950
Award: (12081107)

Krupenko, Sergey

Principal Investigator

Mechanism of Action of a Major Folate Enzyme

NIH/NIDDK
Total: $ 128,471
Award: 1R56AI087541-01A1 (10022246-1)

Luberto, Chiara

Co-PI/Project Director

Host Sphingolipids and Fungal Infection

Maurizio Del Poeta
Total: $ 382,875
Award: 1R56AI087541-01A1 (10022246-1)

Mozes, Christina

Principal Investigator

A Structure-Function Analysis of let-7c miRNA Regulation By Lin28

NIH/NIGMS
Total: $ 52,190
Award: 5F32GM095128-02 (12081139)

Ogretmen, Besim

Principal Investigator

C18-Ceramide in Head and Neck Cancer Growth and Therapy

NIH/NIDCR
Total: $ 339,803
Award: 5R01DE016572-07S1 (11051214)

C18-Ceramide in Head and Neck Cancer Growth and Therapy Diversity Supplement for Raquela Thomas

NIH/NIDCR
Total: $ 39,728
Award: 5R01DE016572-07S1 (11051214)

Regulation of Telomerase by Ceramide in Lung Cancer

NIH/NCI
Total: $ 201,015
Award: 5R01CA088932-10 (11120263)
Ogretmen, Besim  
Co-PI/Project Director  
Spingolipids in Cancer Biology and Therapy (Project 4)  
PI: Yusuf Hannun  
Sponsor: NIH/NCI  
Total: $ 155,455  
Dept: Biochemistry and Molecular Biology  
Award: 5P01CA097132-09 (12040548-8)

MUSC CCSG: Program Leaders Project 1  
PI: Andrew Kraft  
Sponsor: NIH/NCI  
Total: $ 32,244  
Dept: Medicine  
Award: 5P30CA138313-04 (12070914-4)

Saddoughi, Sahar  
Principal Investigator  
Suppression of Lung Cancer Growth by Ceramide  
NIH/NIEHS  
Budget Dates: 08/01/11 - 07/31/12  
Direct F & A Total  
5F30ES019464-02 (11120202) Project Dates: 08/01/10 - 07/31/15 39,445 0 39,445

Schwacke, John  
Co-Investigator  
Prevention of Photoparoxysmal Abnormalities Through Patterned Auditory Stimulation  
PI: Robert Turner  
Sponsor: MIND Institute  
Total: $ 46,000  
Dept: Neurosciences  
Award: (12081180-1)

Schwartz, Justin  
Principal Investigator  
Mechanism-Based Discovery of Protectants against Iron-Dependant Oxidative Injury  
NIH/NIDDK  
Budget Dates: 09/01/11 - 08/30/12  
Direct F & A Total  
1F32DK092070-01A1 (11040653) Project Dates: 09/01/11 - 08/30/12 67,212 0 67,212

Sommer, Gunhild  
Principal Investigator  
Role and Function of RNA-Binding Protein La in Oral Tumor Progression  
NIH/NIDCR  
Budget Dates: 06/01/12 - 05/31/13  
Direct F & A Total  
5R03DE021729-02 (12101373) Project Dates: 06/03/11 - 05/31/13 75,000 35,625 110,625

Spicer, Eleanor  
Co-Investigator  
COBRE in Lipidomics and Pathobiology (Core A)  
PI: Craig Crosson  
Sponsor: NIH/NCRR  
Total: $ 1,139,238  
Dept: Ophthalmology  
Award: 5P20RR017677-10 (12040490-2)

Strickland, Kyle  
Principal Investigator  
Regulation of DNA Methylation by a Major Folate Enzyme  
NIH/NIDDK  
Budget Dates: 05/05/12 - 05/04/13  
Direct F & A Total  
5F30DK083215-03 (12091185) Project Dates: 05/05/10 - 05/04/13 46,800 0 46,800

Szulc, Zdzislaw  
Co-Investigator  
Role and Regulation of Ceramide Synthases in Apoptosis  
PI: Lina Obeid  
Sponsor: NIH/NIA  
Total: $ 294,248  
Dept: Medicine  
Award: 9R01GM097741-13A1 (10071334-1)

COBRE in Lipidomics and Pathobiology (Core B)  
PI: Craig Crosson  
Sponsor: NIH/NCRR  
Total: $ 291,999  
Dept: Ophthalmology  
Award: 5P20RR017677-10 (12040490-7)

Zhang, Yong-Mei  
Principal Investigator  
Development of Topical Treatment for Pseudomonas aeruginosa Wound Infections by Quorum-Sensing Inhibitors Mediated by Poly(amidoamine) (PAMAM) Dendrimers  
DOD  
Budget Dates: 12/15/11 - 12/14/12  
Direct F & A Total  
W81XWH-12-2-0009 (09121815) Project Dates: 12/15/11 - 12/14/14 247,254 84,441 331,695

The Role of DHQ in Chronic Pseudomonas Infection in Cystic Fibrosis  
Cystic Fibrosis Fdn.  
Budget Dates: 04/01/12 - 03/31/13  
Direct F & A Total  
ZHANG1210 (12030305) Project Dates: 04/01/12 - 03/31/13 40,000 3,200 43,200

Co-PI/Project Director  
COBRE in Lipidomics and Pathobiology (Project 2)  
PI: Craig Crosson  
Sponsor: NIH/NCRR  
Total: $ 291,999  
Dept: Ophthalmology  
Award: 5P20RR017677-10 (12040490-7)
Zhang, Yong-Mei

**Mentor**

The Role of DHQ in Quorum-Sending Regulation and Pathogenesis of Pseudomonas Aeruginosa

*Pl*: Jordan Gruber  
*Sponsor*: Cystic Fibrosis Fdn.  
*Total*: $1,500

*Dept*: Biochemistry and Molecular Biology  
*Award*: GRUBER11H0 (11120262-1)

---

Zheng, Wenjin

**Co-Investigator**

**South Carolina Clinical and Translational Research Institute (UL1)**

*Pl*: Kathleen Brady  
*Sponsor*: NIH/NCRR  
*Total*: $301,173

*Dept*: Psychiatry and Behavioral Sciences  
*Award*: 8UL1TR000062-04 (12070938-2)

---

**Cell and Molecular Pharmacology**

Ball, Lauren

**Principal Investigator**

**Orbitrap Mass Spectrometer**

*NIH*

*Project Dates*: 05/01/12 - 04/30/13  
*Direct F & A*: $600,000  
*Total*: $600,000

*Regulation of IGF-1 and Insulin Signaling by O-GlcNAc Glycosylation***

*NIH/NIDCR*

*Project Dates*: 07/01/10 - 06/30/16  
*Direct F & A*: $242,500  
*Total*: $357,688

---

Blumer, Joe

**Principal Investigator**

**AGS4 in G-Protein Signal Processing**

*NIH/NIGMS*

*Project Dates*: 08/01/09 - 05/31/14  
*Direct F & A*: 205,821  
*Total*: 302,803

---

Davis, Jr., Warren

**Principal Investigator**

**ATP Binding Cassette Transporter-2 Regulates Amyloid Precursor Protein Dynamics**

*NIH/NINDS*

*Project Dates*: 09/30/09 - 08/31/13  
*Direct F & A*: 159,688  
*Total*: 172,463

---

Drake, Jr., Richard

**Principal Investigator**

**Glycan Biomarkers of Prostate Cancer in Prostatic Fluids***

*NIH/NCI*

*Project Dates*: 03/27/09 - 01/31/13  
*Direct F & A*: 187,977  
*Total*: 254,870

**Epidemiology Study of Colon Cancer Proteomic Prediction**

*Henry M. Jackson Fdn.*

*Project Dates*: 07/31/13 - 07/31/15  
*Direct F & A*: 69,821  
*Total*: 102,986
Drake, Jr., Richard

**Principal Investigator**

**SmartState Endowed Chair in Proteomics**
MUSC Fdn. (12070856)

<table>
<thead>
<tr>
<th>Budget Dates: 07/01/11 - 06/30/12</th>
<th>Direct</th>
<th>F &amp; A</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Project Dates: 07/01/07 - 06/30/12</td>
<td>161,027</td>
<td>0</td>
<td>161,027</td>
</tr>
</tbody>
</table>

**Co-PI/Project Director**

Tobacco Related Cancer Research: Drake Recruitment Package
Pl: Andrew Kraft
Sponsor: State of SC
Total: $356,481
Award: (12040516-5)

Eblen, Scott

**Principal Investigator**

**Regulation of Ovarian Cancer Multidrug Resistance by MAP Kinases**
NIH/NCI

<table>
<thead>
<tr>
<th>Project Dates: 05/01/09 - 01/31/14</th>
<th>Direct</th>
<th>F &amp; A</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>5R01CA131200-04 (12060767)</td>
<td>201,275</td>
<td>94,841</td>
<td>296,116</td>
</tr>
</tbody>
</table>

**Halushka, Perry**

**Principal Investigator**

**Training Program for Medical Scientists**
NIH/NIGMS

<table>
<thead>
<tr>
<th>Project Dates: 07/01/09 - 06/30/14</th>
<th>Direct</th>
<th>F &amp; A</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>2R01GM082981-04 (12060773)</td>
<td>196,020</td>
<td>93,110</td>
<td>289,130</td>
</tr>
</tbody>
</table>

**Knapp, Daniel**

Co-PI/Project Director

South Carolina COBRE in Oxidants, Redox Balance and Stress Signaling (Core B)
Pl: Kenneth Tew
Sponsor: NIH/NCCR
Total: $268,276
Award: 1P20RR024485-01A2 (09062764-4)
<table>
<thead>
<tr>
<th>Name</th>
<th>Title</th>
<th>Program</th>
<th>Sponsor</th>
<th>Total ($)</th>
<th>Award Number</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lanier, Stephen</td>
<td>Principal Investigator</td>
<td>NSF EPSCoR RII Track 2: Cyberinfrastructure</td>
<td>SC Research Authority</td>
<td>192,801</td>
<td>EPS-0919440 (08121730)</td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Accessory Proteins and G-Protein Signaling Mechanisms</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>NIH/NIDA</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>5R01DA025896-23 (12060789)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Manevich, Yefim</td>
<td>Co-Investigator</td>
<td>Translational Cancer Therapeutics SmartState SC Center of Economic Excellence</td>
<td>Pl: Kenneth Tew</td>
<td>296,881</td>
<td>(12070942-1)</td>
</tr>
<tr>
<td>Neumann, Carola</td>
<td>Principal Investigator</td>
<td>MUSC/Baylor Breast Cancer Research Initiative for Developing Growth and Education (BRIDGE) Program</td>
<td>DOD</td>
<td>360,688</td>
<td>W81XWH-11-2-0229 (10052076)</td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>The Role of Peroxiredoxin1 and Reactive Oxygen Species in Breast Tumor Initiation</strong></td>
<td>NIH/NCI</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>5R01CA131350-03 (12060775)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rosenberg, Steven</td>
<td>Mentor</td>
<td>MUSC/Baylor Breast Cancer Research Initiative for Developing Growth and Education (BRIDGE) Program</td>
<td>DOD</td>
<td>32,244</td>
<td>5P30CA138313-04 (12070914-4)</td>
</tr>
<tr>
<td>Tew, Kenneth</td>
<td>Principal Investigator</td>
<td>South Carolina COBRE in Oxidants, Redox Balance and Stress Signaling (Project 3)</td>
<td>MUSC Fdn.</td>
<td>314,395</td>
<td>1P20RR024485-01A2 (09062764-9)</td>
</tr>
<tr>
<td>Wargovich, Michael</td>
<td>Principal Investigator</td>
<td>Tea Modulation of Colon Carcinogenesis</td>
<td>NIH/NCI</td>
<td>256,150</td>
<td>5P30CA138313-04 (12070914-15)</td>
</tr>
<tr>
<td>Smith, Alison</td>
<td>Principal Investigator</td>
<td>Lung Perfusion Device for Lung Evaluation and Transplantation</td>
<td>Cell and Tissue Systems, Inc.</td>
<td>37,313</td>
<td>R43 HL097449 (10031980)</td>
</tr>
</tbody>
</table>

**Comparative Medicine**
Smith, Alison

**Principal Investigator**

**Feasibility of Unfrozen Sub-Zero Storage of Mammalian Tissues with Insect Anti-Freeze Peptides**
Cell and Tissue Systems, Inc.
Budget Dates: 06/01/10 - 01/31/12 Direct F & A Total
2 R44 DK081233-02 (10051970)
Project Dates: 06/01/10 - 01/31/12 26,840 12,749 39,589

**Evaluation of an Alternative Smooth Muscle Relaxant for Blood Vessel Procurement**
Cell and Tissue Systems, Inc.
(Budget Dates: 04/16/12 - 07/16/12)
Project Dates: 04/16/12 - 07/16/12 12,522 2,504 15,026

Swindle, M.

**Principal Investigator**

**Biocompatibility Testing of Sleep Apnea Devices**
Medtronic, Inc.
Budget Dates: 03/10/11 - 03/30/12 Direct F & A Total
(11033016)
Project Dates: 03/10/11 - 03/30/12 42,354 10,182 52,536

**Evaluation of a Novel CAM Formulation in the Treatment of Diabetic Wounds**
Diabetes Action Research and Educ. Fdn.
(Budget Dates: 01/01/12 - 01/31/12)
Project Dates: 01/01/12 - 01/31/12 4,550 450 5,000

**Preclinical Testing of a Gastro-Jejunostomy Tube Clearing Device in Swine**
Actuated Medical, Inc.
(Budget Dates: 09/12/11 - 09/30/12)
Project Dates: 09/12/11 - 09/30/12 35,650 16,934 52,584

Deans Office - COM

Schaefer, III, John

**Principal Investigator**

**SmartState Center for Clinical Effectiveness and Patient Safety**
MUSC Fdn.
Budget Dates: 07/01/11 - 06/30/12 Direct F & A Total
(11020185)
Project Dates: 07/01/10 - 06/30/12 104,192 0 104,192

**Clinical Effectiveness and Patient Safety Center**
Health Sciences SC
Budget Dates: 07/01/11 - 06/30/12 Direct F & A Total
HSSC2012-002-01 (12060715)
Project Dates: 07/01/11 - 06/30/14 200,000 0 200,000

Dermatology

Burges, Gene

**Principal Investigator**

**Teledermatology High Definition Live Interactive Comparison Study**
NIH/NLM
Budget Dates: 07/01/11 - 06/30/13 Direct F & A Total
HHSN276201100424P (12010116)
Project Dates: 07/01/11 - 06/30/13 84,746 40,254 125,000

Kuo, Benjamin

**Co-Investigator**

Tele dermatology High Definition Live Interactive Comparison Study
Pl: Gene Burges Sponsor: NIH/NLM Total: $ 125,000
Dept: Dermatology Award: HHSN276201100424P (12010116-1)

Family Medicine

Blue, Amy

**Principal Investigator**

**Best Practices in Interprofessional Education**
Robert Wood Johnson Fdn.
Budget Dates: 06/01/12 - 05/31/13 Direct F & A Total
70111 (12081011)
Project Dates: 06/01/12 - 05/31/13 93,279 6,716 99,995

**Co-Investigator**

Faculty Development in Primary Care
Pl: William Hueston Sponsor: HRSA Total: $ 68,158
Dept: Family Medicine Award: 1 D55HP23198-01-00 (12010019-1)

**Residency Training in Primary Care**
Pl: Peter Carek Sponsor: HRSA Total: $ 143,056
Dept: Family Medicine Award: 1 D58HP23256-01 (12010027-1)

Carek, Peter

**Principal Investigator**

**Residency Training in Primary Care**
HRSA
Budget Dates: 09/30/11 - 09/29/12 Direct F & A Total
1 D58HP23256-01 (12010027)
Project Dates: 09/30/11 - 09/29/16 132,459 10,597 143,056

**Funding of HSSC MUSC Extramural Program Officer**
Health Sciences SC
Budget Dates: 07/01/11 - 06/30/12 Direct F & A Total
(12030293)
Project Dates: 07/01/08 - 06/30/12 47,016 0 47,016
### Diaz, Vanessa

**Principal Investigator**

**Impact of Vitamin D on Diabetic Kidney Disease in African Americans**

<table>
<thead>
<tr>
<th>Sponsor</th>
<th>Budget Dates: 08/01/11 - 07/31/12</th>
<th>Direct</th>
<th>F &amp; A</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>NIH/NIDDK</td>
<td>5R03DK089120-02 (11120288)</td>
<td>126,447</td>
<td>56,084</td>
<td>182,531</td>
</tr>
</tbody>
</table>

**Co-Investigator**

**Impact of MRSA Decolonization Therapy on MRSA Infection and Transmission**

<table>
<thead>
<tr>
<th>PI: Arch Mainous</th>
<th>Sponsor: AHRQ</th>
<th>Total: $ 496,813</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dept: Family Medicine</td>
<td>Award: 1R01HS018954-01A1 (1101315-1)</td>
<td></td>
</tr>
</tbody>
</table>

**Hereditary Hemochromatosis and Telomere Length**

<table>
<thead>
<tr>
<th>PI: Arch Mainous</th>
<th>Sponsor: CDC</th>
<th>Total: $ 150,839</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dept: Family Medicine</td>
<td>Award: 1 U01 DD000754-01 (11022213-1)</td>
<td></td>
</tr>
</tbody>
</table>

### Dickerson, Lori

**Principal Investigator**

**A Collaborative Model to Improve BP Control and Minimize Racial Disparities - Trident Family Medicine Residency Site**

<table>
<thead>
<tr>
<th>Sponsor</th>
<th>Budget Dates: 03/01/12 - 02/28/13</th>
<th>Direct</th>
<th>F &amp; A</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Univ. of Iowa</td>
<td>W000632170/R01 HL091841 (12091295)</td>
<td>10,887</td>
<td>5,172</td>
<td>16,059</td>
</tr>
</tbody>
</table>

**A Collaborative Model to Improve BP Control and Minimize Racial Disparities - MUSC Downtown Site**

<table>
<thead>
<tr>
<th>Sponsor</th>
<th>Budget Dates: 03/01/12 - 02/28/13</th>
<th>Direct</th>
<th>F &amp; A</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Univ. of Iowa</td>
<td>1000997637 (12091296)</td>
<td>13,619</td>
<td>3,541</td>
<td>17,160</td>
</tr>
</tbody>
</table>

### Gonsalves, Wanda

**Co-Investigator**

**Transferring and Integrating Graduate Education in Rural Education**

<table>
<thead>
<tr>
<th>PI: Paul Jacques</th>
<th>Sponsor: HRSA</th>
<th>Total: $ 299,685</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dept: Health Professions</td>
<td>Award: 6 D5BHP20435-01-01 (10051959-2)</td>
<td></td>
</tr>
</tbody>
</table>

### Hainer, Barry

**Co-Investigator**

**Residency Training in Primary Care**

<table>
<thead>
<tr>
<th>PI: Peter Carek</th>
<th>Sponsor: HRSA</th>
<th>Total: $ 143,056</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dept: Family Medicine</td>
<td>Award: 1 D5BHP23256-01 (12010027-1)</td>
<td></td>
</tr>
</tbody>
</table>

### Hueston, William

**Principal Investigator**

**Faculty Development in Primary Care**

<table>
<thead>
<tr>
<th>Sponsor</th>
<th>Budget Dates: 09/30/11 - 09/29/12</th>
<th>Direct</th>
<th>F &amp; A</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>HRSA</td>
<td>1 D55HP23198-01-00 (12010019)</td>
<td>63,109</td>
<td>5,049</td>
<td>68,158</td>
</tr>
</tbody>
</table>

### Jenkins, Ruth

**Co-Investigator**

**Enhancing Comparative Effectiveness Research Capabilities in PPRNet**

<table>
<thead>
<tr>
<th>PI: Steven Ornstein</th>
<th>Sponsor: AHRQ</th>
<th>Total: $ 499,606</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dept: Family Medicine</td>
<td>Award: 1R24HS01944801 (10011392-2)</td>
<td></td>
</tr>
</tbody>
</table>

**Dissemination of the PPRNet Model for Improving Medication Safety**

<table>
<thead>
<tr>
<th>PI: Andrea Wessell</th>
<th>Sponsor: AHRQ</th>
<th>Total: $ 295,997</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dept: Family Medicine</td>
<td>Award: 5 R18 HS019593-02 (11051526-1)</td>
<td></td>
</tr>
</tbody>
</table>

**Reducing Inappropriate Antibiotic Prescribing by Primary Care Clinicians**

<table>
<thead>
<tr>
<th>PI: Steven Ornstein</th>
<th>Sponsor: AHRQ</th>
<th>Total: $ 128,108</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dept: Family Medicine</td>
<td>Award: HHSA290200710015/Task Ord (11120228-1)</td>
<td></td>
</tr>
</tbody>
</table>

**Implementation of Alcohol Screening, Intervention and Treatment in Primary Care**

<table>
<thead>
<tr>
<th>PI: Peter Miller</th>
<th>Sponsor: NIH/NIAAA</th>
<th>Total: $ 547,045</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dept: Psychiatry and Behavioral Sciences</td>
<td>Award: 5R01AA016768-04 (12010047-1)</td>
<td></td>
</tr>
</tbody>
</table>

### Kern, Donna

**Co-Investigator**

**Transferring and Integrating Graduate Education in Rural Education**

<table>
<thead>
<tr>
<th>PI: Paul Jacques</th>
<th>Sponsor: HRSA</th>
<th>Total: $ 299,685</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dept: Health Professions</td>
<td>Award: 6 D5BHP20435-01-01 (10051959-2)</td>
<td></td>
</tr>
</tbody>
</table>
Kern, Donna  
**Co-Investigator**
Residency Training in Primary Care  
**PI:** Peter Carek  
**Dept:** Family Medicine  
**Sponsor:** HRSA  
**Total:** $143,056  
**Award:** 1 D58HP23256-01 (12010027-1)

King, Dana  
**Co-Investigator**
Residency Training in Primary Care  
**PI:** Peter Carek  
**Dept:** Family Medicine  
**Sponsor:** HRSA  
**Total:** $143,056  
**Award:** 1 D58HP23256-01 (12010027-1)

Preventing Venous Leg Ulcers with Cryotherapy: A Randomized Clinical Trial  
**PI:** Teresa Kelechi  
**Dept:** Nursing  
**Sponsor:** NIH/NINR  
**Total:** $48,433  
**Award:** 5R01NR012237-02 (12050635-2)

Preventing Venous Leg Ulcers with Cryotherapy: A Randomized Clinical Trial  
**PI:** Teresa Kelechi  
**Dept:** Nursing  
**Sponsor:** NIH/NINR  
**Total:** $542,241  
**Award:** 5R01NR012237-02 (12050635-1)

Mainous, Arch  
**Principal Investigator**
Impact of MRSA Decolonization Therapy on MRSA Infection and Transmission  
**AHRQ**  
**Budget Dates:** 07/01/11 - 04/30/12  
**Direct F & A**  
**Total**
1R01HS018954-01A1 (10101315)  
Project Dates: 07/01/11 - 04/30/16  
363,314  
133,499  
496,813

Hereditary Hemochromatosis and Telomere Length  
**CDC**  
**Budget Dates:** 09/01/11 - 08/31/12  
**Direct F & A**  
**Total**
1 U01 DD000754-01 (11022213)  
Project Dates: 09/01/11 - 08/31/13  
102,264  
48,575  
150,839

A Randomized Recruitment Intervention  
**Univ. of Texas Health Science Center at Houston**  
**Budget Dates:** 09/02/11 - 06/30/12  
**Direct F & A**  
**Total**
0008663D/U24 MD006841-01 (11120110)  
Project Dates: 09/01/11 - 06/30/16  
97,368  
46,250  
143,618

Impact of MRSA Decolonization Therapy on MRSA Infection and Transmission  
**AHRQ**  
**Budget Dates:** 05/01/12 - 04/30/13  
**Direct F & A**  
**Total**
5R01HS018954-02 (12070808)  
Project Dates: 07/01/11 - 04/30/16  
362,569  
137,144  
499,713

Co-PI/Project Director  
**SE VIEW Phase II (PAT RISK ASSESS)**  
**PI:** Sabra Slaughter  
**Dept:** Presidents Office  
**Sponsor:** DOD  
**Total:** $241,769  
**Award:** WB1XWH-11-2-0164 (12030345-10)

Co-Investigator  
Impact of Vitamin D on Diabetic Kidney Disease in African Americans  
**PI:** Vanessa Diaz  
**Dept:** Family Medicine  
**Sponsor:** NIH/NIDDK  
**Total:** $182,531  
**Award:** 5R03DK089120-02 (11120288-1)

Matheson, Eric  
**Principal Investigator**
Evaluation of an Oral Nutritional Supplement Containing AN777 in Older Hospitalized Patients  
**Abbott Labs**  
**Budget Dates:** 11/15/11 - 11/14/14  
**Direct F & A**  
**Total**
BK33 (12050589)  
Project Dates: 11/15/11 - 11/14/14  
63,280  
15,070  
78,350

Shoulder Pain Study- ILPharma  
**CROfessionals, LLC**  
**Budget Dates:** 10/24/11 - 01/31/13  
**Direct F & A**  
**Total**
MRX-7EAT-2006 (12070906)  
Project Dates: 10/24/11 - 01/31/13  
71,416  
17,229  
88,645

Co-Investigator  
Residency Training in Primary Care  
**PI:** Peter Carek  
**Dept:** Family Medicine  
**Sponsor:** HRSA  
**Total:** $143,056  
**Award:** 1 D58HP23256-01 (12010027-1)

Ornstein, Steven  
**Principal Investigator**
Enhancing Comparative Effectiveness Research Capabilities in PPRNet  
**AHRQ**  
**Budget Dates:** 08/01/11 - 07/31/12  
**Direct F & A**  
**Total**
1R24HS01944801 (10011392)  
Project Dates: 08/01/10 - 07/31/12  
330,127  
159,280  
489,407
### College of Medicine Annual Report for Research FY2012

#### Family Medicine

### Research Faculty Activity

<table>
<thead>
<tr>
<th>Principal Investigator</th>
<th>Project Title</th>
<th>Sponsor</th>
<th>Budget Dates:</th>
<th>Direct</th>
<th>F &amp; A</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ornstein, Steven</td>
<td>Reducing Inappropriate Antibiotic Prescribing by Primary Care Clinicians</td>
<td>AHRQ</td>
<td>07/22/11 - 07/31/12</td>
<td>86,853</td>
<td>41,255</td>
<td>128,108</td>
</tr>
<tr>
<td></td>
<td>HHS290200710015/Task Ord (11120228)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Co-PI/Project Director**

**Implementation of Alcohol Screening, Intervention and Treatment in Primary Care**
- PI: Peter Miller
- Sponsor: NIH/NIAAA
- Total: $547,045
- Dept: Psychiatry and Behavioral Sciences

<table>
<thead>
<tr>
<th>Co-Investigator</th>
<th>Project Title</th>
<th>Sponsor</th>
<th>Budget Dates:</th>
<th>Direct</th>
<th>F &amp; A</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rodden, Ann</td>
<td>Residency Training in Primary Care</td>
<td>HRSA</td>
<td>07/22/11 - 07/31/12</td>
<td>200,676</td>
<td>95,321</td>
<td>295,997</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Wessell, Andrea**

**Principal Investigator**

**Dissemination of the PRPNet Model for Improving Medication Safety**
- PI: Andrea Wessell
- Sponsor: AHRQ
- Total: $295,997
- Dept: Family Medicine

<table>
<thead>
<tr>
<th>Co-Investigator</th>
<th>Project Title</th>
<th>Sponsor</th>
<th>Budget Dates:</th>
<th>Direct</th>
<th>F &amp; A</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rodden, Ann</td>
<td>Residency Training in Primary Care</td>
<td>HRSA</td>
<td>07/22/11 - 07/31/12</td>
<td>200,676</td>
<td>95,321</td>
<td>295,997</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Medicine

<table>
<thead>
<tr>
<th>Principal Investigator</th>
<th>Project Title</th>
<th>Sponsor</th>
<th>Budget Dates:</th>
<th>Direct</th>
<th>F &amp; A</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Afrin, Lawrence</td>
<td>An Open-Label Assessment of Safety and Efficacy of Ruxolitinib (Incb018424) in Subjects with Primary Myelofibrosis, Post Essential Thrombocytemia-Myelofibrosis and Post Polycythemia Vera-Myelofibrosis Who have Platelet Counts of 50x109/L to 100x109/L</td>
<td>Incyte Corp.</td>
<td>05/05/11 - 05/31/16</td>
<td>33,028</td>
<td>8,257</td>
<td>41,285</td>
</tr>
<tr>
<td></td>
<td></td>
<td>INCB 18424-258 (11110053)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Characterization of Certain Peripheral Blood Cell Abnormalities Potentially Aiding the Diagnosis of Mast Cell Activation Syndrome</td>
<td>The Mastocytosis Society</td>
<td>04/01/12 - 03/31/13</td>
<td>52,516</td>
<td>0</td>
<td>52,516</td>
</tr>
<tr>
<td></td>
<td></td>
<td>(12020225)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Alternative Dosing Strategy of Ruxolitinib in Patients with Myelofibrosis</td>
<td>Pharmanet</td>
<td>11/17/11 - 11/16/16</td>
<td>59,742</td>
<td>14,186</td>
<td>73,928</td>
</tr>
<tr>
<td></td>
<td></td>
<td>INCB 18424-261 (12030370)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>A Randomized, Phase II, Open-Label Study of the Efficacy and Safety of Orally Administered SAR302503 in Patients with Polycythemia Vera (PV) or Essential Thrombocytemia (ET) Who are Resistant or Intol</td>
<td>Sanofi-Aventis US, Inc.</td>
<td>02/06/12 - 02/17/17</td>
<td>200,552</td>
<td>49,013</td>
<td>249,565</td>
</tr>
<tr>
<td></td>
<td></td>
<td>ARD12042 (12081059)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 3-Arm Study of SAR302503 in Patients with Intermediate-2 or High-Risk Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocytemia Myelofibrosis with Splenomegaly</td>
<td>Sanofi-Aventis US, Inc.</td>
<td>03/16/12 - 03/20/17</td>
<td>527,560</td>
<td>131,140</td>
<td>658,700</td>
</tr>
<tr>
<td></td>
<td></td>
<td>EFC12153 (12091286)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>A Phase 1 Study of LY2784544 Testing Alternative Dosing Regimens in Patients with Myelofibrosis</td>
<td>Eli Lilly</td>
<td>03/21/12 - 03/20/17</td>
<td>176,118</td>
<td>42,779</td>
<td>218,897</td>
</tr>
<tr>
<td></td>
<td></td>
<td>I3X-MC-JHTC (12091298)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### Alberg, Anthony

**Principal Investigator**

**Epidemiology of Ovarian Cancer in African American Women**

Duke Univ.  
203-0312 (12081170)  
Budget Dates: 04/01/12 - 03/31/13  
Project Dates: 04/01/10 - 03/31/15  
Direct: 79,752  
F & A: 22,735  
Total: 102,487

**Co-Investigator**

**South Carolina Clinical and Translational Research Institute (UL1)**

- PI: Kathleen Brady  
- Dept: Psychiatry and Behavioral Sciences  
- Sponsor: NIH/NCRR  
- Award: 5UL1RR029882-03 (11012750-2)  
- Total: $301,173

**A Novel Trial of Smokeless Tobacco for Cessation Induction in Unmotivated Smokers**

- PI: Matthew Carpenter  
- Dept: Psychiatry and Behavioral Sciences  
- Sponsor: NIH/NCI  
- Award: 5R01CA154992-02 (12070935-1)  
- Total: $562,505

**Co-Investigator**

**South Carolina Clinical and Translational Research Institute (SCTR): UL1**

- PI: Kathleen Brady  
- Dept: Psychiatry and Behavioral Sciences  
- Sponsor: NIH/NCATS  
- Award: 8UL1TR000062-04 (12070938-1)  
- Total: $798,196

**Mentor**

**Race, Pathomolecular Signature and Colorectal Cancer Survival**

- PI: Kristin Wallace  
- Dept: Medicine  
- Sponsor: NIH/NCI  
- Award: 1K07CA151864-01A1 (11030805-1)  
- Total: $130,415

---

### Arthur, John

**Principal Investigator**

**Hopkins Lupus Cohort**

Johns Hopkins Univ.  
5R01AR043727-12/2000440 (11051735)  
Budget Dates: 04/01/11 - 03/31/12  
Project Dates: 05/01/08 - 03/31/13  
Direct: 28,256  
F & A: 7,347  
Total: 35,603

**SmartState Center for Renal Disease Biomarkers State Match Endowment Draw**

SC Research Centers of Economic Excellence  
(12091238)  
Budget Dates: 07/01/11 - 06/30/12  
Project Dates: 06/09/08 - 06/30/12  
Direct: 366,516  
F & A: 0  
Total: 366,516

**SmartState Center for Renal Disease Biomarkers**

MUSC Fdn.  
COEE (12101415)  
Budget Dates: 07/01/11 - 06/30/12  
Project Dates: 07/01/09 - 06/30/12  
Direct: 12,167  
F & A: 0  
Total: 12,167

---

### Assey, Valerie

**Co-Investigator**

**Ryan White Part B Program**

- PI: J. Kilby  
- Dept: Medicine  
- Sponsor: SC DHEC  
- Award: HV-1-747 (11022212-2)  
- Total: $47,532

**Ryan White Part B Program**

- PI: J. Kilby  
- Dept: Medicine  
- Sponsor: SC DHEC  
- Award: HV-1-747 (12050659-1)  
- Total: $1,565,105

---

Medical University of South Carolina
Awgulewitsch, A.  
**Principal Investigator**

**Genetics of Alopecia Areata in the C3H/HeJ Mouse**

The Jackson Laboratory

<table>
<thead>
<tr>
<th>Budget Dates: 07/01/11 - 06/30/12</th>
<th>Direct</th>
<th>F &amp; A</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>R01 AR056635-02 (11050360)</td>
<td>21,600</td>
<td>10,260</td>
<td>31,860</td>
</tr>
</tbody>
</table>

Axon, Robert  
**Principal Investigator**

**Better Outcomes for Older Adults Through Safe Transition (BOOST)**

Society of Hospital Medicine

<table>
<thead>
<tr>
<th>Budget Dates: 10/01/11 - 09/30/12</th>
<th>Direct</th>
<th>F &amp; A</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Project BOOST (11041273)</td>
<td>9,600</td>
<td>0</td>
<td>9,600</td>
</tr>
</tbody>
</table>

Baicu, Catalin  
**Co-Investigator**

**mTOR in Growth and Protection of Hypertrophying Myocardium**

PI: Dhandapani Kuppuswamy  
Sponsor: NIH/NHLBI  
Total: $328,556  
Dept: Medicine  
Award: 5R01HL092124-04 (12040510-1)

**Advanced Glyceral End-Products in Human Myocardium**

PI: Michael Zile  
Sponsor: Univ. of Vermont  
Total: $216,246  
Dept: Medicine  
Award: 21649/R01 HL089944-04 (12050590-1)

**Role of Protein Acetylation in NCX1 Expression**

PI: Donald Menick  
Sponsor: NIH/NHLBI  
Total: $365,063  
Dept: Medicine  
Award: 5R01HL095696-04 (12081078-1)

Baker, Deanna  
**Principal Investigator**

**The Role of Sphingosine Kinase 1 in a Mouse Model of Chronic Inflammation**

NIH/NIAMS  
Total: $36,289  
Budget Dates: 07/01/11 - 06/30/12  
Project Dates: 07/01/09 - 06/30/12  
Dept: Medicine  
Award: 5F31AR057307-03 (11042626)

Baker, Nathaniel  
**Co-Investigator**

**ORWH: SCOR on Sex and Gender Factors Affecting Women's Health (Project 2)**

PI: Kathleen Brady  
Sponsor: NIH/NIDA  
Total: $193,035  
Dept: Psychiatry and Behavioral Sciences  
Award: 5P50DA016511-10 (11042208-3)

**A Randomized, Controlled Trial of Varenicline for Adolescent Smoking Cessation**

PI: Kevin Gray  
Sponsor: NIH/NIDA  
Total: $624,216  
Dept: Psychiatry and Behavioral Sciences  
Award: 1U01DA031779-01A1 (11120320-1)

**Buspirone Treatment for Marijuana Dependence**

PI: Aimee McRae  
Sponsor: NIH/NIDA  
Total: $315,339  
Dept: Psychiatry and Behavioral Sciences  
Award: 5R01DA026782-04 (12101372-1)

Balasubramanian, S.  
**Co-Investigator**

**mTOR in Growth and Protection of Hypertrophying Myocardium**

PI: Dhandapani Kuppuswamy  
Sponsor: NIH/NHLBI  
Total: $328,556  
Dept: Medicine  
Award: 5R01HL092124-04 (12040510-1)

**mTOR in Growth and Protection of Hypertrophying Myocardium**

PI: Dhandapani Kuppuswamy  
Sponsor: NIH/NHLBI  
Total: $36,507  
Dept: Medicine  
Award: 5R01HL092124-04 (12040510-2)

Bandyopadhyay, D.  
**Principal Investigator**

**Robust Nonparametric Methods with Variable Selection for Clustered Dental Data**

NIH/NIDCR  
Total: $26,125  
Budget Dates: 07/01/11 - 07/31/11  
Project Dates: 07/01/10 - 07/31/11  
Dept: Medicine  
Award: 5R03DE020114-02 (11051212)

**Co-PI/Project Director**

**Robust Transition Models for the Analysis of Longitudinal Drinking Outcomes**

PI: Stacia DeSantis  
Sponsor: NIH/NIAAA  
Total: $26,125  
Dept: Medicine  
Award: 5R03AA020648-01 (10101104-1)

**Co-Investigator**

**Impact of MRSA Decolonization Therapy on MRSA Infection and Transmission**

PI: Arch Mainous  
Sponsor: AHRQ  
Total: $496,813  
Dept: Family Medicine  
Award: 1R01HS018954-01A1 (10101315-1)
<table>
<thead>
<tr>
<th>Principal Investigator</th>
<th>Institution</th>
<th>Amount</th>
<th>Start Date</th>
<th>End Date</th>
<th>Direct</th>
<th>F &amp; A</th>
<th>Total</th>
<th>Project Dates</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bell, Phillip</td>
<td>Hepato/Renal Fibrocystic Diseases Center (Core C)</td>
<td>Univ. of Alabama, Birmingham</td>
<td>Budget Dates: 07/01/11 - 06/30/12</td>
<td>Direct F &amp; A Total</td>
<td>128,787</td>
<td>61,174</td>
<td>189,961</td>
<td>Project Dates: 09/30/10 - 06/30/15</td>
</tr>
<tr>
<td>Training Grant in Renal Function and Disease</td>
<td>NIH/NIDDK</td>
<td>5T32DK007752-13 (11110094)</td>
<td>Budget Dates: 08/01/11 - 07/31/12</td>
<td>Direct F &amp; A Total</td>
<td>117,528</td>
<td>9,143</td>
<td>126,671</td>
<td>Project Dates: 08/17/98 - 07/31/14</td>
</tr>
<tr>
<td>Co-Investigator</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Principal Investigator</th>
<th>Institution</th>
<th>Amount</th>
<th>Start Date</th>
<th>End Date</th>
<th>Direct</th>
<th>F &amp; A</th>
<th>Total</th>
<th>Project Dates</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bogatkevich, Galina</td>
<td>Role of IQ Motif Containing GTPase Activating Protein 1 in Scleroderma Interstitial Lung Disease</td>
<td>Scleroderma Fdn.</td>
<td>Budget Dates: 01/01/12 - 12/31/12</td>
<td>Direct F &amp; A Total</td>
<td>69,444</td>
<td>5,556</td>
<td>75,000</td>
<td>Project Dates: 01/01/11 - 12/31/12</td>
</tr>
<tr>
<td>Principal Investigator</td>
<td>PHAROS Study</td>
<td>Georgetown University</td>
<td>Budget Dates: 07/01/11 - 12/31/12</td>
<td>Direct F &amp; A Total</td>
<td>103,356</td>
<td>39,391</td>
<td>142,747</td>
<td>Project Dates: 05/01/10 - 04/30/12</td>
</tr>
<tr>
<td>Borst, Marcy</td>
<td>Mechanisms of B Cell Responses in Autoimmune Disease: C10-ARA06-MSC</td>
<td>Duke Univ.</td>
<td>Budget Dates: 05/01/11 - 04/30/12</td>
<td>Direct F &amp; A Total</td>
<td>108,209</td>
<td>38,282</td>
<td>146,491</td>
<td>Project Dates: 09/01/09 - 04/30/13</td>
</tr>
<tr>
<td>Principal Investigator</td>
<td>A Multi-Center, Open-Label, Single-Arm Study to Evaluate the Safety of Administering Rituximab at a More Rapid Infusion Rate in Patients with RA</td>
<td>Pharmameet</td>
<td>Budget Dates: 10/04/11 - 05/31/13</td>
<td>Direct F &amp; A Total</td>
<td>206,188</td>
<td>50,047</td>
<td>256,235</td>
<td>Project Dates: 07/01/11 - 02/28/14</td>
</tr>
<tr>
<td>Brooks, Deborah</td>
<td>Second Study of the Effect of Teriparatide on Femoral Neck Fracture Healing</td>
<td>Eli Lilly</td>
<td>Budget Dates: 01/06/12 - 07/31/15</td>
<td>Direct F &amp; A Total</td>
<td>52,078</td>
<td>12,144</td>
<td>64,222</td>
<td>Project Dates: 01/06/12 - 07/31/15</td>
</tr>
<tr>
<td>Principal Investigator</td>
<td>Rheumatoid Arthritis Retrospective Chart ReviEw Study (ARCHIVE)</td>
<td>Icon Clinical Research, Inc.</td>
<td>Budget Dates: 02/20/12 - 12/31/12</td>
<td>Direct F &amp; A Total</td>
<td>4,880</td>
<td>970</td>
<td>5,850</td>
<td>Project Dates: 02/20/12 - 12/31/12</td>
</tr>
<tr>
<td>Principal Investigator</td>
<td>Mechanisms of B Cell Responses in Autoimmune Disease</td>
<td>Duke Univ.</td>
<td>Budget Dates: 05/01/12 - 04/30/13</td>
<td>Direct F &amp; A Total</td>
<td>103,356</td>
<td>39,391</td>
<td>142,747</td>
<td>Project Dates: 05/01/10 - 04/30/13</td>
</tr>
<tr>
<td>Principal Investigator</td>
<td>Procollagen Binding Proteins in Age-Dependent LV Remodeling</td>
<td>VAMC</td>
<td>Budget Dates: 04/01/12 - 03/31/13</td>
<td>Direct F &amp; A Total</td>
<td>320,500</td>
<td>0</td>
<td>320,500</td>
<td>Project Dates: 04/01/12 - 03/31/16</td>
</tr>
<tr>
<td>Bradshaw, Amy</td>
<td>Systolic Blood Pressure Intervention Trial (SPRINT) Clinical Centers Network</td>
<td>Sponsor: Univ. of Alabama, Birmingham</td>
<td>Total $33,049</td>
<td>Project Dates: 04/01/12 - 03/31/16</td>
<td>320,500</td>
<td>0</td>
<td>320,500</td>
<td>Project Dates: 04/01/12 - 03/31/16</td>
</tr>
<tr>
<td>Name</td>
<td>Role</td>
<td>Project Title</td>
<td>PI / Sponsor</td>
<td>Sponsor / ID</td>
<td>Total Amount</td>
<td>Dept</td>
<td>Award Number</td>
<td></td>
</tr>
<tr>
<td>-----------------------</td>
<td>--------------------</td>
<td>-------------------------------------------------------------------------------</td>
<td>---------------------------------------------</td>
<td>--------------------------------</td>
<td>--------------</td>
<td>-----------------------</td>
<td>--------------------------------------------------------</td>
<td></td>
</tr>
<tr>
<td>Brooks, Deborah</td>
<td>Co-Investigator</td>
<td>Systolic Blood Pressure Intervention Trial (SPRINT) Clinical Center Networks</td>
<td>Ruth Campbell</td>
<td>Univ. of Alabama, Birmingham</td>
<td>$126,443</td>
<td>Medicine</td>
<td>000336417-035/HHSN2682009 (12020176-1)</td>
<td></td>
</tr>
<tr>
<td>Brzezinski, Walter</td>
<td>Co-Investigator</td>
<td>Phosphatidylethanol as an Alcohol Biomarker in Patients with Liver Disease</td>
<td>Scott Stewart</td>
<td>NIH/NIAAA</td>
<td>$280,719</td>
<td>Psychiatry and Behavioral Sciences</td>
<td>5R01AA017911-03 (12010043-1)</td>
<td></td>
</tr>
<tr>
<td>Budisavljevic, Milos</td>
<td>Principal Investigator</td>
<td>A Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Study of H.P. Acthar Gel (Acthar) in Treatment-Resistant Subjects with Persistent Proteinuria and Nephrotic Syndrome Due to Idiopathic Membranous Nephropathy (iMN)</td>
<td>Michael Schmidt</td>
<td>Advanced Technology Institute</td>
<td>$80,639</td>
<td>Microbiology and Immunology</td>
<td>2007-614-05 (09060308-2)</td>
<td></td>
</tr>
<tr>
<td>Buse, Maria</td>
<td>Principal Investigator</td>
<td>Factors That Modify Insulin Action</td>
<td>Kenneth Tew</td>
<td>Univ. of New Mexico Health S</td>
<td>$195,436</td>
<td>Cell and Molecular Pharmacology</td>
<td>1P20RR024485-01A2 (09062764-3)</td>
<td></td>
</tr>
<tr>
<td>Campbell, Ruth</td>
<td>Principal Investigator</td>
<td>Bardoxolone Methyl Evaluation in Patients with CKD and Type 2 Diabetes: The Occurrence of Renal Events</td>
<td>Michael Schmidt</td>
<td>Abbott Labs</td>
<td>$78,350</td>
<td>Family Medicine</td>
<td>BK33 (12050589-1)</td>
<td></td>
</tr>
<tr>
<td>Cantey, J.</td>
<td>Co-Investigator</td>
<td>Copper Antimicrobial Research Program</td>
<td>Eric Matheson</td>
<td>Abbott Labs</td>
<td>$80,639</td>
<td>Biology and Immunology</td>
<td>BK33 (12050589-1)</td>
<td></td>
</tr>
<tr>
<td>Caton, Cathryn</td>
<td>Co-Investigator</td>
<td>Evaluation of an Oral Nutritional Supplement Containing AN777 in Older Hospitalized Patients</td>
<td>Eric Matheson</td>
<td>Abbott Labs</td>
<td>$78,350</td>
<td>Pharmacy and Toxicology</td>
<td>BK33 (12050589-1)</td>
<td></td>
</tr>
</tbody>
</table>
**Cen, Bo**

**Principal Investigator**

**Role of Pim Kinases in Prostate Epithelium Growth**

NIH/NIDDK  
Project Dates: 03/01/11 - 01/31/15  
122,950  
9,836  
132,786

**Cheng, Guangmao**

**Co-Investigator**

**MAP4 Regulation of Cardiac Microtubule Network Density**

PI: Donald Menick  
Sponsor: NIH/NHLBI  
Total: $365,063

**Chin, Steve**

**Principal Investigator**

**Evaluation of the Pharmacokinetics of Trastuzumab Administered Every Three Weeks at Two Different Maintenance Dose Levels to Patients with Metastatic HER2-Positive Gastric or Gastro-Esophageal Junction**

Genentech, Inc.  
Budget Dates: 03/01/11 - 02/27/16  
271,574  
66,768  
338,342

**Christiansen, Neal**

**Principal Investigator**

**A Phase 2, Multi-Center, Single-Arm Study of Eribulin Mesylate with Trastuzumab as First-Line Therapy for Locally Recurrent or Metastatic Human Epidermal Growth Factor Receptor Two (HER2) Positive Breast Cancer**

Elsal, Inc.  
Budget Dates: 02/01/11 - 01/31/13  
120,70819  
120,70819

**Coaxum, Sonya**

**Principal Investigator**

**Role of Epidermal Growth Factor in Activation of Na+/H+ Exchanger in Polycystic Kidney Disease**

NIH/NHLBI  
Project Dates: 09/01/10 - 08/31/13  
107,348  
8,588  
115,936

**Comerford, Lawrence**

**Principal Investigator**

**A Non-Interventional, Long-Term, Post-Marketing Registry of Patients Treated with Certolizumab Pegol (Cimzia) for Crohn's Disease**

MUSC OIP  
Budget Dates: 10/12/11 - 10/31/12  
60,557  
13,508  
74,065
Comerford, Lawrence

**Principal Investigator**

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Subjects with Moderately to Severely

Parexel Intl. Corp.  
Budget Dates: 01/06/12 - 01/06/13  
Direct F & A  
Total

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Subjects with Crohn’s Disease

Parexel Intl. Corp.  
Budget Dates: 01/06/12 - 01/06/13  
Direct F & A  
Total

Methotrexate Response in Treatment of UC (MERIT-UC)

Univ. of North Carolina  
Budget Dates: 08/15/11 - 06/30/12  
Direct F & A  
Total

---

Cooper, IV, George

**Principal Investigator**

Connexin Distribution in Physiological Versus Pathological Cardiac Hypertrophy

VAMC  
Budget Dates: 10/01/11 - 09/30/12  
Direct F & A  
Total

---

Costa, Luciano

**Principal Investigator**

A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients with Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo after Patients Have Achieved Complete Response with First-Line Rituximab-Chemotherapy

Novartis Corp.  
Budget Dates: 01/05/10 - 04/08/13  
Direct F & A  
Total

Phase 2, Trial of Sequential Ofatumumab and Lenalidomide for the Treatment of Chronic Lymphocytic Leukemia (CLL) Patients Previously Exposed to Rituximab

GlaxoSmithKline  
Budget Dates: 01/15/10 - 01/14/15  
Direct F & A  
Total


Covance, Inc.  
Budget Dates: 05/12/10 - 05/11/15  
Direct F & A  
Total

A Phase II, Open-Label, Multi-Center Study of Efficacy, Safety, and Biomarkers in Patients with Previously Untreated Advanced Diffuse Large B-Cell Lymphoma Treated with GA101 (RO5072759) in Combination with CHOP Chemotherapy

INc Research, Inc.  
Budget Dates: 06/20/11 - 07/31/16  
Direct F & A  
Total

A Phase 1B, Multi-Center, Open-Label, Dose-Escalation Study of SAR245409 to Evaluate the Safety, Tolerability, and Clinical Activity of SAR245409 in Combination with Bendamustine and/or Rituximab in Patients with Relapsed or Refractory Indolent B-Cell Non-Hodgkin Lymphoma, Mantle Cell Lymphoma, or Chronic Lymphocytic Leukemia

Sanofi-Aventis US, Inc.  
Budget Dates: 09/14/11 - 09/13/16  
Direct F & A  
Total

Carfilzomib Multiple Myeloma Expanded Access Protocol for Patients with Relapsed and Refractory Disease

Multiple Myeloma Research Fdn.  
Budget Dates: 10/14/11 - 10/13/16  
Direct F & A  
Total
Costa, Luciano  
**Principal Investigator**  
*A Phase III Trial of Cyclophosphamide, Carfilzomib, Thalidomide and Dexamethasone in Patients with Newly Diagnosed Active Multiple Myeloma (CYCLONE)*  
Mayo Clinic  
Project Dates: 10/12/11 - 10/11/16  
Cost: 117,950  
Director F & A  
MC0982 (12040456)

---

Cotton, Peter  
**Principal Investigator**  
*Evaluating Predictors and Interventions in Sphincter of Oddi Dysfunction (EPISOD)*  
NIH/NIDDK  
Project Dates: 09/15/07 - 06/30/14  
Cost: 1,584,047  
Director F & A  
5U01DK074739-05 (11042733)

---

Cuoco, Frank  
**Principal Investigator**  
*Product Performance Platform (PPP)*  
Medtronic, Inc.  
Project Dates: 08/05/10 - 12/31/12  
Cost: 34,768  
Director F & A  
PPP (10063069)

---

Dantzler, Todd  
**Principal Investigator**  
*A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in the Treatment of Patients with Diarrhea-Predominant IBS*  
PPD Development  
Project Dates: 03/20/12 - 03/31/13  
Cost: 65,719  
Director F & A  
JNJ27018966IBS3001 (12091324)

---

DeSantis, Stacia  
**Principal Investigator**  
*Robust Transition Models for the Analysis of Longitudinal Drinking Outcomes*  
NIH/NIAAA  
Project Dates: 09/10/11 - 07/31/13  
Cost: 82,876  
Director F & A  
1R03AA020648-01 (10101104)

---

Dismuke, Clara  
**Co-Investigator**  
*Telephone Delivered Behavioral Skills Intervention for Blacks with T2DM (PARENT)*  
NIH/NIDDK  
Project Dates: 09/10/11 - 07/31/13  
Cost: 508,994  
Director F & A  
SR01DK081121-04 (11050471-1)
<table>
<thead>
<tr>
<th>Principal Investigator</th>
<th>Project Title</th>
<th>Sponsor</th>
<th>Budget Dates</th>
<th>Direct F &amp; A</th>
<th>Total F &amp; A</th>
</tr>
</thead>
<tbody>
<tr>
<td>Drabkin, Harry</td>
<td>Phase 2, Open-Label, Single-Arm, Multi-Center Study for Subjects with Metastatic Renal Cell Carcinoma</td>
<td>Amgen</td>
<td>03/23/09 - 04/30/14</td>
<td>2,000</td>
<td>2,500</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>03/23/09 - 04/30/14</td>
<td>500</td>
<td></td>
</tr>
<tr>
<td></td>
<td>A Randomized, Double-Blind, Placebo-Controlled, Phase III Study to Evaluate the Efficacy and Safety of Pazopanib as Adjuvant Therapy for Subjects with Localized or Locally Advanced RCC Following Nephrectomy</td>
<td>GlaxoSmithKline</td>
<td>03/08/11 - 04/30/12</td>
<td>6,704</td>
<td>8,380</td>
</tr>
<tr>
<td></td>
<td></td>
<td>VEGI13387 (11030908)</td>
<td>03/08/11 - 04/30/12</td>
<td>1,676</td>
<td></td>
</tr>
<tr>
<td></td>
<td>SPORE in Lung Cancer</td>
<td>Univ. of Colorado</td>
<td>05/01/11 - 04/30/12</td>
<td>177,296</td>
<td>258,852</td>
</tr>
<tr>
<td></td>
<td></td>
<td>FY08.046.002/P50 CA058187 (11051837)</td>
<td>05/01/11 - 04/30/12</td>
<td>81,556</td>
<td></td>
</tr>
<tr>
<td></td>
<td>The Combination of Carfilzomib or ONX 0912 Plus Metformin in the Treatment of Selected Hematologic Malignant Diseases and Solid Tumors</td>
<td>Onyx Pharmaceuticals</td>
<td>06/01/12 - 05/31/17</td>
<td>25,000</td>
<td>36,875</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Funded MTA (11120249)</td>
<td>06/01/12 - 05/31/17</td>
<td>11,875</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Neoadjuvant Pazopanib: A Phase II Study to Evaluate the Effect on Disease Response and Recurrence and to Establish Predictive Biomarkers of Drug Activity in Renal Cell Carcinoma</td>
<td>Univ. of North Carolina</td>
<td>12/14/11 - 10/14/16</td>
<td>53,660</td>
<td>65,950</td>
</tr>
<tr>
<td></td>
<td></td>
<td>LCCC #1028 (12050693)</td>
<td>12/14/11 - 10/14/16</td>
<td>12,290</td>
<td></td>
</tr>
<tr>
<td></td>
<td>An Open-Label, Multi-Center, Phase IIb/2 Study of E7080 Alone, and in Combination with Everolimus in Subjects with Unresectable Advanced or Metastatic Renal Cell Carcinoma Following One Prior VEGF-Target</td>
<td>Eisai, Inc.</td>
<td>03/16/12 - 03/15/17</td>
<td>173,205</td>
<td>215,756</td>
</tr>
<tr>
<td></td>
<td></td>
<td>E7080-G000-205 (120911196)</td>
<td>03/16/12 - 03/15/17</td>
<td>42,551</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Phase III Study of BNC105P in Combination with Everolimus or Following Everolimus for Progressive Metastatic Clear Cell Renal Cell Carcinoma Following Prior Tyrosine Kinase Inhibitors</td>
<td>Hoosier Oncology Group</td>
<td>03/13/12 - 04/03/17</td>
<td>45,479</td>
<td>56,161</td>
</tr>
<tr>
<td></td>
<td></td>
<td>GU09-145 (12091271)</td>
<td>03/13/12 - 04/03/17</td>
<td>10,682</td>
<td></td>
</tr>
<tr>
<td>Durkalski, Valerie</td>
<td>A Multi-Center Study of Acute Liver Failure in Adults</td>
<td>UT Southwestern Med. Ctr.</td>
<td>09/01/11 - 08/31/12</td>
<td>266,529</td>
<td>392,174</td>
</tr>
<tr>
<td></td>
<td></td>
<td>GMO-110105/U01 DK058369-1 (11120331)</td>
<td>09/01/11 - 08/31/12</td>
<td>125,645</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Accelerating Drug and Device Evaluation through Innovative Clinical Trial Design - Adaptive Design Trial</td>
<td>Univ. of Michigan</td>
<td>09/01/11 - 08/31/12</td>
<td>37,357</td>
<td>55,102</td>
</tr>
<tr>
<td></td>
<td></td>
<td>3001888366/U01 NS073476-0 (12020269)</td>
<td>09/01/11 - 08/31/12</td>
<td>17,745</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Web-Based Study Database for Cervel Neurotech, Inc.</td>
<td>Cervel Neuro Tech. Inc.</td>
<td>09/16/11 - 09/15/12</td>
<td>82,692</td>
<td>107,500</td>
</tr>
<tr>
<td></td>
<td></td>
<td>(12030393)</td>
<td>09/16/11 - 09/15/12</td>
<td>24,808</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Stroke Hyperglycemia Insulin Network Effort (SHINE) Trial</td>
<td>Univ. of Virginia</td>
<td>08/01/11 - 07/31/12</td>
<td>264,251</td>
<td>385,537</td>
</tr>
<tr>
<td></td>
<td></td>
<td>GC12107-138780/U01 NS0694 (12050643)</td>
<td>08/01/11 - 07/31/12</td>
<td>121,286</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Access to Serious Hepatotoxicity Surveillance Database (SHSD)</td>
<td>UT Southwestern Med. Ctr.</td>
<td>09/15/11 - 09/14/12</td>
<td>59,464</td>
<td>87,710</td>
</tr>
<tr>
<td></td>
<td></td>
<td>GMO121105/HHSF2320111010 (12060738)</td>
<td>09/15/11 - 09/14/12</td>
<td>28,246</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Co-PI/Project Director</th>
<th>Neurological Emergencies Treatment Trial Network Statistical/Data Management Center (NETT)</th>
<th>Sponsor: NIH/NINDS</th>
<th>Total: $1,098,903</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Award: 2U01NS059041-06 (10103097-1)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Evaluating Predictors and Interventions in Sphincter of Oddi Dysfunction (EPISOD): Data - Parent</td>
<td>Sponsor: NIH/NIDDK</td>
<td>Total: $184,472</td>
</tr>
<tr>
<td></td>
<td>Award: 5U01DK074739-05 (11042733-3)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Evaluating Predictors and Interventions in Sphincter of Oddi Dysfunction (EPISOD) (Supplement for Long Term Followup of Enrolled Subjects): Data Coordinating Unit</td>
<td>Sponsor: NIH/NIDDK</td>
<td>Total: $61,268</td>
</tr>
<tr>
<td></td>
<td>Award: 3U01DK074739-05S1 (12010131-3)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
**Durkalski, Valerie**

**Co-Investigator**

**Telephone Delivered Behavioral Skills Intervention for Blacks with T2DM (PARENT)**  
**PI:** Leonard Egede  
**Sponsor:** NIH/NIDDK  
**Total:** $508,994  
**Dept:** Medicine  
**Award:** 5R01DK081121-04 (11050471-1)

**Telephone Delivered Behavioral Skills Intervention for Blacks with T2DM (DIVERSITY SUPPLEMENT)**  
**PI:** Leonard Egede  
**Sponsor:** NIH/NIDDK  
**Total:** $74,222  
**Dept:** Medicine  
**Award:** 5R01DK081121-04 (11050471-2)

---

**Egan, Brent**

**Principal Investigator**

**SC Community Transformation Grant: Hypertension Initiative**  
**Dept:** Medicine  
**Award:** 5R01DK081121-04 (11050471-1)

---

**Egede, Leonard**

**Principal Investigator**

**SE VIEW Phase II (SC TELE DMI)**  
**PI:** Sabra Slaughter  
**Sponsor:** DOD  
**Total:** $97,801  
**Dept:** Presidents Office  
**Award:** W81XWH-11-2-0164 (12030345-4)
Egede, Leonard  
Co-Investigator  
REACH U.S. Southeastern African American Center of Excellence for Elimination of Disparities  
PI: Carolyn Jenkins  
Dept: Nursing  
Sponsor: CDC  
Award: 5 U58 DP001015-05 (11042629-1)  
Total: $ 850,001

Elm, Jordan  
Principal Investigator  
Parkinson’s Disease Clinical Trial: Statistical Center  
Univ. of Texas Health Science Center at Houston  
Budget Dates: 12/01/10 - 05/31/12  
Project Dates: 07/01/09 - 05/31/12  
Direct F & A  
Total  
38,792  18,426  57,218

Co-Investigator  
Neurological Emergencies Treatment Trial Network/Statistical/Data Management Center (NETT)  
PI: Yuko Palesch  
Dept: Medicine  
Sponsor: NIH/NINDS  
Award: 2U01NS059041-06 (10103097-1)  
Total: $ 1,098,903

Fernandes, Jyotika  
Principal Investigator  
Genetic Contributors to Diabetes and Dyslipidemia in African Americans  
Univ. of Virginia  
Budget Dates: 08/01/09 - 07/31/11  
Project Dates: 08/01/09 - 07/31/11  
Direct F & A  
Total  
18,062  8,579  26,641

Feussner, John  
Co-PI/Project Director  
Aging Q3: Quality Education, Quality of Care, Quality of Life  
PI: William Moran  
Dept: Medicine  
Sponsor: Donald W. Reynolds Fdn.  
Award: (12081032-1)  
Total: $ 500,000

Fitzgibbon, Wayne  
Co-PI/Project Director  
Role of Angiotensin II in Medullary Solute and Water Reabsorption  
PI: David Ploth  
Dept: Medicine  
Sponsor: Dialysis Clinics, Inc.  
Award: C-3052A (East Cooper) (09010876-2)  
Total: $ 44,225

MUSC Division of Nephrology Renal Physiology/Pathophysiology Core  
PI: Michael Ullian  
Dept: Medicine  
Sponsor: Dialysis Clinics, Inc.  
Award: C-3465 - Magnolia (128) (12050664-1)  
Total: $ 219,588

Co-Investigator  
Hepato/Renal Fibrocystic Diseases Center (Core C)  
PI: Phillip Bell  
Dept: Medicine  
Sponsor: Univ. of Alabama, Birmingham  
Award: 000402961-001/P30 DK07435-0 (12020269-1)  
Total: $ 189,961

Flume, Patrick  
Principal Investigator  
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of VX-770 in Subjects Aged 12 Years and Older with Cystic Fibrosis Who are Homozygous for the F508del-CFTR Mutation  
Vertex Pharmaceuticals, Inc.  
Budget Dates: 07/28/09 - 08/31/13  
Project Dates: 07/28/09 - 08/31/13  
Direct F & A  
Total  
5,000  1,250  6,250

A Phase 2, Multi-Center, Double-Blinded, Placebo-Controlled, Multiple-Dose Study to Evaluate Safety, Tolerability, Efficacy, Pharmacokinetics and Pharmacodynamics of VX 809 Alone and in Combination with VX 770 in Subjects with Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation  
Vertex Pharmaceuticals, Inc.  
Budget Dates: 08/17/10 - 07/31/12  
Project Dates: 08/17/10 - 07/31/12  
Direct F & A  
Total  
36,376  8,469  44,845

MUSC DiP  
MUSC OIP  
Budget Dates: 11/08/10 - 08/31/12  
Project Dates: 11/08/10 - 08/31/12  
Direct F & A  
Total  
54,076  12,724  66,800

MPEX-209: A Phase, Open-Label, Randomized Trial to Evaluate the Safety and Efficacy of MP-376 Inhalation Solution (Aeroquin) versus Tobramycin Inhalation Solution (TIS) in Stable Cystic Fibrosis Patients
<table>
<thead>
<tr>
<th>Principal Investigator</th>
<th>Rempex Pharmaceuticals, Inc.</th>
<th>Budget Dates: 01/10/11 - 06/30/13</th>
<th>Direct F &amp; A</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>MPEX 209 (11011148)</td>
<td>Project Dates: 01/10/11 - 06/30/13</td>
<td>62,400</td>
<td>15,600</td>
</tr>
</tbody>
</table>

**CFF Patient Registry**

<table>
<thead>
<tr>
<th>PI:</th>
<th>Principal Investigator</th>
<th>Sponsor</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Flume, Patrick</td>
<td>Rempex Pharmaceuticals, Inc.</td>
<td>$78,000</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Cystic Fibrosis Fdn.</th>
<th>Project Dates: 01/01/12 - 12/31/12</th>
<th>Direct F &amp; A</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>C104-11 (12020186)</td>
<td></td>
<td>83,755</td>
<td>83,755</td>
</tr>
</tbody>
</table>

**Therapeutics Development Center (TDC)**

<table>
<thead>
<tr>
<th>PI:</th>
<th>Principal Investigator</th>
<th>Sponsor</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Flume, Patrick</td>
<td>Rempex Pharmaceuticals, Inc.</td>
<td>$83,755</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Cystic Fibrosis Fdn.</th>
<th>Project Dates: 01/01/09 - 12/31/12</th>
<th>Direct F &amp; A</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>(12030296)</td>
<td></td>
<td>78,400</td>
<td>6,272</td>
</tr>
</tbody>
</table>

**Vertex Preceptorship Program**

<table>
<thead>
<tr>
<th>PI:</th>
<th>Principal Investigator</th>
<th>Sponsor</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Flume, Patrick</td>
<td>Rempex Pharmaceuticals, Inc.</td>
<td>$25,000</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Project Dates: 08/23/11 - 08/22/12</th>
<th>Direct F &amp; A</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Preceptorship (12030310)</td>
<td>23,148</td>
<td>1,852</td>
</tr>
</tbody>
</table>

**A Phase 2, Multi-Center, Double-Blinded, Placebo-Controlled, 3-Part Study to Evaluate Safety, Efficacy, Pharmacokinetics and Pharmacodynamics Cotherapy in Subjects with Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation**

<table>
<thead>
<tr>
<th>Quintiles Pacific, Inc.</th>
<th>Project Dates: 09/23/11 - 09/30/12</th>
<th>Direct F &amp; A</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>VX11-661-101 (12040421)</td>
<td></td>
<td>81,270</td>
<td>19,568</td>
</tr>
</tbody>
</table>

**Cystic Fibrosis Questionnaire-Revised (CFQ-R)**

<table>
<thead>
<tr>
<th>PI:</th>
<th>Principal Investigator</th>
<th>Sponsor</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Flume, Patrick</td>
<td>Rempex Pharmaceuticals, Inc.</td>
<td>$100,838</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Behavioral Health Systems Research</th>
<th>Project Dates: 02/08/12 - 02/07/13</th>
<th>Direct F &amp; A</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>CFQ-R (12081026)</td>
<td></td>
<td>9,800</td>
<td>1,825</td>
</tr>
</tbody>
</table>

**Cognitive Evaluation of the Quality of Life Questionnaire-Bronchiectasis (QOL-B) Version 3.0**

<table>
<thead>
<tr>
<th>Univ. of Miami</th>
<th>Project Dates: 12/01/11 - 12/31/12</th>
<th>Direct F &amp; A</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>6683BG - QOL-B (12081147)</td>
<td></td>
<td>8,300</td>
<td>4,150</td>
</tr>
</tbody>
</table>

**Arikace Study - A Randomized, Double-Blind, Placebo-Controlled Study of Liposomal Amikacin for inhalation (Arikace) in Patients with Recalcitrant Nontuberculous Mycobacterial Lung Disease**

<table>
<thead>
<tr>
<th>Chiltern International, Inc.</th>
<th>Project Dates: 03/24/12 - 03/31/13</th>
<th>Direct F &amp; A</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>TR02-112 (12101398)</td>
<td></td>
<td>163,111</td>
<td>40,028</td>
</tr>
</tbody>
</table>

**A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Ivacaftor in Subjects with Cystic Fibrosis Who Have the R117H-CFTR Mutation**

<table>
<thead>
<tr>
<th>PI:</th>
<th>Principal Investigator</th>
<th>Sponsor</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Flume, Patrick</td>
<td>Rempex Pharmaceuticals, Inc.</td>
<td>$203,139</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Project Dates: 03/24/12 - 03/31/13</th>
<th>Direct F &amp; A</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>VX11-770-110 (12111583)</td>
<td>97,660</td>
<td>23,540</td>
</tr>
</tbody>
</table>

**Co-PI/Project Director**

**Clinical Resource Center Alpha-1 Foundation Registry Planning Grant**

<table>
<thead>
<tr>
<th>PI:</th>
<th>Principal Investigator</th>
<th>Sponsor</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Flume, Patrick</td>
<td>Rempex Pharmaceuticals, Inc.</td>
<td>$49,775</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Dept:</th>
<th>Medicine</th>
<th>Award: (12050655-1)</th>
</tr>
</thead>
</table>

**Co-Investigator**

**South Carolina Clinical and Translational Research Institute (UL1)**

<table>
<thead>
<tr>
<th>PI:</th>
<th>Principal Investigator</th>
<th>Sponsor</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Flume, Patrick</td>
<td>Rempex Pharmaceuticals, Inc.</td>
<td>$78,000</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Dept:</th>
<th>Psychiatry and Behavioral Sciences</th>
<th>Award: 5UL1RR029882-03 (11012750-2)</th>
</tr>
</thead>
</table>

**South Carolina Clinical and Translational Research Institute (SCTR): UL1**

<table>
<thead>
<tr>
<th>PI:</th>
<th>Principal Investigator</th>
<th>Sponsor</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Flume, Patrick</td>
<td>Rempex Pharmaceuticals, Inc.</td>
<td>$78,000</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Dept:</th>
<th>Psychiatry and Behavioral Sciences</th>
<th>Award: 8UL1TR000062-04 (12070938-2)</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>PI:</th>
<th>Principal Investigator</th>
<th>Sponsor</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Flume, Patrick</td>
<td>Rempex Pharmaceuticals, Inc.</td>
<td>$78,000</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Dept:</th>
<th>Psychiatry and Behavioral Sciences</th>
<th>Award: 8UL1TR000062-04 (12070938-2)</th>
</tr>
</thead>
</table>

**Ford, Dee**

**Changing the Paradigm of In-Hospital CPR with Informed Assent: A Pilot Study**

<table>
<thead>
<tr>
<th>Univ. of Vermont</th>
<th>Project Dates: 07/01/10 - 06/30/12</th>
<th>Direct F &amp; A</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>24557-01 (12020281)</td>
<td></td>
<td>16,000</td>
<td>1,600</td>
</tr>
</tbody>
</table>

**Co-PI/Project Director**

**Southeastern Virtual Institute for Health Equity and Wellness (SE VIEW)- Project 8**

<table>
<thead>
<tr>
<th>PI:</th>
<th>Principal Investigator</th>
<th>Sponsor</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Flume, Patrick</td>
<td>Rempex Pharmaceuticals, Inc.</td>
<td>$17,600</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Dept:</th>
<th>Presidents Office</th>
<th>Award: W81XWH-10-2-0057 (10071968-21)</th>
</tr>
</thead>
</table>

Medical University of South Carolina 49
Ford, Marvella

**Optimizing Survivorship and Surveillance after Treatment for Colorectal Cancer**
NIH/NCI  
1R21CA152865-01A1 (10110530)  
Project Dates: 09/01/11 - 08/31/13  
Direct F & A Total  
108,750 51,656 160,406

**SC Cancer Disparities Research Center (2 of 2)**
NIH/NCI  
1P20CA157071-01A1 (11041385)  
Project Dates: 09/01/11 - 08/31/13  
Direct F & A Total  
127,988 60,794 188,782

**The South Carolina Collaborative Undergraduate HBCU Student Summer Training Program**
US Army/USAMRAA  
W81XWH-12-1-0043 (11120216)  
Project Dates: 03/01/12 - 02/28/13  
Direct F & A Total  
60,009 4,801 64,810

**Improving Resection Rates among African Americans with NSCLC**
NIH/NCMHD  
1R01MD005892-01A1 (11120246)  
Project Dates: 04/01/12 - 12/31/16  
Direct F & A Total  
250,000 118,750 368,750

**Southeastern US Collaborative CEED (SUCCEED)**
Morehouse School of Medicine, Inc.  
5 US DP000984-05 (12060729)  
Project Dates: 01/01/08 - 09/29/13  
Direct F & A Total  
53,846 16,154 70,000

Co-PI/Project Director
Southeastern Virtual Institute for Health Equity and Wellness (SE VIEW)- Project 4
Pl: Sabra Slaughter  
Dept: Presidents Office  
Award: W81XWH-10-2-0057 (10071968-17)

SE VIEW Phase II (MEDIA STRAT)
Pl: Sabra Slaughter  
Dept: Presidents Office  
Award: W81XWH-11-2-0164 (12030345-8)

Co-Investigator
A Randomized Recruitment Intervention
Pl: Arch Mainous  
Dept: Family Medicine  
Award: 0008663D/U24 MD006941-01 (11120110-1)

Garrett-Mayer, E.

**Biostatistical Services Supporting the NCI’s US-Latin America Clinical Research Network (US-LACRN)**
SAIC-Frederick, Inc.  
12XS433 (12091282)  
Project Dates: 04/24/12 - 09/30/12  
Direct F & A Total  
55,677 26,447 82,124

Co-PI/Project Director
TCR Gene Modified T Cells for Adoptive Immunotherapy (Core B)
Pl: David Cole  
Dept: Surgery  
Award: 1 P01CA154778-01A1 (12020155-4)

MUSC CCSG: Biostatistics
Pl: Andrew Kraft  
Dept: Medicine  
Award: 5P30CA138313-04 (12070914-9)

Co-Investigator
Ethno-Cultural Barriers to Health Literacy/Disease Management in AAs
Pl: Ida Spruill  
Dept: Nursing  
Award: 1R01NR012432-01A1 (11120369-1)

Regulation of the Tumor Microenvironment by KSHV
Pl: Christopher Parsons  
Dept: Medicine  
Award: 5R01CA127905-04 (12070968-1)

Co-Investigator
Regulation of the Tumor Microenvironment by KSHV
Pl: Christopher Parsons  
Dept: Medicine  
Award: 5R01CA142362-03 (12050673-1)

A Novel Trial of Smokeless Tobacco for Cessation Induction in Unmotivated Smokers
Pl: Matthew Carpenter  
Dept: Psychiatry and Behavioral Sciences  
Award: 5R01CA154992-02 (12070935-1)

The Role of Thromboxane A2 (TP) Receptor Beta in Bladder Cancer
Pl: Omar Moussa  
Dept: Pathology and Laboratory Medicine  
Award: 5R01CA127905-04 (12070968-1)
### Gebregziabher, M.

**Co-Investigator**  
Trans-Generational Impact of Maternal Obesity and Diabetes on Health Disparities  
**PI:** Kelly Hunt  
**Dept:** Medicine  
**Sponsor:** Clemson Univ.  
**Total:** $12,033  
**Award:** 1357-209-2007551 (11042946-2)

Longitudinal Assessment of LDL Immune Complexes and Type 1 Diabetes Complications  
**PI:** Kelly Hunt  
**Dept:** Medicine  
**Sponsor:** NIH/NIDDK  
**Total:** $151,502  
**Award:** 5R01DK088778-02 (11051319-1)

### Gelasco, Andrew

**Co-Investigator**  
South Carolina COBRE in Oxidants, Redox Balance and Stress Signaling (Core C)  
**PI:** Kenneth Tew  
**Dept:** Cell and Molecular Pharmacology  
**Sponsor:** NIH/NCRR  
**Total:** $247,178  
**Award:** 1P20RR024485-01A2 (09062764-5)

### Gemmill, Robert

**Co-PI/Project Director**  
SPORE in Lung Cancer  
**PI:** Harry Drabkin  
**Dept:** Medicine  
**Sponsor:** Univ. of Colorado  
**Total:** $258,852  
**Award:** FY08.046.002/P50 CA058187 (11051837-1)

**Co-Investigator**  
The Combination of Carfilzomib or ONX 0912 Plus Metformin in the Treatment of Selected Hematologic Malignant Diseases and Solid Tumors  
**PI:** Harry Drabkin  
**Dept:** Medicine  
**Sponsor:** Onyx Pharmaceuticals  
**Total:** $36,875  
**Award:** Funded MTA (11120249-1)

### Gilkeson, Gary

**Principal Investigator**  
Role of Estrogen Receptors in Lupus-Modulators of the Inflammatory Response  
**PI:** Carol Wagner  
**Dept:** Pediatrics  
**Sponsor:** Thrasher Research Fund  
**Total:** $146,099  
**Award:** (09091142-3)

---

*Medical University of South Carolina*
### Gilkeson, Gary

**Co-Investigator**

**South Carolina Clinical and Translational Research Institute (UL1)**
- PI: Kathleen Brady
- Sponsor: NIH/NICRR
- Total: $301,173
- Dept: Psychiatry and Behavioral Sciences
  - Award: 5UL1RR029882-03 (11012750-2)

**Environmental Determinants of Autoimmunity among African Americans in Coastal SC**
- PI: Diane Kamen
- Sponsor: NIH/NIAMS
- Total: $327,121
- Dept: Medicine
  - Award: 5R21ES017934-03 (11051104-1)

**Environmental Determinants of Autoimmunity among African Americans in Coastal SC (Diversity Supplement for Hazel Breland)**
- PI: Diane Kamen
- Sponsor: NIH/NIEHS
- Total: $95,186
- Dept: Medicine
  - Award: 5R21ES017934-03 (11051104-2)

**South Carolina Clinical and Translational Research Institute (SCTR): UL1**
- PI: Kathleen Brady
- Sponsor: NIH/NCATS
- Total: $2,537,859
- Dept: Psychiatry and Behavioral Sciences
  - Award: 8UL1TR000062-04 (12070938-1)

**South Carolina Clinical and Translational Research Institute (SCTR): UL1**
- PI: Kathleen Brady
- Sponsor: NIH/NCATS
- Total: $798,196
- Dept: Psychiatry and Behavioral Sciences
  - Award: 8UL1TR000062-04 (12070938-2)

**Molecular Mechanisms of the Impact of Fli-1 on Lupus**
- PI: Xian Zhang
- Sponsor: NIH/NIAMS
- Total: $272,160
- Dept: Medicine
  - Award: 5R01AR056670-03 (12080991-1)

**Role of Reactive Intermediates in Lupus Nephritis**
- PI: James Oates
- Sponsor: NIH/NIAMS
- Total: $274,967
- Dept: Medicine
  - Award: 5R01AR045476-13 (12091307-1)

**Role of Reactive Intermediates in Lupus Nephritis-Diversity Supplement**
- PI: James Oates
- Sponsor: NIH/NIAMS
- Total: $49,683
- Dept: Medicine
  - Award: 5R01AR045476-13 (12091307-2)

**Mentor**

**The Role of Sphingosine Kinase 1 in a Mouse Model of Chronic Inflammation**
- PI: Deanna Baker
- Sponsor: NIH/NIAMS
- Total: $36,289
- Dept: Medicine
  - Award: 5F31AR057307-03 (11042626-1)

**The Role of Vitamin D in Systemic Lupus Erythematosus**
- PI: Diane Kamen
- Sponsor: NIH/NIAMS
- Total: $129,465
- Dept: Medicine
  - Award: 5K23AR052364-05 (11051103-1)

**Regulation of Vasculature by Estrogen Receptors During Aging in Mouse Models**
- PI: Margaret Markiewicz
- Sponsor: NIH/NIA
- Total: $118,221
- Dept: Medicine
  - Award: 5K01AG031909-02 (11110093-1)

### Gold, Michael

**Principal Investigator**

**Clinical Partners in Excellence Program**
- St. Jude Medical, Inc.
  - Budget Dates: 09/09/04 - 06/29/12
  - Project Dates: 09/09/04 - 06/29/12
  - Direct: $68,000
  - F & A: $17,000
  - Total: $85,000

**Multi-Center Automatic Defibrillator Implantation with Cardiac Resynchronization Therapy (MADIT-CRT)**
- Univ. of Rochester
  - Budget Dates: 03/03/05 - 06/30/13
  - Project Dates: 03/03/05 - 06/30/13
  - Direct: $4,800
  - F & A: $1,200
  - Total: $6,000

**Effect of Cardiac Resynchronization Therapy (CRT) on the Defibrillation Threshold (DFT) Estimates**
- St. Jude Medical, Inc.
  - Budget Dates: 06-08-002 (08052727)
  - Project Dates: 06-08-002 (08052727)
  - Direct: $4,000
  - F & A: $1,000
  - Total: $5,000

**The Restoration of Atrioventricular Synchrony Trial RESTORE AV**
- The Integra Group
  - Budget Dates: 07/07/11 - 12/31/13
  - Project Dates: 07/07/11 - 12/31/13
  - Direct: $48,210
  - F & A: $11,178
  - Total: $59,388

**Multisensor Chronic Evaluations in Ambulatory Heart Failure Patients (MULTISENSE)**
- Boston Scientific Corp.
  - Budget Dates: 06/08/11 - 12/31/14
  - Project Dates: 06/08/11 - 12/31/14
  - Direct: $166,875
  - F & A: $41,719
  - Total: $208,594

**A Phase 2, Proof of Concept, Randomized, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of Ranolazine and Dronaderone When Given Alone and in Combination on Atrial Fibrillation**
- Gilead Sciences, Inc.
  - Budget Dates: 10/26/11 - 12/31/13
  - Project Dates: 10/26/11 - 12/31/13
  - Direct: $128,269
  - F & A: $31,192
  - Total: $159,461
### Gomez, Juanmanual

**Principal Investigator**

**Safety and Efficacy of Multiple Daily Dosing of Oral LFF571 in Patients with Moderate Clostridium Difficile Infections**

Novartis Corp.  

<table>
<thead>
<tr>
<th>Budget Dates</th>
<th>Direct F &amp; A</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>12/31/11 - 12/31/12</td>
<td>37,398</td>
<td>8,162</td>
</tr>
</tbody>
</table>

**Project Dates:**  
12/31/11 - 12/31/12

### Gooz, Monika

**Co-Investigator**

**Hepato/Renal Fibrocystic Diseases Center (Core C)**

Pl: Phillip Bell  
Sponsor: Univ. of Alabama, Birmingham  
Total: $ 189,961  
Dept: Medicine  
Award: 000402961-001/P30 DK07403 (11042735-1)

### Greenberg, Charles

**Principal Investigator**

**Public Health Surveillance of Bleeding Disorders Outside HTCs**

Duke Univ.  

<table>
<thead>
<tr>
<th>Budget Dates</th>
<th>Direct F &amp; A</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>09/30/11 - 09/29/12</td>
<td>8,840</td>
<td>4,199</td>
</tr>
</tbody>
</table>

**Project Dates:**  
09/30/11 - 09/29/14

### Griffin, Emily

**Principal Investigator**

**ACE: Translational Studies of Insistence on Sameness in Autism**

Univ. of Illinois, Chicago  

<table>
<thead>
<tr>
<th>Budget Dates</th>
<th>Direct F &amp; A</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>08/01/11 - 07/31/12</td>
<td>43,981</td>
<td>20,891</td>
</tr>
</tbody>
</table>

**Project Dates:**  
08/01/10 - 07/31/12

### Hant, Faye

**Co-Investigator**

**Mycophenolate vs Oral Cyclophosphamide in Scleroderma Interstitial Lung Disease (SLS II)**

Pl: Richard Silver  
Sponsor: Univ. of California, Los Angeles  
Total: $ 88,494  
Dept: Medicine  
Award: 1460 G KB111 (12020200-1)

### Hawes, Robert

**Co-Investigator**

**Evaluating Predictors and Interventions in Sphincter of Oddi Dysfunction (EPISOD): Clinical - Parent**

Pl: Peter Cotton  
Sponsor: NIH/NIDDK  
Total: $ 1,001,170  
Dept: Medicine  
Award: 5U01DK074739-05 (11042733-2)

### Headden, Gary

**Principal Investigator**

**Evaluation of Ecallantide for the Acute Treatment of Angiotensin Converting Enzyme Inhibitor Induced Angioedema**

MUSC OIP  

<table>
<thead>
<tr>
<th>Budget Dates</th>
<th>Direct F &amp; A</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>09/27/11 - 02/28/13</td>
<td>51,639</td>
<td>11,409</td>
</tr>
</tbody>
</table>

**Daptomycin Versus Vancomycin in Patients with Skin Infections Due to MRSA (DAPHEOR1006)**

Cubist Pharmaceuticals  

<table>
<thead>
<tr>
<th>Budget Dates</th>
<th>Direct F &amp; A</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>02/10/12 - 02/09/13</td>
<td>37,060</td>
<td>8,515</td>
</tr>
</tbody>
</table>

**Project Dates:**  
02/10/12 - 02/09/13

### Heffernan, Linda

**Principal Investigator**

**Role of Sphingosine Kinase 1 in the p53-Dependent DNA Damage Response**

NIH/NIEMS  

<table>
<thead>
<tr>
<th>Budget Dates</th>
<th>Direct F &amp; A</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>12/01/11 - 11/30/12</td>
<td>39,877</td>
<td>0</td>
</tr>
</tbody>
</table>

**Project Dates:**  
12/01/09 - 11/30/12

### Hermayer, Kathie

**Principal Investigator**

**Randomized, Clinical Trial of Subcutaneous Analog Basal Bolus Therapy Versus Sliding Scale Human Regular Insulin in the Hospital Management of Hyperglycemia in Non-Critically Ill Patient without Known History of Diabetes: The HMH Trial**

Eli Lilly  

<table>
<thead>
<tr>
<th>Budget Dates</th>
<th>Direct F &amp; A</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>08/02/10 - 11/09/11</td>
<td>800</td>
<td>200</td>
</tr>
</tbody>
</table>

**Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results - A Long Term Evaluation (LEADER)**

Novo Nordisk Pharmaceuticals  

<table>
<thead>
<tr>
<th>Budget Dates</th>
<th>Direct F &amp; A</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>10/27/10 - 10/26/15</td>
<td>36,160</td>
<td>9,040</td>
</tr>
</tbody>
</table>

**Project Dates:**  
10/27/10 - 10/26/15
### Hermayer, Kathie
**Co-Investigator**
**REACH U.S. Southeastern African American Center of Excellence for Elimination of Disparities**
**PI:** Carolyn Jenkins  
**Dept:** Nursing  
**Sponsor:** CDC  
**Total:** $850,001  
**Award:** 5 U58 DP001015-05 (11042629-1)

### Highland, Kristin
**Principal Investigator**
**Tadalafil for Sarcoidosis Associated Pulmonary Hypertension (SAPH)**
**Univ. of North Carolina**
**Budget Dates:** 08/16/11 - 08/15/12  
**Direct**  
**F & A**  
**Total**

<table>
<thead>
<tr>
<th>Project Dates</th>
<th>Direct</th>
<th>F &amp; A</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>08/16/11 - 08/15/12</td>
<td>111,030</td>
<td>27,133</td>
<td>138,163</td>
</tr>
</tbody>
</table>

### Hill, Elizabeth
**Co-Investigator**
**South Carolina COBRE in Oxidants, Redox Balance and Stress Signaling (Core C)**
**PI:** Kenneth Tew  
**Dept:** Cell and Molecular Pharmacology  
**Sponsor:** NIH/NCRR  
**Total:** $247,178  
**Award:** 1P20RR024485-01A2 (09062764-5)

### Hoel, David
**Principal Investigator**
**Toxicity of Ra-224 in German Patients Treated for Ankylosing Spondylitis**
**Atomic Energy of Canada, Ltd.**
**Budget Dates:** 04/01/12 - 03/31/14  
**Direct**  
**F & A**  
**Total**

<table>
<thead>
<tr>
<th>Project Dates</th>
<th>Direct</th>
<th>F &amp; A</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>04/01/12 - 03/31/14</td>
<td>10,170</td>
<td>4,830</td>
<td>15,000</td>
</tr>
</tbody>
</table>

### Hoffman, Brenda
**Principal Investigator**
**A Phase IIb, Randomized, Placebo-Controlled Study to Evaluate the Clinical Efficacy and Safety of Induction and Maintenance Therapy with BMS-936557 in Subjects with Active Ulcerative Colitis (UC)**
**IM129-005-056**
**Bristol Myers Squibb**
**Budget Dates:** 05/04/11 - 04/30/14  
**Direct**  
**F & A**  
**Total**

<table>
<thead>
<tr>
<th>Project Dates</th>
<th>Direct</th>
<th>F &amp; A</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>05/04/11 - 04/30/14</td>
<td>5,633</td>
<td>1,408</td>
<td>7,041</td>
</tr>
</tbody>
</table>

### Hoffman, Stanley
**Principal Investigator**
**CSD Peptide-Based Therapeutic Agents in Scleroderma Lung Disease**
**US Army/USAMRAA**
**Budget Dates:** 08/01/11 - 07/31/12  
**Direct**  
**F & A**  
**Total**

<table>
<thead>
<tr>
<th>Project Dates</th>
<th>Direct</th>
<th>F &amp; A</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>08/01/11 - 07/31/12</td>
<td>223,308</td>
<td>106,071</td>
<td>329,379</td>
</tr>
</tbody>
</table>

**Use of Variant Forms of the CSD Peptide in Cell-Based Assays**
**Fibro Therapeutics, Inc.**
**(12010123)**
**Budget Dates:** 07/27/11 - 06/30/13  
**Direct**  
**F & A**  
**Total**

<table>
<thead>
<tr>
<th>Project Dates</th>
<th>Direct</th>
<th>F &amp; A</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>07/27/11 - 06/30/13</td>
<td>28,571</td>
<td>1,429</td>
<td>30,000</td>
</tr>
</tbody>
</table>

**Mentor**
**Anti-Fibrotic and Anti-Inflammatory Roles of Caveolin-1 in Lung Disease**
**PI:** Elena Tourkina  
**Dept:** Medicine  
**Sponsor:** NIH/NIAMS  
**Total:** $123,418  
**Award:** 5K01AR054143-05 (11050362-1)

### Huang, Yan
**Principal Investigator**
**Toll-Like Receptors and Atherosclerosis in Diabetes**
**VAMC**
**Budget Dates:** 10/01/11 - 09/30/12  
**Direct**  
**F & A**  
**Total**

<table>
<thead>
<tr>
<th>Project Dates</th>
<th>Direct</th>
<th>F &amp; A</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>10/01/11 - 09/30/12</td>
<td>261,800</td>
<td>0</td>
<td>261,800</td>
</tr>
</tbody>
</table>

**The Effect of Statin on Diabetes-Associated Periodontal Disease**
**NIH/NIDCD**
**Budget Dates:** 05/01/12 - 04/30/13  
**Direct**  
**F & A**  
**Total**

<table>
<thead>
<tr>
<th>Project Dates</th>
<th>Direct</th>
<th>F &amp; A</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>05/01/12 - 04/30/13</td>
<td>247,500</td>
<td>117,563</td>
<td>365,063</td>
</tr>
</tbody>
</table>

### Huggins, John
**Principal Investigator**
**Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients II**
**Boehringer Ingelheim Pharmaceuticals**
**Budget Dates:** 06/03/11 - 05/31/13  
**Direct**  
**F & A**  
**Total**

<table>
<thead>
<tr>
<th>Project Dates</th>
<th>Direct</th>
<th>F &amp; A</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>06/03/11 - 05/31/13</td>
<td>230,541</td>
<td>57,635</td>
<td>288,176</td>
</tr>
</tbody>
</table>
### Hunt, Kelly

**Principal Investigator**

**Trans-Generational Impact of Maternal Obesity and Diabetes on Health Disparities**

Clemson Univ.  
Budget Dates: 05/01/11 - 04/30/12  
Direct F & A Total  
1357-209-20075551 (11042946)  
Project Dates: 09/25/09 - 04/30/12  
8,158 3,875 12,033

**Longitudinal Assessment of LDL Immune Complexes and Type 1 Diabetes Complications**

NIH/NIDDK  
Budget Dates: 07/01/11 - 06/30/13  
Direct F & A Total  
5R01DK088778-02 (11051319)  
Project Dates: 07/01/10 - 06/30/13  
102,713 48,789 151,502

**Services for REAP Center for Disease Prevention and Health Interventions for Diverse Populations**

VAMC  
Budget Dates: 03/18/11 - 03/17/12  
Direct F & A Total  
PO 534D17133 (12010082)  
Project Dates: 03/18/10 - 03/17/12  
239,627 0 239,627

---

### Jaffa, Ayad

**Principal Investigator**

**Kallikrein and Vascular Disease Risk in Diabetes**

NIH/NHLBI  
Budget Dates: 08/01/11 - 07/31/13  
Direct F & A Total  
5R01HL087986-04 (11120233)  
Project Dates: 09/29/08 - 07/31/13  
251,661 61,549 313,210

---

### Janech, Michael

**Principal Investigator**

**Identification and Validation of Plasma Biomarkers in California Sea Lions**

DOD/ONR  
Budget Dates: 01/05/11 - 01/04/12  
Direct F & A Total  
N00014-08-1-0341 (11021580)  
Project Dates: 01/05/11 - 01/04/13  
201,247 74,084 275,331

---

### Jauch, Edward

**Principal Investigator**

**Repcanalization Therapies and Markers of Stroke Outcome**

Univ. of Cincinnati  
Budget Dates: 05/01/11 - 04/30/12  
Direct F & A Total  
005695/P50 NS044283-09 (11020415)  
Project Dates: 08/01/08 - 04/30/12  
24,537 11,655 36,192

**Interventional Management of Stroke Study III - PI Salary**

Univ. of Cincinnati  
Budget Dates: 09/30/11 - 07/31/15  
Direct F & A Total  
COEUS #7753/U01 NS052220 (11020531)  
Project Dates: 09/30/11 - 07/31/15  
156,494 74,328 230,812

**Repcanalization Therapies and Markers of Stroke Outcomes (SPOTRIAS/STOP-IT) - Per Patient**

Univ. of Cincinnati  
Budget Dates: 05/01/12 - 04/30/13  
Direct F & A Total  
005695 (12081113)  
Project Dates: 08/01/08 - 04/30/13  
15,682 5,304 20,986

**Interventional Management of Stroke Study III - Per Patient**

Univ. of Cincinnati  
Budget Dates: 09/30/11 - 07/31/15  
Direct F & A Total  
COEUS #7753/U01 NS052220 (12091215)  
Project Dates: 09/30/11 - 07/31/15  
31,830 12,108 43,938

---

### Co-Investigator

**Albumin in Acute Stroke (ALIAS) Trial Statistical and Data Coordinating Center**

PI: Yuko Palesch  
Sponsor: NIH/NINDS  
Total: $1,228,232  
Dept: Medicine  
Award: 2R01NS054630-06 (10102049-1)

**Neurological Emergencies Treatment Trial Network Statistical/Data Management Center (NETT)**

PI: Yuko Palesch  
Sponsor: NIH/NINDS  
Total: $1,098,903  
Dept: Medicine  
Award: 2U01NS059041-06 (10103097-1)
<table>
<thead>
<tr>
<th>Name</th>
<th>Role</th>
<th>Title</th>
<th>Sponsor</th>
<th>Budget Dates</th>
<th>Direct F &amp; A</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jauch, Edward</td>
<td>Co-Investigator</td>
<td>STA - Liatest D-Di-Exclusion of Venous Thromboembolism (VTE) (DiET)</td>
<td>Diagnostica Stago, Inc.</td>
<td>$175,938</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kamen, Diane</td>
<td>Principal Investigator</td>
<td>The Role of Vitamin D in Systemic Lupus Erythematosus</td>
<td>NIH/NIAMS</td>
<td>07/01/11 - 09/30/12</td>
<td>Direct F &amp; A</td>
<td>Total</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>5K23AR052364-05 (11051103)</td>
<td>119,875</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Project Dates: 08/03/07 - 09/30/12</td>
<td>9,590</td>
<td>129,465</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Environmental Determinants of Autoimmunity among African Americans in Coastal SC</td>
<td>NIH/NIEMS</td>
<td>07/01/11 - 06/30/12</td>
<td>Direct F &amp; A</td>
<td>Total</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>5R21ES017934-03 (11051104)</td>
<td>293,613</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Project Dates: 09/17/09 - 06/30/13</td>
<td>128,694</td>
<td>422,307</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Mechanisms of B Cell Responses in Autoimmune Disease: Effective Vitamin D3 in the IFNa Signature in Patients with Systemic Lupus Erythematosus</td>
<td>Duke Univ.</td>
<td>05/01/11 - 04/30/13</td>
<td>Direct F &amp; A</td>
<td>Total</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>2030925/U19 AI056363-08 (11051323)</td>
<td>77,028</td>
<td>113,616</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Project Dates: 09/01/11 - 04/30/13</td>
<td>36,588</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kang, Yubin</td>
<td>Principal Investigator</td>
<td>A Phase III Study: Enhancing Donor Cell Engraftment with CXCR4 Antagonist in Hematopoietic Stem Cell Transplantation</td>
<td>Conquer Cancer Fdn.</td>
<td>07/01/11 - 06/30/12</td>
<td>Direct F &amp; A</td>
<td>Total</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>10091385</td>
<td>62,466</td>
<td>66,666</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Project Dates: 07/01/11 - 06/30/12</td>
<td>4,200</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kilby, J.</td>
<td>Principal Investigator</td>
<td>Ryan White Part B Program</td>
<td>SC DHEC</td>
<td>04/01/11 - 03/31/12</td>
<td>Direct F &amp; A</td>
<td>Total</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>HV-1-747 (11022212)</td>
<td>47,532</td>
<td>47,532</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Project Dates: 04/01/11 - 03/31/12</td>
<td>0</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Ryan White Part B Program</td>
<td>04/01/11 - 03/31/12</td>
<td>Direct F &amp; A</td>
<td>Total</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>SC DHEC</td>
<td>1,565,105</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>HV-1-747 (12050659)</td>
<td>1,565,105</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Project Dates: 04/01/11 - 03/31/13</td>
<td>0</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Klein, Richard

Principal Investigator

**Interactions of Lipoproteins and Cells in Diabetes Mellitus**

VAMC

<table>
<thead>
<tr>
<th>Project Dates: 10/01/11 - 09/30/12</th>
<th>Direct</th>
<th>F &amp; A</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>VAMC</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(08051248)</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Lipoproteins and Pigment Epithelial Derived Factor (PEDF) in the Vascular Complications of Diabetes**

Oklahoma University Health Sc. Center

<table>
<thead>
<tr>
<th>Project Dates: 07/01/10 - 06/30/12</th>
<th>Direct</th>
<th>F &amp; A</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>VAMC</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(09080513)</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Knapp, Rebecca

Principal Investigator

**3/8 - Prolonging Remission in Depressed Elderly (PRIDE)**

NIH/NIMH

<table>
<thead>
<tr>
<th>Project Dates: 04/01/11 - 03/31/12</th>
<th>Direct</th>
<th>F &amp; A</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>VAMC</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(11012518)</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**3/8 - Prolonging Remission in Depressed Elderly (PRIDE)**

NIH/NIMH

<table>
<thead>
<tr>
<th>Project Dates: 04/01/12 - 03/31/13</th>
<th>Direct</th>
<th>F &amp; A</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>VAMC</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(12070911)</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Knueper-Hall, Rayna

Principal Investigator

**A Randomized, Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of TC or Four Cycles of AC Followed by Four Cycles of Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women with Node-Positive or High-Risk Node-Negative HER2-Normal Invasive Breast Cancer**

NSABP

<table>
<thead>
<tr>
<th>Project Dates: 10/01/09 - 09/30/14</th>
<th>Direct</th>
<th>F &amp; A</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>NSABP</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(05050275)</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Koch, David

Principal Investigator

**Hepatopulmonary Syndrome and the Role of Endothelin-1 in Human Disease**

Amer. College of Gastroenterology

<table>
<thead>
<tr>
<th>Project Dates: 07/01/09 - 06/30/12</th>
<th>Direct</th>
<th>F &amp; A</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>VAMC</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(09120743)</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**A Multi-Center Group to Study Acute Liver Failure - Protocol Number ALFSG-OCR-002(STOP-ALF)**

UT Southwestern Med. Ctr.

<table>
<thead>
<tr>
<th>Project Dates: 09/01/11 - 08/31/12</th>
<th>Direct</th>
<th>F &amp; A</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>VAMC</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(12081145)</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Korte, Jeffrey

Co-Investigator

**Trans-Generational Impact of Maternal Obesity and Diabetes on Health Disparities**

Sponsor: Clemson Univ.

<table>
<thead>
<tr>
<th>Total: $ 12,033</th>
</tr>
</thead>
<tbody>
<tr>
<td>Award: 1357-209-20075551 (11042946-2)</td>
</tr>
</tbody>
</table>

**The Southern Consortium Node of the Clinical Trials Network**

Sponsor: NIH/NIDA

<table>
<thead>
<tr>
<th>Total: $ 1,326,149</th>
</tr>
</thead>
<tbody>
<tr>
<td>Award: 5U10DA013727-12 (11120348-1)</td>
</tr>
</tbody>
</table>
Kraft, Andrew

**Principal Investigator**

*A Multi-Center, Open-Label, Single-Arm Study of YONDELIS (Trabectedin) for Subjects with Locally Advanced or Metastatic Soft Tissue Sarcoma Who Have Relapsed or are Refractory to Standard of Care Treatment*

Quintiles Pacific, Inc.

**NIH/NCI**

**Budget Dates:** 07/19/05 - 04/19/13

**Direct F & A**

**Total**

ET743-SAR-3002 (05062714)

**Project Dates:** 07/19/05 - 04/19/13

29,400 7,350 36,750

**MUSC CCSG: Disruption of Ceramide Synthesis by CerS2 Depletion as a Tool to Increase Breast Cancer Sensitivity to Taxane Therapy**

NIH/NCI

**Budget Dates:** 08/16/11 - 03/31/13

**Direct F & A**

**Total**

3P30CA138313-03S1 (11011261)

**Project Dates:** 04/01/09 - 03/31/13

33,898 16,102 50,000

**MUSC CCSG: Developmental Funds**

NIH/NCI

**Budget Dates:** 04/01/11 - 03/31/12

**Direct F & A**

**Total**

5P30CA138313-03 (12012102)

**Project Dates:** 04/01/09 - 03/31/14

50,000 23,750 73,750

**SmartState Center for Translational Cancer Therapeutics: Abney Scholars**

MUSC Fdn.

**NIH/NCI**

**Budget Dates:** 04/01/11 - 03/31/12

**Direct F & A**

**Total**

5P30CA138313-03S2 (12010098)

**Project Dates:** 04/01/09 - 03/31/14

39,084 18,565 57,649

**2012 Avon Foundation Safety Net Program**

Avon Fdn.

**NIH/NCI**

**Budget Dates:** 01/01/12 - 12/31/12

**Direct F & A**

**Total**

05-2011-081 (12020204)

**Project Dates:** 01/01/12 - 12/31/12

100,000 10,000 110,000

**Tobacco Related Cancer Research: FY12 Appropriation**

State of SC

**NIH/NCI**

**Budget Dates:** 04/01/12 - 03/31/13

**Direct F & A**

**Total**

5P30CA138313-04 (12070914)

**Project Dates:** 04/01/09 - 03/31/14

950,000 451,250 1,401,250

**A Randomized, Open-Label, Phase II, Multi-Center Trial of Gemcitabine (G) with Pazopanib (P) or Gemcitabine (G) with Docetaxel (T) in Previously Treated Subjects with Advanced Soft Tissue Sarcoma**

GlaxoSmithKline

**NIH/NCI**

**Budget Dates:** 05/30/12 - 05/29/17

**Direct F & A**

**Total**

PZP115785 (12091266)

**Project Dates:** 03/29/12 - 03/28/17

1,541,776 384,319 1,926,095

**MUSC CCSG Supplement: Registration of Clinical Trial Data into the NCI's CTRP**

NIH/NCI

**Budget Dates:** 10/01/12 - 09/30/13

**Direct F & A**

**Total**

3P30CA138313-04S1 (12121755)

**Project Dates:** 10/01/12 - 09/30/13

44,598 21,184 65,782

**Mentor**

Pl: Yubin Kang

Dept: Medicine

Award: 1K08HL103780-01A1 (10110631-1)
Kramer, Rita  

**Principal Investigator**  

A Randomized, Phase 2 Study of the Efficacy and Tolerability of Veliparib in Combination with Temozolomide or Veliparib in Combination with Carboplatin and Paclitaxel versus Placebo Plus  

<table>
<thead>
<tr>
<th>Principal Investigator</th>
<th>Sponsor</th>
<th>Budget Dates: 03/26/12 - 03/25/17</th>
<th>Direct</th>
<th>F &amp; A</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kramer, Rita</td>
<td>Abbott Labs</td>
<td>205,830</td>
<td>50,532</td>
<td>256,362</td>
<td></td>
</tr>
</tbody>
</table>

**Co-PI/Project Director**  

A Randomized, Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of TC or Four Cycles of AC Followed by Four Cycles of Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women with Node-Positive or High-Risk Node-Negative HER2-Negative Invasive Breast Cancer  

<table>
<thead>
<tr>
<th>PI</th>
<th>Sponsor</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rayna Kneuper-Hall</td>
<td>NSABP</td>
<td>$15,250</td>
</tr>
</tbody>
</table>

Kuppuswamy, D.  

**Principal Investigator**  

mTOR in Growth and Protection of Hypertrophying Myocardium  

<table>
<thead>
<tr>
<th>Principal Investigator</th>
<th>Sponsor</th>
<th>Budget Dates: 12/01/11 - 11/30/12</th>
<th>Direct</th>
<th>F &amp; A</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kuppuswamy, D.</td>
<td>NIH/NHLBI</td>
<td>247,500</td>
<td>117,563</td>
<td>365,063</td>
<td></td>
</tr>
</tbody>
</table>

**Co-Investigator**  

MAP4 Regulation of Cardiac Microtubule Network Density  

<table>
<thead>
<tr>
<th>PI</th>
<th>Sponsor</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Donald Menick</td>
<td>NIH/NHLBI</td>
<td>$365,063</td>
</tr>
</tbody>
</table>

Lawson, Andrew  

**Principal Investigator**  

Development and Evaluation of Spatiotemporal Predictive Health Surveillance Tools  

<table>
<thead>
<tr>
<th>Principal Investigator</th>
<th>Sponsor</th>
<th>Budget Dates: 09/01/11 - 08/31/12</th>
<th>Direct</th>
<th>F &amp; A</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lawson, Andrew</td>
<td>NIH/NCI</td>
<td>50,000</td>
<td>23,750</td>
<td>73,750</td>
<td></td>
</tr>
</tbody>
</table>

**Methods to Detect Maternal Exposures and Child Outcomes**  

<table>
<thead>
<tr>
<th>PI</th>
<th>Sponsor</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yuko Palesch</td>
<td>NIH/NINDS</td>
<td>$1,098,903</td>
</tr>
</tbody>
</table>

**Urban Malaria Mapping: A New Methodology to Assess Spatio-Temporal Trends**  

<table>
<thead>
<tr>
<th>PI</th>
<th>Sponsor</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diane Kamen</td>
<td>NIH/NIEHS</td>
<td>$327,121</td>
</tr>
</tbody>
</table>

**Environmental Determinants of Autoimmunity among African Americans in Coastal SC**  

<table>
<thead>
<tr>
<th>PI</th>
<th>Sponsor</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diane Kamen</td>
<td>NIH/NIEHS</td>
<td>$95,186</td>
</tr>
</tbody>
</table>

**Environmental Determinants of Autoimmunity among African Americans in Coastal SC (Diversity Supplement for Hazel Breland)**  

<table>
<thead>
<tr>
<th>PI</th>
<th>Sponsor</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diane Kamen</td>
<td>NIH/NIEHS</td>
<td>$61,384</td>
</tr>
</tbody>
</table>

Leman, Robert  

**Principal Investigator**  

Inappropriate Shock Reduction with PARAD+ Rhythm Discrimination  

<table>
<thead>
<tr>
<th>Principal Investigator</th>
<th>Sponsor</th>
<th>Budget Dates: 11/21/11 - 12/01/14</th>
<th>Direct</th>
<th>F &amp; A</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Leman, Robert</td>
<td>Medpace, Inc.</td>
<td>20,700</td>
<td>4,300</td>
<td>25,000</td>
<td></td>
</tr>
</tbody>
</table>

A Phase, 3 Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of the Effects of Once-Daily Oral Doses of 75 mg Azimilide Dihydrochloride on the Incidence of Cardiovascular Hospitalizations  

<table>
<thead>
<tr>
<th>PI</th>
<th>Sponsor</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Medpace, Inc.</td>
<td>Tulane Univ.</td>
<td>$149,850</td>
</tr>
</tbody>
</table>
**Limehouse, Walter**

**South Carolina Clinical and Translational Research Institute (SCTR): UL1**

**Pl:** Kathleen Brady  
**Sponsor:** NIH/NCATS  
**Total:** $2,537,859  
**Award:** 8UL1TR000062-04 (12070938-1)

**Dept:** Psychiatry and Behavioral Sciences

---

**Litvin, Cara**

**Principal Investigator**

**Improving Recognition and Management of Chronic Kidney Disease in Primary Care**

**AHRQ**  
**Budget Dates:** 07/01/11 - 06/30/12  
**Direct F & A**  
1 K08 HS018984-01A1 (10070799)  
**Project Dates:** 07/01/11 - 06/30/15  
141,340  
10,671  
152,011

---

**Kallikrein and Vascular Disease Risk in Diabetes**

**Pl:** Ayad Jaffa  
**Sponsor:** NIH/NHLBI  
**Total:** $313,210  
**Award:** 5R01HL087986-04 (11120233-1)

**Dept:** Medicine

---

**Lopes-Virella, Maria**

**Principal Investigator**

**Biomarkers of Vascular Disease Progression in Type 1 Diabetes Mellitus**

**NIH/NIDDK**  
**Budget Dates:** 08/01/11 - 07/31/13  
**Direct F & A**  
5R01DK081352-04 (11120241)  
**Project Dates:** 09/01/08 - 07/31/13  
278,002  
117,077  
395,079

---

**Mentor**

**Regulation of 5-HT1A Receptor by Calmodulin**

**Pl:** Sonya Coaxum  
**Sponsor:** NIH/NHLBI  
**Total:** $115,936  
**Award:** 5K01HL095696-04 (11050682-1)

**Dept:** Medicine

---

**Mani, Santhosh**

**Co-Investigator**

**Role of Protein Acetylation in NCX1 Expression**

**Pl:** Donald Menick  
**Sponsor:** NIH/NHLBI  
**Total:** $365,063  
**Award:** 5R01HL095696-04 (12081078-1)
Markiewicz, Margaret  
**Principal Investigator**  
**Regulation of Vasculature by Estrogen Receptors During Aging in Mouse Models**  
NIH/NIA  
Project Dates: 08/01/10 - 07/31/15  
5K01AG031909-02 (11110093)  
Direct F & A Total  
109,639 8,582 118,221  
---  
**Martin, Renee**  
**Principal Investigator**  
**A Phase II, Multi-Center, Randomized, Fasting, Double-Blind, Placebo-Controlled, Safety, Tolerability and Efficacy Study Evaluating a Single-Dose of Intravenous NA-1 in Male and Female Patients Undergoing Endovascular Repair of Brain Aneurysms**  
NoNO, Inc.  
Budget Dates: 06/01/08 - 12/31/11  
3302 (NA-1-002) (08082022)  
Project Dates: 06/01/08 - 12/31/11  
Direct F & A Total  
17,320 4,330 21,650  
---  
**McDermott, Paul**  
**Principal Investigator**  
**Contractile Regulation of Cardiocyte Protein Synthesis**  
VAMC  
Budget Dates: 04/01/12 - 03/31/13  
Project Dates: 04/01/12 - 03/31/13  
Direct F & A Total  
291,400 0 291,400  
---  
**Melvin, Cathy**  
**Principal Investigator**  
**Implementing Evidence-Based Approaches to Reduce Disparities in Colorectal Cancer**  
Univ. of North Carolina  
Budget Dates: 06/01/12 - 08/31/15  
5-33096/US4CA153602 (12111567)  
Project Dates: 06/01/12 - 08/31/15  
Direct F & A Total  
11,600 5,510 17,110  
---  
**Menick, Donald**  
**Principal Investigator**  
**Training to Improve Cardiovascular Therapies**  
NIH/NHLBI  
Budget Dates: 07/01/12 - 06/30/13  
2T32HL007260-36 (11012415)  
Project Dates: 07/01/12 - 06/30/13  
Direct F & A Total  
547,574 35,628 583,202  
---  
**Research Education Program for Minority Medical Students**  
NIH/NHLBI  
Budget Dates: 04/01/12 - 03/31/13  
5R25HL096316-04 (12070971)  
Project Dates: 04/01/12 - 03/31/13  
Direct F & A Total  
99,443 7,955 107,398  
---  
**Menick, Donald**  
**Principal Investigator**  
**MAP4 Regulation of Cardiac Microtubule Network Density**  
NIH/NHLBI  
Budget Dates: 04/01/12 - 03/31/13  
5R01HL094545-03 (12081102)  
Project Dates: 04/01/12 - 03/31/13  
Direct F & A Total  
247,500 117,563 365,063  
---  
**Menick, Donald**  
**Co-Investigator**  
**Protein Acetylation in Glaucomatous Optic Neuropathy**  
NIH/NEI  
Budget Dates: 04/01/12 - 03/31/13  
5R01EY021368-02 (12050694-1)  
Project Dates: 04/01/12 - 03/31/13  
Direct F & A Total  
247,500 117,563 365,063
<table>
<thead>
<tr>
<th>Name</th>
<th>Role</th>
<th>Title</th>
<th>Sponsor</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Menick, Donald</td>
<td>Co-Investigator</td>
<td>Protein Acetylation in Glaucomatous Optic Neuropathy</td>
<td>NIH/NEI</td>
<td>$36,875</td>
</tr>
<tr>
<td></td>
<td></td>
<td>PI: Craig Crosson</td>
<td>Award: 5R01EY021368-02 (12050694-2)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Dept: Ophthalmology</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Meserve, Joseph</td>
<td>Principal Investigator</td>
<td>Clinical Utility of Thromboelastography in the Management of Hematologic Disorders</td>
<td>NIH/NEI</td>
<td>$11,516</td>
</tr>
<tr>
<td></td>
<td></td>
<td>PI: Craig Crosson</td>
<td>Award: 5R01EY021368-02 (12050694-2)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Dept: Ophthalmology</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mohr, Jr., Lawrence</td>
<td>Principal Investigator</td>
<td>Long-Term Lung Health after Exposures to Chlorine Gas</td>
<td>Amer. Society of Hematology</td>
<td>$61,384</td>
</tr>
<tr>
<td></td>
<td></td>
<td>PI: Leonard Egde</td>
<td>Award: 5R01DK081121-04 (11050471-1)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Dept: Medicine</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Moran, William</td>
<td>Principal Investigator</td>
<td>Aging Q3: Quality Education, Quality of Care, Quality of Life</td>
<td>NIH/NIAMS</td>
<td>$57,100</td>
</tr>
<tr>
<td></td>
<td></td>
<td>PI: Donald W. Reynolds Fdn.</td>
<td>Award: 1 D55HP23198-01-00 (12010019-1)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Dept: Medicine</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Morinelli, Thomas</td>
<td>Co-Investigator</td>
<td>Role of Reactive Intermediates in Lupus Nephritis</td>
<td>NIH/NIAMS</td>
<td>$274,967</td>
</tr>
<tr>
<td></td>
<td></td>
<td>PI: James Oates</td>
<td>Award: 5R01AR045476-13 (12091307-1)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Dept: Medicine</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Morris, Pamela</td>
<td>Principal Investigator</td>
<td>A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Safety and Efficacy of Two Different Regimens of Mipomersen in Patients with Familial Hypercholesterolemia</td>
<td>NIH/NIAMS</td>
<td>$258,852</td>
</tr>
<tr>
<td></td>
<td></td>
<td>PI: George Simon</td>
<td>Award: W81XWH-07-1-0348 (10121469-2)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Dept: Medicine</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mullen, Thomas</td>
<td>Principal Investigator</td>
<td>Ceramide Synthases CERS5 and CERS6 Regulate Pathways of Programmed Cell Death</td>
<td>NIH/NIEHS</td>
<td>$37,100</td>
</tr>
<tr>
<td></td>
<td></td>
<td>PI: Jane Charles</td>
<td>Award: 5UR3DD000682-03 (12081146-1)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Dept: Pediatrics</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nasarre, Patrick</td>
<td>Co-Investigator</td>
<td>Development of Anti-Grut-1 Antibody as a Novel Therapeutic Strategy against Breast Cancer</td>
<td>US Army/USAMRAA</td>
<td>$203,385</td>
</tr>
<tr>
<td></td>
<td></td>
<td>PI: Harry Drabkin</td>
<td>Award: FY08.046.002/P50 CA058187 (11051837-1)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Dept: Medicine</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nicholas, Joyce</td>
<td>Co-PI/Project Director</td>
<td>SC Autism and Developmental Disabilities Monitoring Project</td>
<td>CDC</td>
<td>$0</td>
</tr>
<tr>
<td></td>
<td></td>
<td>PI: Jane Charles</td>
<td>Award: 5UR3DD000682-03 (12081146-1)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Dept: Pediatrics</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Nicholas, Joyce

Co-PI/Project Director
SC Autism and Developmental Disabilities Monitoring Project (ADDM)
PI: Jane Charles  Sponsor: CDC  Total: $ 424,999
Dept: Pediatrics  Award: 5UR3DD000682-03 (12081146-2)

SC Autism and Developmental Disabilities Monitoring Project (4 Yr Surveillance)
PI: Jane Charles  Sponsor: CDC  Total: $ 150,000
Dept: Pediatrics  Award: 5UR3DD000682-03 (12081146-3)

Co-Investigator
Biomarkers in Autism of Aripiprazole and Risperidone Treatment (BAART)
PI: C. Devane  Sponsor: NIH/NICHD  Total: $ 651,465
Dept: Psychiatry and Behavioral Sciences  Award: 5R01HD062550-02 (12010064-1)

Autism and Developmental Disabilities Monitoring Network Augmentation with Screening and Assessment
PI: Lydia King  Sponsor: Autism Speaks  Total: $ 275,000
Dept: Pediatrics  Award: 7793 (12040544-1)

Nielsen, Christopher

Principal Investigator
A Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System in the Treatment of Subjects with De Novo Native Coronary Artery Lesions
Advanced Cardiovascular Systems  Budget Dates: 10/20/06 - 05/31/12  Direct F & A Total
SPITIR IV - Protocol 05-3 (06101021)  Project Dates: 10/20/06 - 05/31/12  29,380  7,345  36,725

Novartis Corp  Budget Dates: 04/01/11 - 12/31/16  Direct F & A Total
ACZ885M2301 (11032912)  Project Dates: 04/01/11 - 12/31/16  7,103  1,776  8,879

Nietert, Paul

Co-Investigator
Enhancing Comparative Effectiveness Research Capabilities in PPRNet
PI: Steven Ornstein  Sponsor: AHRQ  Total: $ 499,606
Dept: Family Medicine  Award: 1R24HS01944801 (10011392-2)

South Carolina Clinical and Translational Research Institute (UL1)
PI: Kathleen Brady  Sponsor: NIH/NCRR  Total: $ 301,173
Dept: Psychiatry and Behavioral Sciences  Award: 5UL1RR029882-03 (11012750-2)

Dissemination of the PPRNet Model for Improving Medication Safety
PI: Andrea Wessell  Sponsor: AHRQ  Total: $ 295,997
Dept: Family Medicine  Award: 5 R18 HS019593-02 (11051526-1)

Reducing Inappropriate Antibiotic Prescribing by Primary Care Clinicians
PI: Steven Ornstein  Sponsor: AHRQ  Total: $ 128,108
Dept: Family Medicine  Award: HHSA290200710015/Task Ord (11120228-1)

Implementation of Alcohol Screening, Intervention and Treatment in Primary Care
PI: Peter Miller  Sponsor: NIH/NIAAA  Total: $ 547,045
Dept: Psychiatry and Behavioral Sciences  Award: 5R01AA016768-04 (12010047-1)

South Carolina Clinical and Translational Research Institute (SCTR): UL1
PI: Kathleen Brady  Sponsor: NIH/NCATS  Total: $ 2,537,859
Dept: Psychiatry and Behavioral Sciences  Award: 8UL1TR000062-04 (12070938-1)

South Carolina Clinical and Translational Research Institute (SCTR): UL1
PI: Kathleen Brady  Sponsor: NIH/NCATS  Total: $ 798,196
Dept: Psychiatry and Behavioral Sciences  Award: 8UL1TR000062-04 (12070938-2)

Novgorodov, Sergei

Co-Investigator
Role and Regulation of Ceramide Synthases in Apoptosis
PI: Lina Obeid  Sponsor: NIH/NIA  Total: $ 294,248
Dept: Medicine  Award: 9R01GM097741-13A1 (10071334-1)

Nowling, Tamara

Co-Investigator
Molecular Mechanisms of the Impact of Fli-1 on Lupus
PI: Xian Zhang  Sponsor: NIH/NIAMS  Total: $ 272,160
Dept: Medicine  Award: 5R01AR056670-03 (12080991-1)
<table>
<thead>
<tr>
<th>Principal Investigator</th>
<th>Project Title</th>
<th>Sponsor</th>
<th>Budget Dates:</th>
<th>Direct F &amp; A</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>O'Brien, Paul</td>
<td><strong>A Phase II, Open-Labeled, Randomized Study of MEHD-7945A vs. Cetuximab in Patients with Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck Who Have Progressed During or Following Platinum-Based Chemotherapy</strong></td>
<td>Genentech, Inc.</td>
<td>05/10/12 - 05/09/17</td>
<td>918,586</td>
<td>229,021</td>
</tr>
<tr>
<td></td>
<td>Oates, James</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Unique Biomarkers of Lupus Nephritis Pathology and Response to Therapy</strong></td>
<td>VAMC</td>
<td>04/01/12 - 03/30/13</td>
<td>150,000</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td><strong>Vitamin D Repletion to Improve Endothelial Function in Lupus Patients</strong></td>
<td>VAMC</td>
<td>07/01/11 - 06/30/13</td>
<td>46,296</td>
<td>3,704</td>
</tr>
<tr>
<td></td>
<td><strong>Subcontract with USC for Edith Williams' Pfizer Fellowship in Health Disparities</strong></td>
<td>VAMC</td>
<td>07/01/09 - 06/30/10</td>
<td>2,500</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td><strong>Role of Reactive Intermediates in Lupus Nephritis</strong></td>
<td>VAMC</td>
<td>09/01/11 - 05/31/12</td>
<td>32,789</td>
<td>5,192</td>
</tr>
<tr>
<td></td>
<td><strong>A Research Study to Assess if CC-930 is Safe in Treating Subjects with Discoid Lupus Erythematosus</strong></td>
<td>VAMC</td>
<td>02/09/12 - 01/31/13</td>
<td>75,251</td>
<td>17,213</td>
</tr>
<tr>
<td></td>
<td><strong>Role of Reactive Intermediates in Lupus Nephritis</strong></td>
<td>VAMC</td>
<td>06/01/12 - 05/31/13</td>
<td>274,151</td>
<td>50,499</td>
</tr>
<tr>
<td></td>
<td><strong>Regulation of the Tumor Microenvironment by KSHV</strong></td>
<td></td>
<td></td>
<td>501,173</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Regulation of the Tumor Microenvironment by KSHV</strong></td>
<td></td>
<td></td>
<td>2,671,193</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Role of Reactive Intermediates in Lupus Nephritis</strong></td>
<td></td>
<td></td>
<td>2,968,88</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Role of Reactive Intermediates in Lupus Nephritis</strong></td>
<td></td>
<td></td>
<td>5,096,355</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Regulation and Role of Ceramidase in Inflammation</strong></td>
<td>VAMC</td>
<td>09/30/11 - 10/24/11</td>
<td>200,000</td>
<td>94,248</td>
</tr>
</tbody>
</table>

---

**Note:** The above table lists projects and financial details for various researchers and their projects. Each project includes a title, the principal investigator, and details about the research and funding provided by different organizations and dates.
Obeid, Lina

Co-PI/Project Director
Spingolipids in Cancer Biology and Therapy (Project 3)
PI: Yusuf Hannun
Dept: Biochemistry and Molecular Biology
Sponsor: NIH/NCI
Award: 5P01CA097132-09 (12040548-7)

Total: $ 228,000

Co-Investigator
MUSC CCSG: Disruption of Ceramide Synthesis by CerS2 Depletion as a Tool to Increase Breast Cancer Sensitivity to Taxane Therapy
PI: Andrew Kraft
Dept: Medicine
Sponsor: NIH/NCI
Award: 3P30CA138313-03S1 (11011261-1)

Total: $ 50,000

Mentor
Ceramide Synthases CERS5 and CERS6 Regulate Pathways of Programmed Cell Death
PI: Thomas Mullen
Dept: Medicine
Sponsor: NIH/NIEHS
Award: 5F30ES016975-04 (11042519-1)

Total: $ 37,010

Role of Sphingosine Kinase 1 in a Mouse Model of Chronic Inflammation
PI: Deanna Baker
Dept: Medicine
Sponsor: NIH/NIAMS
Award: 5F31AR057307-03 (12030373-1)

Total: $ 36,289

Regulation of Vasculature by Estrogen Receptors During Aging in Mouse Models
PI: Linda Heffernan
Dept: Medicine
Sponsor: NIH/NIEHS
Award: 5F30ES017379-03 (11042626-1)

Total: $ 432

Role of Sphingosine Kinase 1 in the p53-Dependent DNA Damage Response
PI: Linda Heffernan
Dept: Medicine
Sponsor: NIH/NIEHS
Award: 5F30ES017379-03 (12030373-2)

Total: $ 432

Palesch, Yuko

Principal Investigator
POINT: Platelet-Oriented Inhibition in New TIA
Univ. of California, San Francisco
5823SC/U01NS062835 (08120256)

Total: $ 71,424

Albumin in Acute Stroke (ALIAS) Trial Statistical and Data Coordinating Center
NIH/NINDS
2R01NS054630-06 (10102049)

Total: $ 1,228,232

Neurological Emergencies Treatment Trial Network Statistical/Data Management Center (NETT)
NIH/NINDS
2U01NS059041-06 (10103097)

Total: $ 1,098,903

Interventional Management of Stroke Phase III Trial - SDCC
NIH/NINDS
1U01NS077304-01 (11012863)

Total: $ 487,035

Research Services Agreement
Edge Therapeutics, Inc.
(12010104)

Total: $ 34,000

PROTECT III: Progesterone for Traumatic Brain Injury: Experimental Clinical Treatment
Emory Univ.
S662510/U01 NS062778-03 (12020274)

Total: $ 301,636

Statistical and Data Coordinating Center for the ATACH-2
NIH/NINDS
5U01NS061861-03 (12070896)

Total: $ 296,881

Parsons, Christopher

Principal Investigator
Regulation of the Tumor Microenvironment by KSHV
NIH/NCI
5R01CA142362-03 (12050673)

Total: $ 296,881
Pastis, Nicholas

**Co-PI/Project Director**

**Airway Epithelium Gene Expression in the Diagnosis of Lung Cancer**

*PI: Gerard Silvestri*  
*Sponsor: Allegro Diagnostics, Inc.*  
*Total: $120,000*

*Dept: Medicine*  
*Award: ADX-0001 (10040147-2)*

---

Pickelsimer, E.

**Co-Investigator**

**The Virtual TeleConsult Clinic: Leveraging Cost-Effective Technology to Improve Access to Quality Tertiary Health Care**

*PI: Samir Fakhry*  
*Sponsor: MUSC Fdn.*  
*Total: $296,926*

*Dept: Surgery*  
*Award: 6310-SP (12020253-1)*

---

Pisoni, Roberto

**Co-Investigator**

**Bardoxolone Methyl Evaluation in Patients with CKD and Type 2 Diabetes: The Occurrence of Renal Events**

*PI: Ruth Campbell*  
*Sponsor: MUSC OIP*  
*Total: $97,437*

*Dept: Medicine*  
*Award: RTA 402-C-0903 (11120352-1)*

---

Ploth, David

**Principal Investigator**

**Nephrology Fellows Education and Training in Anemia**

*Multiple Sponsors*  
*Budget Dates: 07/01/03 - 06/30/15*  
*Direct F & A Total*  
*Project Dates: 07/01/03 - 06/30/15 1,500 0 1,500*

**Role of Angiotensin II in Medullary Solute and Water Reabsorption**

*Dialysis Clinics, Inc.*  
*C-3052A (East Cooper) (09010876)*  
*Budget Dates: 03/01/09 - 08/23/11*  
*Direct F & A Total*  
*Project Dates: 03/01/09 - 08/23/11 44,225 0 44,225*

**BID Coordinator Funding**

*Dialysis Clinics, Inc.*  
*C-3387D East Cooper (048) (12060731)*  
*Budget Dates: 07/01/11 - 06/30/14*  
*Direct F & A Total*  
*Project Dates: 07/01/11 - 06/30/14 205,443 0 205,443*

**Blood Pressure in Dialysis Patients**

*Univ. of New Mexico Health Sciences Center*  
*3RA95/R01 DK083424-02 (12081017)*  
*Budget Dates: 07/01/03 - 06/30/15*  
*Direct F & A Total*  
*Project Dates: 07/15/10 - 06/30/13 93,104 17,351 110,455*

---

Ramakrishnan, V.

**Principal Investigator**

**Biostatistics Training for Basic Biomedical Research**

*NIH/NIGMS*  
*Budget Dates: 07/01/11 - 06/30/12*  
*Direct F & A Total*  
*Project Dates: 07/01/05 - 06/30/13 163,496 8,352 171,848*
Ramakrishnan, V.  
**Co-Investigator**  
Southern Consortium Node of the Clinical Trials Network  
Pl: Kathleen Brady  
Sponsor: NIH/NIDA  
**Total:** $ 426,973  
Dept: Psychiatry and Behavioral Sciences  
Award: 3U10DA013727-12S4 (12050600-1)  

*Impact of MRSA Decolonization Therapy on MRSA Infection and Transmission*  
Pl: Arch Mainous  
Sponsor: AHRQ  
**Total:** $ 499,713  
Dept: Family Medicine  
Award: 5R01HS018954-02 (12070808-1)

Reuben, Adrian  
**Principal Investigator**  
*A Multi-Center Trial to Study Acute Liver Failure: Data and Specimen Collection Protocol Acute Liver Injury (ALI)*  
UT Southwestern Med. Ctr.  
**Budget Dates:** 09/01/11 - 08/31/12  
**Direct F & A**  
GMO-111124/U01 DK058369-1 (11120292)  
**Total**  
60,001  
28,500  
88,501

*Evaluation of the Capability of the 13C-Octanoate Breath Test (OBT) Measurement in Patients with Chronic Liver Disease to Differentiate between Presence and Absence of HCC Determined by MRI*  
Exalenz Bioscience Ltd.  
**Budget Dates:** 09/17/11 - 10/01/12  
**Direct F & A**  
HCC-BID-0411 (12030366)  
**Total**  
27,500  
6,250  
33,750

**Co-Investigator**  
Phosphatidylethanol as an Alcohol Biomarker in Patients with Liver Disease  
Pl: Scott Stewart  
Sponsor: NIH/NIAAA  
**Total:** $ 75,000  
Dept: Psychiatry and Behavioral Sciences  
Award: (09120743-2)

Roche, Joelle  
**Co-Investigator**  
Development of Anti-Glut-1 Antibody as a Novel Therapeutic Strategy against Breast Cancer  
Pl: George Simon  
Sponsor: US Army/USAMRAA  
**Total:** $ 203,385  
Dept: Medicine  
Award: W81XWH-07-1-0348 (10121469-2)

**Mentor**  
Hepatopulmonary Syndrome and the Role of Endothelin-1 in Human Disease  
Pl: David Koch  
Sponsor: Am. College of Gastroenter  
**Total:** $ 258,852  
Dept: Medicine  
Award: FY08.046.002/P50 CA058187 (11051837-1)

Romagnuolo, Joseph  
**Principal Investigator**  
*Performance Evaluation of a mSEPT9 Plasma-Based Assay for the Detection of Sessile Serrated Adenomas (SSA) in the Colon in the PRESEPT Cohort*  
Epigenomics, Inc.  
**Budget Dates:** 06/07/11 - 12/31/11  
**Direct F & A**  
SPR0020 (12020235)  
**Total**  
2,900  
100  
3,000

*NAPS2 Continuation Genome Wide Association Study of Pancreatitis*  
Univ. of Pittsburgh  
**Budget Dates:** 09/23/11 - 08/31/12  
**Direct F & A**  
0023323(119869-4)/R56 DK0 (12050689)  
**Total**  
5,400  
2,565  
7,965

**Co-Investigator**  
Evaluating Predictors and Interventions in Sphincter of Oddi Dysfunction (EPISOD) (Supplement for Long Term Followup of Enrolled Subjects): Clinical Coordinating Center  
Pl: Peter Cotton  
Sponsor: NIH/NIDDK  
**Total:** $ 188,731  
Dept: Medicine  
Award: 3U01DK074739-05S1 (12010131-2)

Sahn, Steven  
**Principal Investigator**  
*A Phase 1 Study to Evaluation the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AB0024 in Adult Patients with Idiopathic Pulmonary Fibrosis*  
Gilead Sciences, Inc.  
**Budget Dates:** 10/26/10 - 10/31/12  
**Direct F & A**  
AB0024-201 (10102775)  
**Total**  
157,180  
39,170  
196,350

*A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of the Efficacy and Safety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis*  
Covance, Inc.  
**Budget Dates:** 08/15/11 - 01/31/13  
**Direct F & A**  
PFP-016 (12020210)  
**Total**  
266,712  
66,428  
333,140

*A Prospective, Longitudinal, Non-Pharmacological, Case-Controlled Study to Evaluate Longitudinal Disease Behavior and Biomarker Data Over a 52-Week Period in Idiopathic Pulmonary Fibrosis Patients*  
Covance, Inc.  
**Budget Dates:** 12/20/11 - 12/31/12  
**Direct F & A**  
ASY12295 (12070832)  
**Total**  
22,635  
5,034  
27,669
Salgado, Cassandra

**Co-Investigator**

**Copper Antimicrobial Research Program**

**PI:** Michael Schmidt  
**Dept:** Microbiology and Immunology  
**Sponsor:** Advanced Technology Institute  
**Award:** 2007-614-05 (09060308-2)  
**Total:** $80,639

**Impact of MRSA Decolonization Therapy on MRSA Infection and Transmission**

**PI:** Arch Mainous  
**Dept:** Family Medicine  
**Sponsor:** AHRQ  
**Award:** 1R01HS018954-01A1 (10101315-1)  
**Total:** $496,813

**Impact of MRSA Decolonization Therapy on MRSA Infection and Transmission**

**PI:** Arch Mainous  
**Dept:** Family Medicine  
**Sponsor:** AHRQ  
**Award:** 5R01HS018954-02 (12070808-1)  
**Total:** $499,713

Scott, Lancer

**Principal Investigator**

**Disaster Mental Health Training Tool II**

**Hermes, LLC**  
**Budget Dates:** 01/10/12 - 06/30/12  
**Direct F & A**  
**Total:** 36,882  
**Project Dates:** 01/10/12 - 06/30/14  
**Total:** 48,500

**Co-PI/Project Director**

**Pre-Disaster Mitigation Grant for MUHA (Training - Emergency Medicine)**

**PI:** Wayne Brannan  
**Dept:** Risk Management  
**Sponsor:** SC Emergency Preparedness  
**Award:** (12040538-3)  
**Total:** $236,656

**Pre-Disaster Mitigation Grant for University IOP (Training-Emergency Medicine)**

**PI:** Wayne Brannan  
**Dept:** Risk Management  
**Sponsor:** SC Emergency Preparedness  
**Award:** (12040539-3)  
**Total:** $130,593

Selassie, Anbesaw

**Principal Investigator**

**Risk Factors of Epilepsy Outcomes: Comorbidities in a Population with Epilepsy**

**CDC**  
**Budget Dates:** 09/30/11 - 09/29/12  
**Direct F & A**  
**Total:** 294,234  
**Project Dates:** 09/30/11 - 09/29/15  
**Total:** 425,000

**The SC Traumatic Spinal Cord Injury Registry**

**SC Spinal Cord Injury Fund**  
**Budget Dates:** 07/01/11 - 06/30/12  
**Direct F & A**  
**Total:** 200,000  
**Project Dates:** 07/01/11 - 06/30/16  
**Total:** 200,000

**Co-PI/Project Director**

**Measuring Outcomes after Spinal Cord Injury Throughout South Carolina: A System of Tracking, Research, and Referral**

**PI:** Lee Saunders  
**Dept:** Health Sciences and Research  
**Sponsor:** SC Spinal Cord Injury Fund  
**Award:** SCIRF09-001 (09120850-3)  
**Total:** $195,000

**Co-Investigator**

**Rehabilitation and Research Training Center on Secondary Conditions in Individuals with SCI**

**PI:** James Krause  
**Dept:** Health Sciences and Research  
**Sponsor:** Dept. of Education  
**Award:** H133B090005-1 (12020145-1)  
**Total:** $791,037

**Emergency Department and Hospital Admissions for CV Conditions among Patients with Apparent Treatment Resistant HTN**

**PI:** Brent Egan  
**Dept:** Medicine  
**Sponsor:** Medtronic, Inc.  
**Award:** A1067029 (12070817-1)  
**Total:** $146,782

Shapshak, Dag

**Principal Investigator**

**DHEC HIV Testing in Hospital Emergency Departments**

**SC DHEC**  
**Budget Dates:** 09/30/11 - 12/31/11  
**Direct F & A**  
**Total:** 38,217  
**Project Dates:** 01/31/11 - 12/31/13  
**Total:** 43,949

**DHEC HIV Testing in Hospital Emergency Departments**

**SC DHEC**  
**Budget Dates:** 01/01/12 - 12/31/12  
**Direct F & A**  
**Total:** 65,044  
**Project Dates:** 01/31/11 - 12/31/13  
**Total:** 74,800

Sherman, Carol

**Principal Investigator**

**Phase 3 Study of Pemetrexed, Cisplatin, and Radiotherapy Followed by Consolidation Pemetrexed versus Etoposide, Cisplatin, and Radiotherapy Followed by Consolidation Cytotoxic Chemotherapy of Choice in Patients with Unresectable, Locally Advanced, Stage III Non-Small Cell Lung Cancer Other Than Predominantly Squamous Cell Histology**

**Eli Lilly**  
**Budget Dates:** 09/03/08 - 11/01/13  
**Direct F & A**  
**Total:** 40,853  
**Project Dates:** 09/03/08 - 11/01/13  
**Total:** 51,066
### Sherman, Carol

**Principal Investigator**

**A Randomized, Phase III, Multi-Center, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of MetMAb**

- **Budget Dates:** 10/20/11 - 12/20/16
- **Project Dates:** 10/20/11 - 12/20/16
- **Total:** $1,067,319

**OAM4971g (12060792)**

**Budget Dates:** 10/20/11 - 12/20/16
- **Direct F & A:** $854,755
- **Total:** $212,564

### Shirai, Keisuke

**Principal Investigator**

**A Phase I, Randomized, Open-Label, Multi-Center, Two-Period, Crossover Study to Investigate the Effect of Food on the Pharmacokinetics of a Single Oral Dose of RO5185426, Followed by Administration of 960 mg RO5185426 Twice Daily to BRAF v600E Positive Metastatic Melanoma Patients**

- **Budget Dates:** 02/04/11 - 02/03/16
- **Total:** $1,067,319

**NP25396 (11022327)**

**Budget Dates:** 02/04/11 - 02/03/16
- **Direct F & A:** $1,800
- **Total:** $450

### Silver, Richard

**Principal Investigator**

**DISTOL-1: Digital Ischemic Lesions in Scleroderma Treated with Oral Treprostinil Diethanolamine - A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study**

- **Budget Dates:** 02/11/09 - 06/30/11
- **Project Dates:** 02/11/09 - 06/30/11
- **Total:** $3,963

**TDE-DU-201 (08120990)**

**Budget Dates:** 02/11/09 - 06/30/11
- **Direct F & A:** $3,170
- **Total:** $793

### Co-Investigator

**A Medical Center Network for Optimized Lung Cancer Biospecimen Banking**

- **Sponsor:** Univ. of Virginia
- **Total:** $249,306

**PI:** Chadrick Denlinger
- **Dept:** Surgery
- **Award:** GG11364-137226 (12070909-1)

**A Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Tocilizumab Versus Placebo in Patients with Systemic Sclerosis**

- **Budget Dates:** 01/24/12 - 03/31/15
- **Total:** $143,583

**WA27788 (12070954)**

**Budget Dates:** 01/24/12 - 03/31/15
- **Direct F & A:** $115,446
- **Total:** $28,137
<table>
<thead>
<tr>
<th>Principal Investigator</th>
<th>Project Title</th>
<th>Sponsor</th>
<th>Dept</th>
<th>Award</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Silver, Richard</td>
<td>SmartState Center for Inflammation and Fibrosis Research</td>
<td>SC Research Centers of Economic Excellence</td>
<td>Medicine</td>
<td>12091269</td>
<td>470,957</td>
</tr>
<tr>
<td>Silvestri, Gerard</td>
<td>Airway Epithelium Gene Expression in the Diagnosis of Lung Cancer</td>
<td>Allegro Diagnostics, Inc.</td>
<td>Medicine</td>
<td>10040147</td>
<td>96,000</td>
</tr>
<tr>
<td></td>
<td>Remote Expert Assessment of Lung Cancer (REAL Cancer)</td>
<td>Duke Endowment</td>
<td>Medicine</td>
<td>11010417</td>
<td>128,500</td>
</tr>
<tr>
<td></td>
<td>K24 Mid-Career Investigator Award in Patient-Oriented Research</td>
<td>NIH/NCI</td>
<td>Medicine</td>
<td>11050253</td>
<td>135,925</td>
</tr>
<tr>
<td></td>
<td>Validation for Multi-Gene Test for Lung Cancer Risk (LCRT)</td>
<td>Univ. of Toledo</td>
<td>Medicine</td>
<td>12050601</td>
<td>50,778</td>
</tr>
<tr>
<td>Simon, George</td>
<td>Development of Anti-Glut-1 Antibody as a Novel Therapeutic Strategy against Breast Cancer</td>
<td>US Army/USAMRAA</td>
<td>Medicine</td>
<td>10121469</td>
<td>137,888</td>
</tr>
<tr>
<td></td>
<td>A Randomized, Open-Label, Phase II, 2-Arm, Multi-Center Trial Comparing Maintenance Therapy with Pazopanib or Pemetrexed in Non-Progressing Subjects with Metastatic Stage IVA and IVB Non-Squamous NSCLC after Induction Therapy with Carboplatin or Cisplatin Plus Pemetrexed</td>
<td>Boehringer Ingelheim Pharmaceuticals</td>
<td>Medicine</td>
<td>11013170</td>
<td>26,961</td>
</tr>
<tr>
<td>Slate, Elizabeth</td>
<td>Post-Transcriptional Regulation of Periodontal Disease</td>
<td>Keith Kirkwood</td>
<td>Graduate Studies</td>
<td>1R01DE021423-01A1</td>
<td>$368,750</td>
</tr>
<tr>
<td></td>
<td>Robust Nonparametric Methods with Variable Selection for Clustered Dental Data</td>
<td>Dipankar Bandyopadhyay</td>
<td>Medicine</td>
<td>5R03DE020114-02</td>
<td>$142,239</td>
</tr>
<tr>
<td></td>
<td>S1P Deficiency Prolongs Endothelial Barrier Recovery after Fontan Operation</td>
<td>Kelley Argraves</td>
<td>Regenerative Medicine and Cell Bio</td>
<td>1R21HL109829-01A1</td>
<td>$221,250</td>
</tr>
<tr>
<td>Smith, Edwin</td>
<td>Randomized, Double-Blind, Multi-Center, Parallel-Group Study to Assess the Efficacy, Safety and Tolerability of Macitentan in Patients with Ischemic Digital Ulcers Associated with SSC</td>
<td>Actelion Pharmaceuticals</td>
<td>Medicine</td>
<td>12070888</td>
<td>130,966</td>
</tr>
<tr>
<td>Snider, Ashley</td>
<td>The Role of Sphingolipids in Inflammatory Bowel Disease</td>
<td>VAMC</td>
<td>Medicine</td>
<td>10051962</td>
<td>142,900</td>
</tr>
</tbody>
</table>
Snider, Ashley  
Co-PI/Project Director  
COBRE in Lipidomics and Pathobiology (Core C)  
PI: Craig Crosson  
Sponsor: NIH/NCRR  
Total: $ 182,500  
Dept: Ophthalmology  
Award: 5P20RR017677-10 (1204090-4)  

Spingolipids in Cancer Biology and Therapy (Core C)  
PI: Yusuf Hannun  
Sponsor: NIH/NCI  
Total: $ 71,132  
Dept: Biochemistry and Molecular Biology  
Award: 5P01CA097132-09 (12040548-4)  

Somaiah, Neeta  
Principal Investigator  
A Phase III, Multi-Center, International, Randomized, Double-Blind, Placebo-Controlled Study of Doxorubicin Plus Palifosfamide-tris vs. Doxorubicin Plus Placebo in Patients with Front-line Metastatic Soft Tissue Sarcoma  
Ziopharm Oncology, Inc.  
Budget Dates: 03/03/11 - 03/31/16  
Direct F & A  Total  
IPM3001 (11030802)  
Project Dates: 03/03/11 - 03/31/16 7,200 1,800 9,000  

A Randomized, Controlled Study of Yondelis (Trabectedin) or Dacarbazine for the Treatment of Advanced Liposarcoma or Leiomyosarcoma Previously Treated with an Anthracycline and Ifosfamide  
Johnson and Johnson  
Budget Dates: 05/19/11 - 05/18/16  
Direct F & A  Total  
ET743-SAR-3007 (11042520)  
Project Dates: 05/19/11 - 05/18/16 66,491 16,622 83,113  

A Phase 2, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of IPI-926 in Patients with Metastatic or Locally Advanced (Unresectable) Chondrosarcoma  
Infinity Pharmaceuticals  
Budget Dates: 05/23/11 - 07/31/16  
Direct F & A  Total  
IPI-926-04 (11120226)  
Project Dates: 05/23/11 - 07/31/16 72,771 18,193 90,964  

A Randomized, Phase 3, Multi-Center, Open-Label Study Comparing TH-302 in Combination with Doxorubicin vs. Doxorubicin Alone in Subjects with Locally Advanced Unresectable or Metastatic Soft Tissue Sar  
Parexel Intl. Corp.  
Budget Dates: 10/20/11 - 10/20/16  
Direct F & A  Total  
101646 - TH-CR-406 (12040519)  
Project Dates: 10/20/11 - 10/20/16 256,431 62,983 319,414  

Spassieva, Stefanka  
Co-Investigator  
MUSC CCSG: Disruption of Ceramide Synthesis by CerS2 Depletion as a Tool to Increase Breast Cancer Sensitivity to Taxane Therapy  
PI: Andrew Kraft  
Sponsor: NIH/NCI  
Total: $ 50,000  
Dept: Medicine  
Award: 3P30CA138313-03S1 (11011261-1)  

Steinberg, Daniel  
Principal Investigator  
A Clinical Trial Comparing Cangrelor to Clopidogrel Standard of Care Therapy in Subjects Who Require Percutaneous Coronary Intervention CHAMPION PHOENIX  
The Medicines Co.  
Budget Dates: 08/15/11 - 12/31/13  
Direct F & A  Total  
TMC-CAN-10-01 (12020149)  
Project Dates: 08/15/11 - 12/31/13 193,900 47,600 241,500  

Study of Access Site for Enhancement of PCI for Women  
Duke Univ.  
Budget Dates: 01/04/12 - 01/03/14  
Direct F & A  Total  
SAFE-PCI / SPS181852 (12060772)  
Project Dates: 01/04/12 - 01/03/14 57,000 13,250 70,250  

Sterba, Katherine  
Co-Investigator  
Optimizing Survivorship and Surveillance after Treatment for Colorectal Cancer  
PI: Marvella Ford  
Sponsor: NIH/NCI  
Total: $ 160,406  
Dept: Medicine  
Award: 1R21CA152865-01A1 (10110530-1)  

Improving Resection Rates among African Americans with NSCLC  
PI: Marvella Ford  
Sponsor: NIH/NCMHD  
Total: $ 368,750  
Dept: Medicine  
Award: 1R01MD005892-01A1 (11120246-1)  

Strange, Charlie  
Principal Investigator  
Sarcoidosis and A1AT Genomics and Informatics Center (SAGIC)  
Univ. of Pittsburgh  
Budget Dates: 04/01/12 - 03/31/13  
Direct F & A  Total  
9008517/0U11HL112707 (11051094)  
Project Dates: 04/01/12 - 03/31/15 23,469 11,148 34,617  

Alpha-1 Genetic Counseling Center  
Alpha-1 Assoc.  
Budget Dates: 07/01/11 - 06/30/12  
Direct F & A  Total  
(11120356)  
Project Dates: 07/01/07 - 06/30/12 65,912 0 65,912  

A Long-Term, Randomized, Study of the Safety and Tolerability of a Fixed-Dose Combination of Aclidinium Bormide/Formoterol, Fumarae Compared to Formaoterol Fumurate in Patients with Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease (COPD)
<table>
<thead>
<tr>
<th>Principal Investigator</th>
<th>Project Title/Description</th>
<th>Sponsor</th>
<th>Budget Dates</th>
<th>Direct F &amp; A</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Strange, Charlie</td>
<td>MUSC OIP</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>LAC-MD-32 (12020170)</td>
<td></td>
<td>Project Dates: 08/30/11 - 10/31/12</td>
<td>116,995</td>
<td>27,281</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Direct F &amp; A</td>
<td>116,995</td>
<td>27,281</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Total</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>ACT Study</td>
<td>Alpha-1 Fdn.</td>
<td>Budget Dates: 07/01/11 - 06/30/12</td>
<td>126,795</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Project Dates: 07/01/11 - 06/30/12</td>
<td>126,795</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>Alpha-1 Registry Study</td>
<td>Alpha-1 Fdn.</td>
<td>Budget Dates: 07/01/11 - 06/30/12</td>
<td>128,861</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Project Dates: 07/01/11 - 06/30/12</td>
<td>128,861</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>Clinical Resource Center Alpha-1 Foundation Registry Planning Grant</td>
<td>Alpha-1 Fdn.</td>
<td>Budget Dates: 02/10/12 - 05/10/12</td>
<td>49,775</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Project Dates: 02/10/12 - 05/10/12</td>
<td>49,775</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>Scleroderma Cyclophosphamide or Transplantation: Morbidity and Mortality Follow Up of Participants of the Scleroderma Lung Study</td>
<td>Duke Univ.</td>
<td>Budget Dates: 10/01/11 - 10/31/12</td>
<td>1,920</td>
<td>480</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Project Dates: 10/01/11 - 10/31/12</td>
<td>1,920</td>
<td>480</td>
</tr>
<tr>
<td>Co-Investigator</td>
<td>Mycophenolate vs Oral Cyclophosphamide in Scleroderma Interstitial Lung Disease (SLS II)</td>
<td>Sponsor: Univ. of California, Los Angeles</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Dept: Medicine</td>
<td>Award: 1460 G KB111 (12020200-1)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Rare Lung Disease Clinical Research Network - MILES Trial</td>
<td>LAM Foundation</td>
<td>Budget Dates: 08/01/08 - 07/31/12</td>
<td>34,203</td>
<td>10,802</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Project Dates: 11/10/07 - 07/31/12</td>
<td>34,203</td>
<td>10,802</td>
</tr>
<tr>
<td>Co-Investigator</td>
<td>South Carolina Clinical and Translational Research Institute (UL1)</td>
<td>Sponsor: NIH/NCRR</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Dept: Psychiatry and Behavioral Sciences</td>
<td>Award: 5UL1RR029882-03 (11012750-2)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>A Phase Ib, Open-Label, Multi-Center, Dose-Finding Study of Oral Panobinostat (LBH589) in Combination with Ara-C and Mitoxantrone as Salvage Therapy for Refractory or Relapsed Acute Myeloid Leukemia</td>
<td>Novartis Corp.</td>
<td>Budget Dates: 08/06/10 - 07/31/12</td>
<td>1,920</td>
<td>480</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Project Dates: 08/06/10 - 07/31/12</td>
<td>1,920</td>
<td>480</td>
</tr>
<tr>
<td></td>
<td>SWOG Membership Grant</td>
<td>Southwest Oncology Group</td>
<td>Budget Dates: 01/01/12 - 12/31/12</td>
<td>95,143</td>
<td>12,500</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Project Dates: 01/01/12 - 12/31/12</td>
<td>95,143</td>
<td>12,500</td>
</tr>
<tr>
<td></td>
<td>A Phase 3, Randomized, Controlled, Double-Blind, Multinational Clinical Study of the Efficacy and Safety of Vosaroxin and Cytarabine vs. Placebo and Cytarabine in Patients with First Relapsed or Refractory AML (VALOR)</td>
<td>Icon Clinical Research, Inc.</td>
<td>Budget Dates: 11/18/10 - 11/30/15</td>
<td>498,860</td>
<td>124,715</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Project Dates: 11/18/10 - 11/30/15</td>
<td>498,860</td>
<td>124,715</td>
</tr>
<tr>
<td></td>
<td>A Phase III, Multi-Center, Randomized, Controlled Study to Assess the Efficacy and Safety of ON 01919.6a Administered as a 72-Hour Continuous Intravenous Infusion Every Other Week in Myelodysplastic Syndrome Patients with Excess Blasts Relapsing after, or Refractory to, or Intolerant to Azacitidine or Decitabine</td>
<td>Pharmaceutical Research Associates</td>
<td>Budget Dates: 07/08/11 - 07/07/16</td>
<td>118,084</td>
<td>28,771</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Project Dates: 07/08/11 - 07/07/16</td>
<td>118,084</td>
<td>28,771</td>
</tr>
<tr>
<td></td>
<td>An Open-Label, Phase 1/2 Study of MEDI-551, a Humanized Monoclonal Antibody Directed against CD19, in Adult Subjects with Relapsed or Refractory Advanced B-Cell Malignancies</td>
<td>MedImmune, Inc.</td>
<td>Budget Dates: 04/02/12 - 04/03/17</td>
<td>171,967</td>
<td>42,242</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Project Dates: 04/02/12 - 04/03/17</td>
<td>171,967</td>
<td>42,242</td>
</tr>
<tr>
<td></td>
<td>A Phase 2, Randomized Study of Bortezomib/dexamethasone with or without Elotuzumab in Subjects with Relapsed/Refractory Multiple Myeloma</td>
<td>Bristol Myers Squibb</td>
<td>Budget Dates: 05/07/12 - 05/06/17</td>
<td>71,462</td>
<td>17,116</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Project Dates: 05/07/12 - 05/06/17</td>
<td>71,462</td>
<td>17,116</td>
</tr>
<tr>
<td></td>
<td>A Phase Ib/Iib, Open-Label, Multi-Center, Dose-Escalation Study of Oral Panobinostat (LBH589) Administered with 5-Azacitidine (Vidaza) in Adult Patients with Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML) or Acute myeloid Leukemia (AML)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Name</td>
<td>Role</td>
<td>Title</td>
<td>Sponsor</td>
<td>Total Budget</td>
<td></td>
</tr>
<tr>
<td>-----------------------</td>
<td>-------------------------------</td>
<td>----------------------------------------------------------------------</td>
<td>--------------------------</td>
<td>--------------</td>
<td></td>
</tr>
<tr>
<td>Stuart Robert</td>
<td>Principal Investigator</td>
<td>MUSC CCSG: Clinical Trials</td>
<td>Novartis Corp.</td>
<td>$145,297</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>PI: Andrew Kraft Sponsor: NIH/NCI</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Dept: Medicine Award: 5P30CA138313-04 (12070914-10)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sturdivant Rachel</td>
<td>Co-Investigator</td>
<td>Bardoxolone Methyl Evaluation in Patients with CKD and Type 2 Diabetes: The Occurrence of Renal Events</td>
<td>Biosphere/Merit Medical</td>
<td>$146,420</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>PI: Ruth Campbell Sponsor: MUSC OIP Total: $ 97,437</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Dept: Medicine Award: RTA 402-C-0903 (11120352-1)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Systolic Blood Pressure Intervention Trial (SPRINT) Clinical Center Networks</td>
<td>Univ. of Alabama, Birmingham</td>
<td>$126,443</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>PI: Ruth Campbell Sponsor: Univ. of Alabama, Birmingham Total: $ 126,443</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Dept: Medicine Award: 000336417-035/HHSN2682009 (12020176-1)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Systolic Blood Pressure Intervention Trial (SPRINT) Clinical Center Networks</td>
<td>Univ. of Alabama, Birmingham</td>
<td>$ 124,284</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>PI: Ruth Campbell Sponsor: Univ. of Alabama, Birmingham Total: $ 124,284</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Dept: Medicine Award: 000336417-035/HHSN2682009 (12020176-2)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Taylor Marian</td>
<td>Principal Investigator</td>
<td>A Prospective, Open-Label Study Evaluating the Efficacy of Two Management Strategies (Pantoprazole 40 mg q.a.m. and Taking Pradaxa with Food (within 30 Minutes after a Meal)) on Gastrointestinal Symptoms (GIS) in Patients New with Pradaxa F3</td>
<td>Boehringer Ingelheim Pharmaceuticals</td>
<td>$153,945</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>PI: Ruth Campbell Sponsor: Boehringer Ingelheim Pharmaceuticals Total: $ 123,356</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Dept: Medicine Award: 1160.128 - Pradaxa GIS (12091340)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Project Dates: 04/09/12 - 12/31/14</td>
<td>123,356 Direct F &amp; A</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Project Dates: 04/09/12 - 12/31/14</td>
<td>30,589 Total</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Thomas James</td>
<td>Principal Investigator</td>
<td>A Multi-Center, Double-Blind, Randomized Study to Establish the Clinical Benefit and Safety of Vytorin (Ezetimibe/Simvastatin Tablet) vs. Simvastatin Monotherapy in High-Risk Subjects Presenting with Acute Coronary Syndrome (IMPROVE IT)</td>
<td>Schering-Plough Corp.</td>
<td>$20,190</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>PI: Ruth Campbell Sponsor: Schering-Plough Corp. Total: $ 22,440</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Dept: Radiology Award: Hi-Quality (12040483-1)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Project Dates: 11/01/05 - 10/31/12</td>
<td>22,440 Direct F &amp; A</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Project Dates: 11/01/05 - 10/31/12</td>
<td>5,610 Total</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multinational Trial to Assess the Prevention of Thrombotic Events with Ticagrelor Compared to Placebo on a Background of Acetyl Salicylic Acid (ASA) Therapy in Patients with History of Myocardial Infarction</td>
<td>Brigham and Womens Hospital</td>
<td>$20,190</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>PI: Marcelo Guimaraes Sponsor: Brigham and Womens Hospital Total: $ 16,152</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Dept: Radiology Award: Hi-Quality (12040483-2)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Project Dates: 11/28/10 - 12/14/13</td>
<td>16,152 Direct F &amp; A</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Project Dates: 11/28/10 - 12/14/13</td>
<td>4,038 Total</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Thomas Melanie</td>
<td>Principal Investigator</td>
<td>SmartState Center for Gastrointestinal Cancer Diagnostics: Grace DeWolff Chair in Medical Oncology</td>
<td>MUSC Fdn.</td>
<td>$100,000</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>PI: Marcelo Guimaraes Sponsor: MUSC Fdn. Total: $ 100,000</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Dept: Radiology Award: Hi-Quality (12040483-1)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Project Dates: 07/01/11 - 06/30/12</td>
<td>100,000 Direct F &amp; A</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Project Dates: 07/01/11 - 06/30/12</td>
<td>0 Total</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Todoran Thomas</td>
<td>Principal Investigator</td>
<td>A Phase 4, Randomized, Double-Blind Study Comparing Patient Comfort and Safety between Iodixanol 320 mg i/mL and Iopamidol 370 mg i/mL in Patients Undergoing Peripheral Angiography</td>
<td>GE Healthcare, Inc.</td>
<td>$152,256</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>PI: Marcelo Guimaraes Sponsor: GE Healthcare, Inc. Total: $ 122,405</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Dept: Radiology Award: Hi-Quality (12040483-1)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Project Dates: 07/26/11 - 12/31/12</td>
<td>122,405 Direct F &amp; A</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Project Dates: 07/26/11 - 12/31/12</td>
<td>29,851 Total</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Renal Denervation in Patients with Uncontrolled Hypertension</td>
<td>Medtronic Vascular, Inc.</td>
<td>$208,315</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>PI: Marcelo Guimaraes Sponsor: Medtronic Vascular, Inc. Total: $ 167,752</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Dept: Radiology Award: Hi-Quality (12040483-1)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Project Dates: 09/20/11 - 12/31/15</td>
<td>167,752 Direct F &amp; A</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Project Dates: 09/20/11 - 12/31/15</td>
<td>40,563 Total</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Tourkina, Elena

**Principal Investigator**

**Caveolin-1 Regulation of Altered Functions of Scleroderma Fibrocytes**

NIH/NIAIMS  
4R03AR056767-03 (11050361)  
Budget Dates: 07/01/11 - 06/30/13  
Project Dates: 07/01/11 - 06/30/13  
48,000  
Direct  
F & A  
22,800  
Total  
70,800

**Anti-Fibrotic and Anti-Inflammatory Roles of Caveolin-1 in Lung Disease**

NIH/NIAIMS  
5K01AR054143-05 (11050362)  
Budget Dates: 07/01/11 - 06/30/12  
Project Dates: 07/01/11 - 06/30/12  
114,276  
Direct  
F & A  
9,142  
Total  
123,418

**Caveolin-1 Deficiency Predisposes African Americans to SSc ILD**

Scleroderma Fdn.  
Project Dates: 01/15/12 - 12/31/13  
69,444  
Direct  
F & A  
5,556  
Total  
75,000

**Co-Investigator**

**CSD Peptide-Based Therapeutic Agents in Scleroderma Lung Disease**

PI: Stanley Hoffman  
Sponsor: US Army/USAMRAA  
Total: $329,379

Trojanowska, Maria

**Mentor**

**Regulation of Vasculature by Estrogen Receptors During Aging in Mouse Models**

NIH/NIA  
Total: $118,221

Ullian, Michael

**Principal Investigator**

**MUSC Division of Nephrology Renal Physiology/Pathophysiology Core**

Dialysis Clinics, Inc.  
C-3465 - Magnolia (128) (12050664)  
Budget Dates: 12/01/11 - 03/31/14  
Project Dates: 12/01/11 - 03/31/14  
219,588  
Direct  
F & A  
0  
Total  
219,588

Van Bakel, Adrian

**Principal Investigator**

**Medtronic Chronicle ICD Implantable Cardioverter Defibrillator Clinical Investigational Plan**

Medtronic, Inc.  
REDUCEHIC/Chronical ICD (06091174)  
Budget Dates: 09/21/06 - 12/31/11  
Project Dates: 09/21/06 - 12/31/11  
5,200  
Direct  
F & A  
1,300  
Total  
6,500

**Correlation of Intrathoracic Impedance Measures with Blood and Plasma Volume in Congestive Heart Failure**

Medtronic, Inc.  
Optival (07030103)  
Budget Dates: 03/01/12 - 12/31/12  
Project Dates: 03/01/07 - 12/31/12  
10,525  
Direct  
F & A  
0  
Total  
10,525

**A Facilitated Access Program to Provide Everolimus for Maintenance Patients Completing Therapy in RAD Trials in Solid Organ Transplantation**

Novartis Corp.  
RAD001 A2401 (08031295)  
Budget Dates: 01/09/08 - 08/31/13  
Project Dates: 01/09/08 - 08/31/13  
1,000  
Direct  
F & A  
250  
Total  
1,250

**Effect of Everolimus Immune Therapy on Anti-HLA Antibody Mediated Activation of Endothelial Cells. A Retrospective Mechanistic Substudy of the Novartis Sponsored Trial: A 24-Month, Multi-Center, Randomized, Open-Label Study of Efficacy and Safety Comparing Two Exposures of Concentration-Controlled Everolimus with Reduced Neoral versus 3.0 g MMF with Standard Dose Neoral in de novo Heart Transplant Recipients**

Univ. of California  
1625-P-PC6S3 RAD Substudy (12070810)  
Budget Dates: 10/21/11 - 08/31/13  
Project Dates: 10/21/11 - 08/31/13  
4,180  
Direct  
F & A  
295  
Total  
4,475

Velez, Juan Carlos

**Principal Investigator**

**Angiotensin Metabolite Formation by Podocytes: Implications in Glomerular Injury**

NIH/NIDDK  
5K08DK080944-04 (11051095)  
Budget Dates: 07/01/11 - 06/30/13  
Project Dates: 07/01/08 - 06/30/13  
138,650  
Direct  
F & A  
11,092  
Total  
149,742

**A Multi-Center, Randomized, Controlled, Pivotal Study to Assess the Safety and Efficacy of A Selective Cytophoretic Device (SCD) In Patients with Acute Kidney Injury (AKI)**

CytoPhex, Inc.  
SCD-003 (12121683)  
Budget Dates: 06/28/12 - 06/27/14  
Project Dates: 06/28/12 - 06/27/14  
213,800  
Direct  
F & A  
53,200  
Total  
267,000

Wallace, Kristin

**Principal Investigator**

**Race, Pathomolecular Signature and Colorectal Cancer Survival**

NIH/NCI  
1K07CA151864-01A1 (11030805)  
Budget Dates: 09/21/11 - 08/31/16  
Project Dates: 09/21/11 - 08/31/16  
120,755  
Direct  
F & A  
9,660  
Total  
130,415
Wallace, Kristin  
**Co-Investigator**  
**Epidemiology of Ovarian Cancer in African American Women**  
PI: Anthony Alberg  
Dept: Medicine  
Sponsor: Duke Univ. Total: $102,487  
Award: 203-0312 (12081170-1)

Watson, Patricia  
**Co-Investigator**  
**Targeting the CaSM Oncogene as a Novel Therapy for Pancreatic Cancer**  
PI: David Cole  
Dept: Surgery  
Sponsor: NIH/NCI Total: $270,405  
Award: 5R01CA123159-05 (11110071-1)

Wharton, J.  
**Principal Investigator**  
**Electrophysiology Fellowship Grant for 2011-2012**  
Budget Dates: 07/01/11 - 06/30/12  
Direct F & A Total  
(12010099)  
40,000 0 40,000  
**Educational Grant in Support of a Clinical Fellow in Adult Electrophysiology**  
Budget Dates: 07/01/11 - 06/30/12  
Direct F & A Total  
7167 (12040528)  
40,000 0 40,000  
**TactiCath Contact Force Ablation Study for Atrial Fibrillation**  
Budget Dates: 11/07/11 - 07/31/17  
Direct F & A Total  
VP-002 527 - TOCCASTER (12050606)  
48,160 11,165 59,325

Whelan, Timothy  
**Principal Investigator**  
**Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Ascending Repeated Doses of SAR156597 in Patients with Idiopathic Pulmonary Fibrosis**  
PI: Sanofi-Aventis US, Inc.  
Budget Dates: 02/22/12 - 02/21/13  
Direct F & A Total  
TDR11326 (12081148)  
58,940 13,860 72,800

Willner, Ira  
**Principal Investigator**  
**A Randomized, Open-Label Trial of the Safety and Efficacy of DEB025/Alisporivir in Combination with Pegylated Interferon-a2a and Ribavirin (peg-IFN 2a/RBV) and Boceprevir in Combination with peg-IFN 2a/RBV and Boceprevir in Combination with peg-IFN 2a/RBV and Boceprevir in Combination with peg-IFN 2a/RBV**  
PI: Novartis Corp.  
Budget Dates: 10/21/11 - 06/30/14  
Direct F & A Total  
DEB025A2307 (12050675)  
255,598 63,024 318,622

Wilson, Parker  
**Principal Investigator**  
**Mechanisms of Diabetic Renal Damage: Role of the Kinin Receptors**  
PI: NIH/NIDDK  
Budget Dates: 08/15/11 - 08/14/12  
Direct F & A Total  
1F30DK083208-01A2 (10080550)  
42,605 0 42,605

Wolf, Bethany  
**Co-Investigator**  
**South Carolina Clinical and Translational Research Institute (SCTR): UL1**  
PI: Kathleen Brady  
Dept: Psychiatry and Behavioral Sciences  
Sponsor: NIH/NCATS Total: $2,537,859  
Award: 8UL1TR000062-04 (12070938-1)

**South Carolina Clinical and Translational Research Institute (SCTR): UL1**  
PI: Kathleen Brady  
Dept: Psychiatry and Behavioral Sciences  
Sponsor: NIH/NCATS Total: $798,196  
Award: 8UL1TR000062-04 (12070938-2)

Woolson, Robert  
**Co-Investigator**  
**Albumin in Acute Stroke (ALIAS) Trial Statistical and Data Coordinating Center**  
PI: Yuko Palesch  
Dept: Medicine  
Sponsor: NIH/NINDS Total: $1,228,232  
Award: 2R01NS054630-06 (10102049-1)

**Interventional Management of Stroke Phase III Trial - SDCC**  
PI: Yuko Palesch  
Dept: Medicine  
Sponsor: NIH/NINDS Total: $487,035  
Award: 1U01NS077304-01 (11012863-1)

**Emergency Department and Hospital Admissions for CV Conditions among Patients with Apparent Treatment Resistant HTN**  
PI: Brent Egan  
Dept: Medicine  
Sponsor: Medtronic, Inc. Total: $146,782  
Award: A1067029 (12070817-1)
Wray, Dannah

Co-Investigator

Ryan White Part B Program
Pl: J. Kilby
Dept: Medicine
Sponsor: SC DHEC
Total: $47,532
Award: HV-1-747 (11022212-2)

Ryan White Part B Program
Pl: J. Kilby
Dept: Medicine
Sponsor: SC DHEC
Total: $1,565,105
Award: HV-1-747 (12050659-1)

Yeatts, Sharon

Principal Investigator

BIO-ProTECT
Emory Univ.
Budget Dates: 05/01/11 - 04/30/16
Direct F & A Total
S636366/R01 NS071867-01A1 (10072911)
Project Dates: 05/01/11 - 04/30/16
17,661 8,389 26,050

BIO-ProTECT
Emory Univ.
Budget Dates: 05/01/12 - 04/30/13
Direct F & A Total
(12111530)
Project Dates: 05/01/11 - 04/30/16
11,591 5,506 17,097

Co-Investigator

POINT: Platelet-Oriented Inhibition in New TIA
Pl: Yuko Palesch
Dept: Medicine
Sponsor: Univ. of California, San Franci
Total: $71,424
Award: 5823SC/U01NS062835 (08120256-4)

Research Services Agreement
Pl: Yuko Palesch
Dept: Medicine
Sponsor: Edge Therapeutics, Inc.
Total: $34,000
Award: (12010104-1)

PROTECT III: Progesterone for Traumatic Brain Injury: Experimental Clinical Treatment
Pl: Yuko Palesch
Dept: Medicine
Sponsor: Emory Univ.
Total: $301,636
Award: S662510/U01 NS062778-03 (12020274-1)

Zapka, Jane

Co-Investigator

Optimizing Survivorship and Surveillance after Treatment for Colorectal Cancer
Pl: Marvella Ford
Dept: Medicine
Sponsor: NIH/NCI
Total: $160,406
Award: 1R21CA152865-01A1 (10110530-1)

Ethno-Cultural Barriers to Health Literacy/Disease Management in AAs
Pl: Ida Spruill
Dept: Nursing
Sponsor: NIH/NINR
Total: $348,383
Award: 1R01NR012432-01A1 (11120369-1)

Zhang, Xian

Principal Investigator

Neogenix Bio-Assay Agreement
Neogenix Oncology, Inc.
Budget Dates: 01/26/12 - 01/31/14
Direct F & A Total
(12070815)
Project Dates: 01/26/12 - 01/31/14
21,560 10,241 31,801

Molecular Mechanisms of the Impact of Fli-1 on Lupus
NIH/NIAMS
Budget Dates: 04/01/12 - 03/31/13
Direct F & A Total
5R01AR056670-03 (12080991)
Project Dates: 07/01/10 - 03/31/15
216,000 56,160 272,160

Zhao, Wenle

Co-Investigator

POINT: Platelet-Oriented Inhibition in New TIA
Pl: Yuko Palesch
Dept: Medicine
Sponsor: Univ. of California, San Franci
Total: $71,424
Award: 5823SC/U01NS062835 (08120256-4)

Neurological Emergencies Treatment Trial Network Statistical/Data Management Center (NETT)
Pl: Yuko Palesch
Dept: Medicine
Sponsor: NIH/NINDS
Total: $1,098,903
Award: 2U01NS059041-06 (10103097-1)

3/8 - Prolonging Remission in Depressed Elderly (PRIDE)
Pl: Rebecca Knapp
Dept: Medicine
Sponsor: NIH/NIMH
Total: $23,371
Award: 5U01MH081362-03 (11012518-2)

Evaluating Predictors and Interventions in Sphincter of Oddi Dysfunction (EPISOD): Data - Parent
Pl: Peter Cotton
Dept: Medicine
Sponsor: NIH/NIDDK
Total: $184,472
Award: 5U01DK074739-05 (11042733-3)
Zhao, Wenle

**Co-Investigator**

A Multi-Center Study of Acute Liver Failure in Adults  
PI: Valerie Durkalski  
Dept: Medicine  
Sponsor: UT Southwestern Med. Ctr.  
Total: $392,174  
Award: GMO-110105/U01 DK058369-1 (11120331-1)

Accelerating Drug and Device Evaluation through Innovative Clinical Trial Design - Adaptive Design Trial  
PI: Valerie Durkalski  
Dept: Medicine  
Sponsor: Univ. of Michigan  
Total: $55,102  
Award: 3001688366/U01 NS073476-1 (12020269-1)

PROTECT III: Progesterone for Traumatic Brain Injury: Experimental Clinical Treatment  
PI: Yuko Palesch  
Dept: Medicine  
Sponsor: Emory Univ.  
Total: $301,636  
Award: S662510/U01 NS062778-03 (12020274-1)

Web-Based Study Database for Cervel Neurotech, Inc.  
PI: Valerie Durkalski  
Dept: Medicine  
Sponsor: Cervel Neuro Tech Inc.  
Total: $107,500  
Award: (12030393-1)

Stroke Hyperglycemia Insulin Network Effort (SHINE) Trial  
PI: Valerie Durkalski  
Dept: Medicine  
Sponsor: Univ. of Virginia  
Total: $192,769  
Award: GC12107-138780/U01 NS0694 (12050643-1)

3/8 - Prolonging Remission in Depressed Elderly (PRIDE)  
PI: Rebecca Knapp  
Dept: Medicine  
Sponsor: NIH/NIMH  
Total: $347,081  
Award: 5U01MH081362-04 (12070911-1)

Zile, Michael

**Principal Investigator**

AGE/RAGE Interaction in Patients with Pressure Overload-Induced Heart Failure  
VAMC  
Budget Dates: 04/01/12 - 03/31/13  
Direct F & A  
Total  
CX000415 (12020267)

Advanced Glycational End-Products in Human Myocardium  
Univ. of Vermont  
Budget Dates: 09/15/11 - 05/31/13  
Direct F & A  
Total  
21469/R01 HL089944-04 (12050590)

IDENTIFY- HF - Integrated Diagnostic Evaluation in Non-Therapy Devices For the study of Heart Failure  
Medtronic, Inc.  
Budget Dates: 05/03/12 - 12/31/15  
Direct F & A  
Total  
Identify HF (12101376)

Center for the Study of Molecular Proteomics (SmartState)  
MUSC Fdn.  
Budget Dates: 07/01/11 - 06/30/12  
Direct F & A  
Total  
(13020194)

Co-Investigator

mTOR in Growth and Protection of Hypertrophying Myocardium  
PI: Dhandapani Kuppuswamy  
Dept: Medicine  
Sponsor: NIH/NHLBI  
Total: $328,556  
Award: 5R01HL092124-04 (12040510-1)

Role of Protein Acetylation in NCX1 Expression  
PI: Donald Menick  
Dept: Medicine  
Sponsor: NIH/NHLBI  
Total: $365,063  
Award: 5R01HL095696-04 (12081078-1)

**Microbiology and Immunology**

Atkinson, Carl

**Principal Investigator**

Nanoparticle Coupled Antioxidants for Respiratory Illness in Veterans  
Augusta VA Medical Center  
Budget Dates: 09/30/11 - 08/29/12  
Direct F & A  
Total  
VA247-P-1674 (12050602)

The Role of Complement in the Pathogenesis of Emphysema  
NIH/NHLBI  
Budget Dates: 03/01/12 - 02/28/13  
Direct F & A  
Total  
5R01HL091944-03 (12070885)
Atkinson, Carl  
**Co-Investigator**  
**Complement Mediated Exacerbation of Asthma by Second Hand Smoke**  
PI: Gary Gilkeson  
Sponsor: Charleston Research Institute  
Total: $ 57,568  
Dept: Medicine  
Award: (10062311-2)  

**Complement, Anti-Tumor Immunity and Apoptosis-Based Therapy**  
PI: Stephen Tomlinson  
Sponsor: NIH/NCI  
Total: $ 306,063  
Dept: Microbiology and Immunology  
Award: 1R01CA158179-01A1 (11030479-1)  

Beckham, Thomas  
**Principal Investigator**  
**Evaluation of Acid Ceramidase Over Expression Induced Activation of the Oncogenic Akt Pathway in Prostate Cancer**  
DOD  
W81XWH-11-1-0334 (10052495)  
Budget Dates: 04/11/11 - 11/10/13  
Project Dates: 04/11/11 - 11/10/13  
Direct F & A: 55,998  
Total: $ 59,955  

Guo, Beichu  
**Principal Investigator**  
**The Type I IFN Pathway Constrains Th17-Mediated Autoimmune Diseases**  
NIH/NIAID  
5K22AI087707-02 (12091258)  
Budget Dates: 05/01/12 - 04/30/13  
Project Dates: 05/01/11 - 04/30/13  
Direct F & A: 100,000  
Total: $ 108,000  

Haque, Azizul  
**Principal Investigator**  
**Disruption of HLA Class II-Mediated Immune Recognition of B-Cell Lymphomas**  
NIH/NCI  
5R01CA129560-04 (12050642)  
Budget Dates: 03/01/09 - 12/31/13  
Project Dates: 03/01/09 - 12/31/13  
Direct F & A: 201,275  
Total: $ 296,881  

**Co-Investigator**  
**Inflammation and Degeneration of Optic Nerve in EAE**  
PI: Naren Banik  
Sponsor: NIH/NINDS  
Total: $ 314,580  
Dept: Neurosciences  
Award: 5R01NS065456-03 (11051627-1)  

Li, Zihai  
**Principal Investigator**  
**Roles and Mechanisms of gp96 in Chaperoning Innate Immunity: Diversity Supplement for Crystal Morales**  
NIH/NIAID  
5R01AI070603-06 (11021577)  
Budget Dates: 04/01/11 - 03/31/12  
Project Dates: 04/01/11 - 03/31/12  
Direct F & A: 22,999  
Total: $ 33,923  

**Chaperone Mechanisms in Innate Immunity**  
NIH/NIAID  
2R01AI070603-07A1 (12060777)  
Budget Dates: 06/01/12 - 05/31/13  
Project Dates: 07/01/06 - 05/31/17  
Direct F & A: 250,000  
Total: $ 368,750  

**gp96, TLR and Immunologic Tolerance**  
NIH/NIAID  
5R01AI077283-09 (12060807)  
Budget Dates: 03/01/11 - 02/28/13  
Project Dates: 03/01/09 - 02/28/14  
Direct F & A: 245,025  
Total: $ 361,412  

**Co-PI/Project Director**  
**MUSC CCSG: Program Leaders Project 3**  
PPI: Andrew Kraft  
Sponsor: NIH/NCI  
Total: $ 34,219  
Dept: Medicine  
Award: 5P30CA138313-04 (12070914-14)  

Liu, Bei  
**Co-Investigator**  
**Chaperone Mechanisms in Innate Immunity**  
PPI: Zihai Li  
Sponsor: NIH/NIAID  
Total: $ 368,750  
Dept: Microbiology and Immunology  
Award: 2R01AI070603-07A1 (12060777-1)  

**gp96, TLR and Immunologic Tolerance**  
PPI: Zihai Li  
Sponsor: NIH/NIAID  
Total: $ 361,412  
Dept: Microbiology and Immunology  
Award: 5R01AI077283-09 (12060807-1)  

May, Harold  
**Principal Investigator**  
**Electrochilohogenis: Bioelectrochemical Reduction of CO2 to Butanol**  
DOE  
DE-AR0000089 (10031876)  
Budget Dates: 07/09/11 - 07/08/12  
Project Dates: 07/09/10 - 07/08/13  
Direct F & A: 662,751  
Total: $ 752,407  

**Evaluating the Efficacy of Bioaugmentation for in-situ Treatment of PCB Impacted Sediments**  
Univ. of Maryland  
Budget Dates: 04/12/12 - 04/11/13  
Project Dates: 04/12/12 - 04/11/15  
Direct F & A: 23,130  
Total: $ 34,117
### Morris, Keely

**Principal Investigator**

**The Role of Complement in Hepatic Ischemia Reperfusion Injury and Regeneration**

NIH/NIDDK  
5F30DK089696-03 (12091337)  
Budget Dates: 06/01/12 - 05/31/13  
Direct F & A Total  
40,855 0 40,855

**NIH/NIDDK**  
Budget Dates: 06/01/10 - 05/31/14  
Direct F & A Total  
40,855 0 40,855

### Norris, James

**Co-PI/Project Director**

**Spingolipids in Cancer Biology and Therapy (Project 2)**  
PI: Yusuf Hannun  
Sponsor: NIH/NCI  
Total: $214,188

**Dept:** Biochemistry and Molecular Biology  
**Award:** 5P01CA097132-09 (12040548-6)

### Pandey, Janardan

**Principal Investigator**

**Racially Associated Immunoglobulin G and Fcgamma Receptor Genes and Humoral Immunity to Mucin 1 in Prostate Cancer**

DOD  
W81XWH-10-1-0479 (09051348)  
Budget Dates: 06/16/12 - 07/14/13  
Direct F & A Total  
150,000 70,110 220,110

**NIH**  
Budget Dates: 03/01/10 - 07/14/13  
Direct F & A Total  
41,696 10,424 52,120

### Schmidt, Michael

**Principal Investigator**

**Copper Antimicrobial Research Program**

Advanced Technology Institute  
2007-614-05 (09060308)  
Budget Dates: 07/18/09 - 02/17/12  
Direct F & A Total  
55,232 25,407 80,639

**NIH/NIDDK**  
Budget Dates: 05/01/07 - 02/17/12  
Direct F & A Total  
7,610 3,913 11,523

**Mayo Clinic**

**The Role of the Immune System in Clinical Efficacy of Combination Trastuzumab and Chemotherapy**

KG101016 (12070839)  
Budget Dates: 07/01/11 - 06/30/12  
Direct F & A Total  
41,696 10,424 52,120

## Funding Summary

<table>
<thead>
<tr>
<th>Project</th>
<th>PI Name</th>
<th>Sponsor</th>
<th>Budget Dates</th>
<th>Direct F &amp; A</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>5F30DK089696-03</td>
<td>Morris, Keely</td>
<td>NIH/NIDDK</td>
<td>06/01/12 - 05/31/13</td>
<td>40,855</td>
<td>40,855</td>
</tr>
<tr>
<td>5P01CA097132-09</td>
<td>Norris, James</td>
<td>NIH/NCI</td>
<td>06/01/10 - 05/31/14</td>
<td>40,855</td>
<td>40,855</td>
</tr>
<tr>
<td>W81XWH-10-1-0479</td>
<td>Pandey, Janardan</td>
<td>DOD</td>
<td>06/16/12 - 07/14/13</td>
<td>150,000</td>
<td>220,110</td>
</tr>
<tr>
<td>W81XWH-10-1-0479</td>
<td>Pandey, Janardan</td>
<td>DOD</td>
<td>03/01/10 - 07/14/13</td>
<td>70,110</td>
<td>220,110</td>
</tr>
<tr>
<td>W81XWH-10-1-0479</td>
<td>Schmidt, Michael</td>
<td>NIH/NIDDK</td>
<td>05/01/07 - 02/17/12</td>
<td>25,407</td>
<td>80,639</td>
</tr>
<tr>
<td>W81XWH-10-1-0479</td>
<td>Schmidt, Michael</td>
<td>NIH/NIDDK</td>
<td>07/18/09 - 02/17/12</td>
<td>55,232</td>
<td>80,639</td>
</tr>
<tr>
<td>W81XWH-10-1-0479</td>
<td>Schmidt, Michael</td>
<td>NIH/NIDDK</td>
<td>07/18/09 - 02/17/12</td>
<td>25,407</td>
<td>80,639</td>
</tr>
<tr>
<td>W81XWH-10-1-0479</td>
<td>Schmidt, Michael</td>
<td>NIH/NIDDK</td>
<td>07/18/09 - 02/17/12</td>
<td>55,232</td>
<td>80,639</td>
</tr>
</tbody>
</table>

---

**Medical University of South Carolina**

79
Schmidt, Michael

**Principal Investigator**

**Nuclear Forensics Education Award Program (NFEAP-DHS)**

SCUREF

NF13003 (12111570)

*Budget Dates: 04/30/12 - 12/30/17*

*Direct F & A: 516,292*  
*Total: 537,700*

---

**Rickover Fellowships in Nuclear Engineering-FY13, Modification 011**

SCUREF

DENE001 (12111595)

*Budget Dates: 02/10/11 - 02/09/16*

*Direct F & A: 324,829*  
*Total: 328,878*

---

Sutkowski, Natalie

**Principal Investigator**

**Placenta Growth Factor Inhibition in Head and Neck Cancer**

NIH/NIDCR

5R03DE020129-02 (12010067)

*Project Dates: 04/30/12 - 08/31/12*

*Direct F & A: 75,000*  
*Total: 110,625*

---

Thaxton, Jessica

**Principal Investigator**

**Chemotherapy Necessitates Increased Immune Control of Chronic HHVs: A Cause of Persistent Inflammation Enabling Protracted Fatigue in Breast Cancer Survivors**

DOD

W81XWH-11-1-0704-P00001 (13020152)

*Project Dates: 05/01/12 - 08/31/12*

*Direct F & A: 99,001*  
*Total: 141,535*

---

Tomlinson, Stephen

**Principal Investigator**

**Complement, Anti-Tumor Immunity and Apoptosis-Based Therapy**

NIH/NCI

1R01CA158179-01A1 (11030479)

*Project Dates: 02/01/12 - 01/31/13*

*Direct F & A: 222,750*  
*Total: 361,412*

---

Vasu, C.

**Principal Investigator**

**Dendritic Cell Directed T Cell Negative Regulation for Treating Autoimmunity**

NIH/NIAID

7R01AI073858-05 (12030291)

*Project Dates: 02/01/12 - 01/31/13*

*Direct F & A: 245,025*  
*Total: 361,412*

---

Voelkel-Johnson, C.

**Principal Investigator**

**Exploratory - Developmental Bioengineering Research Grants**

Arizona State University

11-450/R21 CA143505 (12040549)

*Project Dates: 07/01/10 - 06/30/13*

*Direct F & A: 65,883*  
*Total: 97,177*

---

Wright, Cynthia

**Principal Investigator**

**MUSC-Claffin Cooperative for Postdoctoral Academic Career Development**

NIH/NIGMS

5K12GM081265-05 (11110104)

*Project Dates: 08/01/07 - 07/31/13*

*Direct F & A: 352,906*  
*Total: 377,537*

---

**MUSC Minority Student Development Program**

NIH/NIGMS

5R25GM072643-08 (12091254)

*Project Dates: 03/01/05 - 03/30/13*

*Direct F & A: 300,985*  
*Total: 319,797*

---

**MUSC Short-Term Research Education Program to Increase Diversity**

NIH/NHLBI

5R25HL092611-05 (12091262)

*Project Dates: 05/10/08 - 04/30/13*

*Direct F & A: 102,400*  
*Total: 110,592*
### Wu, Jennifer

**Targeting MIC Shedding to Revive Host NKG2D-Mediated Immune Response in Prostate**  
NIH/NCI  
7R01CA149405-03 (12081056)  
Budget Dates: 04/09/12 - 01/31/13  
Project Dates: 08/11/10 - 01/31/15  
Direct F & A: 359,659  
Total: 170,838  
Total: 530,497

### Neurosciences

**Adams, Robert**  
**Twitch (Transcranial Doppler with Transfusions Changing to Hydroxyurea)**  
Baylor Univ.  
101522833/R01 HL095647-03 (11032592)  
Budget Dates: 08/01/11 - 07/31/12  
Direct F & A: 343,819  
Total: 154,646  
Total: 498,465

**Mechanical Retrieval and Recanalization of Stroke Clots Using Embolectomy (MR RESCUE)**  
Univ. of California, Los Angeles  
1580 B PA372/P50 NS044378 (11032593)  
Budget Dates: 05/01/11 - 04/30/12  
Direct F & A: 15,500  
Total: 7,362  
Total: 22,862

**Prevention of Stroke after STOP, A Retrospective Chart Review**  
NIH/NHLBI  
5R01HL096789-03 (12020214)  
Budget Dates: 07/01/11 - 06/30/12  
Direct F & A: 487,522  
Total: 188,057  
Total: 675,579

**SMARTSTATE Stroke Endowed Chair**  
MUSC Fdn.  
(12081037)  
Budget Dates: 07/01/10 - 06/30/12  
Direct F & A: 106,979  
Total: 0  
Total: 106,979

**Hydroxyurea to Prevent CNS Complications of Sickle Cell Disease in Children**  
Johns Hopkins Univ.  
2001433034/R34 HL108756 (12081165)  
Budget Dates: 09/01/11 - 07/31/12  
Direct F & A: 31,095  
Total: 14,770  
Total: 45,865

**CoEE for Stroke State Match Endowment Draw**  
SC Research Centers of Economic Excellence  
(12091243)  
Budget Dates: 06/18/09 - 06/30/12  
Direct F & A: 153,767  
Total: 0  
Total: 153,767

### Adkins, de Anna

**Cortical Stimulation to Enhance Motor Recovery Following Traumatic Brain Injury**  
NIH/NINDS  
7R01NS065866-02 (12050581)  
Budget Dates: 10/01/11 - 04/30/12  
Project Dates: 05/01/11 - 04/30/16  
Direct F & A: 120,262  
Total: 57,124  
Total: 177,386

**Cortical Stimulation to Enhance Motor Recovery Following Traumatic Brain Injury**  
NIH/NINDS  
5R01NS065866-03 (12101384)  
Budget Dates: 05/01/12 - 04/30/13  
Project Dates: 05/01/11 - 04/30/16  
Direct F & A: 183,097  
Total: 69,943  
Total: 253,040

### Aston-Jones, Gary

**Role of Locus Coeruleus in Response Inhibition**  
NIH/NIMH  
1R01MH092868-01A1 (10112283)  
Budget Dates: 07/22/11 - 04/30/12  
Project Dates: 07/22/11 - 04/30/16  
Direct F & A: 314,550  
Total: 106,875  
Total: 421,425
Aston-Jones, Gary

**Principal Investigator**

**Control of Dopamine Neuron Firing Pattern by PI-Coupled Receptors**

Univ. of Texas

<table>
<thead>
<tr>
<th>Budget Dates: 08/01/11 - 07/31/12</th>
<th>Direct F &amp; A</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>1614-35 MUSC/U54NS06658 (12020206)</td>
<td>54,441</td>
<td>25,859</td>
</tr>
</tbody>
</table>

**William E. Murray SmartState Endowed Chair in Neuroscience**

MUSC Fdn.

<table>
<thead>
<tr>
<th>Budget Dates: 07/01/11 - 06/30/12</th>
<th>Direct F &amp; A</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>(12050662)</td>
<td>171,730</td>
<td>0</td>
</tr>
</tbody>
</table>

**Role of Extended Amygdala in Opiate and Cocaine Abuse**

NIH/NIDA

<table>
<thead>
<tr>
<th>Budget Dates: 05/01/12 - 04/30/13</th>
<th>Direct F &amp; A</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>5R37DA006214-24 (12101378)</td>
<td>268,267</td>
<td>136,927</td>
</tr>
</tbody>
</table>

**Role of Locus Coeruleus in Response Inhibition**

NIH/NIMH

<table>
<thead>
<tr>
<th>Budget Dates: 05/01/12 - 04/30/13</th>
<th>Direct F &amp; A</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>5R01MH092868-02 (12101379)</td>
<td>225,000</td>
<td>106,875</td>
</tr>
</tbody>
</table>

Bachman, David

**Co-Investigator**

**Trans-Cranial Direct Current Stimulation to Treat Aphasia: Phase II Trial**

<table>
<thead>
<tr>
<th>PI: Mark George</th>
<th>Sponsor: Univ. of South Carolina</th>
<th>Total: $ 366,517</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dept: Psychiatry and Behavioral Sciences</td>
<td>Award: 12-2114/1U01DC011739-01A1 (12010003-1)</td>
<td></td>
</tr>
</tbody>
</table>

Banik, Naren

**Principal Investigator**

**Inflammation and Degeneration of Optic Nerve in EAE**

NIH/NINDS

<table>
<thead>
<tr>
<th>Budget Dates: 07/01/11 - 06/30/12</th>
<th>Direct F &amp; A</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>5R01NS065456-03 (11051627)</td>
<td>227,358</td>
<td>87,222</td>
</tr>
</tbody>
</table>

**Extra-Nigral Neurodegeneration in Experimental Parkinson's Disease**

NIH/NINDS

<table>
<thead>
<tr>
<th>Budget Dates: 07/01/11 - 06/30/12</th>
<th>Direct F &amp; A</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>5R01NS062327-03 (12010071)</td>
<td>213,137</td>
<td>101,240</td>
</tr>
</tbody>
</table>

Bhat, Narayan

**Principal Investigator**

**Role of a Stress Kinase in AD Pathogenesis**

Amer. Health Assistance Fdn.

<table>
<thead>
<tr>
<th>Budget Dates: 07/01/11 - 06/30/12</th>
<th>Direct F &amp; A</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>(10102059)</td>
<td>133,433</td>
<td>0</td>
</tr>
</tbody>
</table>

Boger, Heather

**Principal Investigator**

**Oxidative Stress and Glutamate Toxicity on Aged Dopaminergic Neurons**

NIH/NIA

<table>
<thead>
<tr>
<th>Budget Dates: 09/15/11 - 08/31/12</th>
<th>Direct F &amp; A</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>4R00AG033687-03 (12010021)</td>
<td>174,748</td>
<td>73,505</td>
</tr>
</tbody>
</table>

Bonilha, Leonardo

**Co-PI/Project Director**

**Presurgical Application of fMRI in Epilepsy**

<table>
<thead>
<tr>
<th>PI: Truman Brown</th>
<th>Sponsor: Medical College of Wisconsin</th>
<th>Total: $ 49,046</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dept: Radiology</td>
<td>Award: 2 R01 NS035929-10A1 (12081096-1)</td>
<td></td>
</tr>
</tbody>
</table>

**Presurgical Application of fMRI in Epilepsy**

<table>
<thead>
<tr>
<th>PI: Truman Brown</th>
<th>Sponsor: Medical College of Wisconsin</th>
<th>Total: $ 53,949</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dept: Radiology</td>
<td>Award: 2 (13010113-1)</td>
<td></td>
</tr>
</tbody>
</table>

Buhusi, Catalin

**Principal Investigator**

**Attentional Processing of Temporal Information**

NIH/NIMH

<table>
<thead>
<tr>
<th>Budget Dates: 04/01/12 - 03/31/13</th>
<th>Direct F &amp; A</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>5R01MH065561-09 (12101344)</td>
<td>198,000</td>
<td>94,050</td>
</tr>
</tbody>
</table>

Buhusi, Mona

**Principal Investigator**

**Memory and proBDNF Processing in the Aged Mouse Hippocampus**

NIH/NIA

<table>
<thead>
<tr>
<th>Budget Dates: 07/01/11 - 06/30/12</th>
<th>Direct F &amp; A</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>1R21AG038767-01A1 (10062841)</td>
<td>123,000</td>
<td>58,425</td>
</tr>
<tr>
<td>Research Faculty Activity</td>
<td>Neurosciences</td>
<td></td>
</tr>
<tr>
<td>---------------------------</td>
<td>--------------</td>
<td></td>
</tr>
<tr>
<td><strong>Cason, Angie</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Principal Investigator</strong></td>
<td>PACD Scholar: Dr. Angie Cason</td>
<td></td>
</tr>
</tbody>
</table>
| Univ. of South Carolina | **Budget Dates:** 07/01/11 - 01/31/12  
| 5 P20 RR016461-11 (12010075) | Direct  
| Project Dates: 02/01/11 - 01/31/12 | F & A  
| Total | 60,527  0  60,527 |
| **Impact of Adolescent Alcohol Exposure on Prefrontal Cortical Function in the Adult** |  
| NIH/NIAAA | **Budget Dates:** 09/01/11 - 08/31/12  
| 5U01AA019967-02 (12020167) | Direct  
| Project Dates: 09/05/10 - 08/31/15 | F & A  
| Total | 231,558  109,990  341,548 |
| **Actin-Dynamics and Spine Remodeling in Ethanol-Induced Plasticity** |  
| NIH/NIAAA | **Budget Dates:** 05/01/12 - 04/30/13  
| 5R01AA010983-15 (12101436) | Direct  
| Project Dates: 05/01/09 - 04/30/14 | F & A  
| Total | 226,002  107,351  333,353 |
| **Co-PI/Project Director** |  
| Alcohol Research Center - Treatment and Implications  
Pl: Carrie Randall | Sponsor: NIH/NIAAA  
*Total: $1,620,001*  
Dept: Psychiatry and Behavioral Sciences  
*Award: 5P50AA010761-17 (12050669-1)* |
| Alcohol Research Center - Treatment and Implications  
Pl: Howard Becker | Sponsor: NIH/NIAAA  
*Total: $145,546*  
Dept: Psychiatry and Behavioral Sciences  
*Award: 5P50AA010761-17 (12050669-2)* |
| **Mentor** |  
| Ethanol Dependence, Drinking and Mechanisms Regulating Accumbal Glutamate Activity  
Pl: Vorani Ramachandra | Sponsor: NIH/NIAAA  
*Total: $49,214*  
Dept: Psychiatry and Behavioral Sciences  
*Award: 1F32AA021321-01 (12020153-1)* |
| **Chimowitz, Marc** |  |
| **Principal Investigator** |  
| **Mechanisms of Stroke in Intracranial Stenosis and Stenting (MoSISS)** |  
| Univ. of Miami | **Budget Dates:** 04/01/11 - 10/31/11  
| R01 NS069938-02 (11012853) | Direct  
| Project Dates: 04/15/10 - 10/31/11 | F & A  
| Total | 1,000  475  1,475 |
| **SmartState Stroke Countess Paolozzi Endowed Chair** |  
| MUSC Fdn. | **Budget Dates:** 07/01/11 - 06/30/12  
| (12081030) | Direct  
| Project Dates: 07/01/10 - 06/30/12 | F & A  
| Total | 59,904  0  59,904 |
| **Biomarkers of Ischemic Outcomes in Symptomatic Intracranial Stenosis (BIOSIS)** |  
| Emory Univ. | **Budget Dates:** 07/01/11 - 06/30/12  
| S443002/R01NS064162 (12101421) | Direct  
| Project Dates: 07/01/10 - 06/30/14 | F & A  
| Total | 6,470  3,073  9,543 |
| **Co-PI/Project Director** |  
| CoEE for Stroke Research State Match Endowment Draw  
Pl: Robert Adams | Sponsor: SC Research Centers of Econ  
*Total: $153,767*  
Dept: Neurosciences  
*Award: (12091243-1)* |
| **Co-Investigator** |  
| South Carolina Clinical and Translational Research Institute (UL1)  
Pl: Kathleen Brady | Sponsor: NIH/NCRR  
*Total: $301,173*  
Dept: Psychiatry and Behavioral Sciences  
*Award: 5UL1RR029882-03 (11012750-2)* |
| South Carolina Clinical and Translational Research Institute (SCTR): UL1  
Pl: Kathleen Brady | Sponsor: NIH/NCATS  
*Total: $2,537,859*  
Dept: Psychiatry and Behavioral Sciences  
*Award: 8UL1TR000062-04 (12070938-1)* |
| South Carolina Clinical and Translational Research Institute (SCTR): UL1  
Pl: Kathleen Brady | Sponsor: NIH/NCATS  
*Total: $798,196*  
Dept: Psychiatry and Behavioral Sciences  
*Award: 8UL1TR000062-04 (12070938-2)* |
| **Cook, James** |  |
| **Principal Investigator** |  
| **The Role of Eicosanoids in Shock** |  
| NIH/NIGMS | **Budget Dates:** 07/01/11 - 06/30/12  
| 5R01GM027673-30 (11040650) | Direct  
| Project Dates: 04/01/80 - 06/30/12 | F & A  
| Total | 237,184  93,531  330,715 |
| **Role of PPAR gamma and PPAR gamma Agonists in Septic Shock** |  
| Childrens Hospital Research Fdn. | **Budget Dates:** 07/01/11 - 06/30/12  
| 104972 M4/R01 GM067202-08 (11051629) | Direct  
| Project Dates: 07/01/08 - 06/30/12 | F & A  
| Total | 40,678  19,322  60,000 |
Das, Arabinda

Co-PI/Project Director

The Efficacy of PF-02341066 (Crizotinib), a Dual ALK/c-Met Inhibitor in Inhibiting Growth of Glioblastoma

PI: Pierre Giglio  
Sponsor: Pfizer, Inc.  
Total: $ 125,784

Dept: Neurosciences  
Award: WS2019273 (12020172-1)

Co-Investigator

Inflammation and Degeneration of Optic Nerve in EAE

PI: Naren Banik  
Sponsor: NIH/NINDS  
Total: $ 314,580

Dept: Neurosciences  
Award: 5R01NS065456-03 (11051627-1)

Edwards, Jonathan

Co-Investigator

Risk Factors of Epilepsy Outcomes: Comorbidities in a Population with Epilepsy

PI: Anbesaw Selassie  
Sponsor: CDC  
Total: $ 425,000

Dept: Medicine  
Award: 1 U01 DP003251-01 (11030164-1)

Fan, Hongkuan

Co-Investigator

The Role of Eicosanoids in Shock

PI: James Cook  
Sponsor: NIH/NIGMS  
Total: $ 330,715

Dept: Neurosciences  
Award: 5R01GM027673-30 (11040650-1)

Feng, Wuwei

Principal Investigator

S-STREAM: A Multi-Center, Observational Study to Evaluate the Simplified-Stroke REhabilitation Assessment of Movement

INC Research, Inc.  
Budget Dates: 01/31/12 - 09/30/13  
Direct F & A  
Total

ASBI801 (12070900)  
Project Dates: 01/31/12 - 09/30/13  
131,740  
32,185  
163,925

Co-PI/Project Director

Randomized Trial of the Innovative Neurotronics WalkAide Compared to Conventional Ankle-Foot Orthosis in Stroke Patients

PI: Steven Kautz  
Sponsor: Innovative Neurotronics, Inc.  
Total: $ 148,320

Dept: Health Sciences and Research  
Award: INSTRIDE (12030312-1)

Frankel, Bruce

Principal Investigator

ACT IV (An International, Randomized, Double-Blind, Controlled Study of Rindopepimut/GM-CSF with Adjuvant Temozolomide in Patients with Newly Diagnosed Surgically Resected EGFRvIII-Positive GBM)

Novella Clinical, Inc.  
Budget Dates: 03/13/12 - 08/31/14  
Direct F & A  
Total

CDX110-04 (12091267)  
Project Dates: 03/13/12 - 08/31/14  
132,266  
32,317  
164,583

Gass, Justin

Principal Investigator

The Role of mGluR5 Receptors in Extinction Learning of Alcohol Cues

NIH/NIAAA  
Budget Dates: 09/20/11 - 08/31/12  
Direct F & A  
Total

1K99AA020537-01 (10101946)  
Project Dates: 09/20/11 - 08/31/13  
126,727  
8,573  
135,300

Giglio, Pierre

Principal Investigator

The Efficacy of PF-02341066 (Crizotinib), a Dual ALK/c-Met Inhibitor in Inhibiting Growth of Glioblastoma

Pfizer, Inc.  
Budget Dates: 10/15/11 - 12/31/12  
Direct F & A  
Total

WS2019273 (12020172)  
Project Dates: 10/15/11 - 12/31/12  
101,227  
24,557  
125,784

A Phase II, Clinical Trial Evaluating DCVax-Brain, Autologous Dendritic Cells Pulsed with Tumor Lysate Antigen for the Treatment of Glioblastoma Multiforme

Northwest Biotherapeutics  
Budget Dates: 05/09/12 - 10/31/14  
Direct F & A  
Total

020221 (12081040)  
Project Dates: 02/13/12 - 02/28/15  
139,184  
33,671  
172,855

Randomized, Double-Blind, Placebo-Controlled Trial of Lacosamide for Seizure Prophylaxis in Patients with Malignant Gliomas

Univ. of Texas MD Anderson Cancer Center  
Budget Dates: 02/27/12 - 08/01/14  
Direct F & A  
Total

BTTC11-01 (12081104)  
Project Dates: 02/27/12 - 02/26/17  
16,600  
3,400  
20,000

Open-Label, Phase 1/2 (Safety Lead-in) of TSC with Concomitant Treatment of Fractionated Radiation Therapy and Temozolomide in Newly Diagnosed GBM Patients to Evaluate Safety and Efficacy

INC Research, Inc.  
Budget Dates: 05/09/12 - 10/31/14  
Direct F & A  
Total

100-202 (12111479)  
Project Dates: 05/09/12 - 10/31/14  
99,505  
24,001  
123,506

Co-Investigator

ACT IV (An International, Randomized, Double-Blind, Controlled Study of Rindopepimut/GM-CSF with Adjuvant Temozolomide in Patients with Newly Diagnosed Surgically Resected EGFRvIII-Positive GBM)

PI: Bruce Frankel  
Sponsor: Novella Clinical, Inc.  
Total: $ 164,583

Dept: Neurosciences  
Award: CDX110-04 (12091267-1)
<table>
<thead>
<tr>
<th>Principal Investigator</th>
<th>Research Title</th>
<th>Sponsor</th>
<th>Budget Dates</th>
<th>Direct</th>
<th>F &amp; A</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gipson, Cassandra</td>
<td>Chronic Adaptations in Glutamatergic and Dopaminergic Signaling in Nicotine Abuse</td>
<td>NIH/NIDA</td>
<td>06/01/12 - 05/31/13</td>
<td>49,214</td>
<td></td>
<td>49,214</td>
</tr>
<tr>
<td></td>
<td></td>
<td>1F32DA033690-01A1 (12060770)</td>
<td>Project Dates: 06/01/12 - 11/30/13</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Granholm, A.</td>
<td>Neuroprotective Effects of Rasagiline and Aminoidan on Dopaminergic and Noradrenergic Neurons in a Double Lesion Parkinson's Disease Model</td>
<td>Teva Pharmaceuticals USA</td>
<td>11/09/11 - 12/31/13</td>
<td>43,087</td>
<td>20,466</td>
<td>63,553</td>
</tr>
<tr>
<td></td>
<td></td>
<td>(12050608)</td>
<td>Project Dates: 11/09/11 - 12/31/13</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Mentor</td>
<td>Role of the Supraspinal Opioidergic Circuit in Prefrontal Transcranial Magnetic Stimulation-Induced Analgesia</td>
<td>Sponsor: NIH/NINDS Total: $36,532</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Pi: Joseph Taylor</td>
<td>Dept: Psychiatry and Behavioral Sciences Award: 1F30DA033748-01 (12020160-1)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gudz, Tatyana</td>
<td>Mitochondrial Ceramide in TBI</td>
<td>VAMC</td>
<td>10/01/11 - 09/30/12</td>
<td>249,900</td>
<td></td>
<td>249,900</td>
</tr>
<tr>
<td></td>
<td></td>
<td>RX000206 (09102971)</td>
<td>Project Dates: 10/01/09 - 09/30/12</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Ceramide and Oligodendrocyte Protection in Stroke</td>
<td>VAMC</td>
<td>07/01/11 - 06/30/12</td>
<td>166,000</td>
<td></td>
<td>166,000</td>
</tr>
<tr>
<td></td>
<td></td>
<td>BX001104 (12121767)</td>
<td>Project Dates: 07/01/11 - 06/30/15</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Halford, Jonathan</td>
<td>High Performance Seizure Monitoring and Alert System</td>
<td>Optima Neuroscience, Inc.</td>
<td>09/30/11 - 08/31/12</td>
<td>55,678</td>
<td>26,447</td>
<td>82,125</td>
</tr>
<tr>
<td></td>
<td></td>
<td>OPT-003-MUSC/R44 NS064647 (11012854)</td>
<td>Project Dates: 09/30/10 - 08/31/13</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Open-Label Study to Assess the Safety and Tolerability of Intravenous Carbamazepine as Short-Term Replacement of Oral Carbamazepine in Adult Patients with Epilepsy</td>
<td>Icon Clinical Research, Inc.</td>
<td>01/10/11 - 12/31/12</td>
<td>322,432</td>
<td>80,608</td>
<td>403,040</td>
</tr>
<tr>
<td></td>
<td></td>
<td>13181A (11012855)</td>
<td>Project Dates: 01/10/10 - 12/31/12</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Brivaracetam Efficacy and Safety Study in Subject with Partial Onset Seizures</td>
<td>Pharmaceutical Research Associates</td>
<td>02/07/11 - 12/31/12</td>
<td>9,360</td>
<td>2,340</td>
<td>11,700</td>
</tr>
<tr>
<td></td>
<td></td>
<td>N01358 (11012856)</td>
<td>Project Dates: 02/07/11 - 12/31/12</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>An Open-Label, Multi-Center, Follow-Up Study to Evaluate the Long-Term, Safety and Efficacy of Brivaracetam Used as Adjunctive Treatment in Subjects Aged 16 Years or Older with Partial Onset Seizures</td>
<td>Pharmaceutical Research Associates</td>
<td>02/07/11 - 01/31/13</td>
<td>14,400</td>
<td>3,600</td>
<td>18,000</td>
</tr>
<tr>
<td></td>
<td></td>
<td>N01379 (11012857)</td>
<td>Project Dates: 02/07/11 - 01/31/13</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>A Double-Blind, Randomized, Placebo-Controlled, Multi-Center, Parallel-Group Study with an OL Extension Phase to Evaluate Efficacy of Adjunct Perampanel in Primary General Tonic-Clonic Seizu</td>
<td>PPD Development</td>
<td>11/16/11 - 11/15/13</td>
<td>251,358</td>
<td>62,090</td>
<td>313,448</td>
</tr>
<tr>
<td></td>
<td></td>
<td>E2007-G000-332 (13203050)</td>
<td>Project Dates: 11/16/11 - 11/15/13</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>On-Line, Real-Time Seizure Prediction</td>
<td>Optima Neuroscience, Inc.</td>
<td>05/01/12 - 04/30/13</td>
<td>25,036</td>
<td>11,892</td>
<td>36,928</td>
</tr>
<tr>
<td></td>
<td></td>
<td>1R43NS076045-01A1 (12111493)</td>
<td>Project Dates: 05/01/12 - 04/30/13</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Utility of Intravenous Lacosamide Compared with Fosphenytoin in the Treatment of Patients with Frequent Nonconvulsive Seizures</td>
<td>Duke Clinical Research Inst.</td>
<td>06/20/12 - 06/30/14</td>
<td>149,700</td>
<td>36,800</td>
<td>186,500</td>
</tr>
<tr>
<td></td>
<td></td>
<td>TRENDS (12121715)</td>
<td>Project Dates: 06/20/12 - 06/30/14</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hinson, Vanessa</td>
<td>CD Probe - Cervical Dystonia - Patient Registry for Observation of BOTOX Efficacy</td>
<td>Allergan, Inc.</td>
<td>04/01/09 - 03/31/13</td>
<td>65,452</td>
<td>16,113</td>
<td>81,565</td>
</tr>
<tr>
<td></td>
<td></td>
<td>MedAff BTX-0718 (09030936)</td>
<td>Project Dates: 04/01/09 - 03/31/13</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Parkinson's Disease Neuroprotection Clinical Trial Center</td>
<td>NIH/NINDS</td>
<td>12/01/09 - 11/30/12</td>
<td>37,461</td>
<td>17,231</td>
<td>54,692</td>
</tr>
<tr>
<td></td>
<td></td>
<td>3U10NS053372-05S2 (09101624)</td>
<td>Project Dates: 05/17/06 - 11/30/12</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Hinson, Vanessa  
**Co-PI/Project Director**  
Creatine Safety, Tolerability, and Efficacy in Huntington's Disease: CREST-E  
PI: Gonzalo Revuelta  
Dept: Neurosciences  
Sponsor: Massachusetts General Hospi  
Award: 5 U01 AT000613 (12030330-1)  
Total: $127,500

Jayanthi, Lankupalle  
**PI:** Sammanda Ramamoorthy  
**Sponsor:** NIH/NIMH  
Total: $219,038

Jhou, Thomas  
**Principal Investigator**  
Habenulomesencephalic Pathway in Aversion, Reward, and Depression  
Dept: Neurosciences  
Award: 5 R21 MH091633-02 (11110044-1)

Joseph, Jane  
**Principal Investigator**  
A Comparative Developmental Connectivity Study of Face Processing  
Dept: Psychiatry and Behavioral Sciences  
Award: 1 R01 DA003906-29 (12101431)

Kalivas, Peter  
**Principal Investigator**  
NAC-1, A Cocaine Regulated mRNA in the Rat Brain  
Neurobiology of Addiction Research Center (NARC)  
NIH/NIDA  
Award: 1 R01 DA033342-01 (11120240-1)

Kara, Prakash  
**Principal Investigator**  
Functional Imaging of Dendritic Spines In Vivo as Markers of Early Brain Disease Existence  
Tuning of Dendrites in Cortical Neurons to Monocular and Binocular Visual Stimuli  
Dept: Neurosciences  
Award: 1 R01 DA033342-01 (11120240-1)
## Kara, Prakash

**Principal Investigator**

**The Receptive Fields of Dendrites and Spines in the Visual Cortex**

NIH/NEI  
5R21EY020985-02 (11120298)  

<table>
<thead>
<tr>
<th>Project Dates</th>
<th>Direct F &amp; A</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>08/01/10 - 10/31/12</td>
<td>120,000</td>
<td>57,000</td>
</tr>
</tbody>
</table>

**Budget Dates:**
08/01/11 - 10/31/12

**Principal Investigator**

**The Receptive Fields of Dendrites and Spines in the Visual Cortex**

NIH/NEI  
5R21EY020985-02 (11120298)  

<table>
<thead>
<tr>
<th>Project Dates</th>
<th>Direct F &amp; A</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>08/01/10 - 10/31/12</td>
<td>120,000</td>
<td>57,000</td>
</tr>
</tbody>
</table>

**Budget Dates:**
08/01/11 - 10/31/12

## Kindy, Mark

**Principal Investigator**

**Complement and Traumatic Brain Injury**

VAMC  
RX000331 (10051963)  

<table>
<thead>
<tr>
<th>Project Dates</th>
<th>Direct F &amp; A</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>05/01/10 - 06/30/13</td>
<td>231,700</td>
<td>0</td>
</tr>
</tbody>
</table>

**Budget Dates:**
05/01/12 - 06/30/13

## Kinsman, Stephen

**Principal Investigator**

**Emergency Use Protocol for EPI-743 in Acutely Ill Patients with Inherited Mitochondrial Respiratory Chain Disease within 90 Days of End of Life Care**

Edison Pharmaceuticals  
EPI-743 (10071665)  

<table>
<thead>
<tr>
<th>Project Dates</th>
<th>Direct F &amp; A</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>07/16/10 - 06/30/13</td>
<td>246,375</td>
<td>60,844</td>
</tr>
</tbody>
</table>

**Budget Dates:**
07/16/10 - 06/30/13

## Lackland, Daniel

**Principal Investigator**

**Etiology of Geographic and Racial Differences in Stroke**

Univ. of Alabama, Birmingham  
000302265-001/U01 NS04158 (12050671)  

<table>
<thead>
<tr>
<th>Project Dates</th>
<th>Direct F &amp; A</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>04/01/08 - 11/30/12</td>
<td>55,560</td>
<td>24,826</td>
</tr>
</tbody>
</table>

**Budget Dates:**
12/01/11 - 11/30/12

## Lavin, Antonieta

**Principal Investigator**

**Effects of Repetitive Cocaine Administration in Activity of Cortical Interneurons**

NIH/NIDA  
5R01DA014698-09 (11110047)  

<table>
<thead>
<tr>
<th>Project Dates</th>
<th>Direct F &amp; A</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>07/01/11 - 06/30/13</td>
<td>192,060</td>
<td>88,348</td>
</tr>
</tbody>
</table>

**Budget Dates:**
07/01/11 - 06/30/13

## Lazaridis, Christos

**Principal Investigator**

**Clot Lysis: Evaluating Accelerated Resolution of IVH Phase III (Clear III)**

Johns Hopkins Univ.  
2000735586/U01 NS062851 (12020276)  

<table>
<thead>
<tr>
<th>Project Dates</th>
<th>Direct F &amp; A</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>07/01/09 - 06/30/12</td>
<td>62,410</td>
<td>16,155</td>
</tr>
</tbody>
</table>

**Budget Dates:**
07/01/11 - 06/30/13

## Magarik, Jordan

**Principal Investigator**

**The Use of the Alberta Stroke Program Early CT Score (ASPECTS) for Non-Contrast and Pefusion-CT Imaging in Acute Ischemic Stroke**

Amer. Heart Assoc.  
(11031010)  

<table>
<thead>
<tr>
<th>Project Dates</th>
<th>Direct F &amp; A</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>07/01/11 - 10/31/11</td>
<td>2,000</td>
<td>0</td>
</tr>
</tbody>
</table>

**Budget Dates:**
07/01/11 - 10/31/11

## South Carolina Clinical and Translational Research Institute (UL1)

**PI:** Kathleen Brady  
**Sponsor:** NIH/NCRR  
**Total:** $301,173  
**Dept:** Psychiatry and Behavioral Sciences  
**Award:** 5UL1RR029882-03 (11012750-2)

**Prevention of Stroke after STOP, A Retrospective Chart Review**

**PI:** Robert Adams  
**Dept:** Neurosciences  
**Sponsor:** NIH/NHLBI  
**Total:** $675,579  
**Award:** 5R01HL096789-03 (12020214-1)

**South Carolina Clinical and Translational Research Institute (SCTR); UL1**

**PI:** Kathleen Brady  
**Sponsor:** NIH/NCATS  
**Total:** $2,537,859  
**Dept:** Psychiatry and Behavioral Sciences  
**Award:** 8UL1TR000062-04 (12070938-1)

**South Carolina Clinical and Translational Research Institute (SCTR); UL1**

**PI:** Kathleen Brady  
**Sponsor:** NIH/NCATS  
**Total:** $798,196  
**Dept:** Psychiatry and Behavioral Sciences  
**Award:** 8UL1TR000062-04 (12070938-2)

**Mentor**

**The Use of the Alberta Stroke Program Early CT Score (ASPECTS) for Non-Contrast and Pefusion-CT Imaging in Acute Ischemic Stroke**

**PI:** Jordan Magarik  
**Dept:** Neurosciences  
**Sponsor:** Amer. Heart Assoc.  
**Total:** $2,000  
**Award:** (11031010-1)
### Mahler, Stephen

**Principal Investigator**

**VTA Glutamate and Orexin Involvement in Cue Reinstatement of Drug Seeking**

NIH/NIDA

<table>
<thead>
<tr>
<th>Project Dates: 01/25/10 - 07/01/12</th>
<th>Direct F &amp; A</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>5F32DA026692-03 (12050560)</td>
<td>52,190</td>
<td>0</td>
</tr>
</tbody>
</table>

### Martz, Gabriel

**Co-Investigator**

**Risk Factors of Epilepsy Outcomes: Comorbidities in a Population with Epilepsy**

PI: Anbesaw Selassie

Sponsor: CDC

Total: $425,000

Dept: Medicine

Award: 1 U01 DP003251-01 (11030164-1)

### McGinty, Jacqueline

**Principal Investigator**

**Drug Abuse Training Program**

NIH/NIDA

<table>
<thead>
<tr>
<th>Project Dates: 01/25/12 - 07/01/12</th>
<th>Direct F &amp; A</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>5T32DA007288-20 (11031016)</td>
<td>52,190</td>
<td>0</td>
</tr>
</tbody>
</table>

**Prefrontal Cortical BDNF and High Fat Food Seeking**

Klarman Family Foundation

<table>
<thead>
<tr>
<th>Project Dates: 06/01/12 - 05/31/13</th>
<th>Direct F &amp; A</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>(12091284)</td>
<td>136,366</td>
<td>150,000</td>
</tr>
</tbody>
</table>

#### Co-PI/Project Director

**Interdisciplinary Women's Health Research at MUSC (Scholar)**

PI: Kathleen Brady

Sponsor: NIH/NICHD

Total: $408,627

Dept: Psychiatry and Behavioral Sciences

Award: 5K12HD05885-05 (1110074-2)

### Mintzer, Jacobo

**Principal Investigator**

**A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Trial of Bapineuzumab (AAB-001, ELN115727) in Patients with Mild to Moderate Alzheimer's Disease Who are ApoE Non-Carriers (Protocol ELN115727-301)**

Janssen Alzheimer Immunotherapy R & D, LLC

<table>
<thead>
<tr>
<th>Project Dates: 01/16/08 - 12/31/12</th>
<th>Direct F &amp; A</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>ELN115727-301 (08011462)</td>
<td>560</td>
<td>700</td>
</tr>
</tbody>
</table>

**A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Trial of Bapineuzumab (AAB-001, ELN115727) in Patients with Mild to Moderate Alzheimer's Disease Who are ApoE4 Carriers (Protocol ELN115727-302)**

Janssen Alzheimer Immunotherapy R & D, LLC

<table>
<thead>
<tr>
<th>Project Dates: 01/16/08 - 12/31/12</th>
<th>Direct F &amp; A</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>ELN115727-302 (08011463)</td>
<td>1,040</td>
<td>1,300</td>
</tr>
</tbody>
</table>

**A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Trial of Bapineuzumab (AAB-001, ELN115727) in Subjects with Mild to Moderate Alzheimer's Disease Who are ApoE Protein E4 Carriers**

Parexel Intl. Corp.

<table>
<thead>
<tr>
<th>Project Dates: 08/01/09 - 07/31/13</th>
<th>Direct F &amp; A</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>3133K1-3001/ B2521002 (09082476)</td>
<td>169,392</td>
<td>211,740</td>
</tr>
</tbody>
</table>

**A Phase 3, Multi-Center, Parallel-Group, Long-Term, Safety and Tolerability, Treatment Trial of Bapineuzumab (AAB 001, ELN115727) in Subjects with Alzheimer's Disease Who Participated in Study ELN115727-301 or in Study ELN115727-302**

Clinical Financial Services, LLC

<table>
<thead>
<tr>
<th>Project Dates: 11/26/09 - 04/30/13</th>
<th>Direct F &amp; A</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>ELN115727-351 (09101202)</td>
<td>115,668</td>
<td>144,585</td>
</tr>
</tbody>
</table>

**Bapineuzumab In Patients with Mild to Moderate Alzheimer's Disease (ApoE4 Non-Carrier)**

Parexel Intl. Corp.

<table>
<thead>
<tr>
<th>Project Dates: 07/23/10 - 01/31/13</th>
<th>Direct F &amp; A</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>B2521001 / 3133K1-3000-US (10082309)</td>
<td>10,378</td>
<td>12,972</td>
</tr>
</tbody>
</table>

**A Double-Blind, Placebo-Controlled, Randomized, Multi-Center Study Evaluating CERE-110 Gene Delivery in Subjects with Mild to Moderate Alzheimer's Disease**

Univ. of California, San Diego

<table>
<thead>
<tr>
<th>Project Dates: 02/01/09 - 06/30/13</th>
<th>Direct F &amp; A</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>ADC-033/U01 AG10483 (10101948)</td>
<td>269,647</td>
<td>300,625</td>
</tr>
</tbody>
</table>

**Alzheimer's Disease Neuroimaging Initiative**

Univ. of California, San Diego

<table>
<thead>
<tr>
<th>Project Dates: 09/30/10 - 08/31/15</th>
<th>Direct F &amp; A</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>AG024904 (11021159)</td>
<td>243,634</td>
<td>279,750</td>
</tr>
</tbody>
</table>
Mintzer, Jacobo  

**Principal Investigator**  
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center, Phase II Study to Evaluate the Efficacy of MABT5102A in Patients with Mild to Moderate Alzheimer’s Disease  
Genentech, Inc.  
Budget Dates: 07/19/11 - 01/31/14  
Direct F & A Total  
ABE4869G (12020158)  
Project Dates: 07/19/11 - 01/31/14 606,797 150,949 757,746  

Citalopram Treatment for Agitation in Alzheimer Dementia  
Johns Hopkins Univ.  
Budget Dates: 09/01/11 - 08/31/12  
ABE4869G (12020158)  
Project Dates: 09/15/08 - 08/31/13 91,402 38,666 130,068  

A Phase 3, Multi-Center, Long-Term, Safety and Tolerability Trial of Bapineuzumab in Subjects with Alzheimer’s Disease Who are Apolipoprotein E4 Carriers and Participated in Study 3133K1-3001  
Icon Clinical Research, Inc.  
Budget Dates: 09/22/11 - 11/30/16  
B2521004 / 3133K1-3003 (12030401)  
Project Dates: 09/22/11 - 11/30/16 561,125 139,497 700,622  

ADCS Infrastructure Support  
Univ. of California, San Diego  
Budget Dates: 01/01/11 - 06/30/12  
PO10323242/AG010483-21 (12101350)  
Project Dates: 01/01/11 - 06/30/12 39,999 10,000 49,999  

Phase II Study to Evaluate the Impact on Biomarkers of Resveratrol Treatment in Patients with Mild to Moderate Alzheimer’s Disease  
Univ. of California, San Diego  
Budget Dates: 11/01/11 - 12/31/14  
AG10483 (12101354)  
Project Dates: 11/01/11 - 12/31/14 163,068 30,932 194,000  

Moorman, David  

**Principal Investigator**  
Role of Prefrontal Networks in Addiction Endophenotypes  
NIH/NIDA  
Budget Dates: 07/01/11 - 05/31/13  
1R21DA032005-01 (10101317)  
Project Dates: 07/01/11 - 05/31/13 200,000 45,125 245,125  

Role of Prefrontal Networks in Addiction Endophenotypes  
NIH/NIDA  
Budget Dates: 06/01/12 - 05/31/13  
5R21DA032005-02 (12101412)  
Project Dates: 07/01/11 - 05/31/13 75,000 35,625 110,625  

Mulholland, Patrick  

**Principal Investigator**  
Stress and Ethanol Dependence: SK Channels and Glutamate  
NIH/NIAAA  
Budget Dates: 02/10/12 - 01/31/13  
1U01AA020930-01 (11021361)  
Project Dates: 02/10/12 - 01/31/17 124,529 59,151 183,680  

Chronic Ethanol and SK2 Potassium Channels  
NIH/NIAAA  
Budget Dates: 07/01/11 - 06/30/13  
5R00AA017922-03 (11051213)  
Project Dates: 07/10/09 - 06/30/13 127,424 60,526 187,950  

Naselaris, Thomas  

**Co-Investigator**  
NSF EPSCoR RII Track 2: Cyberinfrastructure  
PI: Stephen Lanier  
NIH/NIAAA  
Sponsor: SC Research Authority  
Total: $ 192,801  
Dept: Cell and Molecular Pharmacology  
Award: EPS-0919440 (08121730-3)  

New, Natasha  

**Principal Investigator**  
Adolescent Alcohol, Epigenetics, and Alterations in the Adult Prefrontal Cortex  
NIH/NIAAA  
Budget Dates: 09/15/11 - 09/14/12  
1F31AA020445-01A1 (11120234)  
Project Dates: 09/15/11 - 09/14/14 36,703 0 36,703  

Parsegian, Aram  

**Principal Investigator**  
Impact of Meth Self-Administration on GLU and DA in the Corticoaccumbens Pathway  
NIH/NIDA  
Budget Dates: 01/01/12 - 12/31/12  
5F31DA029431-02 (12050559)  
Project Dates: 01/01/11 - 12/31/12 41,242 0 41,242  

Medical University of South Carolina
<table>
<thead>
<tr>
<th>Principal Investigator</th>
<th>Research Topic</th>
<th>Sponsor</th>
<th>Budget Dates:</th>
<th>Direct F &amp; A</th>
<th>Total F &amp; A</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pava, Matthew</td>
<td>Chronic Ethanol's Effects on Endocannabinoid Modulation of Neocortical Up-States</td>
<td>NIH/NIAAA</td>
<td>09/18/10 - 09/17/11</td>
<td>38,752</td>
<td>38,752</td>
</tr>
<tr>
<td>Ramamoorthy, Samman</td>
<td>Genetic Models of Serotonin Transporter Regulation Linked to Mental Disorders</td>
<td>NIH/NIMH</td>
<td>07/01/11 - 06/30/13</td>
<td>219,038</td>
<td></td>
</tr>
<tr>
<td>Reissner, Kathryn</td>
<td>Contributions of Glial Glutamate Transport and Transmission to Drug Abuse</td>
<td>NIH/NIDA</td>
<td>03/01/12 - 02/28/13</td>
<td>120,228</td>
<td></td>
</tr>
<tr>
<td>Revuelta, Gonzalo</td>
<td>Investigation of Cogane (PYM50028) in Early-Stage Parkinson's Disease</td>
<td>Icon Clinical Research, Inc.</td>
<td>04/08/11 - 09/30/12</td>
<td>76,327</td>
<td></td>
</tr>
<tr>
<td>Riedy, Matthew</td>
<td>The Role of the Locus Coeruleus Norepinephrine System in Response Inhibition</td>
<td>NIH/NIMH</td>
<td>08/08/11 - 08/07/12</td>
<td>295,000</td>
<td></td>
</tr>
<tr>
<td>Riegel, Jr., Arthur</td>
<td>Relapse to Cocaine-Seeking: Cellular Adaptations in the Ventral Tegmental Area</td>
<td>NIH/NIDA</td>
<td>04/15/12 - 03/31/2014</td>
<td>295,000</td>
<td></td>
</tr>
<tr>
<td>Salak, Vicky</td>
<td>CD Probe - Cervical Dystonia - Patient Registry for Observation of BOTOX Efficacy</td>
<td>Allergan, Inc.</td>
<td>09/01/10 - 08/31/2013</td>
<td>295,000</td>
<td></td>
</tr>
<tr>
<td>Samanta Ray, Supriti</td>
<td>Extra-Nigral Neurodegeneration in Experimental Parkinson's Disease</td>
<td>NIH/NINDS</td>
<td>09/01/10 - 08/31/2013</td>
<td>295,000</td>
<td></td>
</tr>
<tr>
<td>Sambamurti, Kumar</td>
<td>Small Molecule Inhibitor of Amyloid Precursor Protein Synthesis</td>
<td>Q. R. Pharma</td>
<td>09/15/10 - 08/31/11</td>
<td>10,000</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Dietary Modification of AD Biomarkers</td>
<td>Alzheimer's Assoc.</td>
<td>09/01/11 - 08/31/12</td>
<td>66,666</td>
<td></td>
</tr>
</tbody>
</table>
### See, Ronald

**Principal Investigator**

**Interscience Medication Development for Multiple Risk Factors in Relapse**

NIH/NIDA  
5R01DA021690-05 (11120267)

**Striatal Mechanisms of Relapse to Cocaine Seeking**

NIH/NIDA  
5R01DA010462-15 (12070822)

**Co-PI/Project Director**

ORWH: SCOR on Sex and Gender Factors Affecting Women's Health (Project 1)  
Dept: Psychiatry and Behavioral Sciences  
Sponsor: NIH/NIDA  
Total: $184,782

**Neurobiology of Addiction Research Center (NARC)- CORE B**

PI: Peter Kalivas  
Dept: Neurosciences  
Sponsor: NIH/NIDA  
Total: $345,127

**Neurobiology of Addiction Research Center (NARC)- PROJECT 4**

PI: Peter Kalivas  
Dept: Neurosciences  
Sponsor: NIH/NIDA  
Total: $99,083

### Shen, Haowei

**Co-Investigator**

**Neurobiology of Addiction Research Center (NARC)- PROJECT 1**

PI: Peter Kalivas  
Dept: Neurosciences  
Sponsor: NIH/NIDA  
Total: $168,281

### Smith, Rachel

**Principal Investigator**

**Molecular Mechanisms of Cocaine-Induced Alterations in Accumbens AMPA Receptors**

NIH/NIDA  
5F32DA031519-02 (12070901)

**Takacs, Istvan**

**Co-Investigator**

**A Double-Blind, Placebo-Controlled, Randomized, Multi-Center Study Evaluating CERE-110 Gene Delivery in Subjects with Mild to Moderate Alzheimer's Disease**

PI: Jacobo Mintzer  
Dept: Neurosciences  
Sponsor: Univ. of California, San Diego  
Total: $300,625

### Trantham-Davidson, H.

**Co-Investigator**

**Alcohol Research Center - Treatment and Implications**

PI: Carrie Randall  
Dept: Psychiatry and Behavioral Sciences  
Sponsor: NIH/NIAAA  
Total: $1,620,001

**Turan, Tanya**

**Principal Investigator**

**Characterization of Intracranial Atherosclerotic Stenosis Using HR MRI**

NIH/NINDS  
5K23NS069668-02 (12091236)

**Turner, Raymond**

**Principal Investigator**

**Codman Training Grant - Work Order #2**

Codman and Shurtleff, Inc.  
Project Dates: 12/01/11 - 04/30/12  
Direct: 12,186  
F & A: 5,788  
Total: 17,974

**EV3 Training Event (2/26/12 and 2/27/12)**

ev3 Neurovascular  
Project Dates: 02/24/12 - 06/30/12  
Direct: 17,088  
F & A: 8,117  
Total: 25,205
### Turner, Raymond

**Principal Investigator**

**Work Order #3 - Codman Flow Diverter: Acute In-Vivo Feasibility Lab #1**  
Codman and Shurtleff, Inc  
Budget Dates: 05/11/12 - 06/30/12  
Direct F & A Total  
Project Dates: 05/11/12 - 06/30/12  
14,596 6,933 21,529

**Axium MicroFx Coil Study - Project Agreement #1**  
Tyco Healthcare Group  
Budget Dates: 04/23/12 - 04/23/13  
Direct F & A Total  
Project Dates: 04/23/12 - 04/23/13  
26,288 12,487 38,775

**The THERAPY Trial: The Randomized, Concurrent, Controlled Trial to Assess the Penumbra System's Safety and Effectiveness in the Treatment of Acute Stroke**  
Penumbra, Inc.  
Budget Dates: 05/23/12 - 06/30/13  
Direct F & A Total  
Project Dates: 05/23/12 - 06/30/13  
279,280 69,070 348,350

**Co-Investigator**

**Evaluate C-Arm Dyna CT versus Conventional CT Myelography**  
Pl: Aquilla Turk, III  
Sponsor: Siemens Medical Solutions U  
Total: $164,951  
Dept: Radiology  
Award: MUSC-2011-AX-03-39111-01- (12040531-1)

**A Single Center Experience of Patients Treated with the Penumbra Coil 400 in Conjunction with Stent or Balloon Remodeling**  
Pl: Aquilla Turk, III  
Sponsor: Penumbra, Inc.  
Total: $86,040  
Dept: Radiology  
Award: 4157.A (12050630-1)

Pl: Aquilla Turk, III  
Sponsor: MicroVention, Inc  
Total: $37,205  
Dept: Radiology  
Award: LVIS (12050631-1)

**A Randomized, Concurrent, Controlled Trial to Assess the Safety and Effectiveness of the Separator 3D as a Component of the Penumbra System in the Revascularization of Large Vessel Occlusion in Acute Ischemic Stroke**  
Pl: Aquilla Turk, III  
Sponsor: Penumbra, Inc.  
Total: $141,150  
Dept: Radiology  
Award: Penumbra 3D (12101453-1)

**ACE: Aneurysm Coiling Efficiency Study of the Penumbra Coil 400 System**  
Pl: Aquilla Turk, III  
Sponsor: Penumbra, Inc.  
Total: $31,813  
Dept: Radiology  
Award: ACE (12121691-1)

### Turner, Robert

**Principal Investigator**

**Prevention of Photoparoxysmal Abnormalities Through Patterened Auditory Stimulation**  
MIND Institute  
Budget Dates: 03/01/12 - 02/28/13  
Direct F & A Total  
Project Dates: 03/01/11 - 02/28/13  
46,000 0 46,000

### Varma, Abhay

**Principal Investigator**

**A Prospective, Multi-Center, Nonrandomized Study to Assess Lumbar Fusion Using Interbody Cages with Autograft in Conjunction with Instrumented Postlateral Gutter Fusions Using NanOss BA**  
Pioneer Surgical, Inc.  
Budget Dates: 11/09/10 - 10/31/12  
Direct F & A Total  
Project Dates: 11/09/10 - 10/31/12  
50,576 12,644 63,220

### Vazey, Elena

**Principal Investigator**

**The Locus Coeruleus as a Substrate for Parkinsonian Cognitive Inflexibility**  
Parkinsons Disease Fdn.  
Budget Dates: 07/01/11 - 08/31/12  
Direct F & A Total  
Project Dates: 07/01/11 - 08/31/12  
47,500 0 47,500

### Voeks, Jenifer

**Principal Investigator**

**Carotid Revascularization Endarterectomy vs. Stenting Trial: Long Term Follow-Up**  
Univ. of Alabama, Birmingham  
Budget Dates: 03/15/12 - 12/31/12  
Direct F & A Total  
Project Dates: 03/15/12 - 12/31/16  
67,966 32,284 100,250

### Walker, Aljoeson

**Principal Investigator**

**Randomized Evaluation of Recurrent Stroke Comparing PFO Closure to Established Current Standard of Care Treatment**  
Aga Medical Corp.  
Budget Dates: 09/22/04 - 12/31/16  
Direct F & A Total  
Project Dates: 09/22/04 - 12/31/16  
255,958 61,864 317,822
Wannamaker, Braxton
Co-PI/Project Director
Risk Factors of Epilepsy Outcomes: Comorbidities in a Population with Epilepsy
Pl: Anbesaw Selassie  Sponsor: CDC  Total: $425,000
Dept: Medicine  Award: 1 U01 DP003251-01 (11030164-1)

Waters, R.
Principal Investigator
PACD Scholar: Dr. R. Parrish Waters
Univ. of South Carolina
5 P20 RR16461-11 (12010094)

Woodward, John
Principal Investigator
Ethanol Sensitivity of Native and Cloned NMDA Receptors
NIH/NIAAA
5R37AA009986-17 (12020168)

Obstetrics and Gynecology
Carter, James
Co-Investigator
A 12-Week, Phase 4, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center Trial in Overactive Bladder Subjects to Confirm the Efficacy of 8MG Fesoterodine Compared to 4MG Fesoterodine
Pl: Steven Swift  Sponsor: Parexel Intl. Corp.  Total: $64,556
Dept: Obstetrics and Gynecology  Award: A0221095 (12010093-1)

Creasman, William
Principal Investigator
Gynecologic Oncology Group (COG) Studies
GOG
27469-81 (12111475)

Dempsey-Fanning, A.
Principal Investigator
Kenneth J. Ryan Residency Training Program
Susan Thompson Buffet Fdn.
909.02 (12030367)

Fylstra, Donald
Co-Investigator
A 12-Week, Phase 4, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center Trial in Overactive Bladder Subjects to Confirm the Efficacy of 8MG Fesoterodine Compared to 4MG Fesoterodine
Pl: Steven Swift  Sponsor: Parexel Intl. Corp.  Total: $64,556
Dept: Obstetrics and Gynecology  Award: A0221095 (12010093-1)

Goetzl, Laura
Principal Investigator
Gestational Age Variation in Human Placental Transport Mechanisms
NIH/NICHD
1R01HD069238-01A1 (10091382)
Graybill, Whitney
**Principal Investigator**

*A Randomized, Double-Blind, Phase 3 Trial Comparing EC145 and Pegylated Liposomal Doxorubicin (PLD/Doxil/Caelyx) in Combination Versus PLD in Participants with Platinum-Resistant Ovarian Cancer*

Endocyte, Inc.  
Budget Dates: 05/19/11 - 06/30/16  
Project Dates: 05/19/11 - 06/30/16  
Direct F & A  
Total  
1,440  
360  
1,800

Guillette, Jr., Louis
**Principal Investigator**

*SmartState Center for Marine Genomics*

*Summer Undergraduate Research Program in Oceans and Human Health*

MUSC Fdn.  
Budget Dates: 07/01/11 - 06/30/12  
Project Dates: 07/01/10 - 06/30/12  
Direct F & A  
Total  
88,342  
0  
88,342

Jaiyeoba, Oluwatosin
**Co-Investigator**

*A Randomized, Double-Blind, Placebo-Controlled, Phase II Study of Fluconazole Versus Fluconazole and MGCD290 for the Treatment of Moderate to Severe Acute Vulvovaginal Candidiasis*

Dept: Obstetrics and Gynecology  
Award: 290-005 (12050632-1)

Jaiyeoba, Tosin
**Co-Investigator**

*Prevalence and Clinical Significance of Mycoplasma Genitalium in Our Gynecologic Patients*

Dept: Obstetrics and Gynecology  
Award: TEST MATERIALS (12070829-1)

Johnson, Donna
**Co-Investigator**

*Pre-Eclampsia Triage by Rapid Assay (PETRA) of Novel Biomarkers of Placental Function and Maternal Adaptation*

Dept: Obstetrics and Gynecology  
Award: BSTE-1002 PETRA (10043066-3)

Lazenby, Gweneth
**Co-Investigator**

*A Randomized, Double-Blind, Placebo-Controlled, Phase II Study of Fluconazole Versus Fluconazole and MGCD290 for the Treatment of Moderate to Severe Acute Vulvovaginal Candidiasis*

Dept: Obstetrics and Gynecology  
Award: 290-005 (12050632-1)

Mauldin, Jill
**Co-Investigator**

*Trans-Generational Impact of Maternal Obesity and Diabetes on Health Disparities*

Dept: Medicine  
Award: 1357-209-20075551 (11042946-2)

Newman, Roger
**Principal Investigator**

*Pre-Eclampsia Triage by Rapid Assay (PETRA) of Novel Biomarkers of Placental Function and Maternal Adaptation*

Dept: Obstetrics and Gynecology  
Award: BSTE-1002 PETRA (10043066-4)

The National Standard for Normal Fetal Growth: Twins Study

NIH/NICHD  
Budget Dates: 09/26/10 - 09/25/12  
Project Dates: 09/26/08 - 09/25/12  
Direct F & A  
Total  
192,297  
91,341  
283,638

Co-Investigator

*Preventing Preterm Labor in Low Resource Settings*

Dept: Obstetrics and Gynecology  
Award: OPP1036160 (10110414-1)
Newman, Roger

Co-Investigator
Proteomic Assessment of Preterm Risk (PAPR)
Pl: Scott Sullivan
Dept: Obstetrics and Gynecology
Sponsor: Sera Prognostics Inc
Award: PAPR (12020218-1)
Total: $188,700

Proteomic Assessment of Preterm Risk (PAPR)
Pl: Scott Sullivan
Dept: Obstetrics and Gynecology
Sponsor: Sera Prognostics Inc
Award: PAPR (12020218-2)
Total: $12,470

Rittenberg, Charles

Principal Investigator
Whole Blood Specimen Collection Study Obtained from Pregnant Subjects
Sequenom
SQNM-T21-106 (11033124)
Budget Dates: 04/11/11 - 10/31/12
Project Dates: 04/11/11 - 10/31/12
Direct F & A Total
73,800 18,450 92,250

Role of Galactin 3 in Early-Onset Severe Preeclampsia
BG Medicine, Inc.
Samples (12101347)
Budget Dates: 02/02/12 - 03/29/13
Project Dates: 02/02/12 - 03/29/13
Direct F & A Total
22,892 6,266 29,158

Robinson, Christopher

Principal Investigator
Pre-Eclampsia Triage by Rapid Assay (PETRA) of Novel Biomarkers of Placental Function and Maternal Adaptation
Biosite, Inc.
BSTE-1002 PETRA (10043066)
Budget Dates: 04/30/10 - 08/31/12
Project Dates: 04/30/10 - 08/31/12
Direct F & A Total
59,240 14,810 74,050

Prevalence and Clinical Significance of Mycoplasma Genitalium in Our Gynecologic Patients
Gen-Probe Inc.
TEST MATERIALS (12070829)
Budget Dates: 12/20/11 - 12/19/13
Project Dates: 12/20/11 - 12/19/13
Direct F & A Total
6,000 0 6,000

Soper, David

Principal Investigator
A Randomized, Double-Blind, Placebo-Controlled, Phase II Study of Fluconazole Versus Fluconazole and MGCDS290 for the Treatment of Moderate to Severe Acute Vulvovaginal Candidiasis
MethylGene Inc.
290-005 (12050632)
Budget Dates: 11/11/11 - 12/31/12
Project Dates: 11/11/11 - 12/31/12
Direct F & A Total
187,072 46,018 233,090

Prevalence and Clinical Significance of Mycoplasma Genitalium in Our Gynecologic Patients
Gen-Probe Inc.
TEST MATERIALS (12070829)
Budget Dates: 12/20/11 - 12/19/13
Project Dates: 12/20/11 - 12/19/13
Direct F & A Total
6,000 0 6,000

Sullivan, Scott

Principal Investigator
Preventing Preterm Labor in Low Resource Settings
Bill and Melinda Gates Foundation
OPP1036160 (10110414)
Budget Dates: 05/01/11 - 10/31/12
Project Dates: 05/01/11 - 10/31/12
Direct F & A Total
100,000 0 100,000

Proteomic Assessment of Preterm Risk (PAPR)
Sera Prognostics Inc
PAPR (12020218)
Budget Dates: 08/22/11 - 02/14/13
Project Dates: 08/22/11 - 02/14/13
Direct F & A Total
164,030 37,140 201,170

Swift, Steven

Principal Investigator
A 12-Week, Phase 4, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center Trial in Overactive Bladder Subjects to Confirm the Efficacy of 8MG Fesoterodine Compared to 4MG Fesoterodine
Parexel Intl. Corp.
A0221095 (12010093)
Budget Dates: 09/01/11 - 07/31/12
Project Dates: 09/01/11 - 07/31/12
Direct F & A Total
52,245 12,311 64,556

Vandorsten, J.

Co-Investigator
The National Standard for Normal Fetal Growth: Twins Study
Pl: Roger Newman
Dept: Obstetrics and Gynecology
Sponsor: NIH/NICHD
Award: HHSN275200800014C (10081178-2)
Total: $252,989

The National Standard for Normal Fetal Growth: Twins Study
Pl: Roger Newman
Dept: Obstetrics and Gynecology
Sponsor: NIH/NICHD
Award: HHSN275200800014C (10081178-3)
Total: $30,649
Ophthalmology

Ablonczy, Zsolt

Principal Investigator
The Mechanism of the Outer Blood Retina-Barrier Breakdown
NIH/NEI
5R01EY019065-02 (11051324)

Co-Investigator
MAP4 Regulation of Cardiac Microtubule Network Density
PI: Donald Menick
Dept: Medicine
Sponsor: NIH/NHLBI
Award: 5R01HL094545-03 (12081102-1)

Crosson, Craig

Principal Investigator
COBRE in Lipidomics and Pathobiology
NIH/NCRR
5P20RR017677-10 (12040490)

Protein Acetylation in Glaucomatous Optic Neuropathy
NIH/NEI
5R01EY021368-02 (12050694)

Reversal of RPE Dysfunction Alimera Compounds
Alimera Sciences
(12050695)

SmartState SC Center of Economic Excellence in Vision Science
SC Research Centers of Economic Excellence
(12081131)

SmartState Center for Vision Science Research
MUSC Fdn.
(12111589)

Del Priore, Lucian

Principal Investigator
2012 Unrestricted RPB Grant
Research to Prevent Blindness
(12010846)

Greater NY Regional Research Center for the Study of Retinal Degenerative Diseases
Fdn. Fighting Blindness
C-RM-0710-0542-MUSC03 (12070847)

Evans, M.

Co-Investigator
Three Month Efficacy and Safety Study of a Fixed Combination of Brinzolamide 1% / Brimonidine 0.2% Compared to Brinzolamide 1% and Brimonidine 0.2% All Dosed Three Times Daily in Patients with Open-Angle Glaucoma and/or Ocular Hypertension
PI: Matthew Nutaitis
Dept: Ophthalmology
Sponsor: MUSC OIP
Award: C-10-003 (11041486-2)

Husain, Shahid

Principal Investigator
Opioidergic System: Its Role(s) in Glaucoma
NIH/NEI
5R01EY019081-03 (12101391)

Koutalos, Yiannis

Principal Investigator
Transport Processes in Photoreceptors
NIH/NEI
5R01EY014850-08 (12070841)

Kylistra, Jan

Principal Investigator
12-Month, Multi-Center, 2-Stage (Open-Label, Dose-Escalation, Followed by Masked, Randomized) Single-Dose Study of the Safety and Efficacy of AGN-208397 in Patients with Macular Edema (ME) Associated with Retinal Vein Occlusion (RVO)
Allergan, Inc.
208397-001 (12010102)
Nutaitis, Matthew

**Principal Investigator**

**Three Month Efficacy and Safety Study of a Fixed Combination of Brinzolamide 1% / Brimonidine 0.2% Compared to Brinzolamide 1% and Brimonidine 0.2% All Dosed Three Times Daily in Patients with Open-Angle Glaucoma and/or Ocular Hypertension**

MUSC OIP

C-10-003 (11041486)  
Budget Dates: 06/01/11 - 05/31/12  
Project Dates: 06/01/11 - 05/31/12  
Direct F & A  
Total  
14,629  
3,657  
18,286

**Long-Term, Safety, Follow-up for Subjects Previously Implanted with the AcrySof Cachet Phakic Lens in Clinical Studies C-02-23, C-02-40, C-03-21 and C-05-57**

Alcon, Inc.

C-09-043 (12081053)  
Budget Dates: 02/01/12 - 01/01/13  
Project Dates: 02/01/12 - 01/01/13  
Direct F & A  
Total  
36,205  
8,426  
44,631

Patel, Narendra

**Co-Investigator**

**12-Month, Multi-Center, 2-Stage (Open-Label, Dose-Escalation, Followed by Masked, Randomized) Single-Dose Study of the Safety and Efficacy of AGN-208397 in Patients with Macular Edema (ME) Associated with Retinal Vein Occlusion (RVO)**

PI: Jan Kylstra  
Sponsor: Allergan, Inc.  
Total: $238,944

Dept: Ophthalmology  
Award: 208397-001 (12010102-1)

**12-Month, Multi-Center, 2-Stage (Open-Label, Dose-Escalation, Followed by Masked, Randomized) Single-Dose Study of the Safety and Efficacy of AGN-208397 in Patients with Macular Edema (ME) Associated with Retinal Vein Occlusion (RVO)**

PI: Jan Kylstra  
Sponsor: Allergan, Inc.  
Total: $10,450

Dept: Ophthalmology  
Award: 208397-001 (12010102-2)

Rohrer, Baerbel

**Principal Investigator**

**Alternative Pathway of Complement Activation in Age-Related Macular Degeneration**

NIH/NEI  
5R01EY019320-02 (11120294)  
Budget Dates: 07/01/11 - 06/30/12  
Project Dates: 07/01/10 - 06/30/15  
Direct F & A  
Total  
218,928  
98,605  
317,533

**Neurotrophic Factors and Retinal Degeneration**

Fdn. Fighting Blindness  
NN-NG-PC-0709-0042-PCAC (12020234)  
Budget Dates: 08/01/11 - 07/31/12  
Project Dates: 08/01/09 - 07/31/12  
Direct F & A  
Total  
80,000  
0  
80,000

**Complement Factor H Haplotypes and Smoking in Age-Related Macular Degeneration**

VAMC  
RX000444 (12020261)  
Budget Dates: 10/01/11 - 09/30/12  
Project Dates: 10/01/10 - 09/30/14  
Direct F & A  
Total  
274,600  
0  
274,600

**Complement and AMD**

Alexion Pharmaceuticals  
(12060748)  
Budget Dates: 12/20/11 - 12/19/12  
Project Dates: 12/20/11 - 12/19/12  
Direct F & A  
Total  
75,239  
35,738  
110,977

**Testing Compounds that Target Mitochondrial Metabolism**

MitoChem Therapeutics  
(12111533)  
Budget Dates: 06/01/12 - 05/31/13  
Project Dates: 06/01/12 - 05/31/13  
Direct F & A  
Total  
125,860  
59,784  
185,644

**High Content Metabolic Screens for Anti-Degenerative Agents**

Fdn. Fighting Blindness  
TA-NP-0607-0446-MUSC-WG (12111601)  
Budget Dates: 06/01/12 - 05/31/13  
Project Dates: 06/01/08 - 05/31/13  
Direct F & A  
Total  
200,000  
0  
200,000

**Co-Investigator**

**Inflammation and Degeneration of Optic Nerve in EAE**

PI: Naren Banik  
Sponsor: NIH/NINDS  
Total: $314,580

Dept: Neurosciences  
Award: 5R01NS065456-03 (11051627-1)

Wilson, M.

**Principal Investigator**

**Infant Aphakia Treatment Study (IATS)**

Emory Univ.  
S668052/U10 EY013272-08 (11032898)  
Budget Dates: 06/01/11 - 05/31/12  
Project Dates: 06/01/11 - 05/31/12  
Direct F & A  
Total  
12,609  
5,989  
18,598

**Protocol # 670, A Randomized, Multi-Center, Double-Masked, Parallel-Group Study Assessing the Safety and Efficacy of Loteprednol Etabonate Ophthalmic Gel, 0.5% versus Prednisolone Acetate Ophthalmic S**

Bausch and Lomb  
Budget Dates: 03/15/12 - 05/01/13  
Project Dates: 03/15/12 - 05/01/13  
Direct F & A  
Total  
42,404  
9,851  
52,255
## Orthopaedic Surgery

### Barfield, William

Co-Investigator  
**Kyphosis and Implantation: Modeling a Clinical Phenomenon**  
PI: Richard Gross  
Sponsor: Scoliosis Research Society  
Total: $25,000  
Dept: Orthopaedic Surgery  
Award: (11110072-1)

### Glaser, John

Principal Investigator  
**OREF 2011-2012 Clinician Development Program Residency Enhancement Grant**  
Orthopaedic Res. and Educ. Fdn.  
Budget Dates: 07/01/11 - 06/30/12  
Project Dates: 09/08/09 - 06/30/12  
<table>
<thead>
<tr>
<th>F &amp; A</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>7,223</td>
<td>7,223</td>
</tr>
</tbody>
</table>

### Gross, Richard

Principal Investigator  
**Kyphosis and Implantation: Modeling a Clinical Phenomenon**  
Scoliosis Research Society  
Budget Dates: 07/01/11 - 06/30/12  
Project Dates: 07/01/11 - 06/30/13  
<table>
<thead>
<tr>
<th>F &amp; A</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>25,000</td>
<td>25,000</td>
</tr>
</tbody>
</table>

### Hartsock, Langdon

Principal Investigator  
**Clemson MUSC Orthopedic Research Training Program**  
Clemson Univ.  
Budget Dates: 04/01/08 - 08/31/12  
Project Dates: 04/01/07 - 08/31/12  
<table>
<thead>
<tr>
<th>F &amp; A</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>39,820</td>
<td>39,820</td>
</tr>
</tbody>
</table>

### Kang, Qian

Co-Investigator  
**Experimental and Clinical Studies of Presbyacusis (Project 1)**  
PI: Judy Dubno  
Sponsor: NIH/NIDCD  
Total: $366,268  
Dept: Otolaryngology  
Award: 5P50DC000422-24 (11110049-2)

### Sachs, Barton

Principal Investigator  
**Efficacy and Safety of Expandable Spacer in the Treatment of Degenerative Disc Disease Using the Minimally Invasive Transforaminal Lumbar Interbody Fusion Surgical Approach**  
Globus Medical, Inc.  
Budget Dates: 01/30/12 - 02/01/14  
Project Dates: 01/30/12 - 02/01/14  
<table>
<thead>
<tr>
<th>F &amp; A</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>33,500</td>
<td>33,500</td>
</tr>
</tbody>
</table>

### Otolaryngology

### Ahlstrom, Jayne

Co-Investigator  
**Experimental and Clinical Studies of Presbyacusis (Project 1)**  
PI: Judy Dubno  
Sponsor: NIH/NIDCD  
Total: $366,268  
Dept: Otolaryngology  
Award: 5P50DC000422-24 (11110049-2)

### Connell, Abby

Co-PI/Project Director  
**The MED-EL EAS (Electric-Acoustic System) Using the PULSARCI100 FLEXeas / SONATATI100 FLEXeas and the DUET Speech Processor**  
PI: Ted Meyer  
Sponsor: Med El Corp.  
Total: $500  
Dept: Otolaryngology  
Award: IDE G040002 (10070387-2)

### Day, Terry

Co-PI/Project Director  
**Tobacco Related Cancer Research Pilot Project: A Transdisciplinary Prospective Cohort Study to Understand the Root Causes of the Racial Disparity in HNSCC Survival**  
PI: Andrew Kraft  
Sponsor: State of SC  
Total: $74,987  
Dept: Medicine  
Award: (12040516-8)
Discolo, Christopher

**Principal Investigator**

**A Clinical Study of the Acclarent Tympanostomy Tube Delivery and Iontophoresis Systems In Office (inVENT-visIOn study)**

Acclarent, Inc.  
CPR005022 (12020249)  
Budget Dates: 08/18/11 - 10/31/12  
Direct F & A  
Total

**Co-Investigator**

**A Prospective, Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Phase 1B Study of Oto-201 Given as a Single Intratympanic Injection for Intra-Operative Treatment of Middle Ear Effusion in Pediatric Subjects Requiring Tympanostomy Tube Placement**

Pl: David White  
Sponsor: INC Research, Inc.  
Total: $150,591  
Dept: Otolaryngology  
Award: 201-201101 (12030356-1)

Dubno, Judy

**Principal Investigator**

**Automated Hearing Tests**

Audiology, Inc.  
RC3 DC010986-01 (10903195)  
Budget Dates: 04/08/12 - 03/31/13  
Direct F & A  
Total

**Resources for Mentorship of Clinician Scientists in Hearing and Balance Disorders**

Duke Univ.  
203-9278 (11020945)  
Budget Dates: 12/08/11 - 11/30/14  
Direct F & A  
Total

**Experimental and Clinical Studies of Presbyacusis**

NIH/NIDCD  
5P50DC000422-24 (11110049)  
Budget Dates: 08/01/11 - 07/31/12  
Direct F & A  
Total

**Speech-Perception Training in Older Adults**

Indiana University  
12010037  
Budget Dates: 07/01/11 - 06/30/13  
Direct F & A  
Total

**Collaborative Applied Research Supplement NIDCD**

NIH/NIDCD  
3P50DC000422-24S1 (12091272)  
Budget Dates: 07/01/11 - 07/31/13  
Direct F & A  
Total

**Mentor**

Auditory Temporal Processing in the Aging Ear and Brain  
Pl: Kelly Harris  
Sponsor: NIH/NIDCD  
Total: $128,398  
Dept: Otolaryngology  
Award: 5K23DC008787-05 (12010059-1)

Eckert, Mark

**Principal Investigator**

**Methods for Retrospective Multi-Site Research**

NIH/NICHD  
1R01HD069374-01A1 (11120293)  
Budget Dates: 05/01/12 - 04/30/13  
Direct F & A  
Total

**Co-PI/Project Director**

Experimental and Clinical Studies of Presbyacusis (Project 2)  
Pl: Judy Dubno  
Sponsor: NIH/NIDCD  
Total: $392,287  
Dept: Otolaryngology  
Award: 5P50DC000422-24 (11110049-3)

**Co-Investigator**

Experimental and Clinical Studies of Presbyacusis (Project 1)  
Pl: Judy Dubno  
Sponsor: NIH/NIDCD  
Total: $366,268  
Dept: Otolaryngology  
Award: 5P50DC000422-24 (11110049-2)

**Mentor**

Auditory Temporal Processing in the Aging Ear and Brain  
Pl: Kelly Harris  
Sponsor: NIH/NIDCD  
Total: $128,398  
Dept: Otolaryngology  
Award: 5K23DC008787-05 (12010059-1)

Harris, Kelly

**Principal Investigator**

**Auditory Temporal Processing in the Aging Ear and Brain**

NIH/NIDCD  
5K23DC008787-05 (12010059)  
Budget Dates: 09/01/11 - 08/31/13  
Direct F & A  
Total

**Horwitz, Amy**

**Co-Investigator**

Experimental and Clinical Studies of Presbyacusis (Project 1)  
Pl: Judy Dubno  
Sponsor: NIH/NIDCD  
Total: $366,268  
Dept: Otolaryngology  
Award: 5P50DC000422-24 (11110049-2)
Lambert, Paul

**Principal Investigator**

**A Prospective, Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Phase 2 Study of Oto-104 Given as a Single Intratympanic Injection in Subjects with Unilateral Meniere’s Disease**

INC Research, Inc.

- **Budget Dates:** 07/19/11 - 08/31/13
- **F & A**
- **Total**
- **Direct**
- **107,735**

**Co-Investigator**

**Experimental and Clinical Studies of Presbyacusis (Core B)**

- **PI:** Judy Dubno
- **Sponsor:** NIH/NIDCD
- **Total:** $595,189

- **Dept:** Otolaryngology
- **Award:** 5P50DC000422-24 (11110049-6)

**Lee, Fu-Shing**

**Co-Investigator**

**Automated Hearing Tests**

- **PI:** Judy Dubno
- **Sponsor:** Audiology, Inc.
- **Total:** $121,135

- **Dept:** Otolaryngology
- **Award:** RC3 DC010986-01 (09083195-3)

**Martin-Harris, Bonnie**

**Principal Investigator**

**Respiratory-Swallow Training in Veterans with Oropharyngeal Cancer**

VAMC

- **Budget Dates:** 03/01/12 - 02/28/13
- **Total:** $126,100

- **Direct**
- **F & A**
- **126,100**

**Speech Pathologist and Data Management Research, RHJ, VAMC, Charleston, SC**

VAMC

- **Budget Dates:** 02/21/12 - 02/20/13
- **Total:** 81,200

- **Direct**
- **F & A**
- **81,200**

**Standardization of Videofluoroscopic Swallow Studies for Bottle-Fed Children**

Johns Hopkins Univ.

- **Budget Dates:** 01/01/11 - 12/31/15
- **Total:** 157,266

- **Direct**
- **F & A**
- **106,621**

**Matthews, Lois**

**Co-Investigator**

**Experimental and Clinical Studies of Presbyacusis (Core B)**

- **PI:** Judy Dubno
- **Sponsor:** NIH/NIDCD
- **Total:** $595,189

- **Dept:** Otolaryngology
- **Award:** 5P50DC000422-24 (11110049-6)

**Meyer, Ted**

**Principal Investigator**

**The MED-EL EAS (Electric-Acoustic System) Using the PULSARCI100 FLEXeas / SONATATI100 FLEXeas and the DUET Speech Processor**

Med El Corp.

- **Budget Dates:** 06/23/10 - 06/30/13
- **Total:** 500

- **Direct**
- **F & A**
- **400**

**Co-Investigator**

**A Prospective, Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Phase 2 Study of Oto-104 Given as a Single Intratympanic Injection in Subjects with Unilateral Meniere’s Disease**

- **PI:** Paul Lambert
- **Sponsor:** INC Research, Inc.
- **Total:** $107,735

- **Dept:** Otolaryngology
- **Award:** 104-201102 (12010050-1)

**Mills, John**

**Co-PI/Project Director**

**Experimental and Clinical Studies of Presbyacusis (Core B)**

- **PI:** Judy Dubno
- **Sponsor:** NIH/NIDCD
- **Total:** $595,189

- **Dept:** Otolaryngology
- **Award:** 5P50DC000422-24 (11110049-6)

**Mentor**

**Auditory Temporal Processing in the Aging Ear and Brain**

- **PI:** Kelly Harris
- **Sponsor:** NIH/NIDCD
- **Total:** $128,398

- **Dept:** Otolaryngology
- **Award:** 5K23DC008787-05 (12010059-1)
### Mulligan, Jennifer

**Principal Investigator**

**Effects of Second Hand Smoke On Dendritic Cell Regulation and Function in Chronic Rhinosinusitis**  
Charleston Research Institute  
Budget Dates: 07/01/11 - 06/30/12  
Project Dates: 07/01/10 - 06/30/13  
Direct F & A Total  
(12010077) 87,500 0 87,500

**Mentor**

Inflammatory Role of Fibroblasts in Chronic Rhinosinusitis  
PI: Samuel Oyer  
Dept: Otolaryngology  
Sponsor: Amer. Acad. of Otolaryngology  
Award: (11010943-1)  
Total: $8,000

**Role of VD3 in Atopic CRSwNP**  
PI: Alkis Psaltis  
Dept: Otolaryngology  
Sponsor: American Academy of Otolaryngology  
Award: (12050577-1)  
Total: $7,500

### Nguyen, Shaun

**Principal Investigator**

**Reduction of Staph Aureus Carriage by Non-Antibiotic Nasal Antiseptic**  
Global Life Technologies  
Budget Dates: 07/02/12 - 09/30/12  
Project Dates: 07/02/12 - 09/30/12  
Direct F & A Total  
NOZIN (12121775) 27,000 6,125 33,125

**Co-PI/Project Director**

A Clinical Study of the Acclarent Tympanostomy Tube Delivery and Iontophoresis Systems In Office (inVENT-visiOn study)  
PI: Christopher Discolo  
Dept: Otolaryngology  
Sponsor: Acclarent, Inc.  
Award: CPR005022 (12020249-1)  
Total: $20,250

**A Prospective, Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Phase 1B Study of Oto-201 Given as a Single Intratympanic Injection for Intra-Operative Treatment of Middle Ear Effusion in Pediatric Subjects Requiring Tympanostomy Tube Placement**  
PI: David White  
Dept: Otolaryngology  
Sponsor: INC Research, Inc.  
Award: 201-201101 (12030356-1)  
Total: $150,591

**Co-Investigator**

The MED-EL EAS (Electric-Acoustic System) Using the PULSARC100 FLEXeas / SONATAT100 FLEXeas and the DUET Speech Processor  
PI: Ted Meyer  
Dept: Otolaryngology  
Sponsor: Med El Corp.  
Award: IDE G040002 (10070387-2)  
Total: $500

**A Prospective, Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Phase 2 Study of Oto-104 Given as a Single Intratympanic Injection in Subjects with Unilateral Meniere's Disease**  
PI: Paul Lambert  
Dept: Otolaryngology  
Sponsor: INC Research, Inc.  
Award: 104-201102 (12010050-1)  
Total: $107,735

### Oyer, Samuel

**Principal Investigator**

**Inflammatory Role of Fibroblasts in Chronic Rhinosinusitis**  
Amer. Acad. of Otolaryngology  
Budget Dates: 07/01/11 - 06/30/12  
Project Dates: 07/01/11 - 06/30/12  
Direct F & A Total  
(11010943) 7,200 800 8,000

### Psaltis, Alkis

**Principal Investigator**

**Role of VD3 in Atopic CRSwNP**  
American Academy of Otolaryngic Allergy  
Budget Dates: 11/01/11 - 10/31/12  
Project Dates: 11/01/11 - 10/31/12  
Direct F & A Total  
(12050577) 7,500 0 7,500

### Schlosser, Rodney

**Principal Investigator**

**Nanoparticle Coupled Antioxidants for Respiratory Illness in Veterans**  
VAMC  
Budget Dates: 04/01/12 - 03/31/13  
Project Dates: 04/01/12 - 03/31/15  
Direct F & A Total  
CX000377 (12010052) 150,000 0 150,000

**Mentor**

Inflammatory Role of Fibroblasts in Chronic Rhinosinusitis  
PI: Samuel Oyer  
Dept: Otolaryngology  
Sponsor: Amer. Acad. of Otolaryngology  
Award: (11010943-1)  
Total: $8,000

### Schmiedt, Richard

**Co-Investigator**

Experimental and Clinical Studies of Presbyacusis (Project 3)  
PI: Judy Dubno  
Dept: Otolaryngology  
Sponsor: NIH/NIDCD  
Award: 5P50DC000422-24 (11110049-4)  
Total: $388,103
## Schmiedt, Richard

**Co-Investigator**

**Experimental and Clinical Studies of Presbyacusis (Core B)**

- **PI:** Judy Dubno
- **Dept.:** Otolaryngology
- **Sponsor:** NIH/NIDCD
- **Award:** 5P50DC000422-24 (11110049-6)
- **Total:** $595,189

**Experimental and Clinical Studies of Presbyacusis (Core B)**

- **Dept.:** Otolaryngology

**Sponsor:** NIH/NIDCD

**Total:** $595,189

---

## Soler, Zachery

**Principal Investigator**

**Determinants of Medical and Surgical Treatment Outcomes in Chronic Sinusitis**

- **Oregon Health Sciences University**
- **Budget Dates:** 10/01/11 - 03/31/12
- **Direct F & A:** $14,200
- **Total:** $20,944

**GOTOL0195A_MUSC/R01 DC005 (12040537)**

- **Project Dates:** 10/01/11 - 03/31/16
- **Direct F & A:** $12,562
- **Total:** $39,008

---

## White, David

**Principal Investigator**

**A Prospective, Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Phase 1B Study of Oto-201 Given as a Single Intratympanic Injection for Intra-Operative Treatment of Middle Ear Effusion in Pediatric Subjects Requiring Tympanostomy Tube Placement**

- **INC Research, Inc.**
- **Budget Dates:** 09/22/11 - 10/31/13
- **Direct F & A:** $121,173
- **Total:** $150,591

**G01-201-101 (12030356)**

- **Project Dates:** 09/22/11 - 10/31/13
- **Direct F & A:** $29,418
- **Total:** $49,046

---

## Young, M.

**Principal Investigator**

**Vitamin D Plus Celecoxib Therapy to Stimulate Intratumoral Immune Reactivity**

- **VAMC**
- **Budget Dates:** 10/01/11 - 09/30/12
- **Direct F & A:** $35,099
- **Total:** $35,099

**Heat Shock Protein-Induced Protection against Cisplatin-Induced Hair Cell Death**

- **NIH/NIDCD**
- **Budget Dates:** 09/28/09 - 09/27/15
- **Project Dates:** 09/28/09 - 09/27/14
- **Direct F & A:** $150,000
- **Total:** $150,000

**Macrophage-Driven Progression of Premalignant Oral Lesions Toward Invasiveness**

- **NIH/NIDCR**
- **Budget Dates:** 07/01/08 - 06/30/13
- **Project Dates:** 06/01/03 - 05/31/15
- **Direct F & A:** $240,075
- **Total:** $302,495

**Immunotherapy to Prevent Oral Premalignant Lesion Recurrence and Oral Cancer**

- **NIH/NCI**
- **Budget Dates:** 01/01/09 - 12/31/14
- **Project Dates:** 01/01/09 - 12/31/13
- **Direct F & A:** $201,276
- **Total:** $253,607

---

## Pathology and Laboratory Medicine

### Baker, Tiffany

**Principal Investigator**

**Heat Shock Protein-Induced Protection against Cisplatin-Induced Hair Cell Death**

- **NIH/NIDCD**
- **Budget Dates:** 09/28/11 - 09/27/12
- **Direct F & A:** $35,099
- **Total:** $35,099

**5F30DC010522-03 (11120322)**

- **Project Dates:** 09/28/09 - 09/27/15
- **Direct F & A:** $0
- **Total:** $35,099

### Brown, Erika

**Co-Investigator**

**MUSC/Baylor Breast Cancer Research Initiative for Developing Growth and Education (BRIDGE) Program**

- **PI:** Carola Neumann
- **Dept.:** Cell and Molecular Pharmacology
- **Sponsor:** DOD
- **Award:** W81XWH-11-2-0229 (10052076-1)
- **Total:** $360,688

### Ethier, Stephen

**Principal Investigator**

**Breast Cancer Oncogenes on the 8p11 Amplicon**

- **NIH/NCI**
- **Budget Dates:** 06/01/12 - 05/31/15
- **Direct F & A:** $111,146
- **Total:** $163,461

**5R01CA100724-10 (12121656)**

- **Project Dates:** 06/01/03 - 05/31/15
- **Direct F & A:** $52,315
- **Total:** $134,661

**Amphiregulin Signaling in Human Breast Cancer**

- **NIH/NCI**
- **Budget Dates:** 01/21/12 - 04/30/12
- **Direct F & A:** $92,501
- **Total:** $136,438

**7R01CA130933-04 (12060803)**

- **Project Dates:** 07/01/09 - 04/30/14
- **Direct F & A:** $43,937
- **Total:** $136,438

**Amphiregulin Signaling in Human Breast Cancer**

- **NIH/NCI**
- **Budget Dates:** 05/01/12 - 04/30/13
- **Direct F & A:** $203,097
- **Total:** $298,375

**5R01CA130933-05 (12091306)**

- **Project Dates:** 07/01/09 - 04/30/14
- **Direct F & A:** $95,278
- **Total:** $298,375

**Breast Cancer Oncogenes on the 8p11 Amplicon**

- **NIH/NCI**
- **Budget Dates:** 06/01/12 - 05/31/13
- **Direct F & A:** $262,620
- **Total:** $348,476

**5R01CA100724-10 (12121656)**

- **Project Dates:** 06/01/03 - 05/31/15
- **Direct F & A:** $85,856
- **Total:** $348,476
Ethier, Stephen

Co-PI/Project Director
Tobacco Related Cancer Research: Ethier Recruitment Package
PI: Andrew Kraft
Dept: Medicine
Sponsor: State of SC
Total: $593,612
Award: (12040516-2)

Co-Investigator
MUSC CCSG: Program Leaders Project 1
PI: Andrew Kraft
Dept: Medicine
Sponsor: NIH/NCI
Total: $32,244
Award: 5P30CA138313-04 (12070914-4)

Findlay, Victoria

Co-PI/Project Director
MUSC/Baylor Breast Cancer Research Initiative for Developing Growth and Education (BRIDGE) Program
PI: Carola Neumann
Dept: Cell and Molecular Pharmacology
Sponsor: DOD
Total: $360,688
Award: W81XWH-11-2-0229 (10052076-1)

Co-Investigator
Hematopoietic Stem Cell-Derived Carcinoma Associated Fibroblasts in Tumor
PI: Amanda LaRue
Dept: Pathology and Laboratory Medicine
Sponsor: NIH/NCI
Total: $261,450
Award: 5R01CA149772-02 (12060774-1)

Lang, Hainan

Principal Investigator
Rescuing a Congenital Form of Progressive Hearing Loss in Mice Using Viral Gene Transfer of MicroRNA
Purdue University
Budget Dates: 06/01/12 - 05/31/13
Project Dates: 06/01/12 - 05/31/14
Direct F & A Total
4301-49426/12120772 (12070878) 50,000 0 50,000

Co-PI/Project Director
Experimental and Clinical Studies of Presbyacusis (Project 3)
PI: Judy Dubno
Dept: Otolaryngology
Sponsor: NIH/NIDCD
Total: $388,103
Award: 5P50DC000422-24 (11110049-4)

Co-Investigator
Inner Ear Ion Transport Mechanisms
PI: Bradley Schulte
Dept: Pathology and Laboratory Medicine
Sponsor: NIH/NIDCD
Total: $293,454
Award: 5R01DC000713-20 (11120256-1)

LaRue, Amanda

Principal Investigator
Hematopoietic Stem Cell-Derived Carcinoma Associated Fibroblasts in Tumor
NIH/NCI
Budget Dates: 02/01/12 - 01/31/13
Project Dates: 02/01/11 - 01/31/16
Direct F & A Total
5R01CA149772-02 (12060774) 207,500 53,950 261,450

Co-PI/Project Director
MUSC CCSG: Flow Cytometry and Cell Sorting
PI: Andrew Kraft
Dept: Medicine
Sponsor: NIH/NCI
Total: $69,524
Award: 5P30CA138313-04 (12070914-11)

Co-Investigator
Experimental and Clinical Studies of Presbyacusis (Project 3)
PI: Judy Dubno
Dept: Otolaryngology
Sponsor: NIH/NIDCD
Total: $388,103
Award: 5P50DC000422-24 (11110049-4)

Targeting the ROS-p38 MAPK Pathway as a Novel Strategy for Stem Cell Expansion
PI: Yong Wang
Dept: Pathology and Laboratory Medicine
Sponsor: NIH/NHLBI
Total: $165,007
Award: 5R21HL106451-02 (12040500-1)

Targeting the ROS-p38 MAPK Pathway as a Novel Strategy for Stem Cell Expansion
PI: Yong Wang
Dept: Pathology and Laboratory Medicine
Sponsor: NIH/NHLBI
Total: $18,334
Award: 5R21HL106451-02 (12040500-2)

Lazarchick, John

Principal Investigator
STA - Liatest D-Di-Exclusion of Venous Thromboembolism (VTE) (DIET)
Diagnostica Stago, Inc.
Budget Dates: 08/01/11 - 10/31/12
Project Dates: 08/01/11 - 10/31/13
Direct F & A Total
DIET - N11061406 (12010125) 141,350 34,588 175,938

Safety and Efficacy of NNC 0155-0000-0004 in Prevention and Treatment of Bleeds in Pediatric Previously Untreated Patients with Haemophilia A
Novo Nordisk Pharmaceuticals
Budget Dates: 12/16/11 - 06/30/15
Project Dates: 12/16/11 - 06/30/15
Direct F & A Total
NN7008-3809 (PUP) (12060745) 64,682 15,171 79,853
Lazarchick, John

**Principal Investigator**

**Safety and Efficacy Including Pharmacokinetics of NNC 0129-0000-1003 When Administered for Treatment and Prophylaxis of Bleeding in Patients with Haemophilia A**

Novo Nordisk Pharmaceuticals

Budget Dates: 06/14/12 - 09/30/13

Direct F & A Total

49,990 11,748 61,738

**Co-Investigator**

Characterization of Certain Peripheral Blood Cell Abnormalities Potentially Aiding the Diagnosis of Mast Cell Activation Syndrome

Pl: Lawrence Afrin

Dept: Medicine

Sponsor: The Mastocytosis Society

Total: $52,516

Award: (12020225-1)

**Safety and Efficacy Including Pharmacokinetics of NNC 0129-0000-1003 When Administered for Treatment and Prophylaxis of Bleeding in Patients with Haemophilia A**

Novo Nordisk Pharmaceuticals

Budget Dates: 06/14/12 - 09/30/13

Direct F & A Total

49,990 11,748 61,738

**Mehrotra, Meenal**

**Principal Investigator**

**Hematopoietic Stem Cell Transplantation in Osteogenesis Imperfecta**

NIH/NIAMS

Budget Dates: 04/01/12 - 03/31/13

Direct F & A Total

63,914 5,113 69,027

**Moussa, Omar**

**Principal Investigator**

**The Role of Thromboxane A2 (TP) Receptor Beta in Bladder Cancer**

NIH/NCI

Budget Dates: 04/01/12 - 03/31/13

Direct F & A Total

201,275 95,606 296,881

**Puligilla, C.**

**Principal Investigator**

**Role of Sox2 in Specification of Prosensory and Hair Cell Fate in Mouse Cochlea**

NIH/NIHCD

Budget Dates: 12/01/11 - 11/30/12

Direct F & A Total

168,814 80,186 249,000

**Schulte, Bradley**

**Principal Investigator**

**Inner Ear Ion Transport Mechanisms**

NIH/NIHCD

Budget Dates: 08/01/11 - 07/31/13

Direct F & A Total

200,996 92,458 293,454

**Co-Investigator**

Experimental and Clinical Studies of Presbyacusis (Project 3)

Pl: Judy Dubno

Dept: Otolaryngology

Sponsor: NIH/NIHCD

Total: $388,103

Award: 5P50DC000422-24 (11110049-4)

**Mentor**

Heat Shock Protein-Induced Protection against Cisplatin-Induced Hair Cell Death

Pl: Tiffany Baker

Dept: Pathology and Laboratory Medicine

Sponsor: NIH/NIHCD

Total: $35,099

Award: 5F30DC010522-03 (11120322-1)

**Self, Sally**

**Co-Investigator**

Characterization of Certain Peripheral Blood Cell Abnormalities Potentially Aiding the Diagnosis of Mast Cell Activation Syndrome

Pl: Lawrence Afrin

Dept: Medicine

Sponsor: The Mastocytosis Society

Total: $52,516

Award: (12020225-1)

**Sha, Suhua**

**Principal Investigator**

**Protection from Aminoglycoside Ototoxicity**

Univ. of Michigan

Budget Dates: 07/01/11 - 06/30/12

Direct F & A Total

44,900 21,327 66,227

**Molecular Mechanisms in Noise-Induced Hearing Loss**

NIH/NIHCD

Budget Dates: 04/01/12 - 03/31/13

Direct F & A Total

242,025 113,806 355,831

**Singh, Avtar**

**Principal Investigator**

**Development of S-Nitrosothiol-Based Therapy for Alzheimer's Disease**

VAMC

Budget Dates: 04/01/12 - 03/31/13

Direct F & A Total

150,000 0 150,000
Singh, Avtar  
**Principal Investigator**  
*Mechanisms of Krabbe Disease Pathobiology and Therapy*  
NIH/NINDS  
5R01NS064195-02 (12081084)  
Project Dates: 04/01/11 - 03/31/16  
218,750 103,905 322,656  
**NIH/NINDS**  
Budget Dates: 04/01/12 - 03/31/13  
Direct F & A  
Principal Investigator  
**NITROSYLATION MECHANISMS FOR PROTECTION AGAINST NEUROVASCULAR INFLAMMATORY INJURY**  
NIH/NINDS  
5R01NS072511-02 (12101385)  
Project Dates: 05/01/11 - 04/30/16  
218,750 103,906 322,656  
**NIH/NINDS**  
Budget Dates: 05/01/12 - 04/30/13  
Direct F & A  
Principal Investigator  
Smith, Michael  
**Co-Investigator**  
*The Role of Thromboxane A2 (TP) Receptor Beta in Bladder Cancer*  
PI: Omar Moussa  
Sponsor: NIH/NCI  
Total: $ 296,881  
Dept: Pathology and Laboratory Medicine  
Award: 5R01CA127905-04 (12070968-1)  
Spyropoulos, Demetri  
**Principal Investigator**  
*Mammary Gland Laterality in Normal and Neoplastic Development*  
Univ. of South Carolina  
11-1950/R21HD068993-02 (12101404)  
Project Dates: 04/01/11 - 03/31/16  
113,977 53,126 167,103  
**NIH/NCI**  
Budget Dates: 04/01/12 - 03/31/13  
Direct F & A  
Project Dates: 04/01/11 - 03/31/13  
Direct F & A  
Total  
Spyropoulos, Demetri  
**Principal Investigator**  
*Developmental Transcription Factors in Prostate Cancer*  
Emory Univ.  
S387510/R01CA106826 (12111552)  
Project Dates: 05/01/11 - 04/30/16  
10,848 5,152 16,000  
**NIH/NCI**  
Budget Dates: 03/01/12 - 02/28/13  
Direct F & A  
Project Dates: 03/01/09 - 02/28/14  
Direct F & A  
Total  
Steed, Lisa  
**Principal Investigator**  
*GOM-11-MXGBS2/Repeat Inter-Laboratory Comparison Study for the BD MAX(TM) GBS Assay Migration to the BD MAX(TM) 6-Channel Platform*  
Becton Dickinson  
GOM-11-MXGBS2 (12050684)  
Project Dates: 03/01/11 - 02/28/13  
6,975 1,744 8,719  
**Becton Dickinson**  
Budget Dates: 11/30/11 - 04/30/12  
Direct F & A  
Project Dates: 11/30/11 - 04/30/12  
Direct F & A  
Total  
Steed, Lisa  
**Co-Investigator**  
*Prospective Study into the Performance of the KeyPath*  
Colorado Prevention Center  
MP-2012A (12111558)  
Project Dates: 05/01/11 - 02/28/14  
30,031 6,883 36,914  
**Global Life Technologies**  
Budget Dates: 05/11/12 - 12/31/12  
Direct F & A  
Project Dates: 05/11/12 - 12/31/12  
Direct F & A  
Total  
Turner, David  
**Co-Investigator**  
*SC Cancer Disparities Research Center (2 of 2)*  
PI: Marvella Ford  
Sponsor: NIH/NCI  
Total: $ 188,782  
Dept: Medicine  
Award: 1P20CA157071-01A1 (11041385-1)  
**NIH/NCI**  
Budget Dates: 12/01/11 - 11/30/12  
Direct F & A  
Project Dates: 12/15/10 - 11/30/12  
Direct F & A  
Total  
Wang, Yong  
**Principal Investigator**  
*Targeting the ROS-p38 MAPK Pathway as a Novel Strategy for Stem Cell Expansion*  
NIH/NHLBI  
5R21HL106451-02 (12040500)  
Project Dates: 12/15/10 - 11/30/12  
124,299 59,042 183,341  
**NIH/NHLBI**  
Budget Dates: 12/01/11 - 11/30/12  
Direct F & A  
Project Dates: 12/15/10 - 11/30/12  
Direct F & A  
Total  
**Co-PI/Project Director**  
*SC Cancer Disparities Research Center (2 of 2)*  
PI: Marvella Ford  
Sponsor: NIH/NCI  
Total: $ 188,782  
Dept: Medicine  
Award: 1P20CA157071-01A1 (11041385-1)  
**NIH/NCI**  
Budget Dates: 12/01/11 - 11/30/12  
Direct F & A  
Project Dates: 12/15/10 - 11/30/12  
Direct F & A  
Total  
**Tobacco Related Cancer Research Pilot Project: Contribution of Alternative Splicing to Lung Cancer Progression**  
PI: Andrew Kraft  
Sponsor: State of SC  
Total: $ 75,000  
Dept: Medicine  
Award: (12040516-9)  
**State of SC**  
Budget Dates: 12/01/11 - 11/30/12  
Direct F & A  
Project Dates: 12/15/10 - 11/30/12  
Direct F & A  
Total  
**MUSC CCSG: Program Leaders Project 2**  
PI: Andrew Kraft  
Sponsor: NIH/NCI  
Total: $ 33,662  
Dept: Medicine  
Award: 5P30CA138313-04 (12070914-13)
**Watson, Dennis**

**Co-Investigator**

**Targeting the CaSM Oncogene as a Novel Therapy for Pancreatic Cancer**

**PI:** David Cole  
**Sponsor:** NIH/NCI  
**Total:** $270,405

**Hematopoietic Stem Cell-Derived Carcinoma Associated Fibroblasts in Tumor**

**PI:** Amanda LaRue  
**Sponsor:** NIH/NCI  
**Total:** $261,450

**MUSC CCSG: Program Leaders Project 1**

**PI:** Andrew Kraft  
**Sponsor:** NIH/NCI  
**Total:** $32,244

**The Role of Thromboxane A2 (TP) Receptor Beta in Bladder Cancer**

**PI:** Omar Moussa  
**Sponsor:** NIH/NCI  
**Total:** $296,881

**Molecular Mechanisms of the Impact of Fli-1 on Lupus**

**PI:** Xian Zhang  
**Sponsor:** NIH/NIAMS  
**Total:** $272,160

**Wolff, Daynna**

**Principal Investigator**

**Method Comparison and Clinical Specificity Study: Evaluation of the Infinium HD Cytogenetic Abnormality Test**

**Illumina, Inc**  
**Budget Dates:** 08/30/11 - 08/29/13  
**Direct F & A**  
**Total**

CYTO-001 (12020223)  
**Project Dates:** 08/30/11 - 08/29/13  
128,096  
31,399  
159,495

**Evaluation of the Infinium HD Cytogenetic Abnormality Test Reproducibility Study (CYTO-002)**

**Illumina, Inc**  
**Budget Dates:** 10/30/11 - 10/29/13  
**Direct F & A**  
**Total**

CYTO-002 (12020268)  
**Project Dates:** 10/30/11 - 10/29/13  
16,920  
4,230  
21,150

**Evaluation of the Illumina MiSeqDx Cystic Fibrosis System**

**Illumina, Inc**  
**Budget Dates:** 06/20/12 - 06/19/13  
**Direct F & A**  
**Total**

CF-001 (12121734)  
**Project Dates:** 06/20/12 - 06/19/13  
24,201  
5,425  
29,626

**Won, Je-Seong**

**Co-Investigator**

**Mechanisms of Krabbe Disease Pathobiology and Therapy**

**PI:** Avtar Singh  
**Sponsor:** NIH/NINDS  
**Total:** $322,656

**Znoyko, Iya**

**Co-Investigator**

**Evaluation of the Infinium HD Cytogenetic Abnormality Test Reproducibility Study (CYTO-002)**

**PI:** Daynna Wolff  
**Sponsor:** Illumina, Inc  
**Total:** $21,150

**Evaluation of the Illumina MiSeqDx Cystic Fibrosis System**

**PI:** Daynna Wolff  
**Sponsor:** Illumina, Inc  
**Total:** $29,626

**Woolworth, Julie**

**Co-Investigator**

**Method Comparison and Clinical Specificity Study: Evaluation of the Infinium HD Cytogenetic Abnormality Test**

**PI:** Daynna Wolff  
**Sponsor:** Illumina, Inc  
**Total:** $159,495

**Evaluation of the Infinium HD Cytogenetic Abnormality Test Reproducibility Study (CYTO-002)**

**PI:** Daynna Wolff  
**Sponsor:** Illumina, Inc  
**Total:** $21,150

**Evaluation of the Illumina MiSeqDx Cystic Fibrosis System**

**PI:** Daynna Wolff  
**Sponsor:** Illumina, Inc  
**Total:** $29,626

**Znoryko, Iya**

**Co-Investigator**

**Evaluation of the Infinium HD Cytogenetic Abnormality Test Reproducibility Study (CYTO-002)**

**PI:** Daynna Wolff  
**Sponsor:** Illumina, Inc  
**Total:** $21,150

**Evaluation of the Illumina MiSeqDx Cystic Fibrosis System**

**PI:** Daynna Wolff  
**Sponsor:** Illumina, Inc  
**Total:** $29,626
### Pediatrics

#### Andrews, Anne

**Co-Investigator**  
A Multi-Center, Randomized, Observer-Blinded, Active-Controlled Study to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetics of Ceftaroline Versus Comparator in Pediatric Subjects with Ac PI: Sandra Fowler  
Sponsor: Quintiles Pacific, Inc.  
**Total:** $97,950  
Dept: Pediatrics  
Award: P903-23 (12121730-1)

#### Annibale, David

**Principal Investigator**  
**Perinatal Regional Systems Development**  
Dept: Pediatrics  
Award: P903-23 (12121730-1)

#### Atz, Andrew

**Principal Investigator**  
**Circulating TGF-B Levels in Marfan Syndrome**  
Johns Hopkins Univ.  
(11031865)

**Dr. Andrew Atz Study Chair: Fontan 2 and Fontan 3 Studies**  
New England Research Institutes  
U10 HL68270 (12030392)

**Multi-Center, Double-Blind, Placebo-Controlled, Randomized, Prospective Study of Bosentan as Adjunctive Therapy to Inhaled Nitric Oxide in Management of Persistent Pulmonary Hypertension of the Newborn (PPHN)**  
Actelion Pharmaceuticals  
AC-052-391 (12040508)

**A Phase III, Double-Blind, Placebo-Controlled, Randomized, Multi-Center, Dose Titration Study to Assess the Efficacy, Safety and Pharmacokinetics of Intravenous Conivaptan (Vaprisol) in Pediatric ...**  
Astellas Pharma US, Inc.  
087-CL-096 (12070867)

**Longitudinal Fontan Study (Fontan 3)**  
New England Research Institutes  
U01HL68270 (12121650)

**Co-Pi/Project Director**  
**Pediatric Heart Network Medical University of South Carolina**  
Dept: Pediatrics  
Award: 1U10HL109778-01 (10102672-1)

**Pharmacokinetics and Safety of Valganiclovir in Pediatric Heart Transplant Recipients < 4 Months of Age**  
Dept: Pediatrics  
Award: NP22523 (12040526-1)

**Co-Investigator**  
A Multi-Center, Randomized, Double-Blind, 8 Week Study to Evaluate the Dose Response, Efficacy and Safety of Aliskiren in Pediatric Hypertensive Patients 6-17 Years of Age  
Dept: Pediatrics  
Award: CSPP100A2365 (12080977-1)

**A Multi-Center, Double-Blind, Randomized, 52 Week, Extension Study to Evaluate the Long-Term, Safety, Tolerability and Efficacy of Aliskiren Compared to Enalapril in Pediatric Hypertensive Patients**  
Dept: Pediatrics  
Award: CSPP100A2365E1 (12081042-1)

#### Baatz, John

**Principal Investigator**  
**NASA EPSCoR RID Augmentation Travel Award Program - 2012**  
Coll. of Charleston  
NNX07AL01A (12121632)

**Co-Pi/Project Director**  
**Tobacco Related Cancer Research Pilot Project: Viable Tissue Biorepository from Lung Lobectomy**  
Dept: Medicine  
Award: (12040516-13)
### Bandisode, Varsha
**Co-Investigator**  
Pediatric Heart Network Medical University of South Carolina  
PI: J. Saul  
Sponsor: NIH/NHLBI  
Dept: Pediatrics  
T&G: $430,753  
Award: 1U10HL109778-01 (10102672-1)

### Basco, William
**Principal Investigator**  
**Affordable Care Act: Primary Care Residency Expansion**  
HRSA  
Budget Dates: 09/30/11 - 09/29/12  
Direct F & A: $296,296  
Total: $320,000  
Dept: Pediatrics  
Award: 1T89HP20830-01-00 (10071662)

**Academic Administrative Units in Primary Care**  
HRSA  
Budget Dates: 09/30/11 - 09/29/12  
Direct F & A: $148,148  
Total: $160,000  
Dept: Pediatrics  
Award: 2 D54HP05448-06 (12010030)

**Co-Investigator**  
**Faculty Development in Primary Care**  
PI: William Hueston  
Sponsor: HRSA  
Dept: Family Medicine  
T&G: $68,158  
Award: 1 D55HP23198-01-00 (12010019-1)

### Bowly, Deborah
**Principal Investigator**  
**SEARCH for Diabetes in Youth, Phase 3: MUSC**  
Univ. of North Carolina  
Budget Dates: 09/30/11 - 09/29/12  
Direct F & A: $46,107  
Total: $56,759  
Dept: Pediatrics  
Award: EN3326-402 (12030338)

**A Multi-Center, Observational Study of Pediatric Female Patients with Central Precocious Puberty Receiving Supprelin LA (Histrelin Acetate), a Hydrogel Subcutaneous Implant**  
Clinical Financial Services, LLC  
Budget Dates: 08/26/11 - 10/31/14  
Direct F & A: $16,150  
Total: $19,188  
Dept: Pediatrics  
Award: EN3326-401 (12060740)

**A Postmarketing, Multi-Center, Two-Arm Registry of the Implantation and Explanation of SUPPRELINA LA (histrelin acetate) Subcutaneous Implant and VANTAS (histrelin implant) Subcutaneous Implant**  
Clinical Financial Services, LLC  
Budget Dates: 11/21/11 - 01/31/15  
Direct F & A: $46,107  
Total: $56,759  
Dept: Pediatrics  
Award: EN3326-401 (12060740)

### Cahill, John
**Co-Investigator**  
**Perinatal Regional Systems Development**  
PI: David Annibale  
Sponsor: SC DHEC  
Dept: Pediatrics  
T&G: $175,168  
Award: MC-2-072 (11120252-1)

**Multi-Center, Double-Blind, Placebo-Controlled, Randomized, Prospective Study of Bosentan as Adjunctive Therapy to Inhaled Nitric Oxide in Management of Persistent Pulmonary Hypertension of the Newborn (PPHN)**  
PI: Andrew Atz  
Sponsor: Actelion Pharmaceuticals  
Dept: Pediatrics  
T&G: $154,140  
Award: AC-052-391 (12040508-1)

### Carpenter, Laura
**Co-Investigator**  
**Biomarkers in Autism of Aripiprazole and Risperidone Treatment (BAART)**  
PI: C. Devane  
Sponsor: NIH/NICHD  
Dept: Psychiatry and Behavioral Sciences  
T&G: $651,465  
Award: 5R01HD062550-02 (12010064-1)

**Autism and Developmental Disabilities Monitoring Network Augmentation with Screening and Assessment**  
PI: Lydia King  
Sponsor: Autism Speaks  
Dept: Pediatrics  
T&G: $275,000  
Award: 7793 (12040544-1)

### Charles, Jane
**Principal Investigator**  
**Autism Spectrum Disorders Researchers Guest Speaker**  
SC Developmental Disabilities Council  
Budget Dates: 09/01/11 - 11/30/11  
Direct F & A: $1,500  
Total: $1,500  
Dept: Pediatrics  
Award: 001-21-0068 (12020192)

**SC Autism and Developmental Disabilities Monitoring Project**  
CDC  
Budget Dates: 06/01/12 - 05/31/13  
Direct F & A: $437,262  
Total: $574,999  
Dept: Psychiatry and Behavioral Sciences  
Award: 5R01HD062550-02 (12010064-1)
Charles, Jane  Co-Investigator
Autism and Developmental Disabilities Monitoring Network Augmentation with Screening and Assessment
PI: Lydia King  Sponsor: Autism Speaks  Total: $ 275,000
Dept: Pediatrics  Award: 7793 (12040544-1)

Ellenberger, Shayla  Co-PI/Project Director
Safety and Efficacy Including Pharmacokinetics of NNC 0129-0000-1003 When Administered for Treatment and Prophylaxis of Bleeding in Patients with Haemophilia A
PI: John Lazarchick  Sponsor: Novo Nordisk Pharmaceutical  Total: $ 61,738
Dept: Pathology and Laboratory Medicine  Award: NN7008-3809 (12060745-1)

Safety and Efficacy of NNC 0155-0000-0004 in Prevention and Treatment of Bleeds in Pediatric Previously Untreated Patients with Haemophilia A
PI: John Lazarchick  Sponsor: Novo Nordisk Pharmaceutical  Total: $ 75,900
Dept: Pathology and Laboratory Medicine  Award: NN7008-3809 (PUP) (12060745-2)

Fowler, Sandra  Principal Investigator
Surveillance to Determine Rotavirus Disease Burden
Cincinnati Childrens Hospital  Budget Dates: 12/15/09 - 09/30/12  Direct F & A Total
(09121479)  Project Dates: 12/15/09 - 09/30/12  75,546 18,686 94,432

SC Children’s AIDS Care System (Ryan White Title IV Program)
SC DHEC  Budget Dates: 08/01/11 - 07/31/12  Direct F & A Total
HV-2-098 (12020190)  Project Dates: 08/01/11 - 07/31/12  121,851 12,185 134,036

A Multi-Center, Randomized, Observer-Blinded, Active-Controlled Study to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetics of Ceftaroline Versus Comparator in Pediatric Subjects with Ac
Quintiles Pacific, Inc.  Budget Dates: 06/26/12 - 06/30/13  Direct F & A Total
P903-23 (12121730)  Project Dates: 06/26/12 - 06/30/13  78,560 19,390 97,950

Graham, Eric  Co-Investigator
Pediatric Heart Network Medical University of South Carolina
PI: J. Saul  Sponsor: NIH/NHLBI  Total: $ 430,753
Dept: Pediatrics  Award: 1U10HL109778-01 (10102672-1)

Longitudinal Fontan Study (Fontan 3)
SC DHIS  Budget Dates: 10/01/10 - 09/30/11  Direct F & A Total
(12030282)  Project Dates: 10/01/10 - 02/21/15  32,728 3,272 36,000

Gustafson, Kristina  Principal Investigator
CHIPRA: Quality Demonstration Grant Participation (Qtip)
SC DHIS  Budget Dates: 10/01/10 - 09/30/11  Direct F & A Total
(12030282)  Project Dates: 10/01/10 - 02/21/15  32,728 3,272 36,000

Henshaw, Melissa  Co-PI/Project Director
Southeastern Virtual Institute for Health Equity and Wellness (SE VIEW)- Project 5
PI: Sabra Slaughter  Sponsor: US Army/USAMRAA  Total: $ 248,692
Dept: Presidents Office  Award: W81XWH-10-2-0057 (10071968-18)

Hlavacek, Anthony  Principal Investigator
Transatlantic Networks of Excellence Program: Multi-Scale Modeling of Single Ventricle Hearts for Clinical Decision Support
Leduq Foundation  Budget Dates: 01/01/12 - 12/31/12  Direct F & A Total
09CV04 (09020221)  Project Dates: 07/01/09 - 12/31/14  136,422 13,642 150,064

Hletko, Paul  Principal Investigator
CATCH Us: Sickle Kids Moving On
Amer. Acad. of Pediatrics  Budget Dates: 03/26/12 - 09/30/12  Direct F & A Total
(12081094)  Project Dates: 03/26/12 - 09/30/12  10,460 0 10,460
Hollis, Bruce

**Principal Investigator**

**Randomized Trial of Maternal Vitamin D Supplementation to Prevent Childhood Asthma**

Brigham and Womens Hospital  
104228/U01HL091528 (12060724)  
Budget Dates: 03/01/12 - 02/28/13  
Direct F & A Total  
88,356 40,644 129,000

**Co-PI/Project Director**

Three-Year, Follow-Up Study of a Vitamin D Supplementation Pregnancy Cohort in South Carolina  
Pl: Carol Wagner  
Dept: Pediatrics  
Sponsor: Thrasher Research Fund  
Award: $146,099

**Co-Investigator**

Impact of Vitamin D on Diabetic Kidney Disease in African Americans  
Pl: Vanessa Diaz  
Dept: Family Medicine  
Sponsor: NIH/NIDDK  
Award: 5R03DK089120-02 (11120288-1)

Hudspeth, Michelle

**Principal Investigator**

**BMT Clinical Research Network Data Coordinating Center (Agreement 69254-1040 Protocol Rider #0802)**

National Childhood Cancer Fdn.  
69254-1040/U01 HL69254 (11120344)  
Budget Dates: 07/01/10 - 09/30/12  
Direct F & A Total  
45,583 9,117 54,700

**BMT Clinical Research Network Data Coordinating Center (Agreement 69254-1040 Protocol Rider #0601)**

National Childhood Cancer Fdn.  
69254-1040/U01HL69254 (12091330)  
Budget Dates: 02/01/12 - 01/31/14  
Direct F & A Total  
54,361 8,323 62,684

Hulsey, Thomas

**Co-Investigator**

Three-Year, Follow-Up Study of a Vitamin D Supplementation Pregnancy Cohort in South Carolina  
Pl: Carol Wagner  
Dept: Pediatrics  
Sponsor: Thrasher Research Fund  
Award: $146,099

South Carolina Clinical and Translational Research Institute (UL1)  
Pl: Kathleen Brady  
Dept: Psychiatry and Behavioral Sciences  
Sponsor: NIH/NCRR  
Award: 5UL1RR029882-03 (11012750-2)

Environmental Determinants of Autoimmunity among African Americans in Coastal SC  
Pl: Diane Kamen  
Dept: Medicine  
Sponsor: NIH/NIEHS  
Award: 5R21ES017934-03 (11051104-1)

Environmental Determinants of Autoimmunity among African Americans in Coastal SC (Diversity Supplement for Hazel Breland)  
Pl: Diane Kamen  
Dept: Medicine  
Sponsor: NIH/NIEHS  
Award: 5R21ES017934-03 (11051104-2)

South Carolina Clinical and Translational Research Institute (SCTR): UL1  
Pl: Kathleen Brady  
Dept: Psychiatry and Behavioral Sciences  
Sponsor: NIH/NCATS  
Award: 8UL1TR000062-04 (12070938-1)

South Carolina Clinical and Translational Research Institute (SCTR): UL1  
Pl: Kathleen Brady  
Dept: Psychiatry and Behavioral Sciences  
Sponsor: NIH/NCATS  
Award: 8UL1TR000062-04 (12070938-2)

Jackson, Sherron

**Principal Investigator**

**BABY HUG Follow-up Study II: Clinical Sites**

NIH/NHLBI  
HHSN268201200014C (11020428)  
Budget Dates: 01/10/12 - 12/31/12  
Direct F & A Total  
43,514 20,670 64,184

**TWHICH: A Phase III, Randomized, Clinical Trial to Compare Standard Therapy (Erythrocyte Transfusions) to Alternative Therapy (Hydroxyurea) for the Prevention of Primary Stroke in Pediatric Subjects with Sickle Cell Anemia and Abnormal TCD Velocities**

Baylor Univ.  
101539518/R01 HL095647-03 (12050594)  
Budget Dates: 03/28/11 - 07/31/14  
Direct F & A Total  
85,152 24,862 110,014

Jaroscak, Jennifer

**Co-Investigator**

BMT Clinical Research Network Data Coordinating Center (Agreement 69254-1040 Protocol Rider #0601)  
Pl: Michelle Hudspeth  
Dept: Pediatrics  
Sponsor: National Childhood Cancer Fd  
Award: $62,684

110 Medical University of South Carolina
Key, Janice

**Principal Investigator**

*Sea Island Teen Opportunity for Prevention Programs (STOPP)*

New Morning Fdn.  
(11110054)  
Budget Dates: 07/01/11 - 09/30/12  
Project Dates: 07/01/11 - 09/30/12  
Direct F & A: 181,818  
Total: 18,182  
Total: 200,000

**Co-PI/Project Director**

*Southeastern Virtual Institute for Health Equity and Wellness (SE VIEW)- Project 3*

PI: Sabra Slaughter  
Sponsor: US Army/USAMRAA  
Total: $267,745

Khan, Mush

**Co-Investigator**

*Fatty Acid Oxidation in X-Linked Adrenoleukodystrophy*

PI: Inderjit Singh  
Sponsor: NIH/NINDS  
Total: $316,203

Koch, Frances

**Principal Investigator**

*Trial of Late Surfactant (TOLSURF) to Prevent BPD*

Univ. of California, San Francisco  
6172sc/U01 HL094338-01 (10052077)  
Budget Dates: 09/15/09 - 07/31/12  
Project Dates: 09/15/09 - 07/31/14  
Direct F & A: 6,508  
Total: 3,092  
Total: 9,600

**Principal Investigator**

*Trial of Late Surfactant (TOLSURF) to Prevent BPD*

Univ. of California, San Francisco  
6172sc/U01 HL094338 (11050578)  
Budget Dates: 08/01/11 - 07/31/12  
Project Dates: 09/15/09 - 07/31/14  
Direct F & A: 11,000  
Total: 5,225  
Total: 16,225

King, Lydia

**Principal Investigator**

*Autism and Developmental Disabilities Monitoring Network Augmentation with Screening and Assessment*

Autism Speaks  
7793 (12040544)  
Budget Dates: 02/01/12 - 01/31/13  
Project Dates: 02/01/12 - 01/31/15  
Direct F & A: 250,000  
Total: 25,000  
Total: 275,000

Kolb, Robert

**Principal Investigator**

*The Role of the Primary Cilium in Glomerular Podocyte Cells*

NIH/NIDDK  
5K01DK075652-05 (12101405)  
Budget Dates: 06/01/12 - 05/31/13  
Project Dates: 06/05/08 - 05/31/13  
Direct F & A: 120,625  
Total: 9,650  
Total: 130,275

Kraveka, Jacqueline

**Principal Investigator**

*Childrens Oncology Group Master*

National Childhood Cancer Fdn.  
020869/U10 CA98543-09 (11120115)  
Budget Dates: 03/01/11 - 02/29/12  
Project Dates: 03/01/08 - 02/28/14  
Direct F & A: 4,500  
Total: 900  
Total: 5,400

**Principal Investigator**

*Inhibition of Dihydroceramide Desaturase as a Novel Target for Neuroblastoma Therapy*

Hyundai Hope on Wheels  
(12020157)  
Budget Dates: 12/01/11 - 11/30/12  
Project Dates: 12/01/11 - 11/30/13  
Direct F & A: 50,000  
Total: 0  
Total: 50,000

**Principal Investigator**

*Targeting Dihydroceramide Desaturase in Neuroblastoma*

Rally Fdn.  
(12070852)  
Budget Dates: 04/01/12 - 03/31/13  
Project Dates: 04/01/12 - 03/31/13  
Direct F & A: 20,000  
Total: 0  
Total: 20,000

**Principal Investigator**

*Summer Fellowship - Zack Prudowsky*

St. Baldricks Fdn.  
(12101435)  
Budget Dates: 05/21/12 - 07/27/12  
Project Dates: 05/21/12 - 07/27/12  
Direct F & A: 5,000  
Total: 0  
Total: 5,000

**Principal Investigator**

*Dell Pediatrics Cancer Program*

Van Andel Institute  
MUSC-Dell-GS-40-40214-1 (13020130)  
Budget Dates: 11/01/11 - 10/31/12  
Project Dates: 11/01/11 - 10/31/12  
Direct F & A: 20,000  
Total: 5,000  
Total: 25,000

**Co-PI/Project Director**

*A Randomized, Phase 3, Multi-Center, Open-Label Study Comparing TH-302 in Combination with Doxorubicin vs. Doxorubicin Alone in Subjects with Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma*

PI: Neeta Somaiah  
Sponsor: Parexel Intl. Corp.  
Total: $319,414  
Award: 101646 - TH-CR-406 (12040519-1)
<table>
<thead>
<tr>
<th>Name</th>
<th>Role</th>
<th>Project Description</th>
<th>Sponsor</th>
<th>Total Budget</th>
<th>Dept</th>
<th>Award Number</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lemon, Henry</td>
<td>Principal Investigator</td>
<td>Family Literacy Project 2011-2012</td>
<td>Trident United Way</td>
<td>$55,680</td>
<td>Pediatrics</td>
<td>(10021183)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Visitation Program: MUSC Children’s Care Network and DHEC Healthy Steps Implementation</td>
<td>Childrens Trust of South Carolina</td>
<td>$207,316</td>
<td>Pediatrics</td>
<td>(12091313)</td>
</tr>
<tr>
<td>Macias, Michelle</td>
<td>Principal Investigator</td>
<td>Leadership Education in Neurodevelopmental and Related Disabilities (LEND)</td>
<td>HRSA</td>
<td>$486,440</td>
<td>Presidents Office</td>
<td>(11022852)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Act Early Ambassador to the ADDM Network- Jenner Stipend</td>
<td>Assoc. of University Centers on Disabilities</td>
<td>$4,000</td>
<td>Pediatrics</td>
<td>(12080985)</td>
</tr>
<tr>
<td>Marsh, Linda</td>
<td>Co-Investigator</td>
<td>Sea Island Teen Opportunity for Prevention Programs (STOPP)</td>
<td>Janice Key</td>
<td>$200,000</td>
<td>Pediatrics</td>
<td>(11110054-1)</td>
</tr>
<tr>
<td>McBurney, Patricia</td>
<td>Principal Investigator</td>
<td>Integrating Technologies on a Pediatric Clerkship</td>
<td>InTIME</td>
<td>$13,100</td>
<td>Pediatrics</td>
<td>(12101112)</td>
</tr>
<tr>
<td>McElligott, James</td>
<td>Principal Investigator</td>
<td>Teaching Vaccine Safety Through the TIDE Curriculum</td>
<td>Academic Pediatric Assoc.</td>
<td>$4,400</td>
<td>Pediatrics</td>
<td>(12030345-6)</td>
</tr>
<tr>
<td>McSwain, S. David</td>
<td>Co-Investigator</td>
<td>A Phase III, Double-Blind, Placebo-Controlled, Randomized, Multi-Center, Dose Titration Study to Assess the Efficacy, Safety and Pharmacokinetics of Intravenous Conivaptan (Vaprisol) in Pediatric ...</td>
<td>Andrew Atz</td>
<td>$104,785</td>
<td>Pediatrics</td>
<td>(12070867-1)</td>
</tr>
<tr>
<td>Mennito, Sarah</td>
<td>Co-PI/Project Director</td>
<td>CATCH Us: Sickle Kids Moving On</td>
<td>Paul Hletko</td>
<td>$10,460</td>
<td>Pediatrics</td>
<td>(12061094-1)</td>
</tr>
<tr>
<td>Mills, David</td>
<td>Co-Investigator</td>
<td>A Multi-Center, Randomized, Observer-Blinded, Active-Controlled Study to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetics of Ceftriaxone Versus Comparator in Pediatric Subjects with Ac ...</td>
<td>Sandra Fowler</td>
<td>$97,950</td>
<td>Pediatrics</td>
<td>(12121730-1)</td>
</tr>
<tr>
<td>Pai, G.</td>
<td>Co-Investigator</td>
<td>Biomarkers in Autism of Aripiprazole and Risperidone Treatment (BAART)</td>
<td>C. Devane</td>
<td>$651,465</td>
<td>Psychiatry and Behavioral Sciences</td>
<td>(5R01HD062550-02 (12010064-1)</td>
</tr>
<tr>
<td>Paintlia, Ajaib</td>
<td>Co-Investigator</td>
<td>Cytokines in Glial Cells and EAE Brain</td>
<td>Inderjit Singh</td>
<td>$284,584</td>
<td>Pediatrics</td>
<td>(12040503-1)</td>
</tr>
</tbody>
</table>
Paintlia, Ajaib  
Co-Investigator  
Cytokines in Glial Cells and EAE Brain  
Pl: Inderjit Singh  
Dept: Pediatrics  
Sponsor: NIH/NINDS  
Award: 5R01NS037766-13  
Total: $31,619

Passo, Murray  
Principal Investigator  
ACR REF/Abbott Medical Student Clinical Preceptorship-Elisheva Frankel  
Amer. College of Rheumatology  
Budget Dates: 08/18/11 - 07/17/12  
Project Dates: 08/18/11 - 07/17/12  
F & A: 500  
Total: 500

Paulo, Remberto  
Principal Investigator  
Norditropin National Registry Agreement  
Novo Nordisk Pharmaceuticals  
Budget Dates: 08/09/05 - 12/31/19  
Project Dates: 08/09/05 - 12/31/19  
F & A: 14,400  
Total: 18,000

Purohit, Dilip  
Co-Investigator  
Perinatal Regional Systems Development  
Pl: David Annibale  
Dept: Pediatrics  
Sponsor: SC DHEC  
Award: MC-2-072  
Total: $175,168

Reddy, Sakamuri  
Principal Investigator  
Osteoclast Inhibitory Peptide-1 Therapy for Paget's Disease  
DOD  
W81XWH-09-1-0548  
Budget Dates: 08/01/11 - 07/31/12  
Project Dates: 08/01/09 - 07/31/12  
F & A: 265,190  
Total: 391,155

Roberts, James  
Principal Investigator  
Assessment of Growth of Infants Fed Formula with Probiotics  
MUSC OIP  
10.01.US.INF  
Budget Dates: 08/03/11 - 02/28/13  
Project Dates: 08/03/11 - 02/28/13  
F & A: 52,749  
Total: 64,419

Ruth, Natasha  
Principal Investigator  
ACR REF/Abbott Medical Student Clinical Preceptorship-Rose Tian  
Amer. College of Rheumatology  
Budget Dates: 07/01/11 - 06/30/12  
Project Dates: 07/01/11 - 06/30/12  
F & A: 1,000  
Total: 1,000

Friends of CARRA Research Gift  
Friends of CARRA  
Budget Dates: 07/01/11 - 06/30/13  
Project Dates: 07/01/11 - 06/30/13  
F & A: 2,000  
Total: 2,000
## Ryan, Rita

**Principal Investigator**

**Functional and Lymphocytic Markers of Respiratory Morbidity in Hyperoxic Preemies**

Univ. of Rochester  
PO#415602-G/U01 HL101813 (11120327)  
Project Dates: 07/01/11 - 04/30/15  
Direct F & A Total  
10,742 5,103 15,845

**Functional and Lymphocytic Markers of Respiratory Morbidity in Hyperoxic Preemies**

Univ. of Rochester  
PO#415829-G/U01HL101813 (12081092)  
Project Dates: 07/01/11 - 04/30/15  
Direct F & A Total  
11,600 5,510 17,110

## Saul, J.

**Principal Investigator**

**Pediatric Heart Network Medical University of South Carolina**

NIH/NHLBI  
1U10HL109778-01 (10102672)  
Project Dates: 07/01/11 - 06/30/12  
Direct F & A Total  
292,036 138,717 430,753

## Savage, Andrew

**Principal Investigator**

**Pharmacokinetics and Safety of Valganiclovir in Pediatric Heart Transplant Recipients < 4 Months of Age**

Hoffman-Laroche, Inc.  
NP22523 (12040526)  
Project Dates: 10/14/11 - 10/01/13  
Direct F & A Total  
20,638 4,535 25,173

## Scheurer, Mark

**Co-Investigator**

**Multi-Center, Double-Blind, Placebo-Controlled, Randomized, Prospective Study of Bosentan as Adjunctive Therapy to Inhaled Nitric Oxide in Management of Persistent Pulmonary Hypertension of the Newborn (PPHN)**

PI: Andrew Atz  
Sponsor: Actelion Pharmaceuticals  
Total: $154,140

## Shanmugarajan, S.

**Co-Investigator**

**Osteoclast Inhibitory Peptide-1 Therapy for Paget's Disease**

PI: Sakamuri Reddy  
Sponsor: DOD  
Total: $391,155

## Shatat, Ibrahim

**Principal Investigator**

**A Multi-Center, Randomized, Double-Blind, 8 Week Study to Evaluate the Dose Response, Efficacy and Safety of Aliskiren in Pediatric Hypertensive Patients 6-17 Years of Age**

Novartis Corp.  
CSPP100A2365 (12080977)  
Project Dates: 09/01/11 - 12/31/12  
Direct F & A Total  
80,913 19,478 100,391

**A Multi-Center, Double-Blind, Randomized, 52 Week, Extension Study to Evaluate the Long-Term, Safety, Tolerability and Efficacy of Aliskiren Compared to Enalapril in Pediatric Hypertensive Patients**

Novartis Corp.  
CSPP100A2365E1 (12081042)  
Project Dates: 09/01/11 - 12/31/13  
Direct F & A Total  
37,211 8,553 45,764
Shatat, Ibrahim

Principal Investigator

A Multi-Center, 52-104 Week, Extension Study to Evaluate the Long-Term, Growth and Development of Pediatric Hypertensive Patients 6-17 Years of Age Treated Previously with Aliskiren

Novartis Corp.  
Budget Dates: 09/01/11 - 12/31/15  
Direct F & A Total
CSPP100A2365E2 (12081072)  
Project Dates: 09/01/11 - 12/31/15  
9,986 1,622 11,608

Shirali, Girish

Principal Investigator

COMPASSION Study - Echocardiography Core Laboratory

Edwards Lifesciences  
Budget Dates: 08/01/08 - 01/31/17  
Direct F & A Total
2006-09 (08060470)  
Project Dates: 08/01/08 - 01/31/17  
149,200 37,300 186,500

Co-Investigator

Pediatric Heart Network Medical University of South Carolina  
PI: J. Saul  
Sponsor: NIH/NHLBI  
Total: $430,753  
Dept: Pediatrics  
Award: 1U10HL109778-01 (10102672-1)

Singh, Inderjit

Principal Investigator

Neuroprotection and Myelin Repair Mechanisms in Multiple Sclerosis

VAMC  
Budget Dates: 10/01/11 - 09/30/12  
Direct F & A Total
BX001072 (12020265)  
Project Dates: 10/01/10 - 09/30/14  
237,800 0 237,800

Cytokines in Glial Cells and EAE Brain

NIH/NINDS  
Budget Dates: 12/01/11 - 11/30/12  
Direct F & A Total
5R01NS037766-13 (12040503)  
Project Dates: 08/01/98 - 11/30/14  
214,375 101,828 316,203

Fatty Acid Oxidation in X-Linked Adrenoleukodystrophy

NIH/NINDS  
Budget Dates: 02/01/12 - 01/31/13  
Direct F & A Total
5R01NS022576-27 (12060760)  
Project Dates: 09/09/85 - 01/31/15  
214,375 101,828 316,203

Co-Investigator

Mechanisms of Krabbe Disease Pathobiology and Therapy  
PI: Avtar Singh  
Sponsor: NIH/NINDS  
Total: $322,656  
Dept: Pathology and Laboratory Medicine  
Award: 5R01NS064195-02 (12081084-1)

Spratt, Eve

Co-Investigator

Biomarkers in Autism of Aripiprazole and Risperidone Treatment (BAART)  
PI: C. Devane  
Sponsor: NIH/NICHD  
Total: $651,465  
Dept: Psychiatry and Behavioral Sciences  
Award: 5R01HD062550-02 (12010064-1)

Taylor, Sarah

Principal Investigator

Identifying Vitamin D Deficiency and Effect in Very Low Birth Weight (VLBW) Infants

NIH/NCRR  
Budget Dates: 07/01/11 - 06/30/13  
Direct F & A Total
5K23RR021891-05 (11042628)  
Project Dates: 07/01/07 - 06/30/13  
99,003 7,920 106,923

Teufel, II, Ronald

Co-Investigator

A Multi-Center, Randomized, Observer-Blinded, Active-Controlled Study to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetics of Ceftaroline Versus Comparator in Pediatric Subjects with Ac

PI: Sandra Fowler  
Sponsor: Quintiles Pacific, Inc.  
Total: $97,950  
Dept: Pediatrics  
Award: P903-23 (12121730-1)

Virella-Lowell, I.

Principal Investigator

A Prospective, 5-Year Registry Study to Monitor the Susceptibility to Aztreonam of Pseudomonas Aeruginosa (PA) Isolates from Patients with Cystic Fibrosis in the United States [AIR-CF5]

Gilead Sciences, Inc.  
Budget Dates: 07/11/11 - 01/31/17  
Direct F & A Total
GX-US-205-0128 (12010081)  
Project Dates: 07/11/11 - 01/31/17  
73,460 16,741 90,201

G551D Observational Study

Seattle Childrens Hospital  
Budget Dates: 09/01/11 - 08/31/14  
Direct F & A Total
GOAL-OB-11/PO10434SUB (12081093)  
Project Dates: 09/01/11 - 08/31/14  
16,339 1,307 17,646

A Single-Arm, Open-Label, Multi-Center, Phase IV Trial to Assess Long-Term Safety of Tobramycin Inhalation Powder (TIP) in Patients with Cystic Fibrosis

Novartis Corp.  
Budget Dates: 04/16/12 - 05/31/14  
Direct F & A Total
TBM100C2401 (12101396)  
Project Dates: 04/16/12 - 05/31/14  
92,730 22,433 115,163
### Virella-Lowell, I.

**Co-PI/Project Director**
- **CFF Patient Registry**
  - **PI:** Patrick Flume
  - **Dept:** Medicine
  - **Sponsor:** Cystic Fibrosis Fdn
  - **Award:** C104-11 (12020186-1)
  - **Total:** $83,755

**Therapeutics Development Center (TDC)**
- **PI:** Patrick Flume
- **Dept:** Medicine
- **Sponsor:** Cystic Fibrosis Fdn
- **Award:** (12030296-1)
- **Total:** $84,672

### Wagner, Carol

**Principal Investigator**
- Three-Year, Follow-Up Study of a Vitamin D Supplementation Pregnancy Cohort in South Carolina
  - **Thrasher Research Fund**
  - **Budget Dates:** 12/01/11 - 11/30/12
  - **Direct F & A**
  - **Total**
    - Project Dates: 12/01/09 - 11/30/12
    - 136,681
    - 9,418
    - 146,099

**Co-Investigator**
- **Trial of Late SURfactant (TOLSURF) to Prevent BPD**
  - **PI:** Frances Koch
  - **Dept:** Pediatrics
  - **Sponsor:** Univ. of California, San Franci
  - **Total:** $5,200
    - Award: 6172sc/U01 HL094338-01 (10052077-6)

- **Trial of Late SURfactant (TOLSURF) to Prevent BPD**
  - **PI:** Frances Koch
  - **Dept:** Pediatrics
  - **Sponsor:** Univ. of California, San Franci
  - **Total:** $1,450
    - Award: 6172sc/U01 HL094338-01 (10052077-7)

- **Trial of Late SURfactant (TOLSURF) to Prevent BPD**
  - **PI:** Frances Koch
  - **Dept:** Pediatrics
  - **Sponsor:** Univ. of California, San Franci
  - **Total:** $2,950
    - Award: 6172sc/U01 HL094338-01 (10052077-8)

- **South Carolina Clinical and Translational Research Institute (UL1)**
  - **PI:** Kathleen Brady
  - **Dept:** Psychiatry and Behavioral Sciences
  - **Sponsor:** NIH/NCRR
  - **Total:** $301,173
    - Award: 5UL1RR000062-04 (12070938-1)

- **South Carolina Clinical and Translational Research Institute (SCTR): UL1**
  - **PI:** Kathleen Brady
  - **Dept:** Psychiatry and Behavioral Sciences
  - **Sponsor:** NIH/NCATS
  - **Total:** $2,537,859
    - Award: 8UL1TR000062-04 (12070938-2)

- **Impact of Vitamin D on Diabetic Kidney Disease in African Americans**
  - **PI:** Vanessa Diaz
  - **Dept:** Family Medicine
  - **Sponsor:** NIH/NIDDK
  - **Total:** $182,531
    - Award: 5R03DK089120-02 (11120288-1)

### Zyblewski, Sinai

**Co-PI/Project Director**
- S1P Deficiency Prolongs Endothelial Barrier Recovery after Fontan Operation
  - **PI:** Kelley Argraves
  - **Dept:** Regenerative Medicine and Cell Bio
  - **Sponsor:** NIH/NHLBI
  - **Total:** $221,250
    - Award: 1R21HL109829-01A1 (12010063-1)

### Psychiatry and Behavioral Sciences

**Aciero, Ron**

**Principal Investigator**
- **Prolonged Exposure (PE) for PTSD: Telemedicine versus In Person**
  - **VAMC**
  - **Budget Dates:** 07/01/11 - 06/30/12
  - **Direct F & A**
  - **Total**
    - Project Dates: 07/01/10 - 06/30/14
    - 268,500
    - 0
    - 268,500

- **Innovative Treatment for Female Victims of Military Sexual Trauma (MST)**
  - **SC Dept. of Public Safety**
  - **Budget Dates:** 10/01/11 - 09/30/12
  - **Direct F & A**
  - **Total**
    - Project Dates: 10/01/11 - 09/30/12
    - 26,445
    - 0
    - 26,445

- **Sexual Assault and Domestic Violence Intervention: Training Program for Students in Health Professions**
  - **SC Dept. of Public Safety**
  - **Budget Dates:** 10/01/11 - 09/30/12
  - **Direct F & A**
  - **Total**
    - Project Dates: 10/01/11 - 09/30/12
    - 32,814
    - 0
    - 32,814

- **Genetic and Environmental Risk/Resilience Factors for PTSD in OEF/OIF Veterans**
  - **VAMC**
  - **Budget Dates:** 10/01/11 - 09/30/12
  - **Direct F & A**
  - **Total**
    - Project Dates: 10/01/10 - 09/30/13
    - 97,600
    - 0
    - 97,600
### Acerno, Ron

**Principal Investigator**

**Randomized, Controlled Trial of Sertraline, Prolonged Exposure Therapy and Their Combination of OEF/OIF with PTSD**

Veterans Education & Research Association of V-SUBMUSC-11-30/W81XWH-11 (12060776)

**Budget Dates:** 12/01/11 - 11/30/12  
**Project Dates:** 12/01/10 - 11/30/15

<table>
<thead>
<tr>
<th>Category</th>
<th>Direct</th>
<th>F &amp; A</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Direct F &amp; A</td>
<td>382,928</td>
<td>99,561</td>
<td>482,489</td>
</tr>
</tbody>
</table>

**Co-Investigator**

**Exposure Therapy with and without Simultaneous TMS for PTSD**

PI: Mark George  
Sponsor: US Army/USAMRAA  
**Total:** $175,212

**Dept:** Psychiatry and Behavioral Sciences  
**Award:** W81XWH-10-2-0194 (10011288-2)

### Prevention of Postrape Drug Abuse: Replication Study

PI: Heidi Resnick  
Sponsor: NIH/NIDA  
**Total:** $608,789

**Dept:** Psychiatry and Behavioral Sciences  
**Award:** 5R01DA023099-04 (11040128-1)

### Prevention of Postrape Drug Abuse: Replication Study (Diversity Supplement)

PI: Heidi Resnick  
Sponsor: NIH/NIDA  
**Total:** $326,231

**Dept:** Psychiatry and Behavioral Sciences  
**Award:** 5R01DA030143-03 (12101401-1)

### Trauma Management Therapy for OEF and OIF Combat Veterans

PI: Thomas Uhde  
Sponsor: Univ. of Central Florida  
**Total:** $97,046

**Dept:** Psychiatry and Behavioral Sciences  
**Award:** 24096033-01 (12091209-1)

### Integrated Treatment of OEF/OIF Veterans with PTSD and Substance User Disorders

PI: Sudie Back  
Sponsor: NIH/NIDA  
**Total:** $326,231

**Dept:** Psychiatry and Behavioral Sciences  
**Award:** 5R01DA030143-03 (12101401-1)

### Anderson, Berry

**Co-Investigator**

**Exposure Therapy with and without Simultaneous TMS for PTSD**

PI: Mark George  
Sponsor: US Army/USAMRAA  
**Total:** $175,212

**Dept:** Psychiatry and Behavioral Sciences  
**Award:** W81XWH-10-2-0194 (10011288-2)

### Anton, Jr., Raymond

**Principal Investigator**

**Genetic and Brain Mechanisms of Naltrexone’s Treatment Efficacy for Alcoholism**

NIH/NIAAA  
**Budget Dates:** 05/01/12 - 04/30/13  
**Project Dates:** 05/15/09 - 04/30/14

<table>
<thead>
<tr>
<th>Category</th>
<th>Direct</th>
<th>F &amp; A</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Direct F &amp; A</td>
<td>354,558</td>
<td>157,859</td>
<td>512,417</td>
</tr>
</tbody>
</table>

**Career Development and Mentoring in Clinical/Translational Alcohol Research**

NIH/NIAAA  
**Budget Dates:** 06/01/12 - 05/31/13  
**Project Dates:** 06/05/08 - 05/31/13

<table>
<thead>
<tr>
<th>Category</th>
<th>Direct</th>
<th>F &amp; A</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Direct F &amp; A</td>
<td>207,787</td>
<td>16,623</td>
<td>224,410</td>
</tr>
</tbody>
</table>

**Co-PI/Project Director**

**Alcohol Research Center - Treatment and Implications**

PI: Carrie Randall  
Sponsor: NIH/NIAAA  
**Total:** $1,620,001

**Dept:** Psychiatry and Behavioral Sciences  
**Award:** 5P50AA010761-17 (12050669-1)

**Alcohol Research Center - Treatment and Implications**

PI: Howard Becker  
Sponsor: NIH/NIAAA  
**Total:** $145,546

**Dept:** Psychiatry and Behavioral Sciences  
**Award:** 5P50AA010761-17 (12050669-2)

**Co-Investigator**

**Training in Alcohol Research**

PI: John Woodward  
Sponsor: NIH/NIAAA  
**Total:** $354,521

**Dept:** Neurosciences  
**Award:** 5T32AA007474-25 (12050574-1)

### Back, Sudie

**Principal Investigator**

**Translational Research Training: Stress and Addiction**

NIH/NIDA  
**Budget Dates:** 07/01/11 - 10/30/12  
**Project Dates:** 07/01/07 - 10/30/12

<table>
<thead>
<tr>
<th>Category</th>
<th>Direct</th>
<th>F &amp; A</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Direct F &amp; A</td>
<td>163,782</td>
<td>13,079</td>
<td>176,861</td>
</tr>
</tbody>
</table>

**Drug Abuse Research Training**

NIH/NIDA  
**Budget Dates:** 05/01/12 - 04/30/13  
**Project Dates:** 05/26/06 - 04/30/16

<table>
<thead>
<tr>
<th>Category</th>
<th>Direct</th>
<th>F &amp; A</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Direct F &amp; A</td>
<td>279,804</td>
<td>22,384</td>
<td>302,188</td>
</tr>
</tbody>
</table>

**Integrated Treatment of OEF/OIF Veterans with PTSD and Substance User Disorders**

NIH/NIDA  
**Budget Dates:** 06/01/12 - 05/31/13  
**Project Dates:** 08/01/10 - 05/31/15

<table>
<thead>
<tr>
<th>Category</th>
<th>Direct</th>
<th>F &amp; A</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Direct F &amp; A</td>
<td>227,234</td>
<td>98,997</td>
<td>326,231</td>
</tr>
</tbody>
</table>
Back, Sudie

**Co-Investigator**

**Opioid Abuse and Chronic Pain: An fMRI Model of Negative Reinforcement**

- **PI:** Jeffrey Borckardt  
- **Sponsor:** NIH/NIDA  
- **Total:** $221,250

**Dept:** Psychiatry and Behavioral Sciences

**Award:** 1R03DA029674-01A1 (10071552-1)

The Impact of Real-Time fMRI Feedback on Response to Nicotine Cues

- **PI:** Kathleen Brady  
- **Sponsor:** NIH/NIDA  
- **Total:** $522,176

**Dept:** Psychiatry and Behavioral Sciences

**Award:** 5R33DA026085-04 (11051208-1)

Badanich, Kimberly

**Principal Investigator**

**Orbitofrontal Cortex Dysfunction after Chronic Ethanol Exposure**

- **NIH/NIAAA**  
- **Budget Dates:** 09/05/11 - 01/04/12  
- **Direct F & A:** $17,108  
- **Total:** $17,108

**Dept:** Psychiatry and Behavioral Sciences

**Award:** 5F32AA019610-02 (12020143)

Becker, Howard

**Principal Investigator**

**Preclinical Medications Screening in Alcohol Dependence and Anxiety Models**

- **NIH/NIDDK**  
- **Budget Dates:** 09/29/11 - 09/28/12  
- **Direct F & A:** $235,594  
- **Total:** $343,967

**Dept:** Psychiatry and Behavioral Sciences

**Award:** 2U01AA014095-10 (11020737)

**Ethanol Dependence and Stress Effects on Ethanol Drinking: Role of CRF**

- **NIH/NIAAA**  
- **Budget Dates:** 09/01/11 - 08/31/13  
- **Direct F & A:** $187,324  
- **Total:** $252,647

**Dept:** Psychiatry and Behavioral Sciences

**Award:** 5R01AA018036-04 (12010061)

**Role of Amygdala Glutamate in Tolerance to the Aversive Effects of Ethanol**

- **NIH/NIAAA**  
- **Budget Dates:** 09/01/11 - 08/31/13  
- **Direct F & A:** $13,500  
- **Total:** $19,913

**Dept:** Psychiatry and Behavioral Sciences

**Award:** 3R01AA018036-04S1 (12020187)

**Role of Amygdala Glutamate in Tolerance to the Adverse Effects of Ethanol**

- **NIH/NIAAA**  
- **Budget Dates:** 09/01/11 - 08/31/13  
- **Direct F & A:** $150,000  
- **Total:** $150,000

**Dept:** Psychiatry and Behavioral Sciences

**Award:** BX000813 (12020257)

**Role of BDF in Ethanol Dependence and Escalation of Drinking**

- **VAMC**  
- **Budget Dates:** 02/16/12 - 02/15/14  
- **Direct F & A:** $114,860  
- **Total:** $169,420

**Dept:** Psychiatry and Behavioral Sciences

**Award:** 1F31DA030891-01A1 (10121358)

**Alcohol Research Center - Treatment and Implications**

- **NIH/NIAAA**  
- **Budget Dates:** 01/01/12 - 12/31/12  
- **Direct F & A:** $99,170  
- **Total:** $145,546

**Dept:** Psychiatry and Behavioral Sciences

**Award:** 5P50AA010761-17 (12050669)

**Chronic LY2940094 Effects on Expression of Ethanol Withdrawal Convulsions**

- **Eli Lilly**  
- **Budget Dates:** 02/16/12 - 02/15/14  
- **Direct F & A:** $114,860  
- **Total:** $169,420

**Dept:** Psychiatry and Behavioral Sciences

**Award:** 1F32AA021321-01 (12020153)

Co-PI/Project Director

**Mouse Chronic Intermittent Ethanol (CIE) Core**

- **Pl:** Marcelo Lopez  
- **Sponsor:** NIH/NIAAA  
- **Total:** $396,986

**Dept:** Psychiatry and Behavioral Sciences

**Award:** 1U01AA020929-01 (11021469)

Mentor

**Ethanol Dependence, Drinking and Mechanisms Regulating Accumbal Glutamate Activity**

- **Pl:** Vorani Ramachandra  
- **Sponsor:** NIH/NIAAA  
- **Total:** $49,214

**Dept:** Psychiatry and Behavioral Sciences

**Award:** 1F32AA021321-01 (12020153)

Beckley, Jacob

**Principal Investigator**

**Neuroplasticity Associated with Acute Toluene Inhalation**

- **NIH/NIDA**  
- **Budget Dates:** 07/01/11 - 06/30/12  
- **Direct F & A:** $41,770  
- **Total:** $41,770

**Dept:** Psychiatry and Behavioral Sciences

**Award:** 1F31DA030891-01A1 (10121358)

Book, Sarah

**Principal Investigator**

**Phased Treatment for Social Anxiety and Hazardous Drinking**

- **NIH/NIAAA**  
- **Budget Dates:** 09/01/11 - 08/31/13  
- **Direct F & A:** $247,369  
- **Total:** $342,407

**Dept:** Psychiatry and Behavioral Sciences

**Award:** 5R01AA013379-08 (11120357)

Co-Investigator

**Drug Abuse Research Training**

- **Pl:** Sudie Back  
- **Sponsor:** NIH/NIDA  
- **Total:** $302,188

**Dept:** Psychiatry and Behavioral Sciences

**Award:** 5R25DA020537-07 (12091253)
Borckardt, Jeffrey

**Principal Investigator**

**Opioid Abuse and Chronic Pain: An fMRI Model of Negative Reinforcement**

NIH/NIDA

**Budget Dates:** 07/15/11 - 06/30/13

<table>
<thead>
<tr>
<th>Project</th>
<th>Direct</th>
<th>F &amp; A</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>1R03DA029674-01A1 (10071552)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>150,000</td>
<td>71,250</td>
<td>221,250</td>
</tr>
</tbody>
</table>

**Transcranial Direct Current Stimulation (tDCS) in the Management of Acute Post-Spine Surgery Pain: A Prospective, Randomized, Controlled Trial**

North American Spine Society

**Budget Dates:** 09/01/11 - 08/31/12

<table>
<thead>
<tr>
<th>Project</th>
<th>Direct</th>
<th>F &amp; A</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>30,500</td>
<td>4,575</td>
<td>35,075</td>
</tr>
</tbody>
</table>

**Co-Investigator**

**Exposure Therapy with and without Simultaneous TMS for PTSD**

**PI:** Mark George

**Sponsor:** US Army/USAMRAA

**Budget Dates:** 09/01/11 - 08/31/12

<table>
<thead>
<tr>
<th>Project</th>
<th>Direct</th>
<th>F &amp; A</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>30,500</td>
<td>4,575</td>
<td>35,075</td>
</tr>
</tbody>
</table>

**Brady, Kathleen**

**Principal Investigator**

**South Carolina Clinical and Translational Research Institute (UL1)**

NIH/NCCR

**Budget Dates:** 04/01/11 - 03/31/12

<table>
<thead>
<tr>
<th>Project</th>
<th>Direct</th>
<th>F &amp; A</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>5UL1RR029882-03 (11012750)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>247,785</td>
<td>53,388</td>
<td>301,173</td>
</tr>
</tbody>
</table>

**South Carolina Clinical and Translational Research Institute (TL1)**

NIH/NCCR

**Budget Dates:** 04/01/11 - 03/31/12

<table>
<thead>
<tr>
<th>Project</th>
<th>Direct</th>
<th>F &amp; A</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>5TL1RR029881-03 (11012751)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>2,520</td>
<td>2,722</td>
<td></td>
</tr>
</tbody>
</table>

**INVEST Drug Abuse Research Fellowship**

US Dept. of State

**Budget Dates:** 09/30/11 - 01/31/13

<table>
<thead>
<tr>
<th>Project</th>
<th>Direct</th>
<th>F &amp; A</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>S-IRPO-100-11-R003 (11042106)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>46,000</td>
<td>0</td>
<td>46,000</td>
</tr>
</tbody>
</table>

**ORWH: SCOR on Sex and Gender Factors Affecting Women's Health**

NIH/NIDA

**Budget Dates:** 07/01/11 - 06/30/12

<table>
<thead>
<tr>
<th>Project</th>
<th>Direct</th>
<th>F &amp; A</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>5P50DA016511-10 (11042208)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>574,540</td>
<td>235,538</td>
<td>810,078</td>
</tr>
</tbody>
</table>

**The Impact of Real-Time fMRI Feedback on Response to Nicotine Cues**

NIH/NIDA

**Budget Dates:** 07/01/11 - 06/30/12

<table>
<thead>
<tr>
<th>Project</th>
<th>Direct</th>
<th>F &amp; A</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>5R33DA026085-04 (11051208)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>371,443</td>
<td>150,733</td>
<td>522,176</td>
</tr>
</tbody>
</table>

**Interdisciplinary Women's Health Research at MUSC (Administrative)**

NIH/NICHD

**Budget Dates:** 08/01/11 - 07/31/12

<table>
<thead>
<tr>
<th>Project</th>
<th>Direct</th>
<th>F &amp; A</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>5K12HD055885-05 (11110074)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>459,989</td>
<td>36,800</td>
<td>496,789</td>
</tr>
</tbody>
</table>

**The Southern Consortium Node of the Clinical Trials Network**

NIH/NIDA

**Budget Dates:** 09/01/11 - 08/31/12

<table>
<thead>
<tr>
<th>Project</th>
<th>Direct</th>
<th>F &amp; A</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>5U10DA013727-12 (11120348)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>1,057,243</td>
<td>268,906</td>
<td>1,326,149</td>
</tr>
</tbody>
</table>

**The Southern Consortium Node of the Clinical Trials Network**

NIH/NIDA

**Budget Dates:** 09/01/11 - 08/31/12

<table>
<thead>
<tr>
<th>Project</th>
<th>Direct</th>
<th>F &amp; A</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>3U10DA013727-12S1 (12010066)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>456,617</td>
<td>61,170</td>
<td>517,787</td>
</tr>
</tbody>
</table>

**Southern Consortium Node of the Clinical Trials Network**

NIH/NIDA

**Budget Dates:** 09/01/11 - 08/31/12

<table>
<thead>
<tr>
<th>Project</th>
<th>Direct</th>
<th>F &amp; A</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>3U10DA013727-12S4 (12050600)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>289,473</td>
<td>137,500</td>
<td>426,973</td>
</tr>
</tbody>
</table>

**South Carolina Clinical and Translational Research Institute (SCTR): UL1**

NIH/NCATS

**Budget Dates:** 04/01/12 - 03/31/13

<table>
<thead>
<tr>
<th>Project</th>
<th>Direct</th>
<th>F &amp; A</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>8UL1TR000062-04 (12070938)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>2,729,285</td>
<td>606,770</td>
<td>3,336,055</td>
</tr>
</tbody>
</table>

**South Carolina Clinical and Translational Research Institute (SCTR): KL2**

NIH/NCATS

**Budget Dates:** 04/01/12 - 03/31/13

<table>
<thead>
<tr>
<th>Project</th>
<th>Direct</th>
<th>F &amp; A</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>8KL2TR000060-04 (12070939)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>345,168</td>
<td>26,013</td>
<td>371,181</td>
</tr>
</tbody>
</table>

**South Carolina Clinical and Translational Research Institute (SCTR): TL1**

NIH/NCATS

**Budget Dates:** 04/01/12 - 03/31/13

<table>
<thead>
<tr>
<th>Project</th>
<th>Direct</th>
<th>F &amp; A</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>8TL1TR000061-04 (12070940)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>227,958</td>
<td>13,071</td>
<td>241,029</td>
</tr>
</tbody>
</table>

**Southern Consortium Node of the Clinical Trials Network**

NIH/NIDA

**Budget Dates:** 09/01/11 - 08/31/12

<table>
<thead>
<tr>
<th>Project</th>
<th>Direct</th>
<th>F &amp; A</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>3U10DA013727-12S2 (12081156)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>516,514</td>
<td>40,245</td>
<td>556,759</td>
</tr>
</tbody>
</table>
Brady, Kathleen

**Principal Investigator**

**Ethical Protections in Community Engaged Research**

Univ. of Michigan  
Budget Dates: 01/01/12 - 04/30/12  
Project Dates: 01/01/12 - 04/30/12  
Direct F & A Total  
3UL1RR024986-05S2 (12091191)  
4,563 1,437 6,000

**Co-Investigator**

**Buspirone Treatment for Marijuana Dependence**

PI: Aimee McRae  
Sponsor: NIH/NIDA  
Total: $315,339

**Integrated Treatment of OEF/OIF Veterans with PTSD and Substance User Disorders**

PI: Sudie Back  
Sponsor: NIH/NIDA  
Total: $326,231

**Drug Abuse Research Training**

PI: Sudie Back  
Sponsor: NIH/NIDA  
Total: $302,188

Brawman-Mintzer, Olga

**Principal Investigator**

**Safety and Tolerability of LuAA21004 - Open-Label, Extension Study**

Quintiles Pacific, Inc.  
Budget Dates: 10/12/10 - 09/30/12  
Project Dates: 10/12/10 - 09/30/12  
Direct F & A Total  
LuAA21004_314 (10100687)  
6,624 1,656 8,280

**Phase 3, Multi-Center, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Flexible Dose Titration, Efficacy and Safety Study of SPD489 (MDD)**

Icon Clinical Research, Inc.  
Budget Dates: 10/26/11 - 06/30/13  
Project Dates: 10/26/11 - 06/30/13  
Direct F & A Total  
SPD489-323 (12050651)  
334,571 82,893 417,464

**A Phase 3, Open-Label, Multi-Center, 12-Month Extension Safety and Tolerability Study of SPD489 in Combination with an Antidepressant in the Treatment of Adults with MDD with Residual Symptoms**

Icon Clinical Research, Inc.  
Budget Dates: 10/26/11 - 06/30/14  
Project Dates: 10/26/11 - 06/30/14  
Direct F & A Total  
SPD489-329 (12050652)  
382,860 94,840 477,700

**Co-Investigator**

**Evaluating Predictors and Interventions in Sphincter of Oddi Dysfunction (EPISOD): Clinical - Parent**

PI: Peter Cotton  
Sponsor: NIH/NIDDK  
Total: $1,001,170  
Dept: Medicine  
Award: 5U01DK074739-05 (11042733-2)

**Evaluating Predictors and Interventions in Sphincter of Oddi Dysfunction (EPISOD) (Supplement for Long Term Followup of Enrolled Subjects): Clinical Coordinating Center**

PI: Peter Cotton  
Sponsor: NIH/NIDDK  
Total: $188,731  
Dept: Medicine  
Award: 3U01DK074739-05S1 (12010131-2)

Carpenter, Matthew

**Principal Investigator**

**Stimulus Control and Trajectories of Adolescent Smoking**

NIH/NIDA  
Budget Dates: 09/01/11 - 08/31/12  
Project Dates: 09/01/11 - 08/31/12  
Direct F & A Total  
5K23DA020482-05 (12010026)  
163,849 13,108 176,957

**A Novel Trial of Smokeless Tobacco for Cessation Induction in Unmotivated Smokers**

NIH/NCI  
Budget Dates: 04/01/12 - 03/31/13  
Project Dates: 04/01/11 - 03/31/16  
Direct F & A Total  
5R01CA154992-02 (12070935)  
381,359 181,146 562,505

**Co-PI/Project Director**

**Tobacco Related Cancer Research Pilot Project: A Pilot Translational Study of Sampling NRT for Cessation Induction: Is Motivation Necessary?**

PI: Andrew Kraft  
Sponsor: State of SC  
Total: $74,951  
Dept: Medicine  
Award: (12040516-11)

**Co-Investigator**

**ORWH: SCOR on Sex and Gender Factors Affecting Women's Health (Project 4)**

PI: Kathleen Brady  
Sponsor: NIH/NIDA  
Total: $268,995  
Dept: Psychiatry and Behavioral Sciences  
Award: 5P50DA016511-10 (11042208-4)

**A Randomized, Controlled Trial of Varenicline for Adolescent Smoking Cessation**

PI: Kevin Gray  
Sponsor: NIH/NIDA  
Total: $624,216  
Dept: Psychiatry and Behavioral Sciences  
Award: 1U01DA031779-01A1 (11120320-1)
<table>
<thead>
<tr>
<th>Project Title</th>
<th>PI</th>
<th>Sponsor</th>
<th>Total</th>
<th>Direct F &amp; A</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Measuring and Improving Supervisor Adherence and Competence</td>
<td>Sonja Schoenwald</td>
<td>NIH/NIMH</td>
<td>$206,174</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Integartive Risk Reduction and Treatment for Teen Substance Use Problems and PTSD</td>
<td>Carla Danielson</td>
<td>NIH/NIDA</td>
<td>$626,124</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Stage II Research in Outpatient Treatment for Adolescents with Comorbidty</td>
<td>Ashli Sheidow</td>
<td>NIH/NIDA</td>
<td>$610,230</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Psychological First Aid for Victims of Crime</td>
<td>Michael McCart</td>
<td>NIH/NIMH</td>
<td>$258,125</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Psychological First Aid for Victims of Crime</td>
<td>Michael McCart</td>
<td>NIH/NIMH</td>
<td>$258,125</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Monitoring and Assessing the Impact of Tax and Price Policies on US Tobacco Use</td>
<td></td>
<td>Yale Univ.</td>
<td></td>
<td>Direct F &amp; A</td>
<td></td>
</tr>
<tr>
<td>Effectiveness of Tobacco Control Policies in High vs. Low Income Countries</td>
<td></td>
<td>NIH/NCI</td>
<td></td>
<td>Direct F &amp; A</td>
<td></td>
</tr>
<tr>
<td>National Longitudinal Study of Tobacco Use (NLSTU)</td>
<td></td>
<td>Westat</td>
<td></td>
<td>Direct F &amp; A</td>
<td></td>
</tr>
<tr>
<td>Tobacco Control Policy Evaluation in China and South Korea: The ITC Asia Project</td>
<td></td>
<td>University of Waterloo</td>
<td></td>
<td>Direct F &amp; A</td>
<td></td>
</tr>
<tr>
<td>International Tobacco Policy Survey</td>
<td></td>
<td>University of Waterloo</td>
<td></td>
<td>Direct F &amp; A</td>
<td></td>
</tr>
<tr>
<td>Relapse-Prevention Booklets as Adjunct to a Tobacco Quitline</td>
<td></td>
<td>Moffitt Cancer Center</td>
<td></td>
<td>Direct F &amp; A</td>
<td></td>
</tr>
<tr>
<td>The International Tobacco Control Policy Evaluation Project</td>
<td></td>
<td>University of Waterloo</td>
<td></td>
<td>Direct F &amp; A</td>
<td></td>
</tr>
<tr>
<td>Creating a Healthier Lowcountry: Eating Smart, Moving More, Tobacco Free</td>
<td></td>
<td>SC Tobacco Collaborative</td>
<td></td>
<td>Direct F &amp; A</td>
<td></td>
</tr>
<tr>
<td>Michigan Center for Health Communications Research II</td>
<td></td>
<td>Univ. of Michigan</td>
<td></td>
<td>Direct F &amp; A</td>
<td></td>
</tr>
</tbody>
</table>
Cummings, Kenneth

Co-PI/Project Director
Tobacco Related Cancer Research: Cummings Recruitment - Cost Share for MUCR-2262400-89947-2021-01 - Effectiveness of Tobacco Control Policies in High vs. Low Income Countries
PI: Andrew Kraft  Sponsor: State of SC  Total: $13,200
Dept: Medicine  Award: (12040516-14)

Cost Share for MUCR-2262400-89148-2021-01 (Cummings Recruitment)- Tobacco Control Policy Evaluation in China and South Korea: The ITC Asia Project
PI: Andrew Kraft  Sponsor: State of SC  Total: $4,778
Dept: Medicine  Award: (12040516-16)

Cost Share for MUCR-2262400-89149-2021-01 (Cummings Recruitment)- International Tobacco Policy Survey
PI: Andrew Kraft  Sponsor: State of SC  Total: $4,778
Dept: Medicine  Award: (12040516-17)

Cost Share for MUCR-2262400-89163-9921-01 (Cummings Recruitment)- International Tobacco Control Policy Evaluation Project
PI: Andrew Kraft  Sponsor: State of SC  Total: $4,778
Dept: Medicine  Award: (12040516-18)

Cost Share for SCTC-HSCI Creating a Healthier Lowcountry Project (Cummings Recruitment)
PI: Andrew Kraft  Sponsor: State of SC  Total: $1,991
Dept: Medicine  Award: (12040516-19)

Cunningham, Phillippe

Principal Investigator
Building a Framework to Address Teen Sexting Behaviors
Univ. of Massachusetts, Lowell
Budget Dates: 10/01/11 - 09/30/12  Direct F & A Total
SS10000000015355/2010-MC-C (10042850)  Project Dates: 10/01/10 - 11/30/12  44,644 21,206 65,850

Adherence to IDDM Regimen in Urban Youth
Wayne State Univ.
Budget Dates: 07/01/11 - 05/31/12  Direct F & A Total
WSU08059-A5/R01 DK059067 (12040461)  Project Dates: 09/01/06 - 05/31/12  7,043 3,345 10,388

Multisystemic Therapy to Reduce Health Disparities in Adolescents with Asthma
Wayne State Univ.
Budget Dates: 07/01/11 - 06/30/12  Direct F & A Total
WSU09002-A2/R01 HL087272- (12040464)  Project Dates: 09/01/08 - 06/30/12  25,241 11,989 37,230

Interventionist Procedures for Adherence to Weight Loss Rec in Black Adolescents
Wayne State Univ.
Budget Dates: 07/01/11 - 06/30/12  Direct F & A Total
WSU11089/U01 HL097889-03 (12040465)  Project Dates: 09/28/09 - 06/30/14  9,045 4,296 13,341

Co-Investigator
Measuring and Improving Supervisor Adherence and Competence
PI: Sonja Schoenwald  Sponsor: NIH/NIMH  Total: $206,174
Dept: Psychiatry and Behavioral Sciences  Award: 1R21MH097000-01 (11120271-1)

Danielson, Carla

Principal Investigator
Charleston County Teen and Family EMPOWERR Program
SAMHSA
Budget Dates: 09/30/11 - 09/29/12  Direct F & A Total
5 U79 SP015156-04 (11020430)  Project Dates: 09/30/08 - 09/29/13  257,401 77,932 335,333

Integrative Risk Reduction and Treatment for Teen Substance Use Problems and PTSD
NIH/NIDA
Budget Dates: 04/01/12 - 01/31/13  Direct F & A Total
1R01DA031285-01A1 (11030487)  Project Dates: 04/01/12 - 01/31/17  469,757 156,367 626,124

EC Access Project
Advocates for Youth
Budget Dates: 01/31/12 - 12/31/12  Direct F & A Total
(12091211)  Project Dates: 01/01/11 - 12/21/12  2,000 0 2,000

Co-PI/Project Director
Alcohol Research Center - Treatment and Implications
PI: Carrie Randall  Sponsor: NIH/NIAAA  Total: $1,620,001
Dept: Psychiatry and Behavioral Sciences  Award: 5P50AA010761-17 (12050669-1)

Alcohol Research Center - Treatment and Implications
PI: Howard Becker  Sponsor: NIH/NIAAA  Total: $145,546
Dept: Psychiatry and Behavioral Sciences  Award: 5P50AA010761-17 (12050669-2)
De Arellano, Michael  
**Principal Investigator**  
*Violence against Hispanic Women Network*  
SC Dept. of Public Safety  
1K11027 (11110106)  
Project Dates: 10/01/11 - 09/30/12  
Direct F & A Total  
71,535 0 71,535  
**Co-Investigator**  
*Helping Organizations and Programs Expand: Action for Enduring and Emerging Issues*  
PI: Dean Kilpatrick  
Sponsor: Department of Justice  
Total: $135,010  
**Charleston County Teen and Family EMPOWERR Program**  
PI: Carla Danielson  
Sponsor: SAMHSA  
Total: $335,333  
**Integrative Risk Reduction and Treatment for Teen Substance Use Problems and PTSD**  
PI: Carla Danielson  
Sponsor: NIH/NIDA  
Total: $626,124  

Deas, Deborah  
**Co-PI/Project Director**  
*SE VIEW Phase II (STEER)*  
PI: Sabra Slaughter  
Sponsor: DOD  
Total: $231,963  
Dept: Presidents Office  
Award: W81XWH-11-2-0164 (12030345-5)  

Devane, C.  
**Principal Investigator**  
*Biomarkers in Autism of Aripiprazole and Risperidone Treatment (BAART)*  
NIH/NICHD  
5R01HD062550-02 (12010064)  
Project Dates: 08/01/10 - 06/30/15  
Direct F & A Total  
539,552 111,913 651,465  
**St John's Wort for Drug Abuse Treatment During Pregnancy**  
NIH/NCCAM  
5R21AT006403-02 (12080994)  
Project Dates: 02/01/11 - 02/28/13  
Direct F & A Total  
125,000 59,375 184,375  
**Co-PI/Project Director**  
*Gestational Age Variation in Human Placental Transport Mechanisms*  
PI: Laura Goetzl  
Sponsor: NIH/NICHD  
Total: $584,397  
Dept: Obstetrics and Gynecology  
Award: 1R01HD069238-01A1 (10091382-1)  
**Co-Investigator**  
*Buspirone Treatment for Marijuana Dependence*  
PI: Aimee McRae  
Sponsor: NIH/NIDA  
Total: $315,339  
Dept: Psychiatry and Behavioral Sciences  
Award: 5R01DA026782-04 (12101372-1)  

Donovan, Jennifer  
**Co-Investigator**  
*Gestational Age Variation in Human Placental Transport Mechanisms*  
PI: Laura Goetzl  
Sponsor: NIH/NICHD  
Total: $584,397  
Dept: Obstetrics and Gynecology  
Award: 1R01HD069238-01A1 (10091382-1)  

Dwyer, Gregg  
**Principal Investigator**  
*Internet Crimes against Children: Development of a Typology of Offenders for Use in Prevention, Investigations and Treatment*  
Department of Justice  
2010-MC-CX-4003 (11021582)  
Project Dates: 10/01/10 - 01/31/13  
Direct F & A Total  
210,679 30,740 241,419  
**Protecting Children Online: Using Research-Based Algorithms to Prioritize Law Enforcement Internet Investigations*  
Department of Justice  
2011-MC-CX-0002 (11050579)  
Project Dates: 10/01/11 - 09/30/14  
Direct F & A Total  
218,944 43,784 262,728  

George, Mark  
**Principal Investigator**  
*A Prospective, Multi-Center, Double-Blind, Randomized, Controlled Trial to Explore the Tolerability, Safety and Efficacy of the H-Coil Deep Transcranial Magnetic Stimulation (TMS) in Subjects with Major Depression Disorder (MDD)*  
Brainsway  
CTP-0001-11 (08120989)  
Project Dates: 03/16/09 - 09/15/12  
Direct F & A Total  
2,580 20 2,600  
**Exposure Therapy with and without Simultaneous TMS for PTSD**  
US Army/USAMRAA  
W81XWH-10-2-0194 (10011288)  
Project Dates: 09/28/11 - 09/27/12  
Direct F & A Total  
123,425 51,787 175,212
<table>
<thead>
<tr>
<th>Principal Investigator</th>
<th>Project Title</th>
<th>Budget Dates</th>
<th>Direct F &amp; A</th>
<th>F &amp; A</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>George, Mark</td>
<td>Cognitive Remediation after Trauma Exposure (CREATE Trial)</td>
<td>09/13/11 - 01/31/12</td>
<td>121,554</td>
<td>48,966</td>
<td>170,520</td>
</tr>
<tr>
<td></td>
<td>The Injury and Traumatic Stress (INTRuST) Consortium Biorepository</td>
<td>10/25/11 - 04/30/12</td>
<td>22,661</td>
<td>10,764</td>
<td>33,425</td>
</tr>
<tr>
<td></td>
<td>Focal Electrically-Administered Seizure Therapy (FEAST): A Preliminary Study</td>
<td>10/10/10 - 12/31/12</td>
<td>61,136</td>
<td>15,284</td>
<td>76,420</td>
</tr>
<tr>
<td></td>
<td>The INjury and TRaumatic STress (INTRuST) Consortium Biorepository</td>
<td>10/25/11 - 04/30/14</td>
<td>22,661</td>
<td>10,764</td>
<td>33,425</td>
</tr>
<tr>
<td></td>
<td>NEPI Study in rTMS for Treatment Resistant Depression</td>
<td>09/15/11 - 09/14/12</td>
<td>80,344</td>
<td>38,163</td>
<td>118,507</td>
</tr>
<tr>
<td></td>
<td>The Injury and Traumatic Stress (INTRuST) Consortium Neuroimaging Acquisition and Archival</td>
<td>08/01/11 - 03/31/12</td>
<td>118,204</td>
<td>56,147</td>
<td>174,351</td>
</tr>
<tr>
<td></td>
<td>A Unified Neuroanatomical Model of Speech Production and Perception: Implications for Apraxia of Speech and Conduction Aphasia</td>
<td>02/01/12 - 03/31/13</td>
<td>250,579</td>
<td>115,938</td>
<td>366,517</td>
</tr>
<tr>
<td></td>
<td>A Prospective, Double-Blind, Randomized, Controlled Trial to Evaluate the Safety and Efficacy of the H-Coil Deep TMS in Conjunction with Mood Stabilizers in Subjects with Bipolar Depression BR-BIP-03</td>
<td>02/28/09 - 01/31/14</td>
<td>34,576</td>
<td>16,424</td>
<td>51,000</td>
</tr>
<tr>
<td></td>
<td>Do Spinal and Cortical tDCS Suggest Distinct and Synergistic Neuromechanical Mechanisms for Post-Stroke Walking Recovery?</td>
<td>02/23/12 - 01/02/13</td>
<td>5,000</td>
<td>0</td>
<td>5,000</td>
</tr>
<tr>
<td></td>
<td>Role of the Supraspinal Opioidergic Circuit in Prefrontal rTMS-Induced Analgesia</td>
<td>02/23/12 - 01/02/13</td>
<td>5,000</td>
<td>0</td>
<td>5,000</td>
</tr>
<tr>
<td></td>
<td>Co-PI/Project Director</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>The Impact of Real-Time fMRI Feedback on Response to Nicotine Cues</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>A Prospective, Double-Blind, Randomized, Controlled Trial to Evaluate the Safety and Efficacy of the H-Coil Deep TMS in Conjunction with Mood Stabilizers in Subjects with Bipolar Depression BR-BIP-03</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Do Spinal and Cortical tDCS Suggest Distinct and Synergistic Neuromechanical Mechanisms for Post-Stroke Walking Recovery?</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Role of the Supraspinal Opioidergic Circuit in Prefrontal Transcranial Magnetic Stimulation-Induced Analgesia</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Research Faculty Activity**

**Psychiatry and Behavioral Sciences**

**College of Medicine**

**Annual Report for Research FY2012**

**Medical University of South Carolina**
Gray, Kevin

**Principal Investigator**

**ADHD Trial, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of Molindone Hydrochloride Extended-Release Tablets as Adjunctive Therapy in Children with Impulsive Aggression Comorbid with Attention-Deficit/Hyperactivity Disorder**

MUSC OIP  
810P202 (11051197)  
Budget Dates: 07/27/11 - 07/26/14  
Direct F & A Total  
157,803 36,265 194,068

**A Randomized, Controlled Trial of Varenicline for Adolescent Smoking Cessation**

NIH/NIDA  
1U01DA031779-01A1 (11120320)  
Budget Dates: 06/01/12 - 05/31/13  
Direct F & A Total  
428,356 195,860 624,216

**A 26-Week, Open-Label, Flexible-Dose Trial of Asenapine Extension Treatment to PO6107 in Pediatric Acute Manic or Mixed Episodes Associated with Bipolar 1 Disorder PO5898-0091**

i3 Research  
P06107-0091 (12020152)  
Budget Dates: 07/21/11 - 07/31/13  
Direct F & A Total  
111,996 27,249 139,245

**Efficacy and Safety of 3-Week, Fixed-Dose Asenapine Treatment in Pediatric Acute Manic or Mixed Episodes Associated with Bipolar I Disorder PO6107-0091**

i3 Research  
P05898-0091 (12020151)  
Budget Dates: 07/21/11 - 07/31/13  
Direct F & A Total  
111,996 27,249 139,245

**Open-Label, Extension Study to Evaluate Safety of Molindone Hydrochloride Extended-Release Tablets as Adjunctive Therapy in Children with Impulsive Aggression Comorbid with ADHD**

Jubilant Clinsys, Inc.  
810P203 (12040520)  
Budget Dates: 10/26/11 - 10/31/12  
Direct F & A Total  
24,452 5,363 29,815

Griffin, III, William

**Co-PI/Project Director**

**Alcohol Research Center - Treatment and Implications**

PI: Carrie Randall  
Sponsor: NIH/NIAAA  
Total: $1,620,001

PI: Howard Becker  
Sponsor: NIH/NIAAA  
Total: $145,546

**Ethanol Dependence and Stress Effects on Ethanol Drinking: Role of CRF**

PI: Howard Becker  
Sponsor: NIH/NIAAA  
Total: $293,531

**Chronic Ethanol and SK2 Potassium Channels**

PI: Patrick Mulholland  
Sponsor: NIH/NIAAA  
Total: $187,950

**Role of Amygdala Glutamate in Tolerance to the Aversive Effects of Ethanol**

PI: Howard Becker  
Sponsor: NIH/NIAAA  
Total: $252,647

**Role of Amygdala Glutamate in Tolerance to the Adverse Effects of Ethanol**

PI: Howard Becker  
Sponsor: NIH/NIAAA  
Total: $19,913
Grubaugh, Anouk

**Principal Investigator**

**Improving PTSD Service Delivery for Veterans with Severe Mental Illness**

VAMC  
HX000815 (12121766)  
Budget Dates: 03/01/12 - 02/28/13  
Project Dates: 03/01/12 - 02/28/16  
Direct F & A Total

257,000 0 257,000

**Co-Investigator**

Telephone Delivered Behavioral Skills Intervention for Blacks with T2DM (PARENT)

Pl: Leonard Egede  
Sponsor: NIH/NIDDK  
Total: $508,994  
Award: 5R01DK081121-04 (11050471-1)

Telephone Delivered Behavioral Skills Intervention for Blacks with T2DM (DIVERSITY SUPPLEMENT)

Pl: Leonard Egede  
Sponsor: NIH/NIDDK  
Total: $74,222  
Award: 5R01DK081121-04 (11050471-2)

Hamner, Mark

**Principal Investigator**

**A Proof of Concept, Double-Blind, Randomized, Placebo-Controlled Study of Ganaxolone in PTSD**

SC Research Authority  
2011-605 (10122104)  
Budget Dates: 02/01/12 - 01/31/13  
Project Dates: 10/14/11 - 12/31/18  
Direct F & A Total

60,194 28,593 88,787

An Open-Label, Multi-Center, Rollover, Long-Term Study of Aripiprazole Intramuscular Depot in Patients with Schizophrenia

Covance, Inc.  
31-10-270 (12040471)  
Budget Dates: 10/14/11 - 12/31/18  
Project Dates: 10/14/11 - 12/31/18  
Direct F & A Total

60,580 13,770 74,350

A Multi-Site, Randomized, Controlled Trial of Mindfulness Meditation Therapy for PTSD

VAMC  
(12121768)  
Budget Dates: 04/01/12 - 03/31/13  
Project Dates: 04/01/12 - 03/31/14  
Direct F & A Total

130,518 0 130,518

**Co-Investigator**

Randomized, Controlled Trial of Sertraline, Prolonged Exposure Therapy and Their Combination of OEF/OIF with PTSD

Pl: Ron Acierno  
Sponsor: Veterans Education & Research  
Total: $482,489  
Award: V-SUBMUSC-11-30/W81XWH-11 (12060776-1)

Hanlon, Colleen

**Principal Investigator**

**Cortical Inhibition and Corpus Callosum Integrity in Cocaine Users**

NIH/NIDA  
5K01DA027756-03 (12070824)  
Budget Dates: 01/01/12 - 12/31/12  
Project Dates: 01/15/10 - 12/31/14  
Direct F & A Total

157,851 11,780 169,431

Hanson, Rochelle

**Principal Investigator**

**Trauma Learning Collaborative for DC II**

District of Columbia  
11-MUSC-02 (11051102)  
Budget Dates: 07/01/11 - 09/30/11  
Project Dates: 07/01/11 - 12/31/12  
Direct F & A Total

15,136 0 15,136

**Trauma Learning Collaborative for DC II-FY12**

District of Columbia  
12-MUSC-02 (12030318)  
Budget Dates: 07/01/11 - 09/30/12  
Project Dates: 07/01/11 - 12/31/12  
Direct F & A Total

119,447 0 119,447

**Co-PI/Project Director**

Project BEST: Bringing Empirically Supported Treatments to Children and Families in South Carolina - Phase 2

Pl: Benjamin Saunders  
Sponsor: Dee Norton Lowcountry Childr  
Total: $448,041  
Award: 1790-SP (12070884-1)

Hartwell, Karen

**Co-Investigator**

The Impact of Real-Time fMRI Feedback on Response to Nicotine Cues

Pl: Kathleen Brady  
Sponsor: NIH/NIDA  
Total: $522,176  
Award: 5R33DA026085-04 (11051208-1)

A Randomized, Controlled Trial of Varenicline for Adolescent Smoking Cessation

Pl: Kevin Gray  
Sponsor: NIH/NIDA  
Total: $624,216  
Award: 1U01DA031779-01A1 (11120320-1)

Haynes, Louise

**Co-Investigator**

The Southern Consortium Node of the Clinical Trials Network

Pl: Kathleen Brady  
Sponsor: NIH/NIDA  
Total: $1,326,149  
Award: 5U10DA013727-12 (11120348-1)
Haynes, Louise

Co-Investigator

The Southern Consortium Node of the Clinical Trials Network
Pl: Kathleen Brady Sponsor: NIH/NIDA Total: $517,787
Dept: Psychiatry and Behavioral Sciences Award: 3U10DA013727-12S1 (12010066-1)

Henggeler, Scott

Principal Investigator

Enhancing Juvenile Drug Court Outcomes with EBPs
NIH/NIDA Budget Dates: 09/01/11 - 08/31/13 Direct F & A Total
5R01DA019882-05 (12010069) Project Dates: 09/28/07 - 08/31/13 415,052 159,184 574,236

Co-Investigator

Integrative Risk Reduction and Treatment for Teen Substance Use Problems and PTSD
Pl: Carla Danielson Sponsor: NIH/NIDA Total: $626,124
Dept: Psychiatry and Behavioral Sciences Award: 1R01DA019892-05 (12010069)

Stage II Research in Outpatient Treatment for Adolescents with Comorbidity
Pl: Ashli Sheidow Sponsor: NIH/NIDA Total: $610,230
Dept: Psychiatry and Behavioral Sciences Award: 5R01DA025616-03 (11050991-1)

Psychological First Aid for Victims of Crime
Pl: Michael McCart Sponsor: NIH/NIMH Total: $258,125
Dept: Psychiatry and Behavioral Sciences Award: 1R34MH091203-01A1 (12010057-1)

Holes-Lewis, Kelly

Study of Paliperidone Palmitate 3 month and 1 month Formulations for the Treatment of Subjects with Schizophrenia
Dept: Psychiatry and Behavioral Sciences Award: R092670PSY3011 (12101402)

Hughes-Halbert, C.

Principal Investigator

West Philadelphia Consortium to Address Disparities - Phase II
Univ. of Pennsylvania Budget Dates: 03/01/12 - 02/28/13 Direct F & A Total
550676/5R24MD001594-08 (12081015) Project Dates: 03/01/12 - 02/28/13 49,058 23,303 72,361

Behavioral and Emotional Impact of BRCA Testing in African Americans (BENITA)
Moffitt Cancer Center Budget Dates: 01/01/12 - 06/30/12 Direct F & A Total
60-16368-99-01-G2 (12081016) Project Dates: 01/01/12 - 06/30/16 9,677 1,936 11,613

Disseminating Breast Cancer Prevention to African American Women
AHRQ Budget Dates: 01/01/12 - 08/31/12 Direct F & A Total
7R18HS019339-02 (12101442) Project Dates: 01/01/12 - 08/31/13 806,851 121,728 928,579

Community-Based Navigator Program for Cancer Control in African Americans
Univ. of Pennsylvania Budget Dates: 01/01/12 - 07/31/12 Direct F & A Total
551129/R01CA132656 (12111491) Project Dates: 01/01/12 - 07/31/13 30,617 14,543 45,160

Killeen, Therese

Principal Investigator

A Randomized Trial of Concurrent Treatment for PTSD and Substance Dependence
City College of New York Budget Dates: 07/01/11 - 06/30/12 Direct F & A Total
41654A (12010039) Project Dates: 09/01/08 - 06/30/12 29,135 13,839 42,974

Co-Investigator

The Southern Consortium Node of the Clinical Trials Network
Pl: Kathleen Brady Sponsor: NIH/NIDA Total: $1,326,149
Dept: Psychiatry and Behavioral Sciences Award: 5U10DA013727-12 (11120348-1)

The Southern Consortium Node of the Clinical Trials Network
Pl: Kathleen Brady Sponsor: NIH/NIDA Total: $517,787
Dept: Psychiatry and Behavioral Sciences Award: 3U10DA013727-12S1 (12010066-1)

Buspirone Treatment for Marijuana Dependence
Pl: Aimee McRae Sponsor: NIH/NIDA Total: $315,339
Dept: Psychiatry and Behavioral Sciences Award: 5R01DA026782-04 (12101372-1)
### Kilpatrick, Dean

**Principal Investigator**

**Helping Organizations and Programs Expand: Action for Enduring and Emerging Issues**

- Department of Justice
- **Budget Dates:** 10/01/11 - 03/31/12
- **Total:** $121,014.01

**Traumatic Stress Across the Lifespan: A Biopsychosocial Training Program**

- NIH/NIMH
- **Budget Dates:** 07/01/11 - 06/30/12
- **Total:** $308,660

**IPA for Baber (Boston DVA)**

- VA Boston Healthcare System
- **Budget Dates:** 10/01/10 - 03/31/11
- **Total:** $135,010

**IPA for Resnick (Boston DVA)**

- VA Boston Healthcare System
- **Budget Dates:** 10/01/10 - 03/31/12
- **Total:** $21,675

**IPA for Kilpatrick (Boston DVA)**

- VA Boston Healthcare System
- **Budget Dates:** 10/01/10 - 03/31/12
- **Total:** $66,370

**IPA for Cornelison (Boston DVA)**

- VA Boston Healthcare System
- **Budget Dates:** 10/01/10 - 03/31/12
- **Total:** $10,702

**National Center for Disaster Mental Health Research-Phase I**

- Dartmouth Coll.
- **Budget Dates:** 09/23/08 - 08/31/12
- **Total:** $14,025

**Psychobiology of Trauma and Resilience across the Lifespan**

- NIH/NIMH
- **Budget Dates:** 07/05/06 - 03/31/15
- **Total:** $50,000

### Konadhode, Rodarani

**Co-Investigator**

**Selective Activation of Neurons to Control Narcolepsy**

- PI: Priyattam Shiromani
- Sponsor: NIH/NINDS
- **Total:** $184,375

### Larowe, Steven

**Co-Investigator**

**ORWH: SCOR on Sex and Gender Factors Affecting Women’s Health (Project 4)**

- PI: Kathleen Brady
- Sponsor: NIH/NIDA
- **Total:** $268,995

### Letourneau, Elizabeth

**Principal Investigator**

**Targeting HIV Risks Behaviors in Juvenile Drug Court-Involved Youth**

- NIH/NIDA
- **Budget Dates:** 07/01/11 - 06/30/12
- **Total:** $298,528

**Targeting HIV Risk Behaviors in Juvenile Drug Court-Involved Youth**

- NIH/NIDA
- **Budget Dates:** 07/01/11 - 06/30/12
- **Total:** $37,146
<table>
<thead>
<tr>
<th>Research Faculty Activity</th>
<th>Psychiatry and Behavioral Sciences</th>
</tr>
</thead>
</table>

**Lewis, Alvin**

- **Co-Investigator**
- A 26-Week, Open-Label, Flexible-Dose Trial of Asenapine Extension Treatment to PO6107 in Pediatric Acute Manic or Mixed Episodes Associated with Bipolar 1 Disorder PO5898-0091
  - **PI:** Kevin Gray
  - **Sponsor:** i3 Research
  - **Total:** $139,245
  - **Dept:** Psychiatry and Behavioral Sciences
  - **Award:** P05898-0091 (12020151-1)

- Efficacy and Safety of 3-Week, Fixed-Dose Asenapine Treatment in Pediatric Acute Manic or Mixed Episodes Associated with Bipolar 1 Disorder PO6107-0091
  - **PI:** Kevin Gray
  - **Sponsor:** i3 Research
  - **Total:** $214,908
  - **Dept:** Psychiatry and Behavioral Sciences
  - **Award:** P06107-0091 (12020152-1)

**Li, Xingbao**

- **Co-Investigator**
- Evaluation of Low Emission Neosync EEG Synchronized TMS Technology for the Treatment of Major Depressive Disorder: A Multi-Center, Randomized, Double-Blind, Sham-Controlled Trial
  - **PI:** Mark George
  - **Sponsor:** NeoSync, Inc.
  - **Total:** $214,908
  - **Dept:** Psychiatry and Behavioral Sciences
  - **Award:** P06107-0091 (12020152-1)

- Evaluation of Low Emission Neosync EEG Synchronized TMS Technology for the Treatment of Major Depressive Disorder: A Multi-Center, Randomized, Double-Blind, Sham-Controlled Trial
  - **PI:** Mark George
  - **Sponsor:** NeoSync, Inc.
  - **Total:** $214,908
  - **Dept:** Psychiatry and Behavioral Sciences
  - **Award:** P06107-0091 (12020152-1)

**Liu, Meng**

- **Co-Investigator**
- Hypothalamic Regulation of Sleep
  - **PI:** Priyattam Shiromani
  - **Sponsor:** NIH/NIMH
  - **Total:** $308,780
  - **Dept:** Psychiatry and Behavioral Sciences
  - **Award:** 7R01MH055772-11 (11051210-2)

**Lopez, Marcelo**

- **Principal Investigator**
- Mouse Chronic Intermittent Ethanol (CIE) Core
  - **NIH/NIAAA**
  - **Project Dates:** 02/01/12 - 01/31/17
  - **Direct F & A Total**
  - **Project Dates:** 02/01/12 - 01/31/17
  - **Total Budget:** 269,143 127,843 396,986

- **Co-PI/Project Director**
- Role of Amygdala Glutamate in Tolerance to the Aversive Effects of Ethanol
  - **PI:** Howard Becker
  - **Sponsor:** NIH/NIAAA
  - **Total:** $252,647
  - **Dept:** Psychiatry and Behavioral Sciences
  - **Award:** 5R01AA18036-04 (12010061-1)

- Alcohol Research Center - Treatment and Implications
  - **PI:** Carrie Randall
  - **Sponsor:** NIH/NIAAA
  - **Total:** $1,620,001
  - **Dept:** Psychiatry and Behavioral Sciences
  - **Award:** 5P50AA010761-17 (12050669-1)

- Alcohol Research Center - Treatment and Implications
  - **PI:** Howard Becker
  - **Sponsor:** NIH/NIAAA
  - **Total:** $145,546
  - **Dept:** Psychiatry and Behavioral Sciences
  - **Award:** 5P50AA010761-17 (12050669-2)

- Preclinical Medications Screening in Alcohol Dependence and Anxiety Models
  - **PI:** Howard Becker
  - **Sponsor:** NIH/NIDDK
  - **Total:** $343,967
  - **Dept:** Psychiatry and Behavioral Sciences
  - **Award:** HHSN267200700038C (07050139-5)
Lopez, Marcelo

**Ethanol Dependence and Stress Effects on Ethanol Drinking: Role of CRF**

*PI*: Howard Becker  
*Sponsor*: NIH/NIAAA  
*Total*: $293,531

*Dept*: Psychiatry and Behavioral Sciences  
*Award*: 2U01AA014095-10 (11020737-1)

**Role of Amygdala Glutamate in Tolerance to the Adverse Effects of Ethanol**

*PI*: Howard Becker  
*Sponsor*: NIH/NIAAA  
*Total*: $19,913

*Dept*: Psychiatry and Behavioral Sciences  
*Award*: 3R01AA018036-04S1 (12020187-1)

---

Madan, Alok

**Opioid Abuse and Chronic Pain: An fMRI Model of Negative Reinforcement**

*PI*: Jeffrey Borckardt  
*Sponsor*: NIH/NIDA  
*Total*: $221,250

*Dept*: Psychiatry and Behavioral Sciences  
*Award*: 1R03DA029674-01A1 (10071552-1)

---

Magruder, Kathryn

**Patient and Provider Outcomes of E-Learning in CAMS**

*VAMC*  
*Budget Dates*: 08/01/11 - 07/30/12  
*Direct F & A*: 125,000  
*Total*: 125,000

**The Southern Consortium Node of the Clinical Trials Network**

*PI*: Kathleen Brady  
*Sponsor*: NIH/NIDA  
*Total*: $1,326,149

*Dept*: Psychiatry and Behavioral Sciences  
*Award*: 5U10DA013727-12 (11120348-1)

---

Malcolm, Jr., Robert

**A Fifteen-Month, Prospective, Randomized, Active-Controlled, Open-Label, Flexible-Dose Study of Paliperidone Palmitate Compared with Oral Antipsychotic Treatment in Delaying Time to Treatment Failure in Adults with Schizophrenia Who Have Recently Been Released from Jail**

*Janssen Scientific Affairs, LLC*  
*Budget Dates*: 08/03/10 - 12/31/12  
*Direct F & A*: 7,936  
*Total*: 9,920

*Project Dates*: 08/03/10 - 12/31/12

**SC Initiative for Quality Overweight/Obesity Care**

*Univ. of South Carolina*  
*Budget Dates*: 02/01/11 - 08/13/13  
*Direct F & A*: 29,623  
*Total*: 29,623

*Obesity Grant #034452 (12020241)*  
*Project Dates*: 02/01/11 - 08/13/13

**Effects on Glycemic Control of a Modified Commercial Weight Control Program for Type 2 Diabetics**

*Weight Watchers International, Inc.*  
*Budget Dates*: 09/01/11 - 05/15/14  
*Direct F & A*: 138,063  
*Total*: 143,063

*WWI - Diabetes Study (12020273)*  
*Project Dates*: 09/01/11 - 05/15/14

**Translating Observational Data into a Comprehensive Needs Assessment: Creating a CME Framework to Improve Atrial Fibrillation-Related Stroke Prevention in the Southeast United States Stroke Belt**

*Univ. of Virginia*  
*Budget Dates*: 11/01/11 - 10/31/12  
*Direct F & A*: 10,000  
*Total*: 10,000

*C3900 (12091225)*  
*Project Dates*: 11/01/11 - 10/31/12

**Study of Paliperidone Palmitate 3 month and 1 month Formulations for the Treatment of Subjects with Schizophrenia**

*Janssen Research & Development, LLC*  
*Budget Dates*: 04/16/12 - 10/31/14  
*Direct F & A*: 361,743  
*Total*: 451,429

*R092670PSY3011 (12101402)*  
*Project Dates*: 04/16/12 - 10/31/14

---

Co-Investigator

**Neurobiology of Addiction Research Center (NARC)- CORE C**

*PI*: Peter Kalivas  
*Sponsor*: NIH/NIDA  
*Total*: $116,656

*Dept*: Neurosciences  
*Award*: 5P50DA015369-10 (12081176-4)
McCart, Michael

**Principal Investigator**

**Psychological First Aid for Victims of Crime**

NIH/NIMH  
1R34MH091203-01A1 (12010057)  
Budget Dates: 06/01/12 - 05/31/13  
Project Dates: 06/01/12 - 05/31/15  
175,000  
83,125  
258,125

**Co-PI/Project Director**

**Targeting HIV Risk Behaviors in Juvenile Drug Court-Involved Youth**

PI: Elizabeth Letourneau  
Dept: Psychiatry and Behavioral Sciences  
Award: 3R01DA025880-04S1 (11120125-1)

**Co-Investigator**

**Stage II Research in Outpatient Treatment for Adolescents with Comorbidity**

PI: Ashli Sheidow  
Dept: Psychiatry and Behavioral Sciences  
Total: $610,230

**Targeting HIV Risks Behaviors in Juvenile Drug Court-Involved Youth**

PI: Elizabeth Letourneau  
Dept: Psychiatry and Behavioral Sciences  
Award: 5R01DA025880-04 (11051322-1)

**Learning and Working During the Transition to Adulthood**

PI: Ashli Sheidow  
Dept: Psychiatry and Behavioral Sciences  
Award: 613937/RFS2012070 (12040542-1)

McCauley, Jenna

**Co-Investigator**

**Charleston County Teen and Family EMPOWERR Program**

PI: Carla Danielson  
Dept: Psychiatry and Behavioral Sciences  
Award: 5 U79 SP015156-04 (11020430-1)

**The Southern Consortium Node of the Clinical Trials Network**

PI: Kathleen Brady  
Dept: Psychiatry and Behavioral Sciences  
Award: 5U10DA013727-12 (11120348-1)

**Integrated Treatment of OEF/OIF Veterans with PTSD and Substance User Disorders**

PI: Sudie Back  
Dept: Psychiatry and Behavioral Sciences  
Award: 5R01DA030143-03 (12101401-1)

McRae, Aimee

**Principal Investigator**

**Buspirone Treatment for Marijuana Dependence**

NIH/NIDA  
5R01DA026782-04 (12101372)  
Budget Dates: 06/01/12 - 05/31/13  
Project Dates: 08/15/09 - 05/31/14  
228,084  
87,255  
315,339

**Co-Investigator**

**ORWH: SCOR on Sex and Gender Factors Affecting Women’s Health (Project 2)**

PI: Kathleen Brady  
Dept: Psychiatry and Behavioral Sciences  
Award: 5S50DA016511-10 (11042208-3)

**Southern Consortium Node of the Clinical Trials Network**

PI: Kathleen Brady  
Dept: Psychiatry and Behavioral Sciences  
Award: 3U10DA013727-12S4 (12050600-1)

**Drug Abuse Research Training**

PI: Sudie Back  
Dept: Psychiatry and Behavioral Sciences  
Award: 5R25DA020537-07 (12091253-1)

Miller, Peter

**Principal Investigator**

**Implementation of Alcohol Screening, Intervention and Treatment in Primary Care**

NIH/NIAAA  
5R01AA016768-04 (12010047)  
Budget Dates: 09/01/11 - 08/31/13  
Project Dates: 09/20/08 - 08/31/13  
370,878  
176,167  
547,045

**Development and Evaluation of an Online Dental Student Alcohol Curriculum**

NIH/NIAAA  
5R25AA019647-02 (12070956)  
Budget Dates: 04/01/12 - 03/31/13  
Project Dates: 04/01/11 - 03/31/13  
137,894  
11,032  
148,926

**Co-Investigator**

**Hollywood Smiles**

PI: Renata Leite  
Dept: Stomatology  
Award: 1R21DE021979-01 (11051106-1)

**Phased Treatment for Social Anxiety and Hazardous Drinking**

PI: Sarah Book  
Dept: Psychiatry and Behavioral Sciences  
Award: 5R01AA013379-08 (11120357-1)
Miller, Peter  
**Co-Investigator**  
Drug Abuse Research Training  
PI: Sudie Back  
Dept: Psychiatry and Behavioral Sciences  
Sponsor: NIH/NIDA  
Award: 5R25DA020537-07 (12091253-1)  
Total: $ 302,188

Moran-Santa Maria, M.  
**Co-Investigator**  
ORWH: SCOR on Sex and Gender Factors Affecting Women’s Health (Project 2)  
PI: Kathleen Brady  
Dept: Psychiatry and Behavioral Sciences  
Sponsor: NIH/NIDA  
Total: $ 193,035

Myrick, Donald  
**Principal Investigator**  
A Randomized, Placebo-Controlled Trial of the Dopamine-B-Hydroxylase (DBH) Inhibitor, Nepicastat, for the Treatment of PTSD in OIF/OEF Veterans  
Charleston Research Institute  
Budget Dates: 06/01/12 - 04/30/13  
Direct: $5,236  
F & A: $1,362  
Total: $6,598

Nahas, Ziad  
**Co-Investigator**  
Exposure Therapy with and without Simultaneous TMS for PTSD  
PI: Carrie Randall  
Dept: Psychiatry and Behavioral Sciences  
Sponsor: NIH/NIAAA  
Award: 5P50AA010761-17 (12050669-1)  
Total: $ 1,620,001

Obeid, Jihad  
**Principal Investigator**  
SmartState Endowed Chair in Biomedical Informatics  
MUSC Fdn.  
Budget Dates: 07/01/11 - 06/30/12  
Direct: $39,072  
F & A: 0  
Total: $39,072

Obeid, Jihad  
**Co-Investigator**  
Clinical Resource Center Alpha-1 Foundation Registry Planning Grant  
PI: Charlie Strange  
Dept: Medicine  
Sponsor: Alpha-1 Fdn.  
Award: (12050655-1)  
Total: $ 49,775

South Carolina Clinical and Translational Research Institute (UL1)  
PI: Kathleen Brady  
Dept: Psychiatry and Behavioral Sciences  
Sponsor: NIH/NCRR  
Award: 5UL1RR029882-03 (11012750-2)  
Total: $ 301,173
## Research Faculty Activity

### Psychiatry and Behavioral Sciences

#### Obeid, Jihad

*Co-Investigator*

**South Carolina Clinical and Translational Research Institute (SCTR): UL1**

**PI:** Kathleen Brady  
**Sponsor:** NIH/NCATS  
**Total:** $2,537,859  
**Dept:** Psychiatry and Behavioral Sciences  
**Award:** 8UL1TR000062-04 (12070938-1)

**South Carolina Clinical and Translational Research Institute (SCTR): UL1**

**PI:** Kathleen Brady  
**Sponsor:** NIH/NCATS  
**Total:** $798,196  
**Dept:** Psychiatry and Behavioral Sciences  
**Award:** 8UL1TR000062-04 (12070938-2)

#### O'Neil, Patrick

*Principal Investigator*

**Effects on Glycemic Control of a Modified Commercial Weight Control Program for Type 2 Diabetics**

**Weight Watchers International, Inc.**

**Budget Dates:** 09/01/11 - 08/31/12  
**Direct F & A**  
**Total**

**WWI - Diabetes Study (12020273)**

**Project Dates:** 09/01/11 - 08/31/13  
2,816,964  
302,223  
3,119,187

#### Prisciandaro, James

*Principal Investigator*

**fMRI of Cue-Reactivity and Impulsivity in Recreational vs Dependent Cocaine Users**

**NIH/NIDA**

**Budget Dates:** 04/07/12 - 03/31/13  
**Direct F & A**  
**Total**

**1F32DA032250-01 (10120627)**

**Project Dates:** 04/07/11 - 03/31/14  
49,214  
0  
49,214

#### Ramachandra, Vorani

*Principal Investigator*

**Ethanol Dependence, Drinking and Mechanisms Regulating Accumbal Glutamate Activity**

**NIH/NIAAA**

**Budget Dates:** 04/07/12 - 03/31/13  
**Direct F & A**  
**Total**

**1F32AA021321-01 (12020153)**

**Project Dates:** 04/07/11 - 03/31/14  
1,102,773  
517,228  
1,620,001

#### Randall, Carrie

*Principal Investigator*

**Alcohol Research Center - Treatment and Implications (Admin)**

**NIH/NIAAA**

**Budget Dates:** 01/01/11 - 12/31/11  
**Direct F & A**  
**Total**

**2P50AA010761-16 (09112399)**

**Project Dates:** 12/01/96 - 12/31/15  
60,873  
28,914  
89,787

**Alcohol Research Center - Treatment and Implications**

**NIH/NIAAA**

**Budget Dates:** 01/01/12 - 12/31/12  
**Direct F & A**  
**Total**

**5P50AA010761-17 (12050669)**

**Project Dates:** 12/01/96 - 12/31/15  
1,102,773  
517,228  
1,620,001

*Co-Investigator*

**The Southern Consortium Node of the Clinical Trials Network**

**PI:** Kathleen Brady  
**Sponsor:** NIH/NIDA  
**Total:** $1,326,149  
**Dept:** Psychiatry and Behavioral Sciences  
**Award:** 5U10DA013727-12 (11120348-1)

#### Randall, Patrick

*Co-PI/Project Director*

**Alcohol Research Center - Treatment and Implications**

**NIH/NIAAA**

**Budget Dates:** 01/01/11 - 12/31/11  
**Direct F & A**  
**Total**

**2P50AA010761-16 (09112399)**

**Project Dates:** 12/01/96 - 12/31/15  
60,873  
28,914  
89,787

**Alcohol Research Center - Treatment and Implications**

**NIH/NIAAA**

**Budget Dates:** 01/01/12 - 12/31/12  
**Direct F & A**  
**Total**

**5P50AA010761-17 (12050669)**

**Project Dates:** 12/01/96 - 12/31/15  
1,102,773  
517,228  
1,620,001

*Co-Investigator*

**The Southern Consortium Node of the Clinical Trials Network**

**PI:** Kathleen Brady  
**Sponsor:** NIH/NIDA  
**Total:** $1,326,149  
**Dept:** Psychiatry and Behavioral Sciences  
**Award:** 5U10DA013727-12 (11120348-1)

#### Resnick, Heidi

*Principal Investigator*

**Prevention of Postrape Drug Abuse: Replication Study**

**NIH/NIDA**

**Budget Dates:** 07/01/11 - 06/30/12  
**Direct F & A**  
**Total**

**5R01DA023099-04 (11040128)**

**Project Dates:** 09/15/08 - 06/30/13  
541,671  
135,794  
677,465

*Co-Investigator*

**IPA for Resnick (Boston DVA)**

**PI:** Dean Kilpatrick  
**Sponsor:** VA Boston Healthcare System  
**Total:** $21,675  
**Dept:** Psychiatry and Behavioral Sciences  
**Award:** (12030302-1)
### Rheingold, Alyssa

**Principal Investigator**

**Intensive Case Management for Crime Victims**

<table>
<thead>
<tr>
<th>SC Dept. of Public Safety</th>
<th>Budget Dates: 07/01/11 - 06/30/12</th>
<th>Direct</th>
<th>F &amp; A</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>1V11090 (11030157)</td>
<td>Project Dates: 07/01/11 - 06/30/12</td>
<td>69,688</td>
<td>0</td>
<td>69,688</td>
</tr>
</tbody>
</table>

**Urban Homicide: Services for Family Members of Homicide Victims in Urban Charleston**

<table>
<thead>
<tr>
<th>SC Dept. of Public Safety</th>
<th>Budget Dates: 07/01/11 - 06/30/12</th>
<th>Direct</th>
<th>F &amp; A</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>1V11091 (11030158)</td>
<td>Project Dates: 07/01/11 - 06/30/12</td>
<td>83,192</td>
<td>0</td>
<td>83,192</td>
</tr>
</tbody>
</table>

**Intensive Case Management for Family Members of Homicide Victims**

<table>
<thead>
<tr>
<th>Department of Justice</th>
<th>Budget Dates: 09/01/11 - 10/31/12</th>
<th>Direct</th>
<th>F &amp; A</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>2009-VF-GX-K009</td>
<td>Project Dates: 09/09/09 - 10/31/12</td>
<td>76,045</td>
<td>23,954</td>
<td>99,999</td>
</tr>
</tbody>
</table>

**Co-PI/Project Director**

**Violence against Hispanic Women Network**

<table>
<thead>
<tr>
<th>PI: Michael De Arellano</th>
<th>Sponsor: SC Dept. of Public Safety</th>
<th>Total: $ 63,535</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dept: Psychiatry and Behavioral Sciences</td>
<td>Award: 1K11027 (11110106-1)</td>
<td></td>
</tr>
</tbody>
</table>

**Violence against Hispanic Women Network**

<table>
<thead>
<tr>
<th>PI: Michael De Arellano</th>
<th>Sponsor: SC Dept. of Public Safety</th>
<th>Total: $ 8,000</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dept: Psychiatry and Behavioral Sciences</td>
<td>Award: 1 KS09050 (11110106-2)</td>
<td></td>
</tr>
</tbody>
</table>

**Co-Investigator**

**Charleston County Teen and Family EMPOWERR Program**

<table>
<thead>
<tr>
<th>PI: Carla Danielson</th>
<th>Sponsor: SAMHSA</th>
<th>Total: $ 335,333</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dept: Psychiatry and Behavioral Sciences</td>
<td>Award: 5 U79 SP015156-04 (11020430-1)</td>
<td></td>
</tr>
</tbody>
</table>

**Psychological First Aid for Victims of Crime**

<table>
<thead>
<tr>
<th>PI: Michael McCart</th>
<th>Sponsor: NIH/NIHM</th>
<th>Total: $ 258,125</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dept: Psychiatry and Behavioral Sciences</td>
<td>Award: 1R34MH091203-01A1 (12010057-1)</td>
<td></td>
</tr>
</tbody>
</table>

### Rowland, Melisa

**Principal Investigator**

**MST-Psychiatric Teams/Robin Hood Foundation**

<table>
<thead>
<tr>
<th>MST Group, LLC</th>
<th>Budget Dates: 04/01/10 - 03/31/13</th>
<th>Direct</th>
<th>F &amp; A</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>10040561</td>
<td>Project Dates: 04/01/10 - 03/31/13</td>
<td>80,000</td>
<td>20,000</td>
<td>100,000</td>
</tr>
</tbody>
</table>

**MST-CM Implementation for NY ACS Project**

<table>
<thead>
<tr>
<th>MST Group, LLC</th>
<th>Budget Dates: 02/01/11 - 01/31/13</th>
<th>Direct</th>
<th>F &amp; A</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>MST - NY Project (11020187)</td>
<td>Project Dates: 02/01/11 - 01/31/13</td>
<td>48,434</td>
<td>12,109</td>
<td>60,543</td>
</tr>
</tbody>
</table>

**Co-Investigator**

**Youth Outcomes of BlueSky in New York**

<table>
<thead>
<tr>
<th>PI: Sonja Schoenwald</th>
<th>Sponsor: Annie E. Casey Fdn.</th>
<th>Total: $ 113,616</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dept: Psychiatry and Behavioral Sciences</td>
<td>Award: 96.2013 (11030481-1)</td>
<td></td>
</tr>
</tbody>
</table>

**Youth Outcomes of BlueSky in New York**

<table>
<thead>
<tr>
<th>PI: Sonja Schoenwald</th>
<th>Sponsor: Annie E. Casey Fdn.</th>
<th>Total: $ 233,911</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dept: Psychiatry and Behavioral Sciences</td>
<td>Award: 96.2013 (12081031-1)</td>
<td></td>
</tr>
</tbody>
</table>

### Ruggiero, Kenneth

**Principal Investigator**

**PE-Web: Online Training for VA Providers in Prolonged Exposure for PTSD**

<table>
<thead>
<tr>
<th>VAMC</th>
<th>Budget Dates: 04/01/12 - 03/31/13</th>
<th>Direct</th>
<th>F &amp; A</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>HX000224 (12020262)</td>
<td>Project Dates: 04/01/10 - 03/31/13</td>
<td>361,800</td>
<td>0</td>
<td>361,800</td>
</tr>
</tbody>
</table>

**Co-PI/Project Director**

**National Center for Disaster Mental Health Research-Phase I**

<table>
<thead>
<tr>
<th>PI: Dean Kilpatrick</th>
<th>Sponsor: Dartmouth Coll.</th>
<th>Total: $ 14,025</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dept: Psychiatry and Behavioral Sciences</td>
<td>Award: 365/P60 MH062598 (12050573-1)</td>
<td></td>
</tr>
</tbody>
</table>

**Co-Investigator**

**Charleston County Teen and Family EMPOWERR Program**

<table>
<thead>
<tr>
<th>PI: Carla Danielson</th>
<th>Sponsor: SAMHSA</th>
<th>Total: $ 335,333</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dept: Psychiatry and Behavioral Sciences</td>
<td>Award: 5 U79 SP015156-04 (11020430-1)</td>
<td></td>
</tr>
</tbody>
</table>

**Prevention of Postrape Drug Abuse: Replication Study**

<table>
<thead>
<tr>
<th>PI: Heidi Resnick</th>
<th>Sponsor: NIH/NIDA</th>
<th>Total: $ 608,789</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dept: Psychiatry and Behavioral Sciences</td>
<td>Award: 5R01DA023099-04 (11040128-1)</td>
<td></td>
</tr>
</tbody>
</table>

**Prevention of Postrape Drug Abuse: Replication Study (Diversity Supplement)**

<table>
<thead>
<tr>
<th>PI: Heidi Resnick</th>
<th>Sponsor: NIH/NIDA</th>
<th>Total: $ 68,676</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dept: Psychiatry and Behavioral Sciences</td>
<td>Award: 5R01DA023099-04 (11040128-2)</td>
<td></td>
</tr>
</tbody>
</table>
Sampson, Royce

Co-Investigator
The Southern Consortium Node of the Clinical Trials Network
PI: Kathleen Brady Sponsor: NIH/NIDA Total: $1,326,149
Dept: Psychiatry and Behavioral Sciences Award: 5U10DA013727-12 (11120348-1)

South Carolina Clinical and Translational Research Institute (SCTR): UL1
PI: Kathleen Brady Sponsor: NIH/NCATS Total: $2,537,859
Dept: Psychiatry and Behavioral Sciences Award: 8UL1TR000062-04 (12070938-1)

South Carolina Clinical and Translational Research Institute (SCTR): UL1
PI: Kathleen Brady Sponsor: NIH/NCATS Total: $798,196
Dept: Psychiatry and Behavioral Sciences Award: 8UL1TR000062-04 (12070938-2)

Santa Ana, Elizabeth

Principal Investigator
Impact of GMI and IHMDs for Dually Diagnosed Veterans
VAMC Budget Dates: 07/01/11 - 06/30/12 Direct F & A Total
(09102975) Project Dates: 07/01/08 - 06/30/13 161,897 0 161,897

Co-Investigator
Integrated Treatment of OEF/OIF Veterans with PTSD and Substance Use Disorders
PI: Sudie Back Sponsor: NIH/NIDA Total: $326,231
Dept: Psychiatry and Behavioral Sciences Award: 5R01DA030143-03 (12101401-1)

Saunders, Benjamin

Principal Investigator
TF-CBT for Adjudicated Youth in Residential Treatment
Allegheny-Singer Research Inst. Budget Dates: 05/01/12 - 04/30/13 Direct F & A Total
1 R01 MH095208-01 (10111770) Project Dates: 07/15/11 - 04/30/14 31,405 14,917 46,322

Project BEST: Bringing Empirically Supported Treatments to Children and Families in South Carolina - Phase 2
Dee Norton Lowcountry Childrens Center Budget Dates: 01/01/12 - 12/31/13 Direct F & A Total
1790-SP (12070884) Project Dates: 03/01/11 - 12/31/13 414,853 33,188 448,041

TF-CBT for Adjudicated Youth in Residential Treatment
Allegheny-Singer Research Inst. Budget Dates: 05/01/11 - 04/30/13 Direct F & A Total
R01MH095208-02 (12091189) Project Dates: 07/15/11 - 04/30/14 24,044 11,421 35,465

Co-PI/Project Director
Charleston County Teen and Family EMPOWERR Program
PI: Carla Danielsen Sponsor: SAMHSA Total: $335,333
Dept: Psychiatry and Behavioral Sciences Award: 5 U79 SP015156-04 (11020430-1)

Trauma Learning Collaborative for DC II
PI: Rochelle Hanson Sponsor: District of Columbia Total: $15,136
Dept: Psychiatry and Behavioral Sciences Award: 11-MUSC-02 (11051102-1)

Co-Investigator
Helping Organizations and Programs Expand: Action for Enduring and Emerging Issues
PI: Dean Kilpatrick Sponsor: Department of Justice Total: $135,010
Dept: Psychiatry and Behavioral Sciences Award: 2010-VF-GX-K010 (10041621-2)

Integrative Risk Reduction and Treatment for Teen Substance Use Problems and PTSD
PI: Carla Danielsen Sponsor: NIH/NIDA Total: $626,124
Dept: Psychiatry and Behavioral Sciences Award: 1R01DA031285-01A1 (11030487-1)

Trauma Learning Collaborative for DC II-FY12
PI: Rochelle Hanson Sponsor: District of Columbia Total: $119,447
Dept: Psychiatry and Behavioral Sciences Award: 12-MUSC-02 (12030318-1)

Schaeffer, Cindy

Principal Investigator
Rigorous Evaluation of the Blue Sky Continuum of Evidenced-Based Treatment in New York City
New York Foundling Budget Dates: 09/15/11 - 04/30/13 Direct F & A Total
(12060797) Project Dates: 09/15/11 - 04/30/14 14,894 1,638 16,532

Co-PI/Project Director
Family-Based Treatment for Parental Substance Abuse and Child Maltreatment
PI: Cynthia Swenson Sponsor: NIH/NIDA Total: $643,835
Dept: Psychiatry and Behavioral Sciences Award: 5R01DA029726-02 (11110042-1)
<table>
<thead>
<tr>
<th>Principal Investigator</th>
<th>Title</th>
<th>Sponsor</th>
<th>Budget Dates</th>
<th>Direct</th>
<th>F &amp; A</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Schoenwald, Sonja</td>
<td>Youth Outcomes of BlueSky in New York</td>
<td>Annie E. Casey Fdn.</td>
<td>09/01/11 - 02/29/12</td>
<td>106,516</td>
<td>7,100</td>
<td>113,616</td>
</tr>
<tr>
<td></td>
<td>Measuring and Improving Supervisor Adherence and Competence</td>
<td>NIH/NIMH</td>
<td>06/11/12 - 05/31/13</td>
<td>139,779</td>
<td>66,395</td>
<td>206,174</td>
</tr>
<tr>
<td></td>
<td>Center to Promote Schools as the Context for Urban Children’s Mental Health</td>
<td>Univ. of Illinois, Chicago</td>
<td>04/01/11 - 03/31/12</td>
<td>58,026</td>
<td>27,562</td>
<td>85,588</td>
</tr>
<tr>
<td></td>
<td>Youth Outcomes of BlueSky in New York</td>
<td>Annie E. Casey Fdn.</td>
<td>03/01/12 - 02/28/13</td>
<td>212,647</td>
<td>21,264</td>
<td>233,911</td>
</tr>
<tr>
<td></td>
<td>Advanced Center to Improve Pediatric Mental Health Care (ACIPMHC)</td>
<td>Rady Childrens Hospital San Diego</td>
<td>05/01/12 - 04/30/13</td>
<td>28,827</td>
<td>13,260</td>
<td>42,087</td>
</tr>
<tr>
<td>Serber, Eva</td>
<td>Efficacy of Exercise Videogames for Physical Activity Adoption and Maintenance</td>
<td>Miriam Hospital</td>
<td>09/01/11 - 07/31/12</td>
<td>5,293</td>
<td>2,514</td>
<td>7,807</td>
</tr>
<tr>
<td>Sheidow, Ashli</td>
<td>Stage II Research in Outpatient Treatment for Adolescents with Comorbidity</td>
<td>NIH/NIDA</td>
<td>07/01/11 - 06/30/12</td>
<td>449,225</td>
<td>161,005</td>
<td>610,230</td>
</tr>
<tr>
<td></td>
<td>Learning and Working During the Transition to Adulthood</td>
<td>Univ. of Massachusetts</td>
<td>10/01/11 - 09/30/12</td>
<td>14,649</td>
<td>2,197</td>
<td>16,846</td>
</tr>
<tr>
<td>Shiromani, Priyattam</td>
<td>Basal Forebrain Hypocretin Regulation of Waking</td>
<td>NIH/NINDS</td>
<td>01/01/11 - 02/28/13</td>
<td>35,373</td>
<td>10,257</td>
<td>45,630</td>
</tr>
<tr>
<td></td>
<td>Hypothalamic Regulation of Sleep</td>
<td>NIH/NIMH</td>
<td>01/01/11 - 02/28/13</td>
<td>239,364</td>
<td>69,416</td>
<td>308,780</td>
</tr>
<tr>
<td></td>
<td>Sleep Neurobiology and Circuitry</td>
<td>VAMC</td>
<td>10/01/11 - 09/30/12</td>
<td>150,000</td>
<td>0</td>
<td>150,000</td>
</tr>
<tr>
<td></td>
<td>Selective Activation of Neurons to Control Narcolepsy</td>
<td>NIH/NINDS</td>
<td>06/01/12 - 05/31/13</td>
<td>125,000</td>
<td>59,375</td>
<td>184,375</td>
</tr>
<tr>
<td></td>
<td>Hypothalamic Regulation of Sleep</td>
<td>NIH/NIMH</td>
<td>03/01/12 - 02/28/13</td>
<td>251,538</td>
<td>119,481</td>
<td>371,019</td>
</tr>
<tr>
<td>Smith, Daniel</td>
<td>A Randomized Recruitment Intervention</td>
<td>Arch Mainous</td>
<td>06/01/12 - 05/31/13</td>
<td>125,000</td>
<td>59,375</td>
<td>184,375</td>
</tr>
<tr>
<td>Name</td>
<td>Role</td>
<td>Project Title</td>
<td>PI</td>
<td>Sponsor</td>
<td>Total Funding</td>
<td>Budget Dates</td>
</tr>
<tr>
<td>-----------------</td>
<td>--------------------</td>
<td>-------------------------------------------------------------------------------</td>
<td>------------------------</td>
<td>---------------------</td>
<td>---------------------</td>
<td>--------------------</td>
</tr>
<tr>
<td>Smith, Joshua</td>
<td>Co-Investigator</td>
<td>Phased Treatment for Social Anxiety and Hazardous Drinking</td>
<td>Sarah Book</td>
<td>NIH/NIAAA</td>
<td>$342,407</td>
<td>09/01/11 - 08/31/13</td>
</tr>
<tr>
<td>Sonne, Susan</td>
<td>Co-Investigator</td>
<td>South Carolina Clinical and Translational Research Institute (UL1)</td>
<td>Kathleen Brady</td>
<td>NIH/NIAAA</td>
<td>$301,173</td>
<td>09/01/11 - 08/31/13</td>
</tr>
<tr>
<td></td>
<td></td>
<td>The Southern Consortium Node of the Clinical Trials Network</td>
<td>Kathleen Brady</td>
<td>NIH/NIDS</td>
<td>$1,326,149</td>
<td>09/01/11 - 08/31/13</td>
</tr>
<tr>
<td></td>
<td></td>
<td>The Southern Consortium Node of the Clinical Trials Network</td>
<td>Kathleen Brady</td>
<td>NIH/NID</td>
<td>$517,787</td>
<td>09/01/11 - 08/31/13</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Southern Consortium Node of the Clinical Trials Network</td>
<td>Kathleen Brady</td>
<td>NIH/NID</td>
<td>$426,973</td>
<td>09/01/11 - 08/31/13</td>
</tr>
<tr>
<td></td>
<td></td>
<td>South Carolina Clinical and Translational Research Institute (SCTR): UL1</td>
<td>Kathleen Brady</td>
<td>NIH/NID</td>
<td>$2,537,859</td>
<td>09/01/11 - 08/31/13</td>
</tr>
<tr>
<td></td>
<td></td>
<td>South Carolina Clinical and Translational Research Institute (SCTR): UL1</td>
<td>Kathleen Brady</td>
<td>NIH/NID</td>
<td>$798,196</td>
<td>09/01/11 - 08/31/13</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Ethical Protections in Community Engaged Research</td>
<td>Kathleen Brady</td>
<td>Univ. of Michigan</td>
<td>$6,000</td>
<td>09/01/11 - 08/31/13</td>
</tr>
<tr>
<td>Stewart, Scott</td>
<td>Principal Investigator</td>
<td>Phosphatidylethanol as an Alcohol Biomarker in Patients with Liver Disease</td>
<td>NIH/NIAAA</td>
<td></td>
<td>$280,719</td>
<td>09/01/11 - 08/31/13</td>
</tr>
<tr>
<td></td>
<td>Co-Investigator</td>
<td>Drug Abuse Research Training</td>
<td>Sudie Back</td>
<td>NIH/NIDA</td>
<td>$302,188</td>
<td>09/01/11 - 08/31/13</td>
</tr>
<tr>
<td>Sweat, Michael</td>
<td>Principal Investigator</td>
<td>Synthesizing HIV Behavioral Intervention Effectiveness in Developing Countries</td>
<td>NIH/NIMH</td>
<td></td>
<td>$24,888</td>
<td>09/01/11 - 08/31/13</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Global Epidemics of HIV Sex Workers</td>
<td>Johns Hopkins Univ.</td>
<td></td>
<td>$58,504</td>
<td>09/01/11 - 08/31/13</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Evaluating a Combination of Prevention Interventions to Reduce HIV-1 Transmission in Tanzania's Iringa Region</td>
<td>Johns Hopkins Univ.</td>
<td></td>
<td>$139,414</td>
<td>09/01/11 - 08/31/13</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Synthesizing HIV Behavioral Intervention Effectiveness in Developing Countries</td>
<td>NIH/NIMH</td>
<td></td>
<td>$402,607</td>
<td>09/01/11 - 08/31/13</td>
</tr>
<tr>
<td></td>
<td>Co-Investigator</td>
<td>Targeting HIV Risks Behaviors in Juvenile Drug Court-Involved Youth</td>
<td>Elizabeth Letourneau</td>
<td>NIH/NIDA</td>
<td>$298,528</td>
<td>09/01/11 - 08/31/13</td>
</tr>
<tr>
<td>Principal Investigator</td>
<td>Project Title</td>
<td>Sponsor</td>
<td>Budget Dates</td>
<td>Direct</td>
<td>F &amp; A</td>
<td>Total</td>
</tr>
<tr>
<td>------------------------</td>
<td>---------------</td>
<td>---------</td>
<td>--------------</td>
<td>--------</td>
<td>-------</td>
<td>-------</td>
</tr>
<tr>
<td>Swenson, Cynthia</td>
<td>MST Model with Child Maltreatment</td>
<td>MST Group, LLC</td>
<td>03/01/09 - 06/30/12</td>
<td>67,922</td>
<td>16,980</td>
<td>84,902</td>
</tr>
<tr>
<td></td>
<td></td>
<td>MST Contract (09030628)</td>
<td>03/01/09 - 06/30/12</td>
<td>136,802</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Family-Based Treatment for Parental Substance Abuse and Child Maltreatment</td>
<td>NIH/NIDA</td>
<td>08/01/11 - 07/31/12</td>
<td>450,482</td>
<td>193,353</td>
<td>643,835</td>
</tr>
<tr>
<td></td>
<td></td>
<td>5R01DA029726-02 (11110042)</td>
<td>08/01/10 - 07/31/15</td>
<td>643,835</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Taylor, Joseph</td>
<td>Principal Investigator</td>
<td>Role of the Supraspinal Opioidergic Circuit in Prefrontal Transcranial Magnetic Stimulation-Induced Analgesia</td>
<td>NIH/NINDS</td>
<td>03/22/12 - 03/21/13</td>
<td>36,532</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td></td>
<td>1F30DA033748-01 (12020160)</td>
<td>03/22/12 - 03/21/15</td>
<td>36,532</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Thomas, Suzanne</td>
<td>Co-PI/Project Director</td>
<td>Alcohol Research Center - Treatment and Implications</td>
<td>PI: Carrie Randall</td>
<td>05/01/12 - 04/30/13</td>
<td>217,100</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Sponsor: NIH/NIAAA</td>
<td>Award: 5P50AA010761-17 (1205069-1)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Alcohol Research Center - Treatment and Implications</td>
<td>NIH/NIAAA</td>
<td>08/01/10 - 07/31/15</td>
<td>643,835</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Sponsor: NIH/NIAAA</td>
<td>Award: 5P50AA010761-17 (1205069-1)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Co-Investigator</td>
<td>Phased Treatment for Social Anxiety and Hazardous Drinking</td>
<td>PI: Sarah Book</td>
<td>07/01/11 - 06/30/12</td>
<td>217,100</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Sponsor: NIH/NIAAA</td>
<td>Award: 5P50AA010761-17 (1205069-2)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Development and Evaluation of an Online Dental Student Alcohol Curriculum</td>
<td>NIH/NIAAA</td>
<td>05/01/12 - 07/31/12</td>
<td>81,913</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Sponsor: NIH/NIAAA</td>
<td>Award: 5P50AA010761-17 (1205069-2)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tolliver, Bryan</td>
<td>Principal Investigator</td>
<td>Treatment of Alcohol Dependence and Co-Morbid Bipolar Disorder</td>
<td>NIH/NIAAA</td>
<td>05/01/12 - 04/30/13</td>
<td>217,100</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Sponsor: NIH/NIAAA</td>
<td>Award: 5P50AA010761-17 (1205069-1)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Co-Investigator</td>
<td>ORWH: SCOR on Sex and Gender Factors Affecting Women's Health (Project 2)</td>
<td>PI: Kathleen Brady</td>
<td>05/01/12 - 04/30/13</td>
<td>217,100</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Sponsor: NIH/NIAAA</td>
<td>Award: 5P50AA010761-17 (1205069-2)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tuerk, Peter</td>
<td>Principal Investigator</td>
<td>Psychophysiology of Prolonged Exposure of PTSD with/without Yohimbine</td>
<td>VAMC (10051961)</td>
<td>07/01/11 - 06/30/12</td>
<td>50,000</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Sponsor: US Army/USAMRAA</td>
<td>Award: W81XWH-10-2-0194 (10011288-2)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Co-Investigator</td>
<td>Exposure Therapy with and without Simultaneous TMS for PTSD</td>
<td>PI: Mark George</td>
<td>07/01/11 - 06/30/12</td>
<td>50,000</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Sponsor: Veterans Education &amp; Research</td>
<td>Award: V-SUBMUSC-11-30/W81XWH-11 (12060776-1)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Uhde, Thomas</td>
<td>Principal Investigator</td>
<td>Trauma Management Therapy for OEF and OIF Combat Veterans</td>
<td>Univ. of Central Florida</td>
<td>11/15/10 - 04/30/12</td>
<td>97,046</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Sponsor: US Army/USAMRAA</td>
<td>Award: W81XWH-10-2-0194 (10011288-2)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Trauma Management Therapy for OEF and OIF Combat Veterans</td>
<td>Univ. of Central Florida</td>
<td>11/15/10 - 04/30/12</td>
<td>97,046</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Sponsor: Veterans Education &amp; Research</td>
<td>Award: V-SUBMUSC-11-30/W81XWH-11 (12060776-1)</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Voronin, Konstantin  
Co-Investigator  
Alcohol Research Center - Treatment and Implications  
PI: Carrie Randall  
Sponsor: NIH/NIAAA  
Total: $1,620,001  
Dept: Psychiatry and Behavioral Sciences  
Award: 5P50AA010761-17 (12050669-1)

Alcohol Research Center - Treatment and Implications  
PI: Howard Becker  
Sponsor: NIH/NIAAA  
Total: $145,546  
Dept: Psychiatry and Behavioral Sciences  
Award: 5P50AA010761-17 (12050669-2)

Wang, Zhewu  
Principal Investigator  
Cortical Excitability: Biomarker and Endophenotype in Combat Related PTSD  
VAMC  
Budget Dates: 10/01/11 - 09/30/12  
Project Dates: 10/01/11 - 09/30/15  
Direct F & A Total  
198,000 0 198,000

Zajac, Kristyn  
Co-Investigator  
Stage II Research in Outpatient Treatment for Adolescents with Comorbidity  
PI: Ashli Sheidow  
Sponsor: NIH/NIDA  
Total: $610,230  
Dept: Psychiatry and Behavioral Sciences  
Award: 5R01DA025616-03 (11050991-1)

Psychological First Aid for Victims of Crime  
PI: Michael McCart  
Sponsor: NIH/NIMH  
Total: $258,125  
Dept: Psychiatry and Behavioral Sciences  
Award: 1R34MH091203-01A1 (12010057-1)

Radiation Oncology

Gattoni-Celli, S.  
Principal Investigator  
Vitamin D Supplementation in African American Veterans with Prostate Cancer  
VAMC  
Budget Dates: 01/01/12 - 12/31/12  
Project Dates: 01/01/10 - 12/31/12  
Direct F & A Total  
219,600 0 219,600

Jenrette, Joseph  
Principal Investigator  
Radiation Therapy Oncology Group (RTOG)  
RTOG #4501 (11050987)  
Budget Dates: 01/01/09 - 12/31/14  
Project Dates: 01/01/09 - 12/31/14  
Direct F & A Total  
95,000 14,250 109,250

Marshall, David  
Co-Investigator  
Complement, Anti-Tumor Immunity and Apoptosis-Based Therapy  
PI: Stephen Tomlinson  
Sponsor: NIH/NCI  
Total: $306,063  
Dept: Microbiology and Immunology  
Award: 1R01CA158179-01A1 (11030479-1)

Vanek, Kenneth  
Co-Investigator  
Complement, Anti-Tumor Immunity and Apoptosis-Based Therapy  
PI: Stephen Tomlinson  
Sponsor: NIH/NCI  
Total: $306,063  
Dept: Microbiology and Immunology  
Award: 1R01CA158179-01A1 (11030479-1)

Radiology

Bradshaw, Marques  
Co-Investigator  
A Phase 3, Open-Label, Multi-Center Study for the Assessment of Myocardial Perfusion Using Positron Emission Tomography (PET) Imaging of Fluorine 18 Injection in Patients with Suspected or Known Coronary Artery Disease (CAD)  
PI: Kenneth Spicer  
Sponsor: MUSC OIP  
Total: $138,075  
Dept: Radiology  
Award: BMS747158-301 (11110085-1)

A Phase 2 Assessment of the Diagnostic Accuracy of 99m Tc-MIP-1404 Imaging in Men with High-Risk Prostate Cancer Scheduled for Radical Prostatectomy and Extended Pelvic Lymphnode Dissection Compared to  
PI: Thomas Keane  
Sponsor: Novella Clinical, Inc.  
Total: $152,143  
Dept: Urology  
Award: MIP-1404-201 (12111602-1)

Brown, Truman  
Principal Investigator  
Presurgical Application of fMRI in Epilepsy  
Medical College of Wisconsin  
Budget Dates: 06/15/11 - 05/31/12  
Project Dates: 09/01/97 - 05/31/16  
Direct F & A Total  
33,252 15,794 49,046
<table>
<thead>
<tr>
<th>Name</th>
<th>Role</th>
<th>Project Title</th>
<th>Sponsor</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brown, Truman</td>
<td>Principal Investigator</td>
<td>Presurgical Application of fMRI in Epilepsy</td>
<td>Medical College of Wisconsin</td>
<td>53,949</td>
</tr>
<tr>
<td></td>
<td></td>
<td>2 (130110113)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Project Dates: 09/01/17 - 05/31/16</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Budget Dates: 06/01/12 - 05/31/13</td>
<td>Direct F &amp; A</td>
<td>41,664</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>12,285</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>53,949</td>
</tr>
<tr>
<td></td>
<td>Co-Investigator</td>
<td>Koning Breast CT</td>
<td>Koning Corporation</td>
<td>$20,002</td>
</tr>
<tr>
<td></td>
<td></td>
<td>PI: Etta Pisano</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Dept: Radiology</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Principal Investigator</td>
<td>Scepter C Occlusion Balloon Evaluation Program</td>
<td>MicroVention, Inc</td>
<td>1,500</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Scepter C (12081161)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Project Dates: 03/01/17 - 05/31/17</td>
<td>Direct F &amp; A</td>
<td>1,200</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>300</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>1,500</td>
</tr>
<tr>
<td></td>
<td></td>
<td>VFC Evaluation Program</td>
<td>MicroVention, Inc</td>
<td>3,000</td>
</tr>
<tr>
<td></td>
<td></td>
<td>VFC (12081162)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Project Dates: 03/01/17 - 05/31/17</td>
<td>Direct F &amp; A</td>
<td>2,400</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>600</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>3,000</td>
</tr>
<tr>
<td></td>
<td>Co-Investigator</td>
<td>Evaluate C-Am Dyna CT versus Conventional CT Myelography</td>
<td>Aquilla Turk, III</td>
<td>$164,951</td>
</tr>
<tr>
<td></td>
<td></td>
<td>PI: Aquilla Turk, III</td>
<td>Siemens Medical Solutions U</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Dept: Radiology</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>PI: Aquilla Turk, III</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Dept: Radiology</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>A Randomized, Concurrent, Controlled Trial to Assess the Safety and Effectiveness of the Separator 3D as a Component of the Penumbra System in the Revascularization of Large Vessel Occlusion in Acute Ischemic Stroke</td>
<td>Penumbra, Inc</td>
<td>$141,150</td>
</tr>
<tr>
<td></td>
<td></td>
<td>PI: Aquilla Turk, III</td>
<td>Penumbra 3D</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Dept: Radiology</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>ACE: Aneurysm Coiling Efficiency Study of the Penumbra Coil 400 System</td>
<td>Penumbra, Inc</td>
<td>$31,813</td>
</tr>
<tr>
<td></td>
<td></td>
<td>PI: Aquilla Turk, III</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Dept: Radiology</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cole, Elodia</td>
<td>Co-Investigator</td>
<td>Validation of Imaging Premarket Evaluation and Regulation (VIPER)</td>
<td>DHHS</td>
<td>$570,000</td>
</tr>
<tr>
<td></td>
<td></td>
<td>PI: Etta Pisano</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Dept: Radiology</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gordon, Leonie</td>
<td>Co-Investigator</td>
<td>A Phase 3, Open-Label, Multi-Center Study for the Assessment of Myocardial Perfusion Using Positron Emission Tomography (PET) Imaging of Flurpiridaz F 18 Injection in Patients with Suspected or Known Coronary Artery Disease (CAD)</td>
<td>Penumbra, Inc</td>
<td>$138,075</td>
</tr>
<tr>
<td></td>
<td></td>
<td>PI: Kenneth Spicer</td>
<td>MUSC QIP</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Dept: Radiology</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Guimaraes, Marcelo</td>
<td>Principal Investigator</td>
<td>Detachable Nester Embolization Coil Proof of Concept Testing</td>
<td>Cook, Inc.</td>
<td>17,923</td>
</tr>
<tr>
<td></td>
<td></td>
<td>September Training Event (10071228)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Project Dates: 04/12/10 - 12/31/11</td>
<td>Direct F &amp; A</td>
<td>12,152</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>5,771</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>17,923</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Pharmacomechanical Catheter-Directed Thrombolysis for Acute DVT - ATTRACT Trial</td>
<td>Washington Univ.</td>
<td>54,073</td>
</tr>
<tr>
<td></td>
<td></td>
<td>WU-11-281/U01 HL088476-03 (12020164)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Project Dates: 04/01/11 - 03/31/12</td>
<td>Direct F &amp; A</td>
<td>36,659</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>17,414</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>54,073</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Acute Venous Thrombosis: Thrombus Removal with Adjunctive Catheter-Directed Thrombolysis-Attrac</td>
<td>Washington Univ.</td>
<td>30,000</td>
</tr>
<tr>
<td></td>
<td></td>
<td>ATTRACT - Corporate (12030385)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Project Dates: 10/04/11 - 09/30/12</td>
<td>Direct F &amp; A</td>
<td>24,000</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>6,000</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>30,000</td>
</tr>
<tr>
<td>Principal Investigator</td>
<td>Project Description</td>
<td>Sponsor</td>
<td>Budget Dates</td>
<td>Direct F &amp; A</td>
</tr>
<tr>
<td>------------------------</td>
<td>--------------------</td>
<td>---------</td>
<td>--------------</td>
<td>-------------</td>
</tr>
<tr>
<td>Guimaraes, Marcelo</td>
<td>Phase 3, Prospective, Randomized, Blinded and Controlled Investigation of Hepasphere/Quadrasphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Cancer</td>
<td>Hi-Quality (12040483)</td>
<td>10/28/11 - 03/31/13</td>
<td>128,436</td>
</tr>
<tr>
<td>Helpern, Joseph</td>
<td>BICOEE/Endowed Chair in Brain Imaging</td>
<td>USC Research Foundation</td>
<td>07/01/09 - 06/30/12</td>
<td>511,263</td>
</tr>
<tr>
<td>Jensen, Jens</td>
<td>Axonal Density as a Non-Invasive Biomarker for the Early Prediction and Monitoring of Alzheimer's Disease: an MRI Pilot Study</td>
<td>New York University</td>
<td>08/01/11 - 05/31/12</td>
<td>7,262</td>
</tr>
<tr>
<td>Matheus, Gisele</td>
<td>Safety and Efficacy Evaluation of Dotarem in Magnetic Resonance Imaging (MRI) in Patients with Central Nervous System (CNS) Lesions (Sentio Study)</td>
<td>Univ. of North Carolina</td>
<td>09/01/11 - 07/31/12</td>
<td>12,281</td>
</tr>
<tr>
<td>Pisano, Etta</td>
<td>A Multi-Center, Clinical Study to Acquire Xpress Digital Mammography System Images for Computer Aided Detection Development</td>
<td>Konica Minolta Medical Imaging USA</td>
<td>11/01/10 - 11/30/12</td>
<td>10,438</td>
</tr>
<tr>
<td>Ravenel, James</td>
<td>Centers of Quantitative Imaging Excellence</td>
<td>Amer. Coll. of Radiology</td>
<td>08/01/11 - 07/31/14</td>
<td>6,102</td>
</tr>
<tr>
<td>Roberts, Donna</td>
<td>Safety and Efficacy Evaluation of Dotarem in Magnetic Resonance Imaging (MRI) in Patients with Central Nervous System (CNS) Lesions (Sentio Study)</td>
<td>MUSC OIP</td>
<td>06/09/11 - 06/08/13</td>
<td>34,972</td>
</tr>
<tr>
<td>Schoepf, Uwe</td>
<td>Siemens Core Lab</td>
<td>Siemens Medical Solutions USA</td>
<td>05/01/12 - 06/30/13</td>
<td>888,000</td>
</tr>
<tr>
<td>Spicer, Kenneth</td>
<td>A Phase 3, Open-Label, Multi-Center Study for the Assessment of Myocardial Perfusion Using Positron Emission Tomography (PET) Imaging of Fluorpiridaz F 18 Injection in Patients with Suspected or Known Coronary Artery Disease (CAD)</td>
<td>MUSC OIP</td>
<td>09/27/11 - 09/28/13</td>
<td>112,375</td>
</tr>
<tr>
<td>Name</td>
<td>Position</td>
<td>Project Title</td>
<td>PI/Institution</td>
<td>Sponsor</td>
</tr>
<tr>
<td>-------------------</td>
<td>---------------------------------</td>
<td>-------------------------------------------------------------------------------</td>
<td>--------------------------------------</td>
<td>--------------------------------</td>
</tr>
<tr>
<td>Spicer, Kenneth</td>
<td>Co-PI/Project Director</td>
<td>Alzheimer's Disease Neuroimaging Initiative</td>
<td>Jacobo Mintzer</td>
<td>Univ. of California, San Diego</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Award: AG024904 (11021159-2)</td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Co-Investigator</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Bapineuzumab In Patients with Mild to Moderate Alzheimer's Disease (ApoE4 Non-Carrier)</td>
<td>Jacobo Mintzer</td>
<td>Parexel Intl. Corp.</td>
</tr>
<tr>
<td>Taheri, Saeid</td>
<td>Principal Investigator</td>
<td>Predicting Tissue Fate in Acute Cerebral Ischemia Using BBB Permeability and ADC of Water Measured by Multi-Modal MRI</td>
<td></td>
<td>Amer. Heart Assoc.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Project Dates: 07/01/11 - 06/30/12</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Direct: 63,636</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Total: 70,000</td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Co-Investigator</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Project Dates: 07/12/10 - 06/30/13</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Direct: 20,110</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Total: 29,662</td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Evaluate C-Arm Dyna CT versus Conventional CT Myelography</strong></td>
<td></td>
<td>Siemens Medical Solutions USA</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Project Dates: 11/14/11 - 11/13/12</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Direct: 50,000</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Total: 50,000</td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>A Single Center Experience of Patients Treated with the Penumbra Coil 400 in Conjunction with Stent or Balloon Remodeling</strong></td>
<td></td>
<td>Penumbra, Inc.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Project Dates: 11/01/11 - 10/31/12</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Direct: 69,432</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Total: 86,040</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Project Dates: 11/01/11 - 04/30/13</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Direct: 30,364</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Total: 37,205</td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>MVI Liquid Embolic Project</strong></td>
<td></td>
<td>MicroVention, Inc.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Project Dates: 04/01/12 - 03/31/13</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Direct: 14,288</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Total: 21,075</td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>A Randomized, Concurrent, Controlled Trial to Assess the Safety and Effectiveness of the Separator 3D as a Component of the Penumbra System in the Revascularization of Large Vessel Occlusion in Acute Ischemic Stroke</strong></td>
<td></td>
<td>Penumbra, Inc.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Project Dates: 04/26/12 - 04/25/13</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Direct: 113,120</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Total: 141,150</td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>The Penumbra Coil 400TM vs. Pipeline Embolic Device for the Treatment of Large and Giant Aneurysms in the Anterior Circulation: A Randomized, Concurrent Controlled Trial</strong></td>
<td></td>
<td>Penumbra, Inc.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Project Dates: 06/01/12 - 06/30/13</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Direct: 3,393,711</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Total: 4,241,389</td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>ACE: Aneurysm Coiling Efficiency Study of the Penumbra Coil 400 System</strong></td>
<td></td>
<td>Penumbra, Inc.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Project Dates: 06/01/12 - 07/31/14</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Direct: 26,050</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Total: 31,813</td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Co-Investigator</strong></td>
<td></td>
<td>Codman Training Grant - Work Order #2</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Raymond Turner</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Award: Codman- Work Order 2 (12050699-1)</td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>EV3 Training Event (2/26/12 and 2/27/12)</strong></td>
<td></td>
<td>Raymond Turner</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Award: Training event (12081123-1)</td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Interventional Management of Stroke Study III - Per Patient</strong></td>
<td></td>
<td>Edward Jauch</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Award: COEUS #7753/U01 NS052220 (12091215-1)</td>
</tr>
</tbody>
</table>
**Regenerative Medicine and Cell Biology**

**Allen, Emily**  
**Principal Investigator**  
*A Comparative Analysis of Oxidative Stress-Response in PSW iPSCs and Mouse ESCs*  
NSF  
<table>
<thead>
<tr>
<th>Budget Dates:</th>
<th>Direct</th>
<th>F &amp; A</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>09/01/11 - 08/31/12</td>
<td>40,500</td>
<td>0</td>
<td>40,500</td>
</tr>
</tbody>
</table>

**Argraves, Kelley**  
**Principal Investigator**  
*ST1P Deficiency Prolongs Endothelial Barrier Recovery after Fontan Operation*  
NIH/NHLBI  
<table>
<thead>
<tr>
<th>Budget Dates:</th>
<th>Direct</th>
<th>F &amp; A</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>04/01/12 - 03/31/13</td>
<td>150,000</td>
<td>71,250</td>
<td>221,250</td>
</tr>
</tbody>
</table>

**Co-PI/Project Director**  
*SC COBRE for Developmentally Based Cardiovascular Diseases (Core C: Proteomics)*  
Dept: Regenerative Medicine and Cell Bio  
Award: 3P20RR016434-10S1 (11050254-4)

**Aseeem, Obaidullah**  
**Principal Investigator**  
*The Role of Cubilin in High Density Liporotein Homeostasis*  
Amer. Heart Assoc./Mid-Atlantic  
<table>
<thead>
<tr>
<th>Budget Dates:</th>
<th>Direct</th>
<th>F &amp; A</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>07/01/11 - 06/30/12</td>
<td>23,000</td>
<td>0</td>
<td>23,000</td>
</tr>
</tbody>
</table>

**Barth, Jeremy**  
**Co-Investigator**  
*Palmetto Academy 2012: Palmetto Academy Site at MUSC*  
PI: W. Argraves  
Dept: Regenerative Medicine and Cell Bio  
Award: NNX10AM76H/19-SG-MUSC_Arg (12070959-1)

**Borg, Thomas**  
**Principal Investigator**  
*Dynamic Interaction Between Cardiac Fibroblasts, Myocytes, and the ECM*  
NIH/NHLBI  
<table>
<thead>
<tr>
<th>Budget Dates:</th>
<th>Direct</th>
<th>F &amp; A</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>04/01/12 - 03/31/13</td>
<td>244,854</td>
<td>116,305</td>
<td>361,159</td>
</tr>
</tbody>
</table>

**Bratoeva, Momka**  
**Co-Investigator**  
*Evaluation of Hyaluronic Acid Dys-Regulation as the Driving Mechanism Behind the Apparent Increase in Cancers Seen with an SGLT2 Inhibitor*  
PI: Bryan Toole  
Dept: Regenerative Medicine and Cell Bio  
Award: Pfizer lab (12111591-1)

**Briggs, Laura**  
**Principal Investigator**  
*The Role of BMP4 In the Development of the Dorsal Mesenchymal Protrusion*  
Amer. Heart Assoc.  
<table>
<thead>
<tr>
<th>Budget Dates:</th>
<th>Direct</th>
<th>F &amp; A</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>07/01/11 - 06/30/12</td>
<td>23,000</td>
<td>0</td>
<td>23,000</td>
</tr>
</tbody>
</table>

**Cooley, Marion**  
**Co-Investigator**  
*Fibulin-1 Regulation of the DiGeorge Syndrome Pathogenesis Pathway*  
PI: W. Argraves  
Dept: Regenerative Medicine and Cell Bio  
Award: 5R01HL095067-04 (12040506-1)

---

Medical University of South Carolina 143
### Gentile, Carmine

**Principal Investigator**  

**VEGF/Akt-Mediated Endothelial Nitric Oxide Synthase Phosphorylation as a Regulator of Endothelial Cell Division**  

<table>
<thead>
<tr>
<th>Amer. Heart Assoc./Mid-Atlantic</th>
<th><strong>Project Dates:</strong> 07/01/11 - 06/30/13</th>
<th><strong>Direct</strong></th>
<th><strong>F &amp; A</strong></th>
<th><strong>Total</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>11PRE7530048 (11012413)</td>
<td>23,000</td>
<td>0</td>
<td>23,000</td>
<td></td>
</tr>
</tbody>
</table>

### Gourdie, Robert

**Principal Investigator**  

**Gap Junctional Patterning in Arrhythmic Heart**  

<table>
<thead>
<tr>
<th>NIH/NHLBI</th>
<th><strong>Project Dates:</strong> 04/01/10 - 02/28/14</th>
<th><strong>Direct</strong></th>
<th><strong>F &amp; A</strong></th>
<th><strong>Total</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>5R01HL056728-12 (12091210)</td>
<td>222,750</td>
<td>105,806</td>
<td>328,556</td>
<td></td>
</tr>
</tbody>
</table>

### Grass, George

**Principal Investigator**  

**Functional Interactions of Hyaluronan, CD44, and Emmprin in Breast Cancer Progression**  

<table>
<thead>
<tr>
<th>DOD</th>
<th><strong>Project Dates:</strong> 02/01/10 - 02/28/13</th>
<th><strong>Direct</strong></th>
<th><strong>F &amp; A</strong></th>
<th><strong>Total</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>W81XWH-10-1-0083 (09031042)</td>
<td>40,000</td>
<td>2,040</td>
<td>42,040</td>
<td></td>
</tr>
</tbody>
</table>

### Hsia, Tain-Yen

**Principal Investigator**  

**Elastic Membrane Based Sensors for Wireless Monitoring of Intracardiac Hemodynamics and Oxygenation**  

<table>
<thead>
<tr>
<th>Amer. Heart Assoc.</th>
<th><strong>Project Dates:</strong> 01/01/10 - 12/31/13</th>
<th><strong>Direct</strong></th>
<th><strong>F &amp; A</strong></th>
<th><strong>Total</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>10SDG26000256 (09012039)</td>
<td>69,967</td>
<td>6,996</td>
<td>76,963</td>
<td></td>
</tr>
</tbody>
</table>

### Kern, Christine

**Principal Investigator**  

**The Role of the Matrix Metalloproteinase ADAMTS9 in Cardiovascular Development**  

<table>
<thead>
<tr>
<th>Amer. Heart Assoc.</th>
<th><strong>Project Dates:</strong> 01/01/10 - 12/31/13</th>
<th><strong>Direct</strong></th>
<th><strong>F &amp; A</strong></th>
<th><strong>Total</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>10SDG2610168 (09072142)</td>
<td>70,000</td>
<td>7,000</td>
<td>77,000</td>
<td></td>
</tr>
</tbody>
</table>

### Kern, Michael

**Co-PI/Project Director**  

**Prx1 Isoforms as Matuorgens for Bioengineered Vasculature**  

<table>
<thead>
<tr>
<th>SC Research Authority</th>
<th><strong>Project Dates:</strong> 07/01/11 - 06/30/12</th>
<th><strong>Direct</strong></th>
<th><strong>F &amp; A</strong></th>
<th><strong>Total</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>TO #0063/EPS-0903795 (11042947)</td>
<td>50,000</td>
<td>0</td>
<td>50,000</td>
<td></td>
</tr>
</tbody>
</table>

### Krug, Edward

**Co-Investigator**  

**MUSC-Claflin Cooperative for Postdoctoral Academic Career Development**  

<table>
<thead>
<tr>
<th>Cynthia Wright</th>
<th><strong>Award:</strong> 5K12GM081265-05 (11110104-1)</th>
<th><strong>Total:</strong> $377,537</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Corey Mjaatvedt</th>
<th><strong>Award:</strong> 5R01HL066231-10 (12060749-1)</th>
<th><strong>Total:</strong> $361,350</th>
</tr>
</thead>
</table>

### Co-Investigator**  

**CSPG2 Gene and Cardiac Outlet Morphogenesis**  

<table>
<thead>
<tr>
<th>Amer. Heart Assoc.</th>
<th><strong>Project Dates:</strong> 07/01/11 - 06/30/13</th>
<th><strong>Direct</strong></th>
<th><strong>F &amp; A</strong></th>
<th><strong>Total</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>11PRE7530048 (11012413)</td>
<td>23,000</td>
<td>0</td>
<td>23,000</td>
<td></td>
</tr>
<tr>
<td>Principal Investigator</td>
<td>Project Title</td>
<td>Sponsor</td>
<td>Budget Dates</td>
<td>Direct F &amp; A</td>
</tr>
<tr>
<td>------------------------</td>
<td>---------------</td>
<td>---------</td>
<td>--------------</td>
<td>--------------</td>
</tr>
<tr>
<td>Lacy, Eric</td>
<td>Support for the NOAA Center of Excellence in Oceans and Human Health at the Hollings Marine Laboratory</td>
<td>NOAA</td>
<td>10/01/10 - 09/30/12</td>
<td>59,524</td>
</tr>
<tr>
<td></td>
<td></td>
<td>MOA-2010-050-8136 (10062531)</td>
<td>Project Dates: 10/01/10 - 09/30/12</td>
<td>15,476</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Principal Investigator</th>
<th>Project Title</th>
<th>Sponsor</th>
<th>Budget Dates</th>
<th>Direct F &amp; A</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Markwald, Roger</td>
<td>Mitral Valve Disease: from Genetic Mechanisms to Improved Repair</td>
<td>Leducq Foundation</td>
<td>01/01/12 - 12/31/12</td>
<td>73,171</td>
<td>80,488</td>
</tr>
<tr>
<td></td>
<td></td>
<td>(11010631)</td>
<td>Project Dates: 01/01/08 - 12/31/12</td>
<td>7,317</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Principal Investigator</th>
<th>Project Title</th>
<th>Sponsor</th>
<th>Budget Dates</th>
<th>Direct F &amp; A</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mironov, Vladimir</td>
<td>Mitral Valve Disease: from Genetic Mechanisms to Improved Repair</td>
<td>Leducq Foundation</td>
<td>01/01/12 - 12/31/12</td>
<td>73,171</td>
<td>80,488</td>
</tr>
<tr>
<td></td>
<td></td>
<td>(12070948)</td>
<td>Project Dates: 10/01/07 - 12/31/12</td>
<td>7,317</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Principal Investigator</th>
<th>Project Title</th>
<th>Sponsor</th>
<th>Budget Dates</th>
<th>Direct F &amp; A</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Norris, Russell</td>
<td>Pathogenetic Mechanisms of Myxomatous Mitral Valve Dystrophy</td>
<td>Amer. Heart Assoc.</td>
<td>01/01/12 - 12/31/12</td>
<td>70,000</td>
<td>77,000</td>
</tr>
<tr>
<td></td>
<td></td>
<td>11SDG5270006 (10071550)</td>
<td>Project Dates: 01/01/11 - 12/31/14</td>
<td>7,000</td>
<td></td>
</tr>
</tbody>
</table>
Palatinus, Joseph  
Principal Investigator  
**Connexin 43 Gap Junction Dynamics in the Diabetic Heart**  
NIH/NHLBI  
Budget Dates: 02/01/12 - 01/31/13  
Direct F & A  
Total  
5F30HL095320-04 (12050697)  
Project Dates: 02/01/09 - 01/31/14  
36,637 0 36,637

Pardue, Erin  
Principal Investigator  
**The Influence of Fibulin-1 on Hematopoietically Derived Cell Populations in Heart Valves**  
Amer. Heart Assoc./Mid-Atlantic  
Budget Dates: 07/01/11 - 06/30/12  
Direct F & A  
Total  
10PRE4020031 (10060782)  
Project Dates: 07/01/10 - 06/30/12  
23,000 0 23,000

Reaves, Titus  
Principal Investigator  
**2012 Ernest Everett Just Scientific Symposium**  
SC Research Authority  
Project Dates: 01/01/12 - 04/30/12  
Direct F & A  
Total  
0065 (12070895)  
Project Dates: 01/01/12 - 04/30/12  
10,000 0 10,000

Sugi, Yukiko  
Principal Investigator  
**The Role of BMP in Regulating Valvulogenesis**  
Amer. Heart Assoc./Mid-Atlantic  
Budget Dates: 01/01/12 - 12/31/12  
Direct F & A  
Total  
10GRNT3900044 (10011285)  
Project Dates: 01/01/11 - 12/31/12  
70,000 7,000 77,000

Swaja, Richard  
Principal Investigator  
**Developing Living Tissue-Engineered Cochlear Implants for Hearing Restoration in Deaf and Hard-of-Hearing Infants**  
Clemson Univ.  
Budget Dates: 06/06/10 - 05/31/12  
Direct F & A  
Total  
1270-7559-247-2006591 (07091180)  
Project Dates: 06/06/08 - 05/31/12  
9,818 982 10,800

**Engineering Chronic Spinal Cord Injury Lesion Cavity for Enhanced Regeneration**  
Clemson Univ.  
Budget Dates: 09/29/11 - 09/28/12  
Direct F & A  
Total  
1482-201-2008131/W81XWH-1 (09120849)  
Project Dates: 09/29/10 - 10/29/13  
30,000 14,250 44,250

**Tissue Engineering in Spinal Cord Regeneration**  
Clemson Univ.  
Budget Dates: 04/01/11 - 03/31/12  
Direct F & A  
Total  
1116-7558-2006035 (11032377)  
Project Dates: 04/01/07 - 03/31/12  
46,433 21,359 67,792

**SmartState Center for Advanced Tissue Biofabrication State Match Endowment Draw**  
SC Research Centers of Economic Excellence  
(12101407)  
Project Dates: 06/09/08 - 06/30/12  
4,060,571 0 4,060,571

Toole, Bryan  
Principal Investigator  
**Evaluation of Hyaluronic Acid Dys-Regulation as the Driving Mechanism Behind the Apparent Increase in Cancers Seen with an SGLT2 Inhibitor**  
Pfizer, Inc.  
Budget Dates: 05/31/12 - 05/30/13  
Direct F & A  
Total  
Pfizer lab (12111591)  
Project Dates: 05/31/12 - 05/30/13  
21,000 9,975 30,975

Trusk, Thompson  
Co-PI/Project Director  
**SC COBRE for Developmentally Based Cardiovascular Diseases (Core B: Morphology, Imaging and Instrumentation)**  
Pl: Roger Markwald  
Sponsor: NIH/NCRR  
Total: $ 272,875  
Dept: Regenerative Medicine and Cell Bio  
Award: 3P20RR016434-10S1 (11050254-3)

Twal, Waleed  
Co-Investigator  
**Hereditary Hemochromatosis and Telomere Length**  
Pl: Arch Mainous  
Sponsor: CDC  
Total: $ 150,839  
Dept: Family Medicine  
Award: 1 U01 DD000754-01 (11022213-1)

**Fibulin-1 Regulation of the DiGeorge Syndrome Pathogenesis Pathway**  
Pl: W. Argraves  
Sponsor: NIH/NHLBI  
Total: $ 328,556  
Dept: Regenerative Medicine and Cell Bio  
Award: 5R01HL095067-04 (12040506-1)

**Fibulin-1 Regulation of the DiGeorge Syndrome Pathogenesis Pathway**  
Pl: W. Argraves  
Sponsor: NIH/NHLBI  
Total: $ 36,507  
Dept: Regenerative Medicine and Cell Bio  
Award: 5R01HL095067-04 (12040506-2)

Visconti, Richard  
Co-Investigator  
**Caveolin-1 Regulation of Altered Functions of Scleroderma Fibrocytes**  
Pl: Elena Tourkina  
Sponsor: NIH/NIAMS  
Total: $ 70,800  
Dept: Medicine  
Award: 4R03AR056767-03 (11050361-1)
Wen, Xuejun  
Co-PI/Project Director  
Developing Living Tissue-Engineered Cochlear Implants for Hearing Restoration in Deaf and Hard-of-Hearing Infants  
Pl: Richard Swaja  
Dept: Regenerative Medicine and Cell Bio  
Sponsor: Clemson Univ.  
Award: 1270-7559-247-2006591 (07091180-4)  
Total: $10,800

Engineering Chronic Spinal Cord Injury Lesion Cavity for Enhanced Regeneration  
Pl: Richard Swaja  
Dept: Regenerative Medicine and Cell Bio  
Sponsor: Clemson Univ.  
Award: 1482-201-2008131/W81XWH-1 (09120849-2)  
Total: $44,250

Tissue Engineering in Spinal Cord Regeneration  
Pl: Richard Swaja  
Dept: Regenerative Medicine and Cell Bio  
Award: 1116-7558-209-2006035 (11032377-2)

Tissue Engineering in Spinal Cord Regeneration  
Pl: Richard Swaja  
Dept: Regenerative Medicine and Cell Bio  
Award: 1116-7558-209-2006035 (11032377-3)

Co-Investigator  
Accelerated Elastin Assembly in Vascular Constructs Through Suppression of Proteoglycans  
Pl: W. Argraves  
Dept: Regenerative Medicine and Cell Bio  
Sponsor: SC Research Authority  
Award: TO# 0064/EPS-0903795 (11042840-1)  
Total: $50,000

Wessels, Arno  
Co-Investigator  
CSPG2 Gene and Cardiac Outlet Morphogenesis  
Pl: Corey Mjaatvedt  
Dept: Regenerative Medicine and Cell Bio  
Sponsor: NIH/NHLBI  
Award: 5R01HL066231-10 (12060749-1)  
Total: $361,350

Wilkerson, Brent  
Principal Investigator  
HDL-Associated STP in Endothelial Barrier Function and Atherosclerosis  
Pl: Hongjun Wang  
Dept: Surgery  
Sponsor: Juvenile Diabetes Fdn.  
Award: 5-2012-149 (12030337-1)  
Total: $110,000

Yamaguchi, Naohiro  
Principal Investigator  
Calmodulin Regulation of Cardiac Ca2+ Transporting Channels  
Pl: Corey Mjaatvedt  
Dept: Regenerative Medicine and Cell Bio  
Sponsor: NIH/NHLBI  
Award: 5R01HL066231-10 (12060749-1)  
Total: $361,350

Surgery  
Adams, David  
Co-Investigator  
RGS2, a Novel Target to Promote Islet Graft Survival  
Pl: Hongjun Wang  
Dept: Surgery  
Sponsor: Juvenile Diabetes Fdn.  
Award: 5-2012-149 (12030337-1)  
Total: $110,000

Baker, Megan  
Principal Investigator  
NSABP  
Pl: J. Saul  
Dept: Pediatrics  
Sponsor: NIH/NHLBI  
Award: 1U10HL109778-01 (10102672-1)  
Total: $430,753

Baliga, Prabhakar  
Principal Investigator  
A Program to Increase Living Donation in African Americans  
Pl: Hongjun Wang  
Dept: Surgery  
Sponsor: Juvenile Diabetes Fdn.  
Award: 5-2012-149 (12030337-1)  
Total: $110,000

Proteogenomics for Organ Transplantation: Prediction, Diagnosis, Intervention  
Pl: J. Saul  
Dept: Pediatrics  
Sponsor: NIH/NHLBI  
Award: 1U10HL109778-01 (10102672-1)  
Total: $430,753

Medical University of South Carolina 147
Camp, Ernest  
Principal Investigator  
**Innovative Delivery Strategy for CaSm Gene Therapy in Pancreatic Cancer**  
NIH/NCI  
Budget Dates: 09/01/11 - 08/31/12  
Project Dates: 09/01/10 - 08/31/15  
Direct F & A Total  
5K08CA142904-02 (11120347)  
160,600 12,848 173,448

Chavin, Kenneth  
Principal Investigator  
**A 24 Month, Multi-Center, Open-Label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Concentration-Controlled Everolimus to Eliminate or to Reduce Tacrolimus Compared to Tacrolimus in De Novo Liver Transplant Recipients**  
Novartis Corp.  
Budget Dates: 10/15/07 - 10/15/14  
Direct F & A Total  
RAD001H2304E1 (08051463)  
8,000 2,000 10,000

**Evaluating Nuoigix Long-Term Safety in Transplant ENLIST Registry**  
Parexel Intl. Corp.  
Budget Dates: 02/06/12 - 01/31/13  
Direct F & A Total  
IM103076 (12070949)  
37,480 8,620 46,100

**An Investigation Plan Evaluating the Operative Management of Parenchymal Bleeding by Means of an Adjunctive Application of BoiFoam Surgical Marrix in Liver Surgery**  
Aptiv Solutions  
Budget Dates: 05/22/12 - 10/01/12  
Direct F & A Total  
BARRIER STUDY (12111586)  
9,940 1,860 11,800

Cole, David  
Co-Investigator  
**A Program to Increase Living Donation in African Americans**  
Prabhakar Baliga  
Sponsor: NIH/NIDDK  
Total: $199,832  
Dept: Surgery  
Award: 1R01DK062596-10 (11120270-1)

Denlinger, Chadrick  
Principal Investigator  
**A Medical Center Network for Optimized Lung Cancer Biospecimen Banking**  
Univ. of Virginia  
Budget Dates: 09/20/11 - 09/19/12  
Project Dates: 09/20/10 - 10/19/14  
Direct F & A Total  
GG11364-137226 (12070909)  
169,021 80,285 249,306

Esnaola, Nestor  
Co-PI/Project Director  
**Improving Resection Rates among African Americans with NSCLC**  
Marvella Ford  
Sponsor: NIH/NCMHD  
Total: $368,750  
Dept: Medicine  
Award: 1R01MD005892-01A1 (11120246-1)

Fakhry, Samir  
Principal Investigator  
**The Virtual TeleConsult Clinic: Leveraging Cost-Effective Technology to Improve Access to Quality Tertiary Health Care**  
MUSC Fdn.  
Budget Dates: 07/01/11 - 06/30/12  
Project Dates: 07/01/11 - 06/30/13  
Direct F & A Total  
6310-SP (12020253)  
296,926 0 296,926

Hebra, Andre  
Principal Investigator  
**An Open-Label, Multi-Center Study of the Safety of Twice Daily Oxycodone Hydrochloride Controlled Release Tablets in Opioid Experienced Children from Ages 6 to 16 Years Old, Inclusive, with Moderate**  
MUSC OIP  
Budget Dates: 11/02/11 - 11/01/13  
Project Dates: 11/02/11 - 11/01/13  
Direct F & A Total  
OTR3001 (12020244)  
155,288 35,797 191,085

Ikonomidis, John  
Principal Investigator  
**Age-Dependent Mechanisms for Thoracic Aortic Aneurysms**  
NIH/NIA  
Budget Dates: 09/01/11 - 08/31/12  
Project Dates: 09/01/11 - 08/31/16  
Direct F & A Total  
1R01AG036954-01A1 (10021716)  
206,739 83,951 290,690
**Ikonomidis, John**

**Principal Investigator**

**Multi-Disciplinary Simulation and Training in Cardiac Surgical Crisis Management**
Thoracic Surgery Fdn.  
Budget Dates: 07/01/11 - 06/30/12  
Project Dates: 07/01/11 - 06/30/12  
Direct F & A Total  
23,500 0 23,500

**Transmembrane Proteolytic Induction and Thoracic Aneurysms**
NIH/NHLBI  
Budget Dates: 12/01/11 - 11/30/12  
Project Dates: 12/01/10 - 11/30/14  
Direct F & A Total  
250,000 118,750 368,750

**Co-Investigator**

**Advanced Glycation End-Products in Human Myocardium**
PI: Michael Zile  
Sponsor: Univ. of Vermont  
Total: $216,246

**Jones, Jeffrey**

**Principal Investigator**

**Transforming Growth Factor-Beta Signaling Pathways in Thoracic Aortic Aneurysms**
VAMC  
Budget Dates: 01/01/12 - 12/31/13  
Project Dates: 01/01/11 - 12/31/13  
Direct F & A Total  
256,100 0 256,100

**VAMC IPA for R. Patel: Maladaptive Remodeling in Aging Myocardium**
WJB Dorn VA Medical Center  
Budget Dates: 07/01/11 - 02/29/12  
Project Dates: 07/01/11 - 02/29/12  
Direct F & A Total  
8,110 0 8,110

**VAMC IPA for R. Patel: Proteolytic Enzyme Induction within the Human Myocardial Interstitium**
WJB Dorn VA Medical Center  
Budget Dates: 07/01/11 - 02/29/12  
Project Dates: 07/01/11 - 02/29/12  
Direct F & A Total  
8,110 0 8,110

**Lin, Angello**

**Principal Investigator**

**A Phase 2, Multi-Center, Open-Label, Active, Comparator-Controlled, Extension Trial to Evaluate the Long-Term Safety and Efficacy of CP690,550 in Renal Allograft Recipients**
Icon Clinical Research, Inc.  
Budget Dates: 03/25/09 - 08/21/13  
Project Dates: 03/25/09 - 08/21/13  
Direct F & A Total  
448 112 560

**McGillicuddy, John**

**Principal Investigator**

**A Phase 2/3, Double-Blind, Placebo-Controlled, Two-Part Study (Part 1 Open-Label) to Assess the Safety, Efficacy and Pharmacokinetics of Single Intravenous Doses of ASP8597(Diannexin)**
Astellas Pharma US, Inc.  
Budget Dates: 09/01/12 - 08/31/13  
Project Dates: 09/01/12 - 08/31/17  
Direct F & A Total  
746,237 185,434 931,671

**Mehrotra, Shikhar**

**Principal Investigator**

**Oxidative Stress and AICD in Memory T Cell Persistence**
NIH/NCI  
Budget Dates: 05/01/12 - 04/30/13  
Project Dates: 06/02/10 - 04/30/15  
Direct F & A Total  
201,275 95,606 296,881

**Modulating Tolerance in a Spontaneous Mouse Model of Autoimmune Vitiligo**
Loyola University Chicago  
Budget Dates: 05/01/12 - 04/30/13  
Project Dates: 09/01/10 - 04/30/15  
Direct F & A Total  
80,490 38,233 118,723

**Co-Investigator**

**TCR Gene Modified T Cells for Adoptive Immunotherapy (Core D)**
Pl: David Cole  
Sponsor: Loyola University Chicago  
Total: $118,023

**Co-Investigator**

**TCR Gene Modified T Cells for Adoptive Immunotherapy (Project 3)**
Pl: David Cole  
Sponsor: Loyola University Chicago  
Total: $278,984
Mukherjee, Rupak  
Principal Investigator  
**VAMC IPA: Maladaptive Remodeling in Aging Myocardium**  
WJB Dorn VA Medical Center  
Budget Dates: 07/01/11 - 02/29/12  
Direct F & A Total  
29,296 0 29,296  
Project Dates: 07/01/11 - 02/29/12  

**VAMC IPA: Proteolytic Enzyme Induction within the Human Myocardial Interstitium**  
WJB Dorn VA Medical Center  
Budget Dates: 07/01/11 - 02/29/12  
Direct F & A Total  
29,296 0 29,296  
Project Dates: 07/01/11 - 02/29/12  

Reed, Carolyn  
Principal Investigator  
**American Cancer Society Institutional Research Grant**  
Amer. Cancer Soc.  
Budget Dates: 01/01/12 - 12/31/12  
Direct F & A Total  
150,000 0 150,000  
Project Dates: 01/01/10 - 12/31/12  

**Clinical Research Study Chair Agreement**  
Duke Univ.  
Budget Dates: 12/18/11 - 06/01/12  
Direct F & A Total  
6,400 1,600 8,000  
Project Dates: 12/18/11 - 06/01/12  

Rubinstein, Mark  
Principal Investigator  
**Maximizing Memory T Cell Responses by Matured Post Chemotherapy Dendritic Cells**  
NIH/NCI  
Budget Dates: 03/01/11 - 02/29/12  
Direct F & A Total  
14,525 6,899 21,424  
Project Dates: 03/01/10 - 02/28/13  

**Maximizing Memory T Cell Responses by Matured Post Chemotherapy Dendritic Cells**  
NIH/NCI  
Budget Dates: 03/01/12 - 02/28/13  
Direct F & A Total  
201,275 95,606 296,881  
Project Dates: 03/01/10 - 02/28/13  

Sade, Robert  
Co-Investigator  
**South Carolina Clinical and Translational Research Institute (UL1)**  
PI: Kathleen Brady  
Sponsor: NIH/NCRR  
Total: $ 301,173  
Dept: Psychiatry and Behavioral Sciences  
Award: 5UL1RR029882-03 (11012750-2)  

**South Carolina Clinical and Translational Research Institute (SCTR): UL1**  
PI: Kathleen Brady  
Sponsor: NIH/NCATS  
Total: $ 2,537,859  
Dept: Psychiatry and Behavioral Sciences  
Award: 8UL1TR000062-04 (12070938-2)  

**South Carolina Clinical and Translational Research Institute (SCTR): UL1**  
PI: Kathleen Brady  
Sponsor: NIH/NCATS  
Total: $ 798,196  
Dept: Psychiatry and Behavioral Sciences  
Award: 8UL1TR000062-04 (12070938-1)  

Stroud, Robert  
Principal Investigator  
**VAMC IPA: Maladaptive Remodeling in Aging Myocardium**  
WJB Dorn VA Medical Center  
Budget Dates: 07/01/11 - 02/29/12  
Direct F & A Total  
8,262 0 8,262  
Project Dates: 07/01/11 - 02/29/12  

**VAMC IPA: Proteolytic Enzyme Induction within the Human Myocardial Interstitium**  
WJB Dorn VA Medical Center  
Budget Dates: 07/01/11 - 02/29/12  
Direct F & A Total  
8,262 0 8,262  
Project Dates: 07/01/11 - 02/29/12  

150 Medical University of South Carolina
Wang, Hongjun  
**Principal Investigator**  
_RGS2, a Novel Target to Promote Islet Graft Survival_  
Juvenile Diabetes Fdn.  
5-2012-149 (12030337)  
Budget Dates: 05/01/12 - 04/30/13  
Project Dates: 05/01/12 - 04/30/13  
Direct F & A Total  
100,000 10,000 110,000

Urology

Clarke, Jr., Harry  
**Principal Investigator**  
_A Phase 3, International, Multi-Center, Double-Blind, Placebo-Controlled, Randomized Trial Evaluating the Efficacy and Safety of Multiple Instillations of Intravesical Apaziquone Vs. Placebo in Patients_  
Spectrum Pharmaceutical Research  
SPI-1011 (12070893)  
Budget Dates: 01/06/12 - 08/31/15  
Project Dates: 01/06/12 - 08/31/15  
Direct F & A Total  
651,690 162,048 813,738

Keane, Thomas  
**Principal Investigator**  
_**A Study of Tanezumab as Add-On Therapy to Opioid Medication in Patients with Pain Due to Cancer That Has Spread to Bone**_  
INC Research, Inc.  
A4091003 (09093033)  
Budget Dates: 08/26/09 - 09/30/12  
Project Dates: 08/26/09 - 09/30/12  
Direct F & A Total  
16,960 4,240 21,200

**Open-Label Extension in Cancer Patients**  
INC Research, Inc.  
A4091029 (09093036)  
Budget Dates: 08/26/09 - 09/30/12  
Project Dates: 08/26/09 - 09/30/12  
Direct F & A Total  
4,045 1,011 5,056

**An Open-Label, Multi-Center, Randomized, Phase 2 Study Evaluating the Safety and Efficacy of Docetaxel in Combination with Ramucirumab (IMC-1121B) Drug Product or IMC-18F1 or without Investigational Therapy as Second-Line therapy in patients with Locally Advanced or Metastatic Transitional cell Carcinoma of the Bladder, Urethra, Ureter, or Renal Pelvis Following Disease Progression on First-Line Platinum-Based Therapy**  
Icon Clinical Research, Inc.  
CP20-0902 (12060701)  
Budget Dates: 12/05/11 - 12/31/13  
Project Dates: 12/05/11 - 12/31/13  
Direct F & A Total  
227,869 56,092 283,961

**A Phase 2 Assessment of the Diagnostic Accuracy of 99m Tc-MIP-1404 Imaging in Men with High-Risk Prostate Cancer Scheduled for Radical Prostatectomy and Extended Pelvic Lymphode Dissection Compared To**  
Novella Clinical, Inc.  
MIP-1404-201 (12111602)  
Budget Dates: 05/10/12 - 05/09/14  
Project Dates: 05/10/12 - 05/09/14  
Direct F & A Total  
122,314 29,829 152,143

**Co-Investigator**  
The Role of Thromboxane A2 (TP) Receptor Beta in Bladder Cancer  
PI: Omar Moussa  
Sponsor: NIH/NCI  
Total: $296,881  
Dept: Pathology and Laboratory Medicine  
Award: 5R01CA127905-04 (12070968-1)

Picard, Jonathan  
**Principal Investigator**  
_Phase II, Open-Label, Dose-Finding Study of the Effect of GTx-758 on Total and Free Testosterone Levels in Men with Prostate Cancer Compared to a Luteinizing Hormone Releasing Hormone Agonist_  
GTx, Inc.  
G200705 (12010062)  
Budget Dates: 07/14/11 - 07/31/13  
Project Dates: 07/14/11 - 07/31/13  
Direct F & A Total  
49,132 11,408 60,540

Rames, Ross  
**Principal Investigator**  
_A Multi-Center, Double-Blind, Randomized, Phase 3 Study to Compare the Safety and Efficacy of Intravenous CXA-101/Tazobactam and Intravenous Levofloxacin in Complicated Urinary Tract Infection, Including_  
MUSC OIP  
CXA-cUTI-10-04 (11120358)  
Budget Dates: 10/13/11 - 06/30/13  
Project Dates: 10/13/11 - 06/30/13  
Direct F & A Total  
137,190 31,538 168,728
Rovner, Eric

Principal Investigator

Regulation of Urinary Bladder Smooth Muscle by K+ Channels
Univ. of South Carolina
11-1867/R21 DK083687-01A1 (12060778)
Budget Dates: 09/01/11 - 08/31/12
Project Dates: 09/30/10 - 08/31/12
Direct F & A Total
2,478 1,177 3,655

BK Channel Function and Regulation in Urinary Bladder Smooth Muscle
Univ. of South Carolina
10-1744/R01DK084284 (12091280)
Budget Dates: 09/01/11 - 08/31/12
Project Dates: 09/30/09 - 08/31/14
Direct F & A Total
2,478 1,177 3,655

A Phase 2a, Multi-Center, Randomized, Double-Blinded, Placebo-Controlled Study Evaluating Safety, Tolerability and Efficacy of LiRIS in Women with Interstitial Cystitis Followed by an Open-Label Exten
Taris Biomedical, Inc.
TAR-100-201 (12091292)
Budget Dates: 03/23/12 - 05/31/13
Project Dates: 03/23/12 - 05/31/13
Direct F & A Total
128,590 31,398 159,988
## College of Nursing

### Nursing

**Andrews, Jeannette**  
**Principal Investigator**  

**A Social Ecological Based Smoking Cessation Intervention in Public Housing**  
NIH/NHLBI  
5R01HL090951-04 (12030389)  

<table>
<thead>
<tr>
<th>Budget Dates: 12/01/11 - 11/30/12</th>
<th>Direct</th>
<th>F &amp; A</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Project Dates: 12/01/08 - 11/30/13</td>
<td>533,019</td>
<td>162,784</td>
<td>695,803</td>
</tr>
</tbody>
</table>

**Co-PI/Project Director**  
Southeastern Virtual Institute for Health Equity and Wellness (SE VIEW): Project 10  
PI: Sabra Slaughter  
Sponsor: US Army/USAMRAA  

**Project Dates:** 12/01/08 - 11/30/13  
**Total:** $229,261  
**Award:** W81XWH-10-2-0057 (10071988-23)

**Co-Investigator**  
South Carolina Clinical and Translational Research Institute (UL1)  
PI: Kathleen Brady  
Sponsor: NIH/NCRR  

**Project Dates:** 12/01/08 - 11/30/13  
**Total:** $301,173  
**Award:** 5UL1RR029882-03 (11012750-2)

**Hollywood Smiles**  
PI: Renata Leite  
Sponsor: NIH/NIDCR  

**Project Dates:** 12/01/08 - 11/30/13  
**Total:** $221,250  
**Award:** 1R21DE021979-01 (11051106-1)

**Bissinger, Robin**  
**Principal Investigator**  

**Advanced Education Nursing Traineeship Program**  
HRSA  
2 A10HP08284-05-00 (10120946)  

<table>
<thead>
<tr>
<th>Budget Dates: 07/01/11 - 06/30/12</th>
<th>Direct</th>
<th>F &amp; A</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Project Dates: 07/01/11 - 06/30/12</td>
<td>80,829</td>
<td>0</td>
<td>80,829</td>
</tr>
</tbody>
</table>

**Nurse Faculty Loan Program**  
HRSA  
2 E01HP13019-03-00 (11020840)  

<table>
<thead>
<tr>
<th>Budget Dates: 07/01/09 - 06/30/12</th>
<th>Direct</th>
<th>F &amp; A</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Project Dates: 07/01/09 - 06/30/12</td>
<td>130,551</td>
<td>0</td>
<td>130,551</td>
</tr>
</tbody>
</table>

**Bryant, Deborah**  
**Principal Investigator**  

**The Community Compass Project**  
SC Cancer Alliance  
(11022855)  

<table>
<thead>
<tr>
<th>Budget Dates: 07/01/11 - 06/20/12</th>
<th>Direct</th>
<th>F &amp; A</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Project Dates: 07/01/11 - 06/20/12</td>
<td>8,550</td>
<td>0</td>
<td>8,550</td>
</tr>
</tbody>
</table>

**Improving Access to Breast Cancer Screening and Follow-up Care through Mobile Mammography Services**  
Komen for the Cure/Lowcountry Affiliate  
(12050687)  

<table>
<thead>
<tr>
<th>Budget Dates: 04/01/12 - 03/31/13</th>
<th>Direct</th>
<th>F &amp; A</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Project Dates: 04/01/12 - 03/31/13</td>
<td>81,120</td>
<td>0</td>
<td>81,120</td>
</tr>
</tbody>
</table>

**Medical University of South Carolina**
Bryant, Deborah

Co-Investigator
2012 Avon Foundation Safety Net Program
Pl: Andrew Kraft
Dept: Medicine
Sponsor: Avon Fdn.
Award: 05-2011-081 (12020204-1)
Total: $ 110,000

Southeastern US Collaborative CEED (SUCCEED)
Pl: Marvella Ford
Dept: Medicine
Sponsor: Morehouse School of Medicine
Award: 5 U58 DP000984-05 (12060729-1)
Total: $ 70,000

Conner, Brian

Principal Investigator
VA Nursing Academy (VANA)
VAMC (12010072)
Budget Dates: 07/01/11 - 08/20/11
Project Dates: 07/01/10 - 08/20/11
Direct F & A Total
14,317 0 14,317

Gilden, Gail

Principal Investigator
Advanced Nursing Education Grants
HRSA
1 D09 HP22592-01-00 (10021181)
Budget Dates: 07/01/11 - 06/30/12
Project Dates: 07/01/11 - 06/30/12
Direct F & A Total
246,718 19,737 266,455

Jenkins, Carolyn

Principal Investigator
REACH U.S. Southeastern African American Center of Excellence for Elimination of Disparities
CDC
Budget Dates: 09/30/11 - 09/29/12
Project Dates: 09/30/07 - 09/29/12
Direct F & A Total
697,881 152,120 850,001

Co-Investigator
Telephone Delivered Behavioral Skills Intervention for Blacks with T2DM (PARENT)
Pl: Leonard Egede
Dept: Medicine
Sponsor: NIH/NIDDK
Award: 5R01DK081121-04 (11050471-1)
Total: $ 508,994

Reach U.S. SEA-CEED CTG (Community Transformation Grant)
National Reach Coalition
Budget Dates: 06/01/12 - 05/31/13
Project Dates: 06/01/12 - 05/31/13
Direct F & A Total
89,286 23,214 112,500

Joseph, Amelia

Principal Investigator
Diagnostic Accuracy of Failure to Rescue as a Nurse Sensitive Indicator
VAMC (09102974)
Budget Dates: 10/01/11 - 09/30/12
Project Dates: 10/01/09 - 09/30/12
Direct F & A Total
76,200 0 76,200

Kelechi, Teresa

Principal Investigator
A Physical Activity Intervention, MECALF, to Reduce Pain in Patients with Critically Colonized/Infected Chronic Leg Ulcers
Wound, Ostomy & Continence Nurses Society (11042734)
Budget Dates: 08/01/11 - 07/31/12
Project Dates: 08/01/11 - 07/31/12
Direct F & A Total
9,091 909 10,000

Preventing Venous Leg Ulcers with Cryotherapy: A Randomized Clinical Trial
NIH/NINR
Budget Dates: 01/01/12 - 12/31/12
Project Dates: 03/07/11 - 12/31/14
Direct F & A Total
427,508 163,166 590,674

Co-Investigator
South Carolina Clinical and Translational Research Institute (UL1)
Pl: Kathleen Brady
Dept: Psychiatry and Behavioral Sciences
Sponsor: NIH/NCRR
Award: 5UL1RR029882-03 (11012750-2)
Total: $ 301,173

Drug Abuse Research Training
Pl: Sudie Back
Dept: Psychiatry and Behavioral Sciences
Sponsor: NIH/NIDA
Award: 5R25DA020537-07 (12091253-1)
Total: $ 302,188

Kennedy, Margaret

Principal Investigator
Fostering Developmental Networks for Mentorship of Nurse Faculty: Connections that Count
National League for Nursing (12010070)
Budget Dates: 10/01/11 - 09/30/12
Project Dates: 10/01/11 - 09/30/12
Direct F & A Total
3,150 0 3,150
Laken, Marilyn
Co-Investigator
South Carolina Clinical and Translational Research Institute (UL1)
PI: Kathleen Brady  Sponsor: NIH/NCRR  Total: $301,173
Dept: Psychiatry and Behavioral Sciences  Award: 5UL1RR029882-03 (11012750-2)

SC Community Transformation Grant: Hypertension Initiative
PI: Brent Egan  Sponsor: SC DHEC  Total: $1,128,698
Dept: Medicine  Award: CY-2-798/US$ DP003583 (12040523-1)

Magwood, Gayenell
Co-Investigator
Ethno-Cultural Barriers to Health Literacy/Disease Management in AAs
PI: Ida Spruill  Sponsor: NIH/NINR  Total: $348,383
Dept: Nursing  Award: 1R01NR012432-01A1 (11120369-1)

Mueller, Martina
Co-Investigator
3/8 - Prolonging Remission in Depressed Elderly (PRIDE)
PI: Rebecca Knapp  Sponsor: NIH/NIMH  Total: $23,371
Dept: Medicine  Award: 5U01MH081362-03 (11012518-2)

REACH U.S. Southeastern African American Center of Excellence for Elimination of Disparities
PI: Carolyn Jenkins  Sponsor: CDC  Total: $850,001
Dept: Nursing  Award: 5 U58 DP001015-05 (11042629-1)

Newman, Susan
Principal Investigator
A Peer Navigator Intervention for Individuals with Spinal Cord Injury
NIH/NICHD  Budget Dates: 02/01/12 - 01/31/13  Direct  F & A  Total
5K23HD062637-03 (12060736)  Project Dates: 02/01/10 - 01/31/15  106,677  8,534  115,211
Pope, Charlene

**Principal Investigator**

**Communication Intervention for Adolescent Immunizations: Cluster Randomized Trial**

- **Univ. of Oklahoma**
  - Budget Dates: 02/01/11 - 01/31/12
  - Project Dates: 02/01/11 - 01/31/14
  - Direct F & A: 68,315
  - Total: 100,765

  **RS20110719-01 (10101322)**

**Communication Intervention for Adolescent Immunizations: Cluster Randomized Trial**

- **Oklahoma University Health Sc. Center**
  - Budget Dates: 02/01/12 - 01/31/13
  - Project Dates: 02/01/11 - 01/31/14
  - Direct F & A: 72,780
  - Total: 107,351

  **RS20110719-01 (12101422)**

**Co-Investigator**

**Ethno-Cultural Barriers to Health Literacy/Disease Management in AAs**

- **PI:** Ida Spruill
- **Sponsor:** NIH/NINR
- **Award:** 1R01NR012432-01A1 (11120369-1)
- **Total:** $348,383

**Department:** Nursing

**Smith, Gigi**

**Principal Investigator**

**Caregiving in Youth with Epilepsy**

- **Sigma Theta Tau**
  - Budget Dates: 06/01/12 - 05/31/13
  - Project Dates: 06/01/12 - 05/31/13
  - Direct F & A: 2,000
  - Total: 2,000

**Co-Investigator**

**Risk Factors of Epilepsy Outcomes: Comorbidities in a Population with Epilepsy**

- **PI:** Anbesaw Selassie
- **Sponsor:** CDC
- **Total:** $425,000

**Department:** Medicine

**Spruill, Ida**

**Principal Investigator**

**Ethno-Cultural Barriers to Health Literacy/Disease Management in AAs**

- **NIH/NINR**
  - Budget Dates: 04/01/12 - 01/31/13
  - Project Dates: 04/01/12 - 01/31/15
  - Direct F & A: 236,192
  - Total: 348,383

**Stroud, Sally**

**Principal Investigator**

**Helene Fuld Health Trust Scholarship Fund for Baccalaureate Nursing Students**

- **Helene Fuld Health Trust**
  - Budget Dates: 09/01/11 - 08/31/12
  - Project Dates: 09/01/10 - 08/31/13
  - Direct F & A: 200,000
  - Total: 200,000

**New Careers in Nursing (NCIN) Scholarship Program**

- **Robert Wood Johnson Fdn.**
  - Budget Dates: 09/01/11 - 08/31/12
  - Project Dates: 09/01/11 - 08/31/12
  - Direct F & A: 100,000
  - Total: 100,000

**Stuart, Gail**

**Principal Investigator**

**Expanding the Pipeline of Primary Care Nurse Practitioners in SC**

- **Blue Cross Blue Shield of SC Fdn.**
  - Budget Dates: 05/01/12 - 04/30/13
  - Project Dates: 05/01/12 - 04/30/13
  - Direct F & A: 250,000
  - Total: 250,000

**Treiber, Frank**

**Principal Investigator**

**Stress Reduction: Impact on BP in African American Youth**

- **NIH/NHLBI**
  - Budget Dates: 09/01/10 - 12/31/11
  - Project Dates: 01/16/05 - 12/31/11
  - Direct F & A: 25,032
  - Total: 36,922

**SmartState Endowed Chair of Technology Applications for Disease Prevention, Management, and Risk Reduction**

- **USC Research Foundation**
  - Budget Dates: 07/01/11 - 06/30/12
  - Project Dates: 07/01/11 - 06/30/12
  - Direct F & A: 38,924
  - Total: 38,924

**Ethnic Differences in Stress Induced Sodium Regulation and Blood Pressure**

- **Georgia Health Sciences University**
  - Budget Dates: 03/01/12 - 02/28/13
  - Project Dates: 09/01/10 - 02/28/13
  - Direct F & A: 13,920
  - Total: 20,532
Wagner, Janelle

Co-Investigator
Risk Factors of Epilepsy Outcomes: Comorbidities in a Population with Epilepsy
Pl: Anbesaw Selassie Sponsor: CDC Total: $ 425,000
Dept: Medicine Award: 1 U01 DP003251-01 (11030164-1)

Williamson, Deborah

Principal Investigator
Abrazos Childhood Development Program
Charleston County School District Budget Dates: 07/01/11 - 06/30/12 Direct F & A Total
ABRAZOS (09082064) Project Dates: 07/01/09 - 06/30/12 11,678 0 11,678

Teen Health Advocate Leadership Program Planning Grant
Center for Public Service Communications Budget Dates: 07/01/11 - 06/30/12 Direct F & A Total
2008-09 (12010013) Project Dates: 02/01/08 - 06/30/12 52,727 4,218 56,945

PASOs in South Carolina: Promoting Prevention and Bridging the Gaps for the Vulnerable Latino Population
Univ. of South Carolina Budget Dates: 07/01/11 - 06/30/12 Direct F & A Total
12-2048/6331-SP (12050607) Project Dates: 07/01/10 - 06/30/14 28,417 0 28,417

Teen Health Advocate Leadership Program Planning Grant
Center for Public Service Communications Budget Dates: 07/01/11 - 09/29/12 Direct F & A Total
2008-09 A6 (13010122) Project Dates: 02/01/08 - 08/15/13 9,259 741 10,000

Co-Investigator
Communication Intervention for Adolescent Immunizations: Cluster Randomized Trial
Pl: Charlene Pope Sponsor: Univ. of Oklahoma Total: $ 100,765
Dept: Nursing Award: RS20110719-01 (10101322-1)

Southeastern US Collaborative CEED (SUCCEED)
Pl: Marvella Ford Sponsor: Morehouse School of Medicine Total: $ 70,000
Dept: Medicine Award: 5 U58 DP000984-05 (12060729-1)

Communication Intervention for Adolescent Immunizations: Cluster Randomized Trial
Pl: Charlene Pope Sponsor: Oklahoma University Health S Total: $ 107,351
Dept: Nursing Award: RS20110719-01 (12101422-1)
## RESEARCH FACULTY ACTIVITY FY 2012

### College of Pharmacy

#### Drug Discovery & Biomedical Sciences

<table>
<thead>
<tr>
<th>Principal Investigator</th>
<th>Title</th>
<th>Sponsor</th>
<th>Project Dates</th>
<th>Direct</th>
<th>F &amp; A</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Beeson, Craig</td>
<td>Development of a Neurotensin Analog as an Antiobesity Agent</td>
<td>Halimed Pharmaceuticals, Inc.</td>
<td>09/01/11 - 08/31/12</td>
<td>36,703</td>
<td>0</td>
<td>36,703</td>
</tr>
<tr>
<td></td>
<td>Co-PI/Project Director</td>
<td>South Carolina COBRE in Oxidants, Redox Balance and Stress Signaling (Core C)</td>
<td>09/07/09 - 07/31/13</td>
<td>168,814</td>
<td>80,186</td>
<td>249,000</td>
</tr>
<tr>
<td></td>
<td>Co-Investigator</td>
<td>CSD Peptide-Based Therapeutic Agents in Scleroderma Lung Disease</td>
<td>09/07/09 - 07/31/13</td>
<td>168,814</td>
<td>80,186</td>
<td>249,000</td>
</tr>
<tr>
<td></td>
<td>Co-Investigator</td>
<td>High Content Metabolic Screens for Anti-Degenerative Agents</td>
<td>09/07/09 - 07/31/13</td>
<td>168,814</td>
<td>80,186</td>
<td>249,000</td>
</tr>
<tr>
<td>Blakely, Jennifer</td>
<td>Stimulation of Mitochondrial Biogenesis with 5-HT Receptor Agonists</td>
<td>NIH/NIDDK</td>
<td>09/01/11 - 08/31/12</td>
<td>36,703</td>
<td>0</td>
<td>36,703</td>
</tr>
<tr>
<td></td>
<td>Co-PI/Project Director</td>
<td>South Carolina COBRE in Oxidants, Redox Balance and Stress Signaling (Project 2)</td>
<td>09/01/09 - 08/31/14</td>
<td>186,034</td>
<td>13,148</td>
<td>199,182</td>
</tr>
<tr>
<td></td>
<td>Co-PI/Project Director</td>
<td>South Carolina COBRE in Oxidants, Redox Balance and Stress Signaling (Project 5)</td>
<td>09/01/09 - 08/31/14</td>
<td>186,034</td>
<td>13,148</td>
<td>199,182</td>
</tr>
<tr>
<td></td>
<td>Co-Investigator</td>
<td>South Carolina COBRE in Oxidants, Redox Balance and Stress Signaling (Project 1)</td>
<td>09/01/09 - 08/31/14</td>
<td>186,034</td>
<td>13,148</td>
<td>199,182</td>
</tr>
<tr>
<td>Chou, C.</td>
<td>The Mechanism of Mitochondrial DNA Proofreading in Human Health and Disease</td>
<td>NIH/NIEHS</td>
<td>09/01/11 - 08/31/12</td>
<td>36,703</td>
<td>0</td>
<td>36,703</td>
</tr>
<tr>
<td></td>
<td>Co-PI/Project Director</td>
<td>South Carolina COBRE in Oxidants, Redox Balance and Stress Signaling (Project 5)</td>
<td>09/01/09 - 08/31/14</td>
<td>186,034</td>
<td>13,148</td>
<td>199,182</td>
</tr>
<tr>
<td></td>
<td>Co-Investigator</td>
<td>South Carolina COBRE in Oxidants, Redox Balance and Stress Signaling (Project 1)</td>
<td>09/01/09 - 08/31/14</td>
<td>186,034</td>
<td>13,148</td>
<td>199,182</td>
</tr>
<tr>
<td>Covington, Marisa</td>
<td>Research Training in Bioenergetics, Oxidative Stress and Metabolic Syndromes</td>
<td>NIH/NIDDK</td>
<td>09/01/11 - 08/31/12</td>
<td>36,703</td>
<td>0</td>
<td>36,703</td>
</tr>
<tr>
<td></td>
<td>Liver Preservation for Transplantation</td>
<td>NIH/NIDDK</td>
<td>09/01/11 - 08/31/12</td>
<td>36,703</td>
<td>0</td>
<td>36,703</td>
</tr>
<tr>
<td></td>
<td>Glaxosmithkline Smartstate Endowed Chair in Cancer Drug Discovery</td>
<td>MUSC Fdn.</td>
<td>09/01/11 - 08/31/12</td>
<td>36,703</td>
<td>0</td>
<td>36,703</td>
</tr>
</tbody>
</table>
Lemasters, John

Co-PI/Project Director
South Carolina COBRE in Oxidants, Redox Balance and Stress Signaling (Core D)
PI: Kenneth Tew
Dept: Cell and Molecular Pharmacology
Sponsor: NIH/NCRR
Award: 1P20RR024485-01A2 (09062764-6)
Total: $201,880

MUSC CCΣG: Cell and Molecular Imaging
PI: Andrew Kraft
Dept: Medicine
Sponsor: NIH/NCI
Award: 5P30CA138313-04 (12070914-12)
Total: $88,261

Niemin, Anna-Liisa

Mentor
South Carolina COBRE in Oxidants, Redox Balance and Stress Signaling (Core A2)
PI: Kenneth Tew
Dept: Cell and Molecular Pharmacology
Sponsor: NIH/NCRR
Award: 1P20RR024485-01A2 (09062764-3)
Total: $195,436

Schnellmann, Rick

Principal Investigator
Mitochondrial Biogenesis Promotes Recovery from Oxidant Injury
NIH/NIAMS
Budget Dates: 07/01/11 - 06/30/13
Direct F & A Total
5R01GM094147-04 (11110057) Project Dates: 09/01/08 - 06/30/13 196,020 93,110 289,130

SmartState Center for Cancer Drug Discovery
MUSC Fdn.
(12121694)
Budget Dates: 07/01/11 - 06/30/12
Direct F & A Total
Project Dates: 09/01/07 - 06/30/12 81,945 0 81,945

5-HT Stimulation of Mitochondrial Biogenesis and Acute Kidney Injury
VAMC
Budget Dates: 10/01/11 - 09/30/12
Direct F & A Total
BX000851 (13011800) Project Dates: 10/01/11 - 09/30/14 243,800 0 243,800

Siskind, Leah

Principal Investigator
Role of Ceramide in Aging Related Diseases
VAMC
Budget Dates: 01/01/12 - 03/31/12
Direct F & A Total
(08061962) Project Dates: 01/01/09 - 03/31/12 25,000 0 25,000

Regulation of Kidney Glycosphingolipid Metabolism by Caloric Restriction During Aging
Amer. Federation for Aging
Budget Dates: 07/01/11 - 06/30/12
Direct F & A Total
(10120943) Project Dates: 07/01/11 - 06/30/12 91,093 7,407 98,500

Smith, Charles

Principal Investigator
A Proof-of-Concept Study of the Efficacy of ABC294640 as a Medical Counter Measure for the Mitigation of Gastrointestinal Acute Radiation Syndrome in C57BL/6 Mice
Apogee
Budget Dates: 08/15/11 - 08/14/12
Direct F & A Total
HHSO100201100029C (11120290) Project Dates: 08/15/11 - 08/14/13 318,987 151,518 470,505

Cell Cycle Specific CDK Inhibitors as Potential Anti-Tumor Therapeutics Through REPLACE
Univ. of South Carolina
Budget Dates: 08/01/11 - 07/31/12
Direct F & A Total
09-1634/R01 CA131368 (12020207) Project Dates: 09/25/08 - 07/31/13 12,186 5,788 17,974

Character and Carol Cooper SmartState Endowed Chair in Cancer Drug Discovery
MUSC Fdn.
(12121651)
Budget Dates: 07/01/11 - 06/30/12
Direct F & A Total
Project Dates: 07/01/12 - 06/30/12 40,972 0 40,972

Medical University of South Carolina 159
Smith, Charles  
**Co-Investigator**  
South Carolina Clinical and Translational Research Institute (SCTR): UL1  
Pl: Kathleen Brady  
Dept: Psychiatry and Behavioral Sciences  
**Sponsor:** NIH/NCATS  
Total: $2,537,859  
**Award:** 8UL1TR00062-04 (12070938-1)

South Carolina Clinical and Translational Research Institute (SCTR): UL1  
Pl: Kathleen Brady  
Dept: Psychiatry and Behavioral Sciences  
**Sponsor:** NIH/NCATS  
Total: $798,196  
**Award:** 8UL1TR00062-04 (12070938-2)

**SmartState Center for Cancer Drug Discovery**  
Pl: Rick Schnellmann  
Dept: Drug Discovery & Biomedical Sciences  
**Sponsor:** MUSC Fdn.  
Total: $81,945  
**Award:** (12121694-1)

**Mentor**  
South Carolina COBRE in Oxidants, Redox Balance and Stress Signaling (Core A2)  
Pl: Kenneth Tew  
Dept: Cell and Molecular Pharmacology  
**Sponsor:** NIH/NCRR  
Total: $195,436  
**Award:** 1P20RR024485-01A2 (09062764-3)

**Co-Investigator**  
Mentor  
South Carolina COBRE in Oxidants, Redox Balance and Stress Signaling (Project 4)  
Pl: Kenneth Tew  
Dept: Cell and Molecular Pharmacology  
**Sponsor:** MUSC Fdn.  
Total: $194,105  
**Award:** (12070942-1)

Townsend, Danyelle  
**Co-PI/Project Director**  
South Carolina COBRE in Oxidants, Redox Balance and Stress Signaling (Project 4)  
Pl: Kenneth Tew  
Dept: Cell and Molecular Pharmacology  
**Sponsor:** MUSC Fdn.  
Total: $221,250  
**Award:** 1P20RR024485-01A2 (09062764-10)

Wills, Lauren  
**Principal Investigator**  
Identification and Characterization of Mitochondrial Toxins  
NIH/NIEHS  
**Budget Dates:** 08/01/11 - 09/30/12  
**Project Dates:** 08/01/11 - 09/30/12  
**Direct F & A** 51,326  
**Total** 51,326

**Woster, Patrick**  
**Principal Investigator**  
Identification of LSD1 Inhibitors Targeting Epigenetic Regulation in Tumor Cells  
NIH/NCI  
**Budget Dates:** 02/01/12 - 01/31/13  
**Project Dates:** 04/01/10 - 01/31/15  
**Direct F & A** 197,364  
**Total** 247,468

**SmartState Endowed Chair in Medicinal Chemistry for the Center for Cancer Drug Discovery**  
MUSC Fdn.  
**Budget Dates:** 07/01/11 - 06/30/12  
**Project Dates:** 07/01/11 - 06/30/12  
**Direct F & A** 40,972  
**Total** 40,972

**Pharmacy and Clinical Sciences**

**Bosso, John**  
**Co-Investigator**  
Impact of MRSA Decolonization Therapy on MRSA Infection and Transmission  
Pl: Arch Mainous  
Dept: Family Medicine  
**Sponsor:** AHRQ  
Total: $496,813  
**Award:** 1R01HS018954-01A1 (10101315-1)

Impact of MRSA Decolonization Therapy on MRSA Infection and Transmission  
Pl: Arch Mainous  
Dept: Family Medicine  
**Sponsor:** AHRQ  
Total: $499,713  
**Award:** 5R01HS018954-02 (12070808-1)

LaPointe, Marc  
**Principal Investigator**  
Retrospective Evaluation of Acute Blood Pressure Control in Ischemic Stroke Patients  
The Medicines Co.  
**Budget Dates:** 11/30/09 - 11/30/12  
**Project Dates:** 11/30/09 - 11/30/12  
**Direct F & A** 7,200  
**Total** 9,000

Mauldin, Patrick  
**Principal Investigator**  
SCCP Medicaid Academic Detailing Project - Amendment Ten  
Univ. of South Carolina  
**Budget Dates:** 04/01/11 - 09/17/11  
**Project Dates:** 04/01/07 - 09/17/11  
**Direct F & A** 5,000  
**Total** 5,000

**Co-Investigator**  
South Carolina Clinical and Translational Research Institute (UL1)  
Pl: Kathleen Brady  
Dept: Psychiatry and Behavioral Sciences  
**Sponsor:** NIH/NCRR  
Total: $301,173  
**Award:** 5UL1RR029882-03 (11012750-2)
Mauldin, Patrick

**Co-Investigator**

Interventional Management of Stroke Phase III Trial - SDCC

**PI:** Yuko Palesch  
**Sponsor:** NIH/NINDS  
**Total:** $487,035

**Dept:** Medicine  
**Award:** 1U01NS077304-01 (11012863-1)

Evaluating Predictors and Interventions in Sphincter of Oddi Dysfunction (EPISOD): Clinical - Parent

**PI:** Peter Cotton  
**Sponsor:** NIH/NIDDK  
**Total:** $1,001,170

**Dept:** Medicine  
**Award:** 5U01DK074739-05 (11042733-2)

Evaluating Predictors and Interventions in Sphincter of Oddi Dysfunction (EPISOD) (Supplement for Long Term Followup of Enrolled Subjects): Clinical Coordinating Center

**PI:** Peter Cotton  
**Sponsor:** NIH/NIDDK  
**Total:** $188,731

**Dept:** Medicine  
**Award:** 3U01DK074739-05S1 (12010131-2)

South Carolina Clinical and Translational Research Institute (SCTR): UL1

**PI:** Kathleen Brady  
**Sponsor:** NIH/NCATS  
**Total:** $2,537,859

**Dept:** Psychiatry and Behavioral Sciences  
**Award:** 8UL1TR000062-04 (12070938-1)

South Carolina Clinical and Translational Research Institute (SCTR): UL1

**PI:** Kathleen Brady  
**Sponsor:** NIH/NCATS  
**Total:** $798,196

**Dept:** Psychiatry and Behavioral Sciences  
**Award:** 8UL1TR000062-04 (12070938-2)

Aging Q3: Quality Education, Quality of Care, Quality of Life

**PI:** William Moran  
**Sponsor:** Donald W. Reynolds Fdn.  
**Total:** $500,000

**Dept:** Medicine  
**Award:** (12081032-1)

Trauma Management Therapy for OEF and OIF Combat Veterans

**PI:** Thomas Uhde  
**Sponsor:** Univ. of Central Florida  
**Total:** $97,046

**Dept:** Psychiatry and Behavioral Sciences  
**Award:** 24096033-01 (12091209-1)

Wisniewski, C.

**Principal Investigator**

SCCP SCORxE Academic Detailing Project

**Univ. of South Carolina**

**Budget Dates:** 07/01/11 - 02/22/12  
**Project Dates:** 07/01/11 - 02/22/12  
**Direct F & A**  
**Total**

12-1977 (12020229)  
21,480 0 21,480

SCCP SCORxE Academic Detailing Project

**Univ. of South Carolina**

**Budget Dates:** 02/22/12 - 02/21/13  
**Project Dates:** 07/01/11 - 02/21/13  
**Direct F & A**  
**Total**

12-1977 (12101388)  
12,677 0 12,677

**Co-Investigator**

SCCP Medicaid Academic Detailing Project - Amendment Ten

**PI:** Patrick Mauldin  
**Sponsor:** Univ. of South Carolina  
**Total:** $5,000

**Dept:** Pharmacy and Clinical Sciences  
**Award:** 08-1470/PO#81994 (11041375-2)